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PREFACE
This thesis is a collection of some of the studies I have undertaken over the last 3.5 years 
while working as a Research Assistant in the T cell modulation group at the Cardiff 
University School of Medicine. The work contained within is linked by the common 
theme of optimising interactions between peptide-Major Histocompatibility (pMHC) 
molecules, the T cell receptor (TCR), and/or coreceptor that engages these ligands. The 
work of the T cell modulation group is heavily focused on translational medicine. This 
aspect of biomedicine is also strongly encouraged by my funding body, the Wellcome 
Trust. My focus on translational aspects of interactions with pMHC ligands took my work 
in several different directions. Initially, I examined ways of improving interactions with 
pMHC that could be used to ameliorate the detection of antigen-specific T cells by flow 
cytometry. My studies have improved this technology to a point where I can now 
reliably claim to be able to stain the majority of relevant T cells with their cognate 
multimeric antigen. The approaches I helped pioneer are now in use all over the world. 
This work is reported in Chapters 3 and 5, and has resulted in two published primary 
data papers. A third paper that examines pMHC multimer valency (described in Chapter 
4) is in preparation. In addition to the above-mentioned work aimed at improving T cell- 
related diagnostics using pMHC multimers, I also explored potential ways of improving 
TCR/pMHC interactions for therapeutic approaches. Specifically, I was interested in 
exploring whether TCRs displaying enhanced affinities for antigen would be useful in the 
clinic. These studies necessitated that we establish optimal TCR gene transfer protocols 
in Cardiff. I took the lead on these optimisation studies (Chapter 6). With the TCR gene 
transfer technology optimised, I was able to investigate whether increasing functional 
avidity of TCR-redirected T cells could be achieved by removing defined N-glycosylation 
sites within the TCR constant domain. This work was based on my observation that the 
desialylation of T cells improved the surface engagement of pMHC multimers and the 
recognition of cognate antigen when displayed naturally on a target cell surface. These 
studies were taken forward in Chapter 7. As part of my work with affinity enhanced 
TCRs, I was fortunate to test a novel set of TCR-based soluble therapeutic reagents 
comprising affinity-enhanced TCRs (Chapter 8). The enhanced TCRs were generated by 
phage display and directed evolution using techniques that were pioneered by my T cell 
modulation group colleague Jonathan Boulter while working at Avidex Ltd.
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ABSTRACT
ap T cells are some of the most important cells in our bodies as they: (i) orchestrate 
immunity and are key elements in the control of infection; (ii) are important for the 
natural eradication of cancer; (iii) hold the key to successful vaccination; (iv) are an 
important factor in transplant rejection; (v) cause all autoimmune diseases; and, (iv) 
mediate many allergic reactions. Consequently, T cells sit at the heart of most human 
pathologies and it is very important that we understand how these pivotal cells operate, 
ap T cells recognise short 'foreign' peptides bound to major histocompatibility complex 
(MHC) molecules; the antigen specificity of T cells is conferred by the highly variable 
complementarity determining regions (CDRs) of the ap T cell receptor (TCR) that interact 
with the peptide-binding platform of the MHC. The CD8 and CD4 glycoproteins on the T 
cell surface also act as receptors for pMHC class I and II, respectively in concert with the 
TCR. CD8 and CD4 and have been termed 'coreceptors' to reflect this role. The pivotal 
role T cells play in pathogen protection, cancer immunity and autoimmunity has ensured 
that there is a huge interest in the detection, understanding and manipulation of 
antigen-specific T cells. Recent advances using fluorochrome-conjugated multimeric 
pMHC molecules in conjunction with flow cytometry have revolutionised the study of 
antigen-specific T cells by enabling direct visualisation, enumeration, phenotyping and 
clonotyping of these important cells. In the decade since their initial description such 
multimeric pMHC molecules have been used in over 7000 published studies and there 
are now half a dozen commercial enterprises aimed at manufacturing such reagents. My 
laboratory has described that pMHC multimer staining and the sensitivity of T cells to 
antigen density are dependent on TCR/pMHC affinity. We have also shown that the 
interaction affinity required for good pMHC multimer staining can be substantially 
higher than that required for T cell activation. As a result, current technology does not 
detect all T cells that can respond to a particular pMHC antigen. This failure represents a 
significant problem for the detection of anti-cancer and autoimmune T cells which tend 
to have weaker binding TCRs. In this thesis I describe how the physical detection of T 
cells with low affinity TCRs can be improved by: (i) enhancing coreceptor binding; (ii) 
enhancing the valency of pMHC and fluorochrome within pMHC multimers by using a 
larger multimerization scaffold; and, (iii) the use of the protein tyrosine kinase inhibitor 
(PKI) dasatinib. These 'tricks' can all be used to detect and isolate antigen-specific T cells 
that remain undetected by current technologies. I also examine several possibilities for 
enhancing TCR recognition. First, I optimise a system for stable TCR expression in 
primary CD8+ T lymphocytes (Chapter 6). Second, I show that the antigen-sensitivity of 
CD8+ T cells can also be enhanced by the removal of surface sialic acid residues from the 
sugars that coat glycoproteins on the surface of all mammalian T cells, and I explore this 
effect in more detail by examining whether the removal of particular N-glycosylation 
sites on an ap TCR accounts for the increase in antigen sensitivity observed. Finally, I 
experiment with a means of using soluble TCRs to redirect lysis by polyclonal CD8+ T cells 
using TCR-anti-CD3 fusion constructs called Immune mobilising monoclonal TCRs Against 
Cancer/Virus (ImmTAC/Vs). In summary, my results have uncovered several important 
'tricks' for improved physical detection of T cells and these methodologies are already 
being employed by numerous research laboratories across the globe to identify and 
characterise antigen-specific T cell responses. Furthermore, I have also shown that 
enhanced affinity TCRs might provide effective therapeutic reagents either when 
transferred into recipient host T cells by gene transfer or when used as soluble 
molecules to recruit polyclonal T cell populations.
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pMHCI peptide Major Histocompatibility Complex Class 1
pMHCII peptide Major Histocompatibility Complex Class II
RANTES Regulated on Activation, Normal T Expressed and Secreted
RCR Replication Competent Retrovirus
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis
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SFFV Spleen Focus Forming Virus
SIN Self-Inactivating (vector)
SIV Simian Immunodeficiency Virus
SPR Surface Plasmon Resonance
TAA Tumour-Associated Antigen
TAP Transporter associated with Antigen Processing
TCR T Cell Receptor
TGF Transforming Growth Factor
Thl Type 1 helper T cells
Th2 Type II helper T cells
TNF Tumour Necrosis Factor
WPRE Woodchuck hepatitis virus Post-transcriptional Regulatory Element
WT-1 Wilms' Tumour antigen 1
Fluorochromes
APC Allophycocyanin
APC-Cy7 Allophycocyanin Cychrome-7
FITC Fluorescein isothiocyanate
PB Pacific Blue
PE Phycoerythrin
PE-Cy7 Phycoerythrin Cychrome-7
PerCP Peridinin Chlorophyll Protein
Signal transduction components
ITAM Immunoglobulin receptor family Tyrosine based Activation Motif
LAT Linker for Activation of T cells
Lck Lymphocyte specific protein tyrosine kinase
PI3K Phosphatidylinositol-3-Kinase
PKC Protein Kinase C
PTK Protein Tyrosine Kinase
PTKI Protein Tyrosine Kinase Inhibitor
SH Src Homology domain
SMACs Supramolecular activation clusters
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ZAP-70 Zeta Associated Protein of 70 KD
Amino Acids
A Ala
C Cys
D Asp
E Glu
F Phe
G Gly
H His
1 lie
K Lys
L Leu
M Met
N Asn
P Pro
a Gin
R Arg
S Ser
T Thr
V Val
W Trp
Y Tyr
Alanine
Cysteine
Aspartic acid
Glutamic acid
Phenylalanine
Glycine
Histidine
Isoleucine
Lysine
Leucine
Methionine
Asparagine
Proline
Glutamine
Arginine
Serine
Threonine
Valine
Tryptophan
Tyrosine
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Summary
The work contained within this thesis is linked by the common theme of optimising 
interactions between peptide-Major Histocompatibility complex (pMHC) molecules and the 
T cell receptor (TCR) and/or coreceptor that engages them. I explore several different 
translational aspects that touch on a wide range of biomedical topics. I will begin by 
providing an overview of the mammalian immune system with special emphasis on human 
T cells and the molecular interactions they use to detect, and remove, threats to the host. In 
later chapters I will examine how enhanced interactions with pMHC molecules can be used 
to improve the physical detection of T cell using fluorochrome-conjugated antigens in 
conjunction with modern polychromatic flow cytometry. I will therefore introduce this 
technology in this general introduction. Later chapters also examine methodologies for 
using enhanced TCRs in therapeutic strategies for curing viral disease and cancer. I will 
introduce these aspect here by examining the role T cells play in clearing the body of 
infected or dysregulated cells. Finally, I will put my own studies in context by reviewing the 
current strategies that are in use for harnessing T cells for therapeutic benefit before 
introducing the aims of the research work I have undertaken as part of my PhD studies.
1.1 Overview of the immune system
Mammals live in a world inhabited by a multitude of pathogenic organisms which are 
constantly evolving. In order to protect themselves, they rely on a highly sophisticated 
immune system, that itself evolves to keep pace with the pathogens that threaten the host 
organism's existence. A fundamental feature of the immune system is its ability to detect 
structural aspects of the pathogen that distinguishes it from host tissues. The level of 
discrimination is fine-tuned to eliminate the threat of toxicity without causing damage to 
the host tissues the immune system serves to protect. In order to deal with the vast number 
and sophisticated evasion mechanisms displayed by pathogens and their toxins, the 
immune system employs a division of labour between two types of immune response: 
innate and adaptive. The innate branch of the immune system is a hard-wired response 
encoded by genes in the host's germline that specialise in the recognition of molecular
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patterns that are a common feature of many microbes and other host-invading organisms 
(Fraser et al. 1998; Janeway and Medzhitov 2002). Although the innate branch of the 
immune system is relatively inflexible in terms of the number of pathogenic organisms it 
can respond to, it has the advantage of acting rapidly once a potentially harmful object is 
encountered. The fast action of the response is attributed to the broad expression of 
pattern recognition molecules on a large number of cells. The key players in the innate 
immune response are phagocytic cells (monocytes, macrophages, and neutrophils), cells 
that release inflammatory mediators (eosinophils and basophils), natural killer cells and 
molecular components such as complement (Delves and Roitt 2000a; Delves and Roitt 
2000b; Janeway and Medzhitov 2002). The components of the adaptive immune response 
are encoded by gene elements capable of undergoing somatic rearrangements to generate 
a vast repertoire of antigen-binding molecules greatly exceeding the number of primitive 
pattern recognition receptors (PRRs) produced by the innate immune system.
The adaptive immune response relies on B and T lymphocytes, which mediate the humoral 
(soluble) and cellular arms of the response, respectively (Delves and Roitt 2000a; Delves and 
Roitt 2000b). Unlike the germline-encoded recognition molecules of the innate immune 
response, the antigen-specific receptors of the adaptive immune response are encoded by 
somatically-rearranged gene elements that make up T cell receptor (TCR, of two types: a{3 
and y6) and immunoglobulin; Ig (B cell receptor, BCR) genes. It is estimated that the human 
adaptive immune response is capable of generating approximately 1014 BCRs, 1018 a(S TCRs 
and 1020 y6 TCRs (Davis and Bjorkman 1988; Venturi et al. 2008). Since each B and T cell 
expresses a potentially unique antigen recognition receptor (BCR or TCR, respectively), the 
proportion of cells specific for a particular antigen at any given time is very small. As a 
consequence, the responding lymphocytes must undergo expansion to reach sufficient 
numbers before an effective attack on the pathogen is initiated. This need to proliferate 
explains why the adaptive response takes longer to come into effect than the innate 
response. Another important feature of the adaptive immune response is 'immunological 
memory', whereby lymphocytes that have previously encountered antigen enter into an 
apparently dormant state in which the cells can persist until they are re-challenged with
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antigen. These 'memory cells' retain immune memory of a particular antigen for years even 
decades after their initial encounter (Obar and Lefrancois 2010b). Consequently, memory 
cells are capable of eliciting a rapid response on repeated encounters with the same 
antigen. Although, the innate and adaptive branches of the immune response are often 
seen as completely separate entities, they complement each other; with the innate 
response acting as the first line of defence allowing the cells of the adaptive response to 
clonally expand and take over the fight against infection once sufficient numbers of cells 
have been reached a few days later. The interplay between aspects of the innate and 
adaptive braches of the immune response is essential in an effective immune system.
1.2 T cell development and selection
In order to recognise the vast universe of pathogenic antigens, T cells must be equipped 
with a diverse repertoire of TCRs. This incredible level of diversity (up to 1018 possible 
human TCRs) is achieved through the somatic rearrangement of gene elements encoding 
TCR alpha and beta chains, which are designated: variable (V), diversity (D), and joining (J) 
gene elements (Schatz et al. 1992). The TCR alpha chain is assembled from Va Ja, whilst the 
beta chain comprises all three types of element VpDpJp (Bonilla and Oettgen 2010). Because 
the segments are rearranged randomly, millions of different TCR specificities are generated, 
with additional diversity provided by the enzyme terminal deoxynucleotidyl transferase 
(TdT) which adds additional deoxynucleotides into certain VDJ junctions (Nguyen et al. 
2007). Due to its random nature, this process is also responsible for the generation of non­
functional TCRs, in addition to TCRs with specificities directed against self-antigens. The 
selection of T cells carrying only functional and non-autoaggressive TCRs takes place in the 
thymus (Godfrey et al. 1993). This complex lymphoid organ is subdivided into three 
compartments, each with a distinct role:
i) Subcapsular zone: The site where immature bone marrow-derived pro-thymocytes 
proliferate, differentiate, and rearrange their TCR P chains.
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ii) Thymic cortex: The site where TCR a chain rearrangement takes place, and the 
incorporation of some of these a chains into ap TCRs. The mature ap TCRs are subsequently 
tested for functionality through their recognition of self-MHC molecules presented by the 
cortical epithelium in a process called positive selection (Nitta et al. 2008).
Hi) Thymic medulla: The site where mature T thymocytes are screened for autoreactivity, by 
subjecting their TCRs to an extensive array of self-antigens expressed on specialised thymic 
medullary epithelial cells. This process is called negative selection.
Thymocytes capable of recognising self MHC molecules progress from the thymic cortex to 
the medulla (positive selection), whilst those that fail to do so die by neglect. In the thymic 
medulla, thymocytes that recognise self-antigen with affinities greater than a set threshold 
undergo deletion by apoptosis (negative selection), and the surviving cells exit into the 
periphery (Savage and Davis 2001). The stringent selection process ensures that only ~5% of 
developing T cells are permitted to enter circulation, and those that make it display very 
weak/ intermediate affinities for self-antigen (Sebzda et al. 1999).
1.3 T cell antigen recognition and effector function
T cells are a major player in the adaptive arm of the immune response. There are two 
subsets of T cells; ap and y6 T cells. The majority of human T cells in the periphery express 
the ap TCR on their surface. The ap TCR mediates recognition of short peptide fragments 
processed within cells and presented on their surface in association with Major 
Histocompatibility Complex (MHC) molecules (Davis et al. 1998). This requirement for the T 
cell to recognise antigenic peptides only in the context of MHC molecules permits the T cell 
to ignore free extracellular antigen, shifting its focus on to the recognition of infected or 
cancerous cells. There are two classes of MHC molecules; Whereas MHC class I (MHCI) 
molecules are expressed on all nucleated cells, MHC class II (MHCII) are only expressed by 
'professional' antigen presenting cells (APC) such as macrophages, dendritic cells (DCs), B 
cells, and activated human (but not murine) ap and y6 T cells. Peptides presented on MHCI
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molecules are derived from cytosolic degradation of all the proteins within the cell, 
permitting the recognition of aberrant proteins as found in virally-infected or malignantly- 
transformed cells (Janeway 2001). MHCI-associated peptides are typically 8-11 amino acids 
in length. MHCII-restricted peptides are longer, varying between 13 and 17 amino acids in 
length, although shorter or longer lengths are not uncommon (Chicz et al. 1992; Sercarz and 
Maverakis 2003). MHCII-associated peptides are derived from lysosomal degradation of 
proteins ingested outside the cell (e.g. phagocytosed bacteria).
The differing nature of the two MHC structures and their associated peptides lends itself to 
recognition by two functionally distinct classes of ap T cells: CD8 + T cells and CD4+ T cells. 
The nomenclature and function of CD8 + T cells and CD4+ T cells arises from the type of 
coreceptor they express in conjunction with their TCR: CD8 , and CD4, respectively. The 
coreceptors CD8  and CD4 are cell surface glycoproteins, which are associated closely with 
the TCR on the surface of a T cell. The main function of CD8  and CD4 is thought to be 
enhancing T cell signalling by contacting MHC molecules and by interacting with cytosolic 
components of the TCR signalling machinery. Peptide-MHCI (pMHCI) is recognised by CD8 + 
cytotoxic T lymphocytes or 'killer' T cells, which as their name suggests posses the cytotoxic 
activity to kill infected or neoplastic cells. They do this by releasing a number of cytolytic 
enzymes such as granzymes (proteases that remain sequestered in lytic granules), and 
soluble factors such as tumour necrosis factor (TNF), interferon-y (IFN-y), and macrophage 
inflammatory protein ip (MIP-lp) with wide-ranging anti-pathogenic effects (Kagi et al. 
1996; Lieberman 2003). pMHCII molecules are recognised by CD4+ T helper (Th) cells.
1.4 Molecular mechanisms of T cell recoenition
1.4.1 MHCI and MHCII structures and antigen processing
The human MHC, designated Human Leukocyte Antigen (HLA), is encoded on the short arm 
of chromosome 6 . HLA class I molecules (designated HLA-A, -B, and -C) are cell-surface 
heterodimeric glycoproteins consisting of a polymorphic transmembrane a-chain (or class I 
heavy chain) which is subdivided into ai, a2, and a3 domains and is non-covalently associated
30
Chapter 1
with an invariable 02-microglobulin (0 2 ^) (Bjorkman 1997). The ai, ct2, and 0 3  domains come 
together to form a binding groove for the antigenic peptide that is closed at both ends, 
allowing for some 'bulging' of the peptide in the middle of the groove. The a3 domain of the 
HLA class I heavy chain interacts with the CD8  coreceptor on CD8 + T cells. The composite 
structure of peptide and MHCI is the target of the MHCI-restricted ap TCR on the surface of 
CD8 * T cells (Figure 1.1 A), in a phenomenon called 'MHC restriction' (Zinkernagel and 
Doherty 1997).
As for HLA class I molecules, there are three classes of HLA class II molecules designated 
HLA-DR, HLA-DQ, and HLA-DP (Bjorkman 1997). The HLA class II molecule is a complex 
formed from the non-covalent association of an a and a P domain (instead of the p2m 
subunit as in HLA class I), and unlike p2m both chains span the membrane. Both the a and P 
chains contain a short cytoplasmic tail, a transmembrane region, and two extracellular 
domains; a x and a2 for the alpha chain, and Pi and p2 for the beta chain. The ai and pa come 
together to form the peptide binding groove, not dissimilar in structure from the MHCI ai- 
a2 arrangement (Bjorkman 1997). The a2 and p2 subunits provide support for the peptide 
binding groove, whist the p2 domain also forms the point of contact for the CD4 coreceptor. 
The interaction of pMHCII molecules with the CD4 coreceptor restricts pMHCII recognition 
to CD4+ T helper cells (Figure 1.1 B and (Konig et al. 1996)).
1.4.1a MHCI antigen presentation: endogenous pathway
The process by which intracellular proteins are degraded into peptides suitable for 
presentation in the context of MHCI molecules is referred to as the MHCI antigen processing 
pathway. The molecular machinery that generates these endogenous peptide antigens and 
delivers the peptide-MHCI molecules to the cell surface is outlined in Figure 1.2 A. 
Essentially, peptide fragments are generated from cellular proteins through the action of a 
proteolytic machine composed of >25 subunits called the proteasome (Niedermann 2002). 
The proteasome is constitutively expressed in all cells, where its main role is the 
degradation of proteins as part of normal cellular homeostasis. However, if a pathogenic 
threat is detected, release of IFNy by cells such as macrophages signals a transformation of
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apTCR apTCR
pMHCI pMHCII
Ko ~ 1 5 0 p M  Kd >500 pM
Figure 1.1: The TCR/pMHCI/CD8 and TCR/pMHCII/CD4 interactions. Ribbon diagram 
representations of crystal structures of ap TCR/pMHCI/CD8 (A) and a(3 TCR/pMHCII/CD4 
(B) complexes. Three dimensional dissociation constants (K0 values) for the TCR/pMHC and 
the pMHC/coreceptor interactions are indicated. Importantly, the TCR/pMHCII interaction 
is ~5 fold weaker than the TCR/pMHCI interaction, and pMHCII/CD4 binding is substantially 
weaker than pMHCI/CD8 association. (Structures kindly provided by D. Cole).
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A
B
Figure 1.2: T cell antigen presentation pathways. A. Cellular pathway for the processing of 
endogenous antigens. Antigenic proteins found within the cell are degraded into peptides 
by the immunoproteasome and transported into the endoplasmic reticulum (ER) by the 
transporter associated with antigen processing (TAP l  and 2). Some of these peptides can 
bind to MHC class I molecules and are transported to the cell surface for immune 
surveillance by the TCRs of CD8* T cells. B. Cellular pathway for the processing of 
exogenous antigens. Proteins from outside the cell are taken up by phagocytosis or 
endocytosis and are degraded into peptides by the action of enzymes and the acidic 
environment of fusion with lysosomes. Merging of antigen peptide and MHC II -containing 
compartments and the removal of the invariant chain (li) from the MHC II allows binding of 
peptides, before upregulation to the cell surface for presentation to CD4+ T cells. (Figure 
adapted from Chaplin 2010).
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the proteasome into an immunoproteasome. The role of the immunoproteasome is the 
production of peptide fragments of appropriate length and charge for binding into the 
groove of MHCI molecules. On exiting the (immuno)proteasome, the peptides are 
transported to the endoplasmic reticulum (ER), aided by a transporter composed of two 
ATP-binding cassette subunits termed the transporter associated with antigen processing 1 
and 2 (TAPI and TAP2). Inside the ER, loading of peptide into the peptide-binding groove of 
MHCI heavy chain is assisted by the ER protein tapasin with the help of chaperone proteins 
calreticulin and calnexin. Interaction of the p2m subunit with peptide-MHCI heavy chain- 
calnexin complex stabilises the structure and causes the chaperone calnexin to dissociate. 
The complete pMHCI complex passes through the Golgi apparatus before being transported 
to the cell surface in exocytic vesicles.
1.4.1b MHCII antigen presentation: exogenous pathway
Extracellular antigens destined for MHCII presentation are imported into the cell for 
processing in endocytic vehicles, and include proteins derived from bacteria, viral particles, 
allergens and environmental proteins. Fusion of endosomes with lysosomes causes 
acidification, which leads to the degradation of the captured proteins (Turley et al. 2000). 
Once MHCII molecules have been synthesised and assembled in the ER, they are 
transported to the MHCII loading compartment where they can associate with the peptides 
generated in acidic late endosomes. To gain access to the MHCII peptide-binding groove, 
peptides must displace the invariant chain (li) that shields the groove. The acidic 
environment inside the MHCII loading compartment leads to the partial degradation of li, 
and the remaining peptide fragment is exchanged for antigenic peptides with the help of 
the HLA-DM molecule, which itself is structurally related to MHCII (Sadegh-Nasseri et al. 
2008). The complete pMHCII molecules are transported to the cell surface in endosomes. 
The steps of the exogenous presentation pathway are summarised in Figure 1.2 B.
1.4.1c Cross-presentation
Although the processing of antigen for MHCI and MHCII presentation was thought to occur 
by the two distinct pathways described above, recent studies have shown that under
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certain circumstances antigen from outside the cell can also be presented on MHCI 
molecules. This phenomenon is designated cross-presentation, and plays an important role 
in antiviral immunity whereby viral escape mechanisms can inhibit aspects of the 
endogenous pathway of antigen presentation (Sigal et al. 1999).
1.4.2 TCR/pMHC/CD8 (or CD4)
1.4.2a The TCR/pMHC interaction
Recognition of pMHC complexes by T cells is mediated by the TCR. This cell surface structure 
is composed of an a and a p chain linked covalently by a disulphide bridge (van der Merwe 
and Davis 2003). Each chain is subdivided into four regions: a membrane-distal variable 
region (Va or VP), and a membrane-proximal immunoglobulin-like constant region (Cot or 
C{3), a transmembrane region, and a short cytoplasmic region. The TCR Va or vp domains 
make up the pMHC binding site by each contributing three complementarity-determining 
regions (CDR1-3) which are characterised by a very high degree of variability. The CDR2 and 
CDR3 loops of each TCR a and p chain position themselves over the MHC (ai and a2 
domains of MHCI, or ai and pi domains of MHCII), and the CDR3 loops make contact with 
the antigenic peptide. Based on crystal structures solved for several TCR/pMHC complexes, 
the aP TCR is thought to bind pMHC in a diagonal fashion with the Va domain positioned 
over the N-terminal of the antigenic peptide and the VP positioned over the C-terminal 
((Hennecke and Wiley 2001; Rudolph and Wilson 2002) and Figure 1.1). Figure 1.3 depicts 
the key molecules involved in antigen recognition at the CD8 + T cell/ antigen presenting cell 
(APC) interface.
1.4.2b The coreceptors CD8 and CD4
The cell surface glycoproteins CD8  and CD4 were initially described as markers of the two T 
cells subsets: cytotoxic T lymphocytes and T helper cells, respectively (Swain 1983). Their 
role in T cell activation was proposed nearly ten years later when it was shown that anti- 
CD8  and anti-CD4 antibodies block T cells activation in response to antigen (Janeway 1992). 
It is now well established that CD8  and CD4 are important in enhancing T cell sensitivity to
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Cytotoxic T cell
CD8 aa/pMHC I 
Interaction
op TCR/pMHC I 
Interaction
Figure 1.3: The TCR/pMHCI/CD8 interaction: target cell recognition by a CD8* T cells.
Three dimensional dissociation constants (Kq values) for the TCR/pMHC and the 
pMHCI/CD8 interactions are indicated. (Figure kindly provided by D.C ole).
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antigen and are required for optimal activation by most T cells. The level of enhancement 
varies between different T cells and antigens, but a report by Holler and Kranz suggested 
that CD8  may enhance CD8 + T cell sensitivity to antigen by as much as 106 fold (Holler and 
Kranz 2003). Both coreceptors have also been shown to play important roles in T cell 
development (Fung-Leung et al. 1991; Rahemtulla et al. 1991; Van Laethem et al. 2007).
The extracellular domains of CD4 and CD8  coreceptors bind to MHC (Doyle and Strominger, 
1987; Norment et al., 1988), whereas their cytosolic domains bind to Lck, a non-receptor 
protein tyrosine kinase (Marth et al., 1986, Rudd et al., 1988; Veillette et al., 1988). A 
principal role of the coreceptors is in sequestering Lck. Since the TCR lacks intrinsic kinase 
activity, it must rely on the coreceptors to deliver the sequestered Lck within its vicinity. 
Phosphorylation of specific phosphotyrosine motifs by Lck marks the early events of the T 
cell signalling cascade, described in Section 1.4.4. A landmark study by Van Laethem et al. 
demonstrated the importance of the coreceptors in shaping the T cell repertoire by showing 
that ap T cells extracted from CD8/CD4 knockout mice were capable of recognising antigen 
independently of MHC (Van Laethem et al. 2007). In the absence of the coreceptors, TCR 
activation is mediated by passive capture of 'free' Lck, resulting in TCR-antigen engagement 
independently of MHC (Van Laethem et al. 2007). Importantly, these dual coreceptor 
knockout mice rapidly succumb to autoimmune conditions, highlighting the difficulty of 
modulating ap TCR signalling intensity in the absence of CD4 and CD8  (Van Laethem et al.
2007). The Lck-sequestering role of CD8/CD4 functions to ensure that the body only 
generates T cells that recognise MHC-restricted ligands, thus limiting reactivity with self and 
promoting interaction of T cells with other cells. As this thesis is primarily concerned with 
antigen recognition by MHCI-restricted CD8 + T cells, more time will be dedicated to the CD8  
coreceptor with some mention of CD4 where relevant.
1.4.2c The structure and function of the CD8 coreceptor
The CD8  coreceptor is assembled from two chains and exists in two different forms on the 
cell surface: either as an aa homodimer or as an ap heterodimer (Moebius et al. 1991; Terry 
et al. 1990). Whilst CD8 ap is exclusively present on the surface of CD8 + T cells, expression of
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CD8 aa is restricted to y6  T cells, NK cells, memory a|3 T cells, or a special subset of 
intraepithelial lymphocytes (IEL) residing in the gut (Gangadharan and Cheroutre 2004; 
Madakamutil et al. 2004). Each a and 3 chain is subdivided into four domains: a membrane 
distal immunoglobulin-like ectodomain, a heavily glycosylated membrane-proximal 
extended polypeptide stalk, a transmembrane domain, and a cytoplasmic domain (Gao et 
al. 2000; Zamoyska 1998). Although the CD8  a and (3 subunits are topologically similar, they 
show some differences in the stalk and cytoplasmic regions which reflect their different 
functions. The CD8 a cytoplasmic tail has been shown to associate with signalling molecule 
Lck, and is involved in mediating efficient signal transduction leading to T cell activation 
(Veillette et al. 1988). The CD8(3 cytoplasmic tail is palmitoylated at position C179 and is 
responsible for the recruitment of the CD8  coreceptor to lipid rafts, which are specialised 
membrane microdomains rich in sphingolipids, cholesterol and molecules associated with T 
cell signalling (Arcaro et al. 2000; Viola 2001). The CD8|3 tail also increases the efficiency of 
CD8 + T cell signal transduction by crosslinking components of the CD3 machinery with the 
a{3 TCR (Arcaro et al. 2000; Doucey et al. 2003). Briefly, the CD4 coreceptor is a single 
polypeptide composed of four immunoglobulin-like domains designated D1-D4 (Brady and 
Barclay 1996; Wu et al. 1997).
1.4.2d The pMHCI/CD8 interaction
An association between the CD8  coreceptor and pMHCI was first postulated by Norment 
and colleagues, by showing that B cells expressing pMHCI molecules were able to bind cells 
transfected with high levels of CD8 aa even in the absence of a TCR/pMHCI interaction 
(Norment et al. 1988). Subsequently, a crystal structure of the human pMHCI/CD8 aa 
confirmed that the a chain of CD8  does indeed make contact with the 0 3  domain of pMHCI 
((Gao et al. 1997) and Figure 1.3). The structure also revealed that the CD8 aa binds to non- 
polymorphic regions distinct from the polymorphic ai and (*2 regions which form the 
peptide-binding groove recognised by the TCR.
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1.4.2e The pMHCII/CD4 interaction
A crystal structure of a human CD4 amino-terminal two-domain fragment complexed with 
the murine MHCII l-AK has revealed that the D1 domain of CD4 binds to non-polymorphic 
regions of the MHCII molecule (0 2  and P2) (Wang et al. 2001). The fact that CD4 contacts the 
MHCII molecule at a site distinct from the TCR binding site is reminiscent of the MHCI 
interaction with the CD8  coreceptor. However, whereas both domains of CD8  cooperatively 
bind MHCI molecules, only one domain (the N-terminal D1 domain) of CD4 makes contact 
with MHCII, whilst the second tandem CD4 domain remains distal to the interface (Wang et 
al. 2 0 0 1 ).
1.4.3 Kinetics of the TCR/pMHC and the pMHC/coreceptor interactions 
1.4.3a Kinetics of the TCR/pMHC interaction
Compared to the strength of most antibody-antigen interactions (dissociation constants (K0) 
of <1 nM, (Mason and Williams 1980)), the majority of natural TCR-antigen interactions are 
extremely weak (Cole et al. 2007; Gao et al. 2000). The KD for the TCR/pMHCI interaction 
normally ranges 1-50 pM (Gao et al. 2000). The kinetics of such weak, non-covalent protein- 
protein interactions can be measured using 3D or 2D technologies. To date, the majority of 
TCR/pMHC binding interactions have only been analysed three-dimensionally using a 
technique called surface plasmon resonance (SPR) (Davis et al. 1998; Gascoigne et al. 2001; 
Stone et al. 2009). In SPR experiments measuring TCR/pMHC binding, the pMHC is 
immobilised on a 'sensor chip' and the TCR is pumped over the surface of the chip. As the 
protein in solution binds to the immobilised protein, there is a change in refractive index at 
the surface of the sensor chip that is detected by the instrument using polarised light. This is 
related to the mass of protein close to the surface of the chip and thus allows measurement 
of binding kinetics in real-time. This method for measuring protein-protein interactions is 
classed as 3D chemistry because the protein present in the soluble phase is free to move 
about in three dimensions prior to binding its ligand. Although, in general, a good 
correlation has been demonstrated between the kinetics of binding (in particular the off- 
rate) and the strength of T cell activation (Davis et al. 1998; Gascoigne et al. 2001; Stone et
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al. 2009), some researchers argue that SPR experiments are not an accurate representation 
of T cell/APC interactions.
In a biological setting, when a T cell encounters its target APC, the TCR and pMHC molecules 
are tethered to two opposing membranes and are therefore constrained to move in two 
dimensions. In view of this, 2D chemistry techniques have been developed for the purpose 
of measuring TCR/pMHC interactions with physiologically-relevant accuracy. A number of 
different methods have been developed to measure protein-protein interactions in two 
dimensions. In the fluorescence approach, TCR-expressing cells are placed on a glass- 
supported bilayer reconstituted with lipid-anchored, fluorescently-labelled pMHC ligands 
(Dustin et al. 1996; Dustin et al. 1997). TCR/pMHC interactions locally deplete free pMHC, 
creating a density gradient that drives net diffusion of free ligands into the contact area. 
This further pushes the process toward formation of more TCR/pMHC interactions and 
diffusion of more free pMHC into the contact area, leading to ligand accumulation within 
the contact area, as revealed by the higher fluorescence intensity inside than outside the 
contact region. Alternatively, 2D affinities can be determined mechanistically, whereby, 
interacting receptor/ligand complexes physically link two cells or a cell to a surface. The 
binding kinetics of TCR/pMHC interactions can be quantified by several mechanical methods 
such as the flow-chamber (Kaplanski et al. 1993), the micropipette (Chesla et al. 1998; 
Huang et al. 2010) and the centrifugation methods (Piper et al. 1998). The differences in 
kinetic measurements obtained by 2D and 3D approaches relate to how molecules 
approach each other. Instead of approaching each other by free diffusion, as in 3D SPR 
systems, molecules in 2D experiments are brought together (and apart) by membranes to 
which they are anchored. Furthermore, as molecules are brought in together to interact, 
more degrees of freedom are lost on binding of soluble molecules in a 3D setting than 
membrane-anchored molecules in 2D experiments. This greater entropic penalty incurred 
by free-flowing molecules in SPR experiments is thought to be accountable for the 
differences in kinetic measurements determined using 2D and 3D systems (Dustin et al. 
2001; Huang et al. 2010).
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Compared to 3D-derived data, 2D affinities and on-rates of the TCR for a panel of pMHC 
ligands possess far broader dynamic ranges, which are much more closely matched to that 
of their corresponding T cell responses (Huang et al. 2010). For instance, the low affinity 
characteristic of TCR/pMHC interactions in 3D is explained by a slow association rate (Kon~ 
1 0  2- 1 0  4 M 'V1) rather than a fast dissociation rate (K0ff~ 0.5-0.01 s’1) (Davis et al. 1998). The 
slow association rate is thought to be a consequence of conformational flexibility at the 
TCR/pMHC interface (Willcox et al. 1999a). The best 3D parameter for TCR/pMHC affinity is 
however the dissociation rate, with agonist pMHC dissociating the slowest (Davis et al. 
1998; Gascoigne et al. 2001; Stone et al. 2009). Contrastingly, in 2D, the affinities between a 
TCR and its antigenic pMHCs are driven by rapid association rates and rapid dissociation 
rates (up to 8,300-fold faster than off-rates determined in 3D) (Huang et al. 2010). 
Evaluation of TCR/pMHC kinetics in 2D therefore proposes a scenario whereby T cells 
rapidly and serially engage a few agonist pMHCs (via their TCRs) in a large self pMHC 
background.
It has been shown that the CD8  coreceptor can increase TCR/pMHCI on-rates (Gakamsky et 
al. 2005; Laugel et al. 2007) and reduce off-rates (Laugel et al. 2007; Wooldridge et al. 
2005), at the same time as stabilising the TCR/pMHCI interaction by approximately two-fold 
(Wooldridge et al. 2005). The ability of CD8  to influence TCR/pMHCI binding kinetics has 
been attributed to the existence of spatially localised TCR-coreceptor adducts, which are 
predicted to be substantially better at engaging pMHCI antigen than if the TCR and CD8  
were spatially distinct (Arcaro et al. 2001; Doucey et al. 2003; Wooldridge et al. 2003; 
Wooldridge et al. 2006). The currently proposed models of TCR association with pMHC and 
how this leads to T cell activation are discussed in section 1.4.5.
1.4.3b Kinetics of the pMHCI/CD8 and pMHCII/CD4 interactions
SPR analysis of the human pMHCI/CD8  interaction has revealed that the affinity of this 
interaction is very low (Ko  ^ 90-220 pM) (Figure 1.3), and is similar for both homodimeric 
and heterodimeric forms of CD8  (Gao et al. 2000; Garcia et al. 1996; Wyer et al. 1999). 
However, the pMHCI/CD8  interaction displays some interesting kinetics as the dissociation
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of CD8 (aa) from the prevalent pMHCI allele HLA A2 is extremely rapid (K0ff > 18s) (Wyer et 
al. 1999). As a result, the duration of a single TCR/pMHCI interaction can encompass many 
pMHCI/CD8  association and dissociation events. The MHCII/CD4 interaction is much weaker 
(Kd > 200 pM) than the MHCI/CD8  interaction, making its kinetics difficult to measure 
accurately by SPR (Xiong et al. 2001).
1.4.4 Overview of T cell activation 
1.4.4a The immunological synapse
In addition to the coreceptor (CD8  or CD4), the antigen specific ot(3 TCR is present on the T 
cell surface in association with the CD3 complex composed of four invariant accessory 
subunits present in the ratio y6 £2k  (van der Merwe and Davis 2003; Weiss and Littman 
1994). The main role of the CD3 machinery is to transduce signals to the interior of the cell 
when the TCR makes contact with cognate pMHC (Salmond et al. 2009). T cell activation 
also involves a host of antigen independent cell-cell interactions including CD2 (LFA-2), 
CD40L, LFA-1, and CD28 located on the T cell surface, which contact CD58 (LFA-3), CD40, 
ICAM-1, and CD80 (B7.1)/CD86 (B7.2) on the surface of APCs, respectively. Collectively, the 
interactions act to strengthen T cell-APC contact and regulate T cell activation (Bennett et 
al. 1998; Jenkins et al. 1991). Whereas effector and memory subsets of T cells that have 
previously come into contact with antigen can become activated relatively independently of 
the co-stimulatory signals provided by these extra interactions, naive T cells that have never 
encountered antigen require costimulation. On encounter of an APC, a T cell initiates a 
process of cell surface molecular rearrangement culminating in the formation of organised 
cell-cell interfaces termed 'immunological synapses' or supramolecular activation clusters 
(SMAC) (Grakoui et al. 1999). The SMAC is organised into: i) a central area (cSMAC) in which 
the TCR-CD3 complex, its coreceptors CD8/CD4 and the costimulatory protein CD28 are 
positioned for optimal interaction with pMHC, CD80 and CD8 6  on the APC; and, ii) a 
peripheral area (pSMAC) where LFA-1, CD43, CD45, and ICAM-1 are sequestered. These 
latter molecules located in the pSMAC regulate the activity initiated by the cSMAC 
members. Although SMACs have taught immunologists a great deal about the mechanisms 
involved in T cell-antigen recognition, these types of structures are generally only observed
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when very high peptide concentration (> 100 pM) are presented (Monks et al. 1998). Such 
antigen densities are unnatural, and 'real' activation in vivo occurs at much lower antigen 
densities (as few as ~ 10 pMHC copies per cell) (Irvine et al. 2002; Purbhoo et al. 2004; 
Valitutti et al. 1995). Furthermore, the formation of a SMAC can take several hours and 
requires for the T cell to be stationary in relation to the APC (lezzi et al. 1998). With the 
availability of increasingly more powerful imaging techniques, it was observed that T cells 
interact with their target APCs in a dynamic manner (Miller et al. 2004; Miller et al. 2002). In 
a process called 'serial triggering', a single T cell is able to sequentially interact with several 
APCs (Valitutti et al. 1995). This ensures that T cells are highly efficient at recognising and 
responding to their target APCs even at very low effector to target ratios. As a result of low 
levels of antigenic peptide presentation and the dynamic and rapid nature of T cells/APC 
interactions, it is likely that the immunological synapse does not involve the formation of a 
SMAC, but smaller more transient versions of such structures.
1.4.4b The TCR/CD3 complex
In resting cells, the CD3£ subunit exists in a partially phosphorylated state. However on 
productive engagement of pMHC by the TCR and CD4/CD8 coreceptor couple, special 
tyrosine residues located in regions of the CD3e and CD3^  subunits known as the 
immunoreceptor tyrosine-based activation motifs (ITAMs) become fully phosphorylated by 
a member of the Src family of tyrosine kinases called Lck (Barber et al. 1989). The 
phosphorylation of CD3  ^ takes place in a series of ordered steps, all of which must be 
completed for full T cell activation (Kersh et al. 1998). Each step of the phosphorylation 
process represents a checkpoint, progression through which is related to the ability of a 
particular pMHC ligand to activate a given TCR. Therefore, any factor that influences the 
multistep CD3£ phosphorylation process will affect the outcome of TCR engagement (Kersh 
et al. 1998).
1.4.4c The protein tyrosine kinase Lck
Early phosphorylation events triggered by TCR engagement of foreign pMHC is mediated by 
protein tyrosine kinases (PTKs). PTKs are grouped into families: Src or Syk, which differ
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structurally (Chan et al. 1994). The aforementioned Lck is a Src PTK, and is expressed 
abundantly in T cells. Structurally, Lck is similar to other members of the Src family and 
contains three Src homology (SH) domains designated SHI-3. SHI is a protein tyrosine 
kinase domain with intrinsic ATPase activity and an autophosphorylation site at residue 394. 
Phosphorylation of tyrosine-394 is thought to initiate the phosphorylation events of the T 
cell signalling cascade (Abraham and Veillette 1990). The SH2 and SH3 domains mediate 
protein-protein contacts between phosphotyrosine-containing motifs (Fantl et al. 1992). 
The termini of Lck also have important roles. The amino terminus of Lck remains associated 
with the plasma membrane (Resh and Ling 1990) and interacts with CD8 /  CD4 coreceptors 
(Shaw et al. 1990), whilst the carboxyl terminus of Lck contains a negative regulatory 
tyrosine at position 505, the phosphorylation of which inactivates Lck (Veillette et al. 1988; 
Weiss and Littman 1994). The PTK Csk is responsible for the phosphorylation of the 
tyrosine-505, and consequently inhibition of Lck (Chow and Veillette 1995). Lck is positively 
regulated by the tyrosine phosphatase CD45, the most abundant glycoprotein expressed on 
the surface of T cells (Thomas 1989). CD45 is found associated with Lck in resting T cells 
(Guttinger et al. 1992). On TCR/pMHC engagement, CD45 releases Lck by dephosphorylating 
the negative regulatory phosphate on tyrosine-505 (Ostergaard and Trowbridge 1990). 
Chapter 5 of this thesis investigates how inhibition of Lck by a PTK inhibitor dasatinib can be 
exploited to improve the detection of low avidity T cells with pMHC tetramers.
1.4.4dT cell signal transduction cascade
A productive engagement of a TCR with its cognate pMHC and an interaction between 
pMHC and CD8/CD4 coreceptors results in the activation of Src kinases Lck and Fyn (Weiss 
and Littman 1994). Phosphorylation of CD3  ^ITAM motifs by these kinases provides docking 
sites for downstream signalling elements (Nel 2002; Nel and Slaughter 2002). The Syk family 
PTK zeta chain-associated protein of 70 kD (ZAP-70) subsequently binds to the CD3 complex 
via the phosphotyrosine motifs, and is in turn phosphorylated by Lck (Chan et al. 1995). On 
activation, ZAP-70 acquires the ability to recruit and activate adaptor proteins which 
possess no intrinsic enzymatic activity but are responsible for bringing together members of 
the signalling cascade that would not associate with each other if left unaided (Myung et al.
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2000). One of the most important adaptor proteins in the signalling cascade is the linker for 
activation in T cells (LAT). LAT is an integral membrane-associated protein whose principal 
function is to recruit downstream signalling proteins including Grb2, PLC-yl, Cbl, SOS, Vav, 
and SLP-76, thus linking extracellular TCR/pMHC engagement to intracellular signals. LAT 
interacts with these signalling proteins via its 1 0  tyrosine residues, which once 
phosphorylated by ZAP-70 can bind to SH2 domains of proteins found downstream in the 
signalling cascade (Zhang et al. 1998). At this stage the signal transduction pathway 
branches out into secondary pathways, but it ultimately culminates in the nucleus, where 
transcription factors such as NF-kB, NFAT, and AP-1 are activated (Kuo and Leiden 1999; 
Myung et al. 2000). Activation of these and other transcription factors elicits novel patterns 
of gene expression and results in proliferation, differentiation, and effector functions.
1.4.5 TCR triggering and models of T cell activation
Although we are starting to piece together the details about molecular interactions that 
take place on TCR association with pMHC antigen, we do not yet fully understand how the 
TCR transduces signals across the plasma membrane, a process referred to as TCR 
triggering. The central conundrum in TCR triggering is how the engagement of TCR with 
antigen leads to ITAM phosphorylation. Despite numerous publications on the subject, no 
unanimous consensus has thus far been reached. However, three basic categories of TCR 
triggering models have been proposed, the key features of which are outlined below:
1.4.5a Aggregation models
The notion behind this group of models stems from observations that aggregation of TCRs 
by antibody or pMHC multimer binding is sufficient to initiate TCR triggering (Qian and 
Weiss 1997; Weiss and Littman 1994). According to aggregation models, TCR triggering is 
thought to occur by increasing the proximity of the TCR/CD3 complex to signalling 
molecules such as the Src kinases Lck and Fyn (Boniface et al. 1998; van der Merwe 2001). 
The models rely on the fact that either specific pMHC molecules exist on the antigen 
presenting cell in high numbers, or that cognate pMHC are able to form dimers with self- 
pMHC. Reports that a single specific pMHC is sufficient to induce TCR triggering (Irvine et al.
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2002; Purbhoo et al. 2004), and limited evidence for the existence of covalent pMHC 
heterodimers have put serious doubt on the plausibility of aggregation models. However, a 
possibility remains that TCR aggregation could amplify triggering initiated by other 
mechanisms (Minguet et al. 2007).
1,4.5b Conformational change models
Conformational change models propose that on ligation of cognate pMHC, the TCR 
undergoes a structural conformational change that is propagated to the CD3 complex, 
initiating the tyrosine phosphorylation events. Although there was some initial evidence for 
such a conformational change (Gil et al. 2002), analysis of a large number of TCR/pMHC 
structures has conclusively shown that TCR binding to pMHC is not accompanied by any 
consistent conformational change within the TCR that could lead to signal transduction 
(Rudolph et al. 2006). Van der Merwe and colleagues have recently postulated that because 
pMHC and TCR/CD3 are anchored in the plasma membrane of two distinct cells, the binding 
of pMHC may exert a pulling force on the TCR, which could change its orientation with 
respect to the CD3 subunits (Choudhuri and van der Merwe 2007). Although plausible, it is 
not certain whether the TCR/pMHC interaction is sufficiently strong or long-lived to 
generate the forces required for this to happen.
1.4.5c Segregation models
Two types of model fall into this category: i) the kinetic segregation model; and, ii) the lipid 
raft model.
i) Kinetic segregation model
The kinetic segregation model postulates that the immunological synapse is organised into 
multiple zones, with some zones being devoid of molecules with large ectodomains, such as 
the inhibitory tyrosine phosphatases. Trapping of TCR/CD3 in these zones results in the 
constitutive phosphorylation of CD3 ITAMs by Src kinases, potentially leading to TCR 
triggering (Davis and van der Merwe 1996). The model is supported by a number of key 
observations including that: i) inhibitory phosphatases segregate from areas of TCR
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triggering (Lin and Weiss 2003); ii) truncation of phosphatase ectodomains inhibits TCR 
triggering (Irles et al. 2003); and, iii) elongation of the pMHC complex inhibits TCR triggering 
(Choudhuri et al. 2005). However the evidence does not establish whether the environment 
within these zones is alone sufficient to induce TCR triggering.
ii) Lipid raft model
The lipid raft model proposes that TCR binding to pMHC leads to TCR association with lipid 
rafts, which are areas of the plasma membrane enriched in molecules associated with TCR 
signal transduction such as Lck (Kabouridis et al. 1997), Fyn (van't Hof and Resh 1999), LAT 
(Zhang et al. 1998b), and the coreceptors CD4 (Crise and Rose 1992) and CD8  (Arcaro et al. 
2000). A key piece of evidence in support of the lipid raft model of T cell activation is the 
fact that the CD8  coreceptor (5 chain is selectively palmitoylated (Arcaro et al. 2000). As a 
consequence, CD8  ap (but not CD8  aa) is responsible for recruiting the TCR to the lipid 
rafts, where it co-localises with Lck. In a similar fashion: i) Fyn has been shown to associate 
preferentially with CD3 in lipid rafts (van't Hof and Resh 1999); and, ii) the formation of 
dipalmitoylated CD4/Lck complexes was demonstrated in CD4+ T cells (Maroun and Julius 
1994). The recruitment of TCRs to these rafts is predicted to lead to phosphorylation of 
TCR/CD3 ITAMs and ultimately TCR triggering. Although a substantial body of evidence 
supporting the role of lipid raft localisation in TCR signalling has been published (reviewed in 
(Horejsi 2005)), a greater number of studies have challenged these claims (Glebov and 
Nichols 2004; Zhu et al. 2005).
A number of other models have been proposed to address the important question of how a 
relatively small number of agonist pMHC molecules can trigger a much larger number of 
TCRs (Valitutti et al. 1995). The principles behind two favoured models are summarised 
below:
1.4.5d Serial triggering model
The serial triggering model postulates that each 'foreign' pMHC serially engages many TCRs, 
one after another (Valitutti and Lanzavecchia 1997). The model is consistent with the short­
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lived nature of the majority of TCR/pMHC interactions and dictates a requirement for an 
optimal half-life for a given TCR/pMHC complex. Interactions with half-lives exceeding this 
optimum are predicted to be less effective. The serial triggering model therefore predicts 
that there exists an 'affinity ceiling' for TCR/pMHC interactions beyond which T cell 
activation will become less efficient (Sewell 2002). Schmid et al. have recently tested this 
hypothesis and concluded that above a defined TCR affinity threshold, T cell avidity and 
function were not further enhanced (Schmid et al. 2010). These findings imply that TCRs 
may not need to be optimised beyond a given affinity threshold to achieve best 
functionality.
1.4.5e Kinetic proofreading model
The kinetic proofreading model proposes that TCR signalling goes through a series of 
sequential steps, the completion of which is essential for full activation. On dissociation of 
the antigen, these steps are fully reversed (McKeithan 1995; Rabinowitz et al. 1996). To 
summarise, despite the extensive amount of research effort dedicated to studying the 
events that take place following TCR/pMHC engagement and preceding T cell activation, the 
process of TCR triggering remains poorly understood. And although experimental evidence 
supports some of the models described here better than others, it is likely that these 
models are not mutually exclusive. In view of this, the true mechanism of TCR triggering 
may encompass aspects of several of the models described.
1.5 Glvcosvlation and T cell antigen recognition
Nearly all mammalian cell surface proteins are terminally modified by glycosylation. These 
cell surface oligosaccharides have many roles, the importance of which becomes apparent 
in cases where the glycosylation pathway is disrupted (Schachter and Freeze 2009). Glycans 
regulate lateral mobility of proteins in the plasma membrane, influence protein-protein 
interactions, and mediate organisation of proteins into domains (Baum 2002). Glycosylation 
is also extremely important for cells of the immune system, where carbohydrate 
interactions can influence lymphocyte development, migration and responsiveness (Daniels
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et al. 2002). For instance, early studies with carbohydrate-binding plant lectins have 
demonstrated that the cell surface glycosylation profile for a T cell changes dramatically 
during thymocyte development (Despont et al. 1975; Pink 1983; Reisner et al. 1976). More 
specifically, the maturation of thymocytes coincides with increased expression of terminal 
negatively-charged sialic acid residues (Baum et al. 1996; Gillespie et al. 1993; Reisner et al. 
1976). In addition to the mass restructuring of glycans during T cell development in the 
thymus, mature T cells experience changes in glycosylation of cell surface proteins during 
activation and on transition into the memory state (Galvan et al. 1998; Harrington et al. 
2000). Thus, the extent of protein modification by glycosylation fluctuates throughout the 
lifetime of a lymphocyte, and this remodelling of cell surface carbohydrate is accompanied 
by changes in T cell antigen sensitivity (Brennan et al. 2006; Daniels et al. 2002; Galvan et al. 
1998; Garcia et al. 2005; Garcia and Miller 2003; Lowe 2001; Pappu and Shrikant 2004). 
Chapter 7 of this thesis explores the potential of altering the level of cell surface 
glycosylation to enhance T cell sensitivity to antigen.
1.6 pMHC multimers as tools for the detection, characterisation and isolation of T cells
The TCR/pMHC interaction is weak and typically lasts only a matter of seconds at 
physiological temperatures, making soluble pMHC monomers inadequate reagents for the 
detection and characterisation of specific T cell responses. A pioneering study by John 
Altman and colleagues presented a means of extending the life-time of the TCR/pMHC 
interaction by multimerizing soluble pMHC molecules (Altman et al. 1996). These first pMHC 
'tetramers' consisted of four pMHC molecules around an avidin-biotin scaffold (O'Callaghan 
C et al. 1999), and are still the most common form of pMHC multimer used to date. 
Although different manufacturing techniques are employed by different research groups, 
pMHC tetramers are essentially assembled from soluble biotinylated pMHC monomers 
complexed with fluorochrome-conjugated avidin or streptavidin molecules in a 4:1 ratio.
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1.6.1 The avidity effect
In physical terms, affinity can be described as the strength of the reaction (or bond) 
between a single antigen and its specific receptor, comprising the sum of the attractive and 
repulsive forces operating between these two entities. In contrast, the avidity of a 
multimeric interaction is a measure of the overall strength of binding between each antigen 
and its cognate receptor. If affinity describes the strength of a single bond, than avidity 
equates to the combined synergistic strength of multiple bond interactions, which is greater 
than the sum of the individual affinities. In the biological setting, avidity is a property of 
molecules with multiple binding sites, where it refers to the combined affinities of each of 
the binding sites for their respective ligands. Measurement of monomeric and multimeric 
TCR/pMHC interactions by surface plasmon resonance (SPR) has demonstrated that the 
avidity for a set of interactions far exceeds the sum of the contributing affinities (Laugel et 
al. 2005). This 'avidity effect' arises because the probability of all monomeric interactions 
dissociating simultaneously is exceedingly small. With respect to pMHC tetramers, three of 
the four pMHC arms are capable of engaging surface TCRs simultaneously (McMichael and 
O'Callaghan 1998), greatly reducing the probability of complete pMHC tetramer dissociation 
even if one of the TCR/pMHC contacts is momentarily disrupted (Figure 1.4). The avidity 
effect extends the half-life of TCR/pMHC interactions from seconds (as monomer) to several 
hours (as tetramer), making them extremely useful tools for specific surface staining of T 
cells in a variety of laboratory and increasingly clinical applications. However, the avidity 
effect does not come into play for all pMHC multimer binding events as it relies on the 
duration of the monomeric TCR/pMHC interaction. To take advantage of the avidity effect, 
the first monomer or 'arm' of the pMHC multimer must associate with a cognate TCR for 
long enough to enable a second pMHC 'arm' to bind a second TCR. A TCR/pMHCI 
interaction of Kd £ 40 pM is required to observe good pMHC tetramer staining using 
standard techniques (Laugel et al. 2007). The on-rate of the initial TCR/pMHC interaction is 
also critical, as it determines the probability of a second TCR/pMHC interaction taking place. 
Engagement of two or more pMHC monomers within a given pMHC multimer is believed to 
determine whether the molecule is captured from solution (Wooldridge et al. 2009; 
Wooldridge et al. 2005). As described in the next section, the likelihood of a pMHC multimer
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pMHCI TetramerCytotoxic T cell
Phytoerythrin
Streptavidin
pMHCI
Cytotoxic T Cell Surface
Figure 1.4: A tetramer binding to cognate TCR/CD8  complexes. pMHCI tetramers consist 
of four biotinylated peptide-HLA complexes bound to a single streptavidin molecule, 
conjugated to a fluorescent dye. Tetramerisation extends the half lives of TCR/pMHCI 
interactions from seconds to several hours due to 'avidity'; a multiple of the binding 
affinities of individual monomers. Avidity arises because the probability of all monomeric 
TCR/pMHCI interactions dissociating simultaneously is significantly reduced. Each 'arm' of 
the tetram er will undergo a large number of dissociation/association events before the 
te tram er eventually drops off the surface of the CD8+ T cell.
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binding to the surface of a T cell is greatly dependent on the density of surface TCRs as well 
as their distribution within the lipid bilayer (Wooldridge et al. 2009).
1.6.2 The importance of staining conditions
The ability of a given pMHC multimer to stain a particular T cell depends on a number of 
factors, which can be adjusted to increase the staining efficiency:
1.6.2a Concentration
i) pMHC concentration:
Increasing the concentration of pMHC multimer is especially beneficial for weak TCR/pMHC 
interactions. However, care must be taken to ensure that the increase in specific pMHC 
multimer staining is not accompanied by concomitant increases in background staining.
ii) TCR concentration:
It is a known fact that the amount of surface TCR can fluctuate dramatically throughout a T 
cell's lifetime ((Drake et al. 2005; Xiao et al. 2007) and unpublished). It has been shown that 
large increases in surface TCR concentration are achieved by incubating T cells with a 
reversible protein tyrosine kinase inhibitor called dasatinib for 3 hours (Weichsel et al.
2008). In Chapter 5 of this thesis I evaluate how the treatment of T cells with dasatinib and 
other similar reagents leads to a substantial improvement in specific T cell staining with 
pMHC tetramers.
1.6.2b Temperature
At physiological temperatures, pMHC multimers that have productively engaged TCRs on 
the surface of a T cell are rapidly internalised into endocytic vesicles (Whelan et al. 1999). 
The trapped pMHC multimers can no longer dissociate from the T cell surface, meaning that 
performing staining at 37°C is particularly beneficial for weak TCR/pMHC interactions with 
short binding half-lives. T cell homeostasis is slower at low temperatures (4°C), which 
greatly reduced the internalisation of TCR-bound pMHC multimers (Whelan et al. 1999). 
Thus at low temperatures, the staining intensity depends wholly on the surface-bound
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pMHC multimers and consequently the ability of these reagents to remain in association 
with surface TCR. Since pMHC multimer-induced TCR triggering is toxic to T cells, processes 
where pMHC multimers are used to isolate or sort cells for culturing or cloning are typically 
performed at low temperatures (Cebecauer et al. 2005).
1.6.2c Duration of staining
While pMHC tetramers typically display very rapid association kinetics and are able to attain 
their optimal staining intensity after a few minutes, other pMHC multimeric reagents such 
as dextramers (see Chapter 4) require longer incubation periods.
1.6.26 Anti-coreceptor antibody
Staining with pMHC multimers is generally performed in conjunction with antibodies 
specific for various cell-surface markers. Some of these antibodies, and in particular anti- 
CD8  and anti-CD4 antibodies, have disruptive effects on pMHC multimer staining 
(Wooldridge et al. 2003; Wooldridge et al. 2006). The hindering effect of certain antibodies 
can be overcome by staining with pMHC tetramers before the addition of antibodies 
(Whelan et al. 1999; Wooldridge et al. 2003; Wooldridge et al. 2006), or by using non­
blocking/enhancing coreceptor antibodies ((Wooldridge et al. 2003) and Clement et al. 
submitted).
1.6.3 pMHCI versus pMHCII multimers
The use of pMHCII multimers is less widespread than the use of pMHCI multimers, largely 
due to the TCR/pMHCII interaction being substantially weaker than TCR/pMHCI binding 
(Cole et al. 2007). In addition, the CD4 coreceptor does nothing to enhance TCR/pMHCII 
binding (Boniface et al. 1998; Crawford et al. 1998; Hamad et al. 1998) in contrast to the 
way CD8  stabilises the TCR/pMHCI interaction (Choi et al. 2003; Laugel et al. 2007; Pittet et 
al. 2003). Both of these factors explain why the majority of TCR/pMHCII associations fall 
below the affinity threshold required for tetramer staining.
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1.6.4 Higher valency pMHC multimers
Although the pMHC tetramer is the most popular form of pMHC-based reagent, and is 
considered optimal for the detection of T cells by flow cytometry and fluorescence 
microscopy, other valencies of pMHC have been explored. The efficiency of lower (dimers) 
and higher (pentamers, octamers, and pMHC-coated magnetic beads) valencies of pMHC 
have been demonstrated by a number of groups (Bakker and Schumacher 2005; Buslepp et 
al. 2001; Ogg et al. 1999). In addition to my work with pMHC tetramers, I evaluate the 
merits of a novel type of pMHC multimer called a dextramer. Dextramers comprise large 
numbers of pMHC monomers bound to streptavidin molecules arranged around a dextran 
polymer scaffold laden with multiple copies of a fluorochrome. Whether the higher valency, 
the predicted conformational freedom of pMHC molecules, or the large number of 
fluorochrome moieties per reagent offer some advantage over standard pMHC tetramers in 
the labelling of T cells is explored in Chapter 4 of this thesis.
1.6.5 Applications of pMHC multimers 
1.6.5a Grading T cell responses
It has been shown that T cells within a population primed to respond to a particular antigen 
display intrinsically different sensitivities to that antigen (Alexander-Miller 2000; Alexander- 
Miller et al. 1996). Numerous studies have subsequently demonstrated that T cells capable 
of recognising very low antigen densities are more effective than their less sensitive 
counterparts at eliminating tumours and virally-infected cells in vivo (Alexander-Miller et al. 
1996; Dutoit et al. 2001; Sedlik et al. 2000; Yee et al. 1999; Zeh et al. 1999). In view of this, it 
is becoming increasingly accepted that the quality of T cells responding to an antigen is as 
important as their quantity. Assessing the quality of a responding T cell population is of 
outmost significance in adoptive T cell therapy, where the antigen sensitivity and 
functionality of T cells can greatly influence the outcome of the therapy. pMHC multimers 
have become invaluable tools for 'grading' the quality of antigen-specific T cell populations 
for clinical and laboratory applications.
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1.6.5b Specific sorting and cloning of Tcells
The purity of a T cell population responding to a particular antigen can be increased by sort- 
cloning pMHC-labelled T cells. However, care must be taken to minimise the toxic effects of 
pMHCI multimers (Cebecauer et al. 2005a). Most cell sorting protocols recommend 
reducing staining times in addition to performing the staining at low temperatures (see 
Section 1.6.2b).
1.6.5c T cell activation
Soluble pMHC multimers have been used to examine the activation requirements of T cells. 
Importantly, pMHC multimer-induced activation has enabled the study of TCR/pMHC and 
pMHC/coreceptor interactions in isolation without altering the kinetics of these interactions 
that is inherent to studies using antibodies targeting these components.
1.6.5d Identification and isolation of anti-tumour, anti-viral, and autoreactive T cells ex 
vivo
Both adoptive T cell therapy (Section 1.8.2) and TCR gene transfer therapy (Section 1.8.3) 
rely on the availability of specific T cell populations, which can be isolated from individuals 
by means of pMHC multimer sorting. The apparent correlation between pMHC tetramer 
staining and monomeric TCR/pMHC interaction affinity (Laugel et al. 2007) suggests that, in 
general, it will be more difficult to stain T cells specific for tumour-associated and self­
antigens compared to T cells directed against viral antigens. In view of this, improvements in 
the pMHC multimer staining efficiency are urgently needed. Furthermore, persistent viral 
infection often results in the exhaustion of T cell populations (Oxenius et al. 2002). In such 
cases, pMHC multimers allow the identification of T cells that express the antigen-specific 
TCR but are no longer capable of making an immune response (Barnes et al. 2004). Isolation 
of these cognate TCR genes and their subsequent transfer to autologous T cells restores 
their functionality, and constitutes an important aspect of TCR gene transfer therapy.
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1.6.5e Manipulation of T cells in vivo
Soluble pMHC multimers might be useful for suppressing unwanted T cell responses or for 
boosting desirable responses in vivo. Published examples of pMHC multimers include: the ex 
vivo removal of alloreactive T cells before transplantation (Kappel et al. 2006), the deletion 
of autoimmune T cells for the prevention of diseases such as type I diabetes (Casares et al. 
2002; Masteller et al. 2003) and arthritis (Zuo et al. 2002), and the priming of beneficial T 
cell responses in vivo (Maile et al. 2001). New generations of 'suicide' pMHC multimers, 
coupled to radioactive isotopes or biological poisons are also being developed with 
therapeutic implications (Hess et al. 2007; Yuan et al. 2004).
1.7 The role of CD8* T cells in the recognition and eradication of virallv-infected and 
tumour cells
The immune system has evolved to respond primarily to foreign pathogens. While CD8 + T 
cells effectively target and eradicate acute viral infections, the persistence of foreign 
antigens encountered in chronic viral infection results in a dysfunctional immune response. 
Furthermore, many pathogens associated with chronic viral infection display variable 
antigenicity profiles and employ multiple evasion techniques to escape immune detection. 
In contrast, cancer; a disease of the developed world associated with an increasingly aging 
population, represents a relatively new challenge for the immune system. The poor 
immunogenicity of tumour-associated antigens, the immunosuppressive tumour 
microenvironment, and the low frequency of functional tumour-reactive T cells result in 
inefficient cancer targeting. In this section, I describe the various challenges faced by the 
CD8 + T cell response in the eradication of chronic viral pathogens and tumour-transformed 
cells, while the subsequent section (1 .8 ) deals with the therapeutic methods employed to 
overcome the immunological barriers presented by these diseases.
1.7.1 Viral infections
The adaptive immune response has developed an elegant strategy for the detection and 
eradication of host cells infected with pathogenic viruses. The key event in this battle
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against infection is the recognition of viral peptide fragments presented in the context of 
MHC class I molecules, by CD8 + T cells. In response to pressures from the immune response, 
viruses have in turn evolved ingenious evasion strategies.
1.7.1a Problems associated with viral antigen recognition
The majority of the mechanisms by which viruses are able to trick the host's immune 
defences involve the mutation of their genomes to prevent or alter the display of viral 
antigens via the MHCI antigen presentation pathway. Examples of viruses targeting stages 
of the MHCI antigen presentation pathway are summarised in Table 1.1 (Hansen and 
Bouvier 2009). Since the work described in this thesis deals primarily with HIV infection, 
reference to other viral pathogens will be kept to a minimum.
The detection of cells infected with a family of viruses called retroviruses poses a particular 
challenge for CD8 + T cells. Retroviruses are exemplified by the human immunodeficiency 
virus (HIV). HIV is responsible for inducing acquired immunodeficiency syndrome (AIDS), 
one of the most destructive diseases in human history. AIDS develops following depletion of 
CD4+ T cells as they become infected with HIV. The majority of AIDS patients die due to the 
inability of the weakened immune system to control opportunistic infection. The 
devastating nature of retroviruses such as HIV stems primarily from their single-stranded 
RNA genomes, which are much more prone to spontaneous mutagenesis than the double- 
stranded DNA genomes of other common viruses that target human cells. Thus, in addition 
to employing non-mutational strategies of escape such as the Nef-mediated 
downregulation of MHCI, HIV can mutate to disable or alter presentation of peptide antigen 
on MHCI molecules. For instance, the virus can mutate epitopes that are normally available 
for presentation to anti-viral T cells in a way that interferes with recognition by their TCRs. 
In some cases however, by mutating to escape from a CD8 + T cell response a virus can incur 
significant structural or functional penalties. With respect to HIV, studies of both the simian 
immunodeficiency virus (SIV) model and of natural HIV infection have shown that the virus 
loses 'fitness' whilst attempting to escape from certain CD8 + T cell responses (Crawford et 
al. 2007; Friedrich et al. 2004; Leslie et al. 2004). Furthermore, HIV-infected individuals
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whose CD8 + T cells target the virus through these epitopes show improved viral clearance 
and have longer life expectancy (Leslie et al. 2004). Such studies have set forth the analogy 
of viruses such as HIV to 'walking a tightrope' by balancing the need to escape from the host 
CD8 * T cell response with the need to preserve 'fitness'.
Virus Effect on MHCI antigen presentation pathway
Epstein-Barr virus 
(EBV)
EBV nuclear antigen 1 (EBNA1) acts as a proteasomal processing 
inhibitor.
Herpes simplex 
virus (HSV)
HSV protein ICP47 prevents transport of viral protein into the ER for 
processing by blocking peptide binding to TAP.
Human
cytomegalovirus
(HCMV)
HCMV protein US6  prevents transport of viral protein into the ER 
for processing by inhibiting ATP binding to TAP.
Adenovirus Adenovirus protein E3-19K retains peptide-loaded MHCI molecules 
in the ER.
Human
cytomegalovirus
(HCMV)
HCMV proteins US2 and US11 target MHCI molecules for 
degradation by the proteasome.
Kaposi's sarcoma- 
associated virus 
(KSHV)
KSHV proteins kK3 and kK5 induce rapid endocytosis of cell surface 
pMHCI molecules into lysosomal vesicles for degradation.
Human
immunodeficiency 
virus (HIV)
HIV protein Nef downregulates pMHCI molecules from the cells 
surface.
Table 1.1: Examples of viral evasion by targeting the pMHC class I antigen presentation 
pathway.
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Currently, the most widely used treatment for HIV infection is the administration of highly 
active anti-retroviral therapy (HAART). Modern HAART regimens are combinations (or 
'cocktails') comprising at least three anti-retroviral agents; inhibitors targeting reverse 
transcriptase and protease enzymes, which are essential for retroviral replication. In light of 
the fact that CD8 + T cells play a vital role in the detection and eradication of virally-infected 
cells, recent therapeutic developments have focused on supplementing the patients' own 
immune system with CD8 + T cells targeting HIV-derived epitopes. The numerous means by 
which this can potentially be achieved are outlined in Section 1.8.
1.7.2 Cancer
Cancer is one of the leading causes of death in industrialised nations, and is likely to become 
the most fatal disease threatening humanity as our average life expectancy increases in the 
near future. Cancer arises when the checkpoints monitoring cellular replication, growth, 
and/or death are no longer properly regulated due to mutations affecting the proteins 
involved in these key processes. Generally, a healthy cell must accumulate approximately 6  
mutations targeting different aspects of cell metabolism, homeostasis and physiology 
before malignant growth occurs, permitting a cancerous tumour to develop (Hanahan and 
Weinberg 2000). Curing cancer is a challenging prospect that requires the destruction of 
every malignant cell whilst minimising the toxicity to the host's healthy tissues. An attractive 
way of eradicating cancer would be to induce an immune response to selectively target the 
tumour without inducing autoreactivity.
A functional relationship between cancers and the immune system was proposed as early as 
1863, when an infiltration of leukocytes was detected in an excised tumour (Virchow 1863). 
Since then, our increased understanding of immune cell function has reinforced these initial 
speculations about the involvement of the immune response in the prevention and 
clearance of cancer. The recognition and eradication of cancer cells by the immune system 
is termed cancer immunosurveillance (Smyth et al. 2001). As key mediators and effectors of 
the adaptive immune response, T cells were proposed to play a critical role in the control of 
malignant cell growth. Evidence that T cells can help control tumour development was
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demonstrated by reports of tumour prevalence in individuals with HIV-induced 
immunodeficiency (Goedert 2000) and incidence of carcinogen-induced tumours in 
immunosuppressive mouse models (Shankaran et al. 2001). Further evidence that 
manipulation of the immune response (and in particular T cells) can cause the regression of 
established tumours came from a study in which the cytokine interleukin-2 (IL-2) was 
administered to patients with metastatic kidney cancer or melanoma (Rosenberg et al. 
1985). IL-2 is an immune regulator produced by CD4+ T-helper cells, and is responsible for 
large-scale expansion of effector CD8+ T cells. Since IL-2 has no direct effect on the viability 
of malignant cells alone, its anti-tumour effect in vivo was attributed to the expansion of 
CD8+ T cells with tumour-lytic activity.
In view of this, the modern approach for the treatment of cancer has attempted to distance 
itself from systemically toxic conventional treatments such as chemotherapy, in favour of 
engaging the immune response. Unfortunately, efforts to launch a therapeutic response by 
the patient's immune system have not been entirely successful. In the recombinant IL-2 
administration study for instance, although regression of tumours was observed, the typical 
response rate was low (~8% complete response, and ~9% partial response in a study of 409 
kidney cancer and melanoma patients) (Rosenberg et al. 1998). Furthermore, the 
magnitude of the response varied from patient to patient (Rosenberg et al. 1998). Since 
then, better understanding of the molecular basis of tumour-host interactions has provided 
some explanations for the limitations of the immune system in the fight against cancer.
1.7.2a Problems associated with cancer antigen recognition
Malignant tumours exhibit a variety of highly sophisticated tricks for evading attack from T 
cells:
1) Establishment of an immunosuppressive tumour microenvironment; the tumour can 
tolerise T cells to evade T cell recognition by the following mechanisms:
i) Downregulation of some MHC class I alleles for low surface antigen presentation.
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ii) Reduction in expression of co-stimulatory signals by the tumour cells, which can 
result in anergy or deletion of naive T cells on exposure to antigen.
iii) Manipulation of immune cells by secretion of immunosuppressive chemokines 
and cytokines such as transforming growth factor-fj (TGF-0).
iv) Recruitment of regulatory T cells (Tregs) into the tumour microenvironment.
v) Tissue remodelling; solid tumours can provide a physical barrier for the infiltration 
of T cells and APC.
vi) Induction of hypoxia (oxygen deprivation) within regions of the tumour has been 
shown to inhibit CD8+ T cell-dependent cytotoxicity (Hamai et al. 2010).
2) Selection pressure mounted by the immune response can encourage the persistence of 
malignant cells that have altered their antigenic profile to avoid T cell-mediated recognition 
(Chouaib et al. 1997).
1.7.2b Thymic deletion of autoreactive T cells during the process of negative selection
A further great concern in tumour immunology is a shortage of suitable candidates to act as 
tumour antigens and the subsequent lack of T cells that can recognise them. As mentioned 
previously, tumours arise due to the malignant transformation of healthy cells, meaning 
that the majority of processed antigen presented in the context of MHCI molecules on the 
tumour cell surface is identical to self-antigens presented by healthy cells (Rosenberg 2001). 
Recognition of self-antigens by T cells would result in autoimmunity, a condition that the 
immune system has developed strategies to minimise. Tolerance to self-antigens is built up 
by thymic deletion, whereby thymocytes recognising self-peptides undergo apoptosis (Nitta 
et al. 2008; Surh and Sprent 1994). This process of negative selection is highly dependent on 
both the strength of the TCR/pMHC interaction and the amount of antigen presented in the 
thymus (Ashton-Rickardt et al. 1994; Sebzda et al. 1994). These restrictions enable T cells 
with TCR/pMHC interactions below a certain affinity threshold to leave the thymus and 
enter the periphery (Liu et al. 1995; Oehen et al. 1994). A T cell repertoire that has been 
shaped by such a mechanism of self-tolerance contains few tumour-reactive T cells, and 
those that do graduate into the periphery generally display low affinities for cognate
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antigen (Kisielow et al. 1988). For instance, many common tumour-associated self-antigens, 
including NY-ESO-1- and MAGE-A3-derived epitopes (see Table 1.2), have been found 
expressed in the thymus (Gotter et al. 2004). Any T cells responding to these antigens are 
thus subject to thymic tolerance mechanisms, explaining the low frequency of NY-ESO-1- 
and MAGE-A3-specific T cells in the periphery. Furthermore, there is evidence to suggest 
that the activity of any self-antigen-reactive T cells that enter the periphery may be 
hampered by mechanisms of peripheral tolerance induction including clonal deletion (Rocha 
and von Boehmer 1991), suppression by regulatory T cells (Tregs) (Wing et al. 2008), or 
anergy (Ramsdell and Fowlkes 1992; Willimsky and Blankenstein 2005).
1,7.2c Which antigens are recognised in human cancers?
With the aim of generating an effective cancer therapy, significant effort has been devoted 
to the identification of tumour-associated antigens (TAAs) recognised by anti-tumour CD8+ T 
cells that are shared between individuals. Unfortunately, the majority of these TAAs are 
non-mutated self-antigens (Rosenberg 2001). Some of the common TAAs dealt with in this 
thesis are summarised in Table 1.2. However, for the reasons described in the previous 
paragraph, the endogenous T cell repertoire responding to these antigens is likely to be 
small in size and activity (Romieu et al. 1998). Consequently, a number of therapeutic 
approaches have been investigated and developed to address this major issue (Section 1.8).
TAA name: Description:
gplOO A melanocyte differentiation antigen (Adema et al. 1993; Cox et al. 
1994).
MAGE-A3 A cancer testis antigen expressed by a wide variety of tumours (Celis et 
al. 1994; Gaugler et al. 1994).
Melan-A/
MART-1
A lineage-specific antigen expressed by a large proportion of primary and 
metastatic melanomas (Coulie et al. 1994; Kawakami et al. 1994).
NY-ESO-1 A cancer testis antigen expressed in multiple myeloma, melanoma and a 
range of other cancers (Chen et al. 1997)
Table 1.2: Four commonly targeted tumour-associated antigens (TAAs).
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1.8 Current strategies for manipulation of immune system for targeting disease
1.8.1 Vaccination
Vaccination represents the most cost-effective and successful approach for the prevention 
of infectious diseases, and is second only to sanitation in terms of the estimated number of 
lives it has saved. Since the advent of widespread vaccination, the incidence of many 
diseases such as measles, mumps, diphtheria, poliomyelitis and rubella has dropped 
significantly. The greatest triumph of vaccination has been the global eradication of 
smallpox. In the sixteenth century, before tenner's discovery of vaccination, smallpox was a 
lethal disease, as widespread as cancer or heart disease are in modern times, but with the 
difference that the majority of its victims were infants and young children. No endemic 
cases of the disease have been reported since 1980. Therefore, due entirely to the success 
of vaccination, smallpox is a disease of the past.
The purpose of vaccines is to prime the recipient's immune response (hence an alternative 
name for vaccination is immunisation) in order to generate immunological memory in the 
form of memory T cells. If successful, vaccination will elicit a heightened, more effective 
immune response on re-exposure to a specific antigen. There are two categories of 
vaccines: i) prophylactic vaccines, which are administered prior to the exposure to pathogen 
and aim to offer protective immunity (eg. smallpox vaccine); and, ii) therapeutic vaccines, 
which are administered following disease diagnosis, and aim to increase the frequency of 
antigen-specific T cells targeting antigens associated with the disease (eg. cancer vaccines). 
Over the years, several vaccination strategies have been developed, which use different 
forms of immunising agent: i) whole organism (attenuated live/dead); ii) purified (subunit) 
antigen; iii) recombinant antigen; iv) synthetic peptide; v) recombinant vector; and, vi) DNA 
derived from the pathogen. All these approaches have one thing in common: they elicit a 
specific immune response to the immunising agent without causing the disease they are 
designed to prevent.
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Despite the fact that vaccination is the most successful medical intervention ever 
developed, there are two areas where vaccines are not yet particularly effective: i) 
pathogens of variable antigenicity (such as HIV); and, ii) cancer.
1.8.1a Vaccines targeting pathogens of variable antigenicity (specifically HIV)
Prophylactic vaccination represent the most cost-effective and successful approach for the 
prevention of infectious disease. However, vaccination against pathogens of variable 
antigenicity such as HBV (Michel et al. 2001), HCV (Leroux-Roels et al. 2005), and HIV 
(Oxenius et al. 2002a), has not been entirely promising. Developing a vaccine against a 
pathogen of variable antigenicity like HIV is problematic. As described in section 1.7.1a, HIV 
is a retrovirus, capable of undergoing rapid mutagenesis to evade from the immune 
response. Selecting a suitable antigen for immunisation against this virus presents a 
veritable challenge. The gravity of the situation is illustrated by the fact that a recent clinical 
trial conducted in Thailand was hailed as promising after eliciting a mere 30% reduction in 
HIV infection. Such a low level of efficiency is clearly unacceptable, and there is currently no 
publicly available vaccine against HIV (Vaccari et al. 2010).
1.8.1b Cancer vaccines
Although a handful of successful cancer vaccines exist, these typically target tumours that 
have been induced as a result of viral infection: Hepatitis B vaccine (Maugh 1981) and very 
recently, the human papillomavirus (HPV) vaccine (Frazer et al. 2010). The expression of 
viral antigens on the surface of these virally-induced tumour cells easily distinguishes them 
from healthy cells. However, the majority of cancer vaccines fail to induce an effective anti­
tumour immune responses. An extensive survey summarising the results of cancer 
vaccination trials showed that a mere 3% of >600 patients enrolled showed an objective 
response to the vaccination regimens (Rosenberg et al. 2004). This response rate is within 
the range for spontaneous remissions. A major reason for the failure of cancer vaccination is 
the limited repertoire of T cells capable of responding to the tumour antigens concerned 
(Kisielow et al. 1988). Anti-tumour vaccines are typically designed around epitopes that are 
over-expressed on tumours but are indistinguishable from the antigens presented by
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healthy cells. Thus, any T cells specific for these antigens are likely to have undergone 
deletion during the process of negative selection in the thymus, or display very low affinities 
for the target antigen. Other causes of poor anti-cancer vaccine success include rapid 
degradation of target peptide antigens by proteases, possible immunosuppressive 
mechanisms restricting the activity of primed T cells (see section 1.7.2a), and the severely 
weakened immune defences in patients typically enrolled in phase I/ll studies (Rosenberg et 
al. 2004). Improving the efficacy of anti-tumour vaccines would require the identification of 
TAAs that are restricted to tumour cells and are not presented by healthy tissues.
1.8.2 Adoptive T cell therapy (ACT)
The low frequency of anti-tumour T cells in the periphery has been blamed for the 
disappointing outcome of anti-cancer peptide vaccination trials. A sensible solution would 
thus involve increasing anti-tumour T cell numbers by adoptively transferring T cells of a 
desired specificity to a patient. Adoptive T cell therapy (ACT) aims to do just that, and works 
by providing an individual with mature antigen-responsive allogeneic or autologous T cell 
subsets, with the hope that the infused cells would eliminate a tumour or pathogen and 
prevent its reoccurrence. Figure 1.5 A summarises the main steps involved in the adoptive 
transfer of lymphocytes.
Primary CD8+ T cells have been selected as the cells of choice for adoptive therapy for their 
cytotoxicity, and the fact that unlike other cytolytic cell subsets they display a high degree of 
specificity by recognising antigen in the form of peptide-MHC class I. There are a number of 
protocols for obtaining CD8+ T cells specific for a desired cancer or viral antigen. The 
preferred sources of cancer antigen-specific T cell are peripheral blood or tumour 
specimens, the latter are often enriched for tumour-infiltrating lymphocytes (TILs). Because 
many patients are already primed to their tumours, the main challenge is improving the 
quantity and quality of the desired T cell subset (Germeau et al. 2005). The use of pMHC 
multimers for the ex vivo isolation of antigen-specific T cells using fluorescence cell sorting is 
by far the most effective means of obtaining a pure population of effector cells of a desired 
specificity. Once isolated, the T cells are expanded using microbeads coated with anti-CD3
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A. Adoptive T cell therapy (ACT)
B.
2. Activation and expansion of TILs
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Figure 1.5: Two variations of T cell-mediated immunotherapy. Although the figure
illustrates a scheme for tumour eradication, the same procedures are applicable to the 
treatment of viral disease.
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and anti-CD28 antibodies, and in the case of CD8+ T cells a combination of IL-2 and IL-15 
cytokines. Since anti-tumour T cells are typically characterised by their low affinity for 
antigen, techniques aimed at enhancing the strength of TCR/pMHC interaction and thus the 
detection with pMHC multimers, have been developed for the visualisation of cells which 
are not detected by conventional means. Chapters 3, 4, and 5 deal with the sort of 'tricks' 
that can be employed to substantially improve T cell detection using pMHC multimer 
technology.
Adoptive cell transfer for the treatment of tumours is not a novel concept; it was first 
demonstrated in humans in the 1960s when Chester Southam and colleagues found that 
subcutaneous growth of human tumour autografts transferred to patients bearing 
advanced cancers was prevented by the cotransfer of autologous leukocytes (Southam et al. 
1966). Despite its early discovery, there are few cases of FDA-approved ACT being carried 
out today. The success of ACT in the clinic is hampered by a number of factors:
i) Firstly, the isolation of TAA-specific T cells from the self-restricted repertoire can be 
problematic. In the majority of cancer patients, the frequency of TAA-primed lymphocytes 
present in circulation is very low. Often, excision of the tumour must be performed to elute 
any TILs present.
ii) Secondly, the T cells isolated from an individual must undergo optimal and safe expansion 
in vitro. Two main expansion protocols are employed: i) The polyclonal activation of T cells, 
based on the assumption that a high proportion of these cells is equipped with the desired 
TAA specificities; and, ii) The clonal expansion of cells. Although this second approach 
guarantees antigen specificity without the possibility of coinfusion of hindering regulatory 
and immunosuppressive T cell subsets, it suffers from being costly and labour-intensive. 
Following observations that many cancer patients exhibit a substantial T cell response to 
their tumours, the more rapid cost-effective polyclonal expansion approach has been 
adopted when conducting randomised clinical trials (Rapoport et al. 2005). This polyclonal
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approach is also favoured from an ethical perspective, since it ensures that the treatment is 
given to all patients and not just the minority that have tumour-reactive TILs.
iii) Thirdly, the ability of a CD8+ T cell clone to expand in culture and respond to a given 
antigen in vitro does not guarantee its success at fighting tumours and infection in vivo. 
Once infused into an individual, the CD8+ T cells must not only target antigen specifically, 
but also retain effector function, homing potential and persistence in vivo. Efforts are being 
made to ensure that the protocols used to expand T cells in culture retain, or where 
possible, improve the quality of the immune response once the cells are re-infused into the 
individual undergoing therapy. In addition, studies with melanoma patients have shown 
that chemotherapy-induced host conditioning prior to adoptive T cell transfer improves the 
persistence of adoptively-transferred T cells by providing them with a niche (Dudley et al. 
2002; Rosenberg et al. 2004). Under these lymphopenic conditions, approximately 50% of 
patients receiving adoptive T cell therapy for metastatic melanoma showed reductions in 
their tumour burden (Rosenberg and Dudley 2004).
iv) Finally, adoptive T cell therapy relies on the presence of tumour-specific T cells within 
the T cell repertoire, and that these T cells are in turn functional. Since many tumour- 
reactive T cells are either deleted during thymic development or display pitifully weak 
affinities for cognate antigen, the availability of suitable T cell candidates for use in ACT is 
often limited. Furthermore, patients selected to receive ACT (at this early stage of its 
implementation) suffer from aggressive forms of cancer which become too advanced for 
treatment by the time sufficient numbers of T cells have been expanded for infusion.
Although I have mainly addressed ACT as an anti-cancer therapy, the same principles and 
drawbacks apply for the treatment of viral infections. Albeit, the biggest challenge for anti­
viral ACT is the identification and isolation of CD8+ T cells capable of successfully targeting 
viral escape mutants. Nevertheless, a number of studies have demonstrated the 
effectiveness of adoptive T cell therapy for the protection of bone marrow transplant 
patients from CMV- and EBV-mediated diseases, which are a major concern during the post­
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transplant immunodeficiency period (Haque et al. 2002; Rooney et al. 1995; Walter et al. 
1995). As mentioned in the previous paragraph, a limitation of conventional adoptive 
therapy is the time-consuming (~ 3 months) process associated with the detection, isolation 
and generation of substantial numbers of autologous antigen-specific CD8+ T cells required 
to treat a patient. The aggressive nature of many lymphoproliferative disorders means that 
there is a high likelihood of the condition proving fatal before a treatment is provided. An 
initiative led by Prof. D Crawford aims to reduce the large time gap between disease 
diagnosis and treatment by generating a T cell bank comprising hundreds of EBV- and CMV- 
specific CD8+ T cell lines derived from a wide range of donors with varied HLA profiles. The 
cell bank ensures that suitable numbers of allogeneic partly HLA-matched CD8+ T cells are 
readily available for treatment. Adoptive transfer of these antigen-specific banked CD8+ T 
cells has thus far shown considerable success in the treatment of EBV-associated malignant 
disorders including CNS lymphomas (Haque et al. 2007; Haque et al. 2002; Wynn et al.
2005).
1.8.3 TCR gene transfer therapy
Given the limitations of the endogenous T cell repertoire specific for tumour-associated 
antigens, and the inadequacy of anti-viral CD8+ T cells in targeting certain viral escape 
mutants, the development of adoptive therapies that utilise TCR gene-modified T cells 
seems an attractive prospect. The concept behind TCR gene therapy is simple, stemming 
from the fact that the TCR is the only structure on the T cell surface that dictates antigen 
recognition (Rudolph et al. 2006). Subsequently, the transfer of genes encoding a particular 
TCR to another T cell should result in a shift in antigen specificity in the recipient cell whilst 
preserving its effector functions. The main steps involved in TCR gene therapy are outlined 
in Figure 1.5 B. The proof of principle that the transfer of TCR genes is sufficient to endow 
recipient T cells with the specificity of donor cells was first shown by Steinmetz and 
colleagues in 1986 (Dembic et al. 1986). The authors used a cosmid vector to deliver the a 
and p TCR genes to a cytotoxic T cell hybridoma by means of protoplast fusion. Since this 
exciting discovery, TCR gene transfer has seen some significant developments: addressing 
the quality of TCR genes, the various TCR gene delivery methods used, and the efficiency of
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exogenous TCR expression on the surface of recipient T cells. These developments are 
described in more detail in Chapter 6 of this thesis.
1.8.3a Potential risks associated with TCR gene transfer 
General risks associated with retroviral vectors
The introduction of a live virus into host cells raises serious issues with regard to safety, 
especially in cases where the virus is used as a vector for the introduction of therapeutic 
genes, such as T cell receptors in TCR gene transfer therapy. A theoretical safety concern 
during vector production is that a replication competent retrovirus (RCR) is generated. This 
can happen if recombination takes place between the main retroviral vector and genomes 
of packaging plasmids or the host cell (Temin 1990). The probability of this depends upon 
the amount of nucleotide sequence homology between the vector and other retroviral or 
cellular sequences. Measures to reduce the likelihood of RCR formation include separation 
of the trans-acting and c/'s-acting elements required for viral assembly and replication on 
separate plasmids, and reducing the amount of sequence homology among the constructs.
The ability of retroviruses to integrate into the host genome also raises the probability of 
insertional mutagenesis and malignant transformation if the promoter elements of the virus 
become suddenly flanked by genes involved in growth control. The dangers of such an event 
were illustrated by a study in which 2 out of 10 children receiving retroviral vector therapy 
for an inherited metabolic disorder went on to develop T cell leukaemia as a consequence 
of the treatment (Hacein-Bey-Abina et al. 2008; Hacein-Bey-Abina et al. 2003). The 
introduction of self-inactivating vectors, and a transition to using vectors derived from non- 
oncogenic lentiviruses with low mitotic indexes has greatly reduced the probability of this 
happening again (Anson and Fuller 2003).
Specific risks for TCR gene transfer: TCR chain mispairing
A potential problem that arises from the introduction of a T cell receptor into T cells that 
already express their own native TCR is the mispairing of the endogenous TCR a and p 
chains with the exogenous TCR a and p chains. If this occurs, a single T cell can theoretically 
express a total of four different TCRs: native, exogenous, and two mispaired variants. Since
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TCRs have to compete for available CD3 molecules for expression at the cell surface, the 
formation of mispaired TCRs can reduce the expression of relevant TCR a($ heterodimers, 
resulting in insufficient function of transduced T cells. The generation of TCRs with novel 
and unknown specificities through chain mispairing carries a potential risk of some of these 
TCRs being autoreactive. The dangers of TCR mispairing have not as yet been fully assessed, 
with some groups reporting associated pathology (Bendle et al. 2009; Bendle et al. 2010; 
van Loenen et al. 2010), whilst others observing no adverse effects (Johnson et al. 2009; 
Morgan et al. 2006; Robbins et al. 2011). Several strategies have been developed to reduce 
the level of mispairing and enhance the association of exogenous TCRs with CD3 molecules. 
Boulter et al. engineered a means of encouraging exogenous TCR a and 0 chains to 
preferentially pair with each other by mutating defined residues in the constant regions to 
cysteines, which can participate in the formation of an additional disulphide bond between 
the transduced TCR chains (Boulter et al. 2003; Cohen et al. 2007; Kuball et al. 2007). Other 
groups have reported improvements in TCR pairing and enhanced association with CD3 
molecules by i) exchanging the human TCR constant regions for murine ones, ii) introducing 
retroviral vectors encoding small interfering RNA (siRNA) constructs that specifically 
downregulate endogenous TCR, or by iii) fusing TCR chains to CD3  ^molecules to bypass the 
need for endogenous CD3 (Cohen et al. 2006; Okamoto et al. 2009; Sebestyen et al. 2008). 
The 868 TCR used in this investigation lacks any of the above modifications but has 
undergone codon optimisation for enhanced expression in mammalian cells. Codon 
optimisation works by minimising some of the problems associated with expressing 
transgenes in mammalian cells, including transcriptional silencing, low mRNA half-life, 
alternative splicing events, premature polyadenylation and limited availability of certain 
tRNAs (Bradel-Tretheway et al. 2003). Altering the GC-content, modifying the secondary 
structure of the resultant mRNA transcript, and adapting the codon bias with respect to 
non-limiting tRNA pools of the mammalian cell act to increase the efficiency of 
transcription, stability of the transcript, and ultimately allow for a high level of protein 
production within the mammalian host. It is one of the aims of this chapter to determine 
the extent of TCR chain mispairing when a codon-optimised 868 TCR is transduced into 
primary CD8+T lymphocytes.
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1.8.3b Advantages of TCR gene transfer therapy over ACT
TCR gene transfer therapy offers several important advantages over adoptive T cell therapy:
i) Firstly, TCR gene therapy is substantially more rapid. If a TCR specific for a particular 
antigen is known, its genes can be delivered to autologous T cells (derived from the 
individual receiving the therapy) and the cells expanded in a matter of days.
ii) Secondly, the T cells with the desired specificities may not be naturally present in the T 
cell repertoire. The potential of introducing TCR genes into T cells, thus endowing them with 
new specificities represents an attractive solution.
iii) Thirdly, TCR gene therapy offers the prospect of modifying TCRs (in terms of affinity, 
expression levels, signalling and TCR chain pairing), and thus the functionality of the 
recipient T cell population.
TCR gene transfer therapy is particularly important in tumour immunology, where the 
available tumour-reactive T cell repertoire is weakened by thymic selection. Three different 
approaches can be employed to ensure that the TCRs used for TCR gene transfer have a 
sufficiently high affinity for the target antigen: i) using xenoreactive TCRs that contain 
murine sequence elements; ii) using alloreactive TCRs that have not undergone thymic 
selection; or, iii) subjecting TCRs derived from peripheral T cells to artificial affinity 
maturation procedures. The use of xenoreactive TCRs for TCR gene therapy is relatively 
uncommon, due to the 'foreign' nature of murine TCR regions. In contrast, a number of 
studies have demonstrated the successful application of TCR gene transfer for the 
treatment of human leukaemias by endowing T cells with a high affinity alloreactive TCR 
specific for an epitope of the Wilms' tumour antigen 1 (WT1) (Baird and Simmons 1997; 
Morris et al. 2006; Oji et al. 2003c; Oji et al. 2003b; Oji et al. 2003a). The WT1 antigen is 
overexpressed in a large number of human cancers but assumes normal expression levels in 
healthy tissues, making it a good candidate for TCR gene therapy. It will be very interesting 
to see how the promising results achieved with the WTl-specific alloreactive TCR in the
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laboratory translate into the clinical setting. A phase I trial is currently underway to address 
this.
In cases where high affinity TCRs cannot be extracted naturally from the T cell repertoire 
either by staining with low avidity pMHC multimers or by priming with low concentrations 
of antigen, they must be generated artificially. Two developments have helped solve the 
problem of low TCR affinities: yeast and phage display techniques. Using yeast display, 
Holler et al. were able to increase the KD of the 2C TCR over 100-fold to 9nM (Holler et al. 
2000). The most effective means of generating high affinity TCRs for use in TCR gene 
transfer is now considered to be TCR phage display (Li et al. 2005). With this approach, TCR 
genes are displayed on the surface of the M13 bacteriophage, fused to the gene III of the 
phage. Essentially, a library of phage expressing a surface TCR gene is screened for high 
affinity TCR/pMHC interactions using immobilised pMHC molecules of interest. Rounds of 
bacterial re-infection and panning of immobilised pMHC selects for the highest affinity 
variants. Mutations in the highest affinity CDR sequences are then combined in a single high 
affinity TCR (Li et al. 2005). This process is described in more detail in section 8.1.2 of 
Chapter 8. Phage display has the following attributes: i) it can be applied to any TCR; ii) it 
does not include a mutant selection step with clonotypic antibodies (unlike yeast display); 
and, iii) it can be used to screen library sizes of > 1010 variants. This approach has been used 
to improve the affinity of TCRs by a million-fold to pM affinities (Laugel et al. 2005). More 
recent unpublished studies have produced TCRs with affinities for cognate antigen in the fM 
range and that bind with half-lives > 48 hours. Several studies have demonstrated the 
success of high affinity TCRs generated by phage display in targeting both tumour- 
associated (Zhao et al. 2007) and viral (Varela-Rohena et al. 2008b) antigens in vitro and in 
murine models. The latter study, documenting how enhancing TCR affinity is beneficial to 
the clearance of rapidly mutating viruses such as HIV from culture, represents an 
international collaborative effort involving research groups from the University of 
Pennsylvania, and Oxford and Cardiff Universities (Varela-Rohena et al. 2008). The ultimate 
advantage of TCR gene therapy is that it not an entirely personalised approach, and can be 
used in any individual provided they carry the restricting HLA allele for a particular cognate
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TCR/pMHC pair. One can envisage whole libraries of delivery vectors encoding a broad 
range of TCR genes being compiled to target the most common epitopes associated with 
cancer and viral infections.
1.8.3c Limitations of TCR gene transfer therapy over ACT
Despite sounding very promising, TCR gene therapy is without its limitations. In a clinical 
trial involving melanoma cancer patients, the success of conventional adoptive T cell 
therapy with expanded Melan-A specific TILs (~50% response rate, (Rosenberg and Dudley 
2004)) was far greater than the anti-melanoma activity of the TCR-transduced lymphocytes 
(2/15 patients showed tumour regression, (Morgan et al. 2006)). These observations 
suggest that the efficiency of TCR gene therapy should be improved to achieve a better 
clinical outcome. The measures taken to improve the success of TCR gene therapy are 
discussed in Chapter 6 of this thesis. Whilst optimisation of TCR gene therapy is under way, 
a number of safety issues must also be considered. The introduction of TCR specificities that 
lie outside the normal T cell repertoire have the potential to cause autoimmunity. New 
unknown specificities can theoretically be generated by the mispairing of the introduced 
and endogenous TCR chains. Although evidence of autoimmunity arising from TCR 
mispairing has been difficult to produce, a recent murine study has shown some cause for 
concern (Bendle et al. 2010). A further risk of autoimmunity is posed by transfer of a TCR 
which is derived from a donor with a different MHC haplotype than the recipient. In such a 
situation, CD8* T cells transduced with the donor TCR can potentially react towards 
allogeneic MHC molecules presenting self-antigen. In view of this, the compatibility 
between donor TCRs and recipient MHC haplotype profiles should be assessed for each 
individual receiving TCR gene therapy. Because enhancing the affinity of a TCR is thought to 
correlate with increased crossreactivity (the property of a single TCR to recognise more than 
one antigen) (Mason 1998), altering the affinity of a TCR must be treated with caution. The 
side effects associated with enhanced TCR affinity were demonstrated in a TCR gene 
transfer clinical trial conducted with patients undergoing treatment for melanoma (Johnson 
et al. 2009). During the trial period 30% of patients responded to the treatment, but a small 
number exhibited destruction of healthy melanocytes in the skin, eye and ear, resulting in
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the conditions vitiligo, uveitis and hearing loss, respectively. Although this is an extreme 
and isolated case, this study highlights the importance of rigorous testing of engineered T 
cells in an in vitro setting prior to administering them to patients. It also highlights the need 
for the identification of TAAs that differ from the self-antigens expressed on healthy tissues. 
However, in comparison to induction of T cell immunity by vaccination and adoptive T cell 
transfer, TCR gene transfer is likely to prove itself the most useful in the clinical setting, 
provided any associated immunopathology issues are rapidly resolved. Periodic vaccination 
with peptide antigen following T cell transfer may then be relied upon for enhancing the 
beneficial immune response.
1.8.4 Chimeric Antigen Receptors (CARs)
As described in the previous section, TCR gene transfer therapy has shown considerable 
promise in redirecting immune recognition to target tumours and virally-infected cells. 
However, the use of TCRs is this context is limited by a number of factors, namely; i) the 
requirement for an antigen-restricting HLA allele; ii) the downregulation of pMHCI 
complexes from the surface of the tumour or virally infected targets; and, iii) the difficulty 
of finding suitable antigens for TCR recognition. The use of chimeric antigen receptors 
(CARs) represents an alternative approach to targeted immune therapy, and promises to 
bypass some of these problems. The concept of CARs originated in the 1980s, when 
Professor Zelig Eshhar's group first demonstrated that the functional redirection of a T cell 
to a protein antigen could be achieved by the expression of a receptor consisting of a 
protein-binding domain fused to a T cell signalling molecule (Gross et al. 1989). The 
archetypal CAR consists of a single-chain antibody fragment (scFv) capable of binding 
antigen, fused (either directly or via a spacer) to a component of the T cell receptor 
complex, which on antigen binding primes the engrafted T cell for cytotoxic activity. The 
combination of various extracellular, transmembrane and signalling domains has lead to the 
development of a multitude of different CARs. There appears to be little reported rational 
strategies for CAR structure design, with many groups simply opting for their favourite 
structural and functional components. Table 1.4 contains examples of various CAR
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structures that have been developed to date, and highlights the preference for CD3  ^
(primarily due to the large number of ITAMs) and FceRly as signalling domains.
1.8.4a Advantages and disadvantages of CAR versus TCR immunotherapy
The use of CARs in immunotherapy has a number of advantages over the use of TCRs. 
Firstly, the CAR approach bypasses the need for MHC restriction, meaning it is more generic 
and applicable in all patients, not just those harbouring a particular HLA allele. Secondly, 
CARs overcome the clever defences of tumours and viruses that can escape from TCR- 
mediated recognition through the downregulation of MHCI expression (see sections 1.7.1 
and 1.7.2). Thirdly, many CAR structures are manufactured using antibody technology, and 
thus are able to target any antigen for which an antibody is available, thus bypassing the 
need for MHC-associated antigen. However, the recognition of surface proteins rather than 
processed peptide carries associated risks. This is especially true for tumour recognition, 
where the degree of tumour specificity and relative expression of target antigen on normal 
tissue may be a source of toxicity. A recent in vivo murine study reported that T cells 
engrafted with a CD19-specific CAR bearing a CD3£ signalling domain resulted in 
considerable depletion of healthy B cells (Cheadle et al. 2009). Efforts are currently 
underway to quantify the level of off-target toxicity that is acceptable for CAR-based 
immunotherapy, and limit damage to healthy tissues accordingly. A further advantage of 
CARs over TCRs is that they carry their own signalling domains and therefore do not rely on 
the interaction with components of the CD3 complex for cell surface expression and 
function. As a result, CARs can be delivered into cells other than T cells, harnessing their 
different effector functions. Although the development of non-T cell CAR therapy is still at a 
relatively early stage, a number of studies have successfully demonstrated the suitability of 
CARs for the transduction of NK cells. Primary CD3'CD56+ human NK cells transduced with a 
retroviral vector encoding a Neu/HER2-specific CD3£CD28 receptor showed redirected 
function against cell lines presenting cognate antigen in vitro and in short term in vivo 
assays (Kruschinski et al. 2008). NK cells have also been shown to be permissive to RNA- 
based electroporation with a CD19-specific CAR, following which they gained specificity for 
transformed B cells (Li et al. 2009). In summary, over twenty years of research has seen the
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transfer of CARs into the clinical setting with CAR-transduced T cells now reported in 
completed trials for the treatment of HIV (Mitsuyasu et al. 2000) and cancer (Kershaw et al.
2006). Going head to head with TCR-based therapies, it remains to be seen whether CARs 
offer an overall therapeutic advantage in the long term.
Antigen Spacer Transmembrane Signalling domain Reference
Specificity Domain
CEA - CD3S CD3{ (Gilham et al. 2002)
Neu/HER2 - CD3£ CD3i; (Stancovski et al. 1993)
gpl20 CD8 CD3S CD3^ (Patel et al. 1999)
gplOO CD8 CD8 CD3^ (Masiero et al. 2005)
CD19 - CD3S CD3£ (Cheadle et al. 2009)
OKT8 CD8 CD8 CD3  ^(mutated) (Chae et al. 2004)
TCR - H2-Kb CD3  ^(mutated) (Geiger et al. 2001)
CEA - CD3s CD3e (Nolan et al. 1999)
DAP 10 CD19 CD8 DAP 10 (Marin et al. 2007)
CEA hlgG FceRly FceRly (Heuser et al. 2003)
CEA hlgGl FceRly FceRly (Hombach et al. 2007)
CEA CD8 FceRly FceRly (Haynes et al. 2001)
Neu/HER2 - FceRly FceRly (Eshhar et al. 1993)
CEA hlgGl FcyRI FcyRI (Biglari et al. 2006)
TCR - H2-Kb CD3^ Lck (Geiger et al. 2001)
TNP - CD4or CD8 Syk (Fitzer-Attas et al. 1998)
TNP - CD4or CD8 ZAP-70 (Fitzer-Attas et al. 1998)
Table 1.4: Examples of Chimeric Antigen Receptors (CARs).
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1.9 Aims of the thesis
Chapter 1
The work contained within this thesis aims to explore diagnostic and therapeutic uses of 
optimised interactions between peptide-Major Histocompatibility complex (pMHC) 
molecules and the T cell receptor (TCR) and/or coreceptor that engages them. Specifically, I 
aimed to:
1) Experiment with a number of 'tricks' to improve the detection of T cells using soluble 
pMHC multimers;
2) Explore the use of TCRs in TCR gene transfer;
3) Investigate the role of glycosylation in antigen recognition by the TCR and,
4) To assess the therapeutic potential of novel reagents based on high affinity soluble TCRs.
78
Chapter 2
2
MATERIALS AND METHODS
2.1 Reagents and consumables.............................................................................................. 83
2.1.1 Antibodies.......................................................................................................... 83
2.1.1a Activating antibodies........................................................................... 83
2.1.1b Fluorescent conjugated anti-human antibodies for detection of cell 
surface protein expression............................................................................. 83
2.1.2 Cellular dyes...................................................................................................... 83
2.1.3 Peptides............................................................................................................. 83
2.1.4 Protein tyrosine kinase inhibitors (PKIs)...........................................................84
2.1.4a Dasatinib.............................................................................................. 84
2.1.4b Other PKIs............................................................................................ 84
2.1.5 Cell culture media and associated reagents.....................................................84
2.1.5a PSG media (Penicillin, Streptomycin, Glutamine)...............................84
2.1.5b RIO media............................................................................................ 85
2.1.5c CK media.............................................................................................. 85
2.1.5d 293 T cell culture media (DMEM-10).................................................85
2.1.5e Freezer mix.......................................................................................... 85
2.1.6 Bacterial plasmids.............................................................................................. 85
2.1.7 Viral vector and packaging plasmids................................................................. 86
2.2 Mammalian cell lines and clones..................................................................................... 86
2.2.1 Human CD8+T cell lines....................................................................................86
2.2.2 Human CD8+T cell clones.................................................................................86
2.2.3 Culture of human CD8+T cell lines and clones...................................................87
2.2.4 Human CD4+T cell lines and clones..................................................................87
2.2.5 Other cell types................................................................................................. 88
2.2.5a Stable HLA A2-expressing C1R B cell clones........................................88
2.2.5b TO cells................................................................................................. 88
2.2.5c T2 cells................................................................................................. 88
79
Chapter 2
2.2.5d 293 T (HEK 293) lentiviral packaging cell line......................................88
2.2.6 Cryopreservation of cells................................................................................. 89
2.3 Mammalian cell-based techniques.................................................................................. 89
2.3.1 Counting cells with Trypan blue........................................................................ 89
2.3.2 Preparation of peripheral blood mononuclear cells (PBMC)............................89
2.3.3 Preparation of cord blood mononuclear cells (CBMC).....................................90
2.3.4 MACS bead isolation......................................................................................... 91
2.3.5 Generation of human CD8+ T cell clones by limiting dilution...........................91
2.4 Bacterial cell-based techniques........................................................................................ 92
2.4.1 Bacterial culture media and strains................................................................... 92
2.4.1a LB low salt media................................................................................. 92
2.4.1b TYP media............................................................................................ 92
2.4.1c Agar plates........................................................................................... 92
2.4.1d Bacterial strains................................................................................... 92
2.4.2 Making competent bacterial cells..................................................................... 93
2.4.3 Transformation of competent bacterial cells by heat shock method...............93
2.4.4 Target gene expression in bacterial cell culture............................................... 93
2.5 Molecular Biology..............................................................................................................94
2.5.1 DNA-based techniques...................................................................................... 94
2.5.1a Mini-prep of plasmid DNA................................................................... 94
2.5.1b Maxi-prep of plasmid DNA.................................................................. 94
2.5.1c Quantification of DNA.......................................................................... 95
2.5.1d DNA sequencing.................................................................................. 95
2.5.le Ethanol precipitation........................................................................... 96
2.5.I f  PCR site directed mutagenesis (PCR-SDM)..........................................96
2.5.2 RNA-based techniques...................................................................................... 97
2.5.2a In vitro transcription (IVT)................................................................... 97
2.5.2b Transient transfection (Electroporation of IVT mRNA).......................97
2.6 Lentiviral technologies..................................................................................................... 98
2.6.1 Viral assembly.................................................................................................. 98
80
Chapter 2
2.6.1a Initial method...................................................................................... 98
2.6.1b Revised method................................................................................... 98
2.6.2 Transfection of packaging cell line and processing of viral supernatant..........98
2.6.2a Initial method...................................................................................... 98
2.6.2b Revised method................................................................................... 99
2.6.3 Transduction of lymphocytes............................................................................ 99
2.6.3a Initial method...................................................................................... 99
2.6.3b Revised method................................................................................. 100
2.6.4 Titering viral supernatant and calculating multiplicity of infection (MOI) 100
2.7 Protein Chemistry........................................................................................................... 101
2.7.1 Inclusion body preparation............................................................................. 101
2.7.2 Fast protein liquid chromatography (FPLC)..................................................... 102
2.7.3 Production of soluble human biotinylated peptide-MHCI monomers...........102
2.7.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)...105
2.7.5 Estimating protein concentration by UV spectrophotometry........................106
2.8 pMHCmultimer technology............................................................................................106
2.8.1 Manufacture of pMHCI tetramers.................................................................. 106
2.8.2 pMHCI tetramer decay experiments............................................................... 107
2.8.3 pMHCI tetramer association experiments...................................................... 107
2.8.4 Assembly of pMHC dextramers....................................................................... 107
2.9 Treatment of cells with dasatinib and neuraminidase...................................................110
2.9.1 Dasatinib treatment........................................................................................ 110
2.9.2 Neuraminidase treatment............................................................................... 110
2.10 Flow cytometry..............................................................................................................110
2.10.1 pMHC tetramer staining of T cell clones, lines and PBMC............................110
2.10.2 pMHC dextramer staining of T cell clones, lines and PBMC.........................110
2.10.3 Gating strategy for phenotyping PBMC........................................................ I l l
2.11 CD8+T cell effector function assays.............................................................................. I l l
2.11.1 Enzyme linked immunospot (ELISpot) assay for interferon-y (IFNy).......... I l l
81
Chapter 2
2.11.2 Enzyme linked immunosorbent assay (ELISA) for macrophage inflammatory
protein-ip (MIP-10).................................................................................................. 113
2.11.2a MIP-10 ELISA for combinatorial peptide library screening.............. 113
2.11.3 Cytometric bead array (CBA)......................................................................... 115
2.11.4 TCR/CD8 downregulation assay.................................................................... 115
2.11.5 Intracellular cytokine staining (ICS) for measuring CD8+T cell effector 
functions....................................................................................................................115
2.11.6 Infection of TO and primary CD4+ T cells with HIV-1 and intracellular staining 
for the HIVgag p24 protein....................................................................................... 116
2.11.7 Fluorometric assessment of T lymphocyte antigen-specific lysis (FATAL)-a flow
cytometric cytotoxicity assay................................................................................... 117
2.12 Fluorescence microscopy........................................................................................... 119
82
Chapter 2
2.1 Reaeents and consumables
2.1.1 Antibodies
2.1.1a Activating antibodies
Anti-CD3 and anti-CD28 unconjugated antibodies were purchased from Pharmingen, BD 
Biosciences (San Jose, CA).
2.1.1b Fluorescent conjugated anti-human antibodies for detection of cell surface protein 
expression
Anti-CD3F,TC' PerCP' PECy7, anti-CD4FITC' PE' Cy‘5PE PerCPCy5 5' APC, anti-CD8F,TC' PE' PerCP' APC' Q‘705/ anti- 
TCRapF,TC PE, pan-TCRy6PE, anti-CD25PE-APC, anti-CD69flTC-APCCv7’ APC, anti-CD19APC’ APCCv?, anti- 
CD28apc, anti-CD45RAPE' PECv7, anti-CD45ROECD (T“ as Red|, anti-CCR7PECv7, anti-CD107aFITC, 
VividPaci,H: Blue and Viaprobe™ were purchased from Pharmingen, BD Biosciences (San Jose, 
CA). Anti-HLA-A2 BB7.2 was purchased from Serotec (Oxford, U.K.). The panel of anti-TCR 
vpFrrc, pe antjbodies (Appendix 5 for a full list) was purchased from Beckman Coulter and 
Immunotech Coulter (Fullerton, CA). The anti-TCR Vp5 (a)Frrc and anti-TCR Va2FITC were 
purchased from Thermo Fisher Scientific.
2.1.2 Cellular dyes
Carboxyfluorescein diacetate Succinimydyl Ester (CFSE)
CFSE powder was purchased from Invitrogen and suspended in ddH20 to give a 10 mM 
stock solution, which was sterile filtered, dispensed in to 10 pi aliquots and stored at -20°C. 
Aliquots were thawed once and not re-frozen.
2.1.3 Peptides
Peptides used in the study were HLA A2 restricted and prepared to >95% purity (for pMHC 
tetramer refolds) or 50% purity (crude fragments for all other readouts) by PepScan 
(Netherlands). All peptides were received in powder form and dissolved in DMSO, prior to 
dilution in RPMI medium to the desired concentration. Peptides were pulsed onto target
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cells (all assays apart from ELISpot) by incubating 106 CIR cells in 1 ml of RIO media (see 
section 2.1.5 below) with peptide, for a minimum of 1 hour at 37°C, 5% C02.
2.1.4 Protein kinase inhibitors (PKIs)
2.1.4a Dasatinib
N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-l-yl)-2-methylpyrimidin-4- 
ylamino) thiazole-5-carboxamide (BMS-354825) alternatively known as dasatinib was 
synthesized as described previously (Lombardo et al. 2004). Biological activity was tested in 
a cell death titration assay on BA/F3 bcr-abl cells as described in (Magnusson et al. 2002). 
Dasatinib was dissolved in DMSO to a concentration of 1 mM, and stored in aliquots at - 
20°C. Once thawed, these stocks were stored at 4°C and used within 3-4 days of thawing as 
the reagent had a limited stability at this temperature. The 1 mM DMSO stock was diluted 
1/10,000 in PBS on the day of experimentation to achieve a working solution of 100 nM. 
Subsequent 1/2 dilution in cellular assays yielded a final concentration of 50 nM, which was 
the standard concentration used unless stated otherwise.
2.1.4b Other PKIs
Staurosporine was purchased from Biomol (Exeter, U.K.). Lck inhibitor II, genestein, 
herbimycin A, PP2 and PP3 were all purchased from Calbiochem (San Diego, CA). The PKIs 
were dissolved in DMSO and stored at -20°C, prior to being diluted in PBS and tested in 
assays at concentrations of 1 nM, 3 nM, 5 nM, 10 nM, 20 nM, 100 nM, 250 nM, 500 nM, and 
lp M .
2.1.5 Cell culture media and associated reagents 
2.1.5a P56 media (Penicillin, Streptomycin, Glutamine)
Roswell Park Memorial Institute medium-1640 (RPMI-1640) supplemented with 2 mM L- 
glutamine, 100 units/ml penicillin, and 100 pg/ml streptomycin.
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2.1.5b RIO media
PSG supplemented with 10% heat inactivated (at 56°C for 1 hour) foetal calf serum (FCS; 
Sigma Aldrich, Poole, U.K., and PAA Laboratories Limited, Pasching, Austria).
2.5.1c CK media
RIO supplemented with 2.5% Cellkines (Helvetica Healthcare, Geneva), 200 lU/ml IL-2 
(Pharmacy) and 25 ng/ml IL-15 (PeproTech, London, U.K.).
2.5.1d 293 T cell culture media (DMEM-10)
Dulbecco modified Eagle's minimal essential media (DMEM), supplemented with 2 mM L- 
glutamine, 100 units/ml penicillin, 100 pg/ml streptomycin, 1% sodium pyruvate, and 10% 
heat inactivated FCS.
2.5.1e Freezer mix
PSG supplemented with 10% sterile domethyl sulfoxide (DMSO; Sigma Aldrich, Poole, U.K.) 
and 50% FCS, passed through a 0.2 p filter.
RPMI-1640, DMEM, phosphate buffer saline (PBS), L-glutamine, penicillin, streptomycin, 
sodium pyruvate, and 0.5% trypsin in HBSS were purchased from Gibco, Invitrogen (Paisley, 
U.K.).
2.1.6 Bacterial plasmids
The pUC19 plasmid used for all the cloning steps prior to transfer into a lentiviral vector 
originates from the University of California and can be purchased commercially from a 
number of suppliers (eg. NEB, Sigma). The plasmid was modified in my laboratory by 
insertion of a restriction cassette for shuttling TCR alpha and beta fragment in and out of 
the plasmid. A TCR alpha chain sequence was inserted via Xba I and Xho I restriction 
enzymes, while the TCR beta chain sequence was Kpn I and Not I restriction enzymes. The 
pUC19 vector was further modified by insertion of a 2A peptide-encoding sequence and a 
SGSG spacer sequence in between the insertion sites for TCR alpha and beta genes
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(Appendix 1 C). A schematic of the modified pUC19 x-SGSG-2A-y shuttle vector can be found 
in Chapter 6 of this thesis (Figure 6.5).
2.1.7 Viral vector and packaging plasmids
The Lenti-SxW lentiviral vector and the packaging plasmids pMD.2G and pA8.91 were kindly 
donated by Qasim Waseem (Molecular Immunology Unit, UCL, London) and are fully 
documented in (Demaison et al. 2002).
2.2 Mammalian cell lines and clones
2.2.1 Human CD8+T cell lines
Blood from HLA A*0201 (HLA A2 from hereon) positive donors was used to generate CD8+T 
cell lines. CD8+ T cells were initially stimulated by exposure to peptide-pulsed autologous 
peripheral blood mononuclear cells (PBMCs). CD8+ T cell lines specific for the human 
telomerase reverse transcriptase (hTERT)54o.548 (ILAKFLHWL) and Melan-A26-35 (ELAGIGILTV) 
epitopes, both restricted by HLA A2, were generated by pulsing 6xl06 PBMC from an HLA A2 
individual with cognate peptide at concentrations of 1 pM and 100 pM respectively, for 1 
hour at 37°C. Cells were subsequently washed and resuspended in RIO only. After 3 days, 
increasing amounts of lnterleukin-2 (IL-2) were gradually added to the media, reaching a 
maximum concentration of 20 lU/ml by day 14. Expansion of antigen specific CD8+ T cells 
was assessed by FACS staining with cognate peptide/HLA A2 tetramers and anti-CD8 
antibody conjugated to a fluorochrome, as well as by Interferon-y (IFNy) enzyme linked 
immunospot (ELISpot) (section 2.11.1).
2.2.2 Human CD8*T cell clones
The ILA1 CD8+ T cell clone is specific for the HLA A2 restricted human telomerase reverse 
transcriptase (hTERT) epitope ILAKFLHWL (hTERTs^^g). Mell3 and Mel5 CD8+T cell clones 
are specific for the HLA A2 restricted M elan-A 26-35 epitope ELAGIGILTV. 3F2 CD8+ T cell clone 
recognises the HLA A2-restricted epitope of the preproinsulin (PPI15-24; ALWGPDPAAA) 
antigen, called ALW. CD8+ T cell lines responding to the three epitopes mentioned were
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initially expanded by exposure to peptide-pulsed autologous PBMC in RIO and then further 
stimulated with mixed irradiated allogeneic feeder PBMC from three unrelated donors in 
PSG media supplemented with foetal calf serum and antibiotics together with 
phytohemaglutinin (PHA) (4 pg/ml) and T-STIM (10%; BD Biosciences) or Cellkines (2.5%; 
Helvetica Healthcare, Geneva) instead of T-STIM for clone 3F2. ILA1, Mell3, Mel5 and 3F2 
clones were all generated by limiting dilution culture from the peptide-specific T cells lines 
(section 2.3.5).
2.2.3 Culture of human CD8* T cell lines and clones
CD8 + T cells were grown from cryopreserved stocks in 24-well tissue culture plates in CK 
media for two weeks following restimulation using 5 pg/ml PHA with 5xl06 irradiated 
allogeneic PBMC in 2 ml of media per well of a 24 well tissue culture plate. Following this, 
the cells were maintained in CK media for several months without the need for 
restimulation with antigen and/or irradiated autologous PBMC feeders. CD8 + T cell clones 
maintained and cultured in the presence of IL-15 for three months exhibited an identical 
activation profile in terms of early tyrosine phosphorylation events and effector function 
(specific lysis of antigen-bearing target cells, production of macrophage inflammatory 
protein 10 (MIP-10) and IFNy) to CD8 +T cells maintained in media supplemented with IL-2 
alone.
2.2.4 Human CD4+T cell lines and clones
The CD4+ T cell clone (Flu2-5) specific for the HLA DR*0101-restricted influenza virus A 
HA307-319 epitope PKYVKQNTLKLAT (PKY) was kindly donated by A. Godkin (Cardiff University, 
Cardiff). The JF-HA CD4+ T cell line specific for the same Flu epitope was kindly donated by T. 
Scriba (Oxford University, Oxford). The CD4+ T cell lines and clones were cultured in the 
same way as CD8 + T cells with the exception that no Cellkines were added to the culture 
media.
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2.2.5 Other cell types
2.2.5a Stable HLA A2-expressing C1R B cell clones
Endotoxin free pcDNA3.1 mammalian expression vectors (Invitrogen) with inserts encoding 
either full length HLA A2 or one of the following mutants: HLA A2 DT227/8KA, HLA A245V, 
HLA A2 Q115E or chimeric HLA A2/Kb (where the a3 HLA A2 domain has been substituted 
with the a3 of murine H-2Kb) were generated then linearised before transfection into the 
C1R cell line by electroporation. The C1R cell line is a Class I negative Epstein-Barr virus 
(EBV) transformed B cell line cultured in RIO (Storkus et al. 1989; Messer et al. 1992). The 
transfected C1R cell lines were cloned by limiting dilution (section 2.3.5). The clones were 
then regularly tested for HLA A2 expression by staining with HLA A2 conformation specific 
antibody clone BB7.2 conjugated to FITC (Serotec; Oxford, U.K.), and analysed on the 
FACSCalibur flow cytometer. All clones showed 100% HLA A2 expression, with equal MFIs in 
the FL1 channel.
2.2.5b TO cells
A CD4+ T cell line typically employed for the study of HIV-1 infection. TO cells were cultured 
in RIO media.
2.2.5c T2 cells
A CD4+ T cell line typically employed for the study of HIV-1 infection and peptide binding 
assays. The cells are very similar to TO cells but are deficient in TAP, and are thus only 
capable of exogenous peptide presentation. T2 cells were cultured in RIO media.
2.2.5d 293 T (HEK 293) lentiviral packaging cell line
The 293 T cell line was originally derived from human embryonic kidney (HEK) cells by 
transformation of cultured cells with sheared adenovirus-5 DNA (Graham et al. 1977) 293 T 
cells were chosen as the packaging cell line for the production of the lentiviral particles due 
to its ease of transfection. 293 T is an adhesive cell line, and was therefore cultured in 
specialised tissue culture flasks (T25, T75, and T175) and petri dishes (all supplied by Fisher 
Scientific), in 293 T cell culture media (DMEM-10). Cultures reaching 100% confluency were
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removed from the tissue culture plastic by incubation with 0.5% trypsin in HBSS (Gibco, 
Invitrogen) washed with 293T culture media (DMEM-10) to remove the trypsin, and split 
every 2 days to ensure log phase growth. The passage numbers were kept low, as the 
lentiviral titre from 293T cells decreases after 1 month of continuous culture.
2.2.6 Cryopreservation of cells
2-10 x 106 lymphocytes were pelleted at 500 x g (Sorvall RT 6000D centrifuge; Dupont 
Instruments) for 5 minutes then resuspended in 1 ml freezer mix and transferred to a 
cryovial (Nunc). Cryovials were stored in polystyrene containers at -80°C for 48 hours before 
being transferred to liquid nitrogen containers for long term storage. When required, cell 
stocks were rapidly thawed at 37°C to minimize cell death, washed once in PSG to remove 
the DMSO, and resuspended in appropriate culture media.
2.3 Mammalian cell-based techniques
2.3.1 Counting cells with Trypan blue
An aliquot of cells was mixed with an equal volume of 0.1% Trypan blue in PBS (w/v) and 
loaded on to an improved Neubaur haemocytometer (Weber Scientific International 
Limited, Lancing, U.K.). Viable cells assuming a colourless appearance were counted at 100 
times magnification on a light microscope (Olympus CK40 model).
2.3.2 Preparation of peripheral blood mononuclear cells (PBMC)
Typically 50 ml of peripheral blood was collected into a sterile 50 ml Falcon tube (BD 
Biosciences) containing the anti-coagulant heparin (Unihep Leo) at 1000 units/ml. PBMC 
were generated by Ficoll-Hypaque density gradient centrifugation. Peripheral blood was 
gently layered onto an equal volume of Ficoll-Hypaque solution (Lymphoprep, Nycomed) 
and centrifuged for 15 minutes at 733 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) 
with the break off. The buffy coat layer was gently removed from the gradient interface 
using a sterile Pasteur pipette and placed in a 20 ml universal for washing. Cells were
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washed twice with PSG by centrifugation at 600 x g for 10 minutes followed by 500 x g for 5 
minutes (Sorvall RT 6000D centrifuge; Dupont Instruments), with maximum break. After the 
final wash, cells were resuspended in R10 and kept in the incubator at 37°C/5% C02.
2.3.3 Preparation of cord blood mononuclear cells (CBMC)
Typically 30ml of blood was collected from the umbilical cord of a newborn during an 
elected caesarean section. Since isolation of cord blood neutrophils had to be performed for 
other projects in the group, isolation of CBMC employed a different protocol from that used 
for standard PBMC isolation. Following blood collection, 5 ml of anti-coagulant and calcium- 
chelator sodium citrate (Martindale Pharma) was added to 30ml of blood, and centrifuged 
at 500 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) for 20 minutes at RT with no 
break. All plasma was then gently removed with a Pasteur pipette and placed into a 15 ml 
falcon tube, before being centrifuged at 833 x g (Sorvall RT 6000D centrifuge; Dupont 
Instruments) for 20 minutes at RT to give platelet-poor plasma (PPP). PPP and 90% Percoll 
(Sigma-Aldrich) 10% saline (Sigma-Aldrich) were used make up the gradient in a 15 ml falcon 
tube:
42%- 0.84 ml 90% Percoll + 1.16 ml PPP (top layer)
51%-1.02 ml 90% Percoll + 0.98 ml PPP (bottom layer)
Meanwhile, 6 ml of dextran (Pharmacosmos, Holbaek, Denmark) was added to the sodium 
citrate layer, before making the volume up to the original 30 ml with warm (37°C) saline 
(Sigma-Aldrich, Poole, U.K.). The cell/saline mixture was left to incubate for 30 minutes in a 
water bath set to 37°C. The uppermost cell-rich layer was aspirated and centrifuged at 500 x 
g (Sorvall RT 6000D centrifuge; Dupont Instruments) for 6 minutes at RT, before being 
resuspended in 2 ml PPP and gently layered onto the Percoll-PPP gradient. The loaded 
gradient was centrifuged at 433 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) for 
13 minutes at RT with no break. The neutrophil (lower layer) and lymphocyte (upper layer) 
were collected using a Pasteur pipette, washed in PSG, and resuspended in appropriate 
media. To increase the yield of this procedure, which is not optimal for lymphocyte
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isolation, the remaining volume of Percoll-PPP-cell mixture was again separated using the 
standard lymphocyte isolation protocol (section 2.3.2).
2.3.4 MACS bead isolation
For positive CD8+T cell selection: 107 cells were resuspended in 80 pi of chilled MACS buffer 
(PBS, 0.5% FCS, 2 mM EDTA; filtered), to which 20 pi anti-CD8 antibody coated microbeads 
(Miltenyi Biotech) were added. The cells and beads were agitated together for 15 minutes 
at 4°C. The mixture was washed by adding 1-2 ml MACS buffer and centrifugation at 300 x g 
for 10 minutes (Sorvall RT 6000D centrifuge; Dupont Instruments). The supernatant was 
aspirated and the cells resuspended in 500 pi of MACS buffer and administered to a 25 ms 
MACS separation column (Miltenyi Biotech) equilibrated with 500 pi MACS buffer, held in a 
MACS magnet (MACS). The CD8 negative cells passed through the column and were 
discarded with the flow through, or used as feeder cells after irradiation. The column was 
washed by running 3 x 500 pi MACS buffer through it, and the CD8+T cells were eluted by 
application of 1 ml MACS buffer and a plunger. The CD8+ T cells were isolated with 99% 
purity. This protocol also applies to CD4+, CD25+ selection for isolation of CD4+ T cells and 
Tregs from PBMC, however the latter procedure also involved an initial depletion of CD4', 
CD127Lo cells.
For the anti-Fluorescein isothiocyanate (FITC)/anti-Phycoerythrin (PE) isolations: The 
protocol was identical to the one above except for the cells being stained with a particular 
antibody (or pMHCI tetramer) conjugated to FITC or PE fluorochromes, and the beads were 
coated with anti-FITC and anti-PE secondary antibodies.
2.3.5 Generation of human CD8* T cell clones by limiting dilution
Cloning mix consisting of 2xl06 PBMCs and 2xl05 peptide-pulsed allogeneic B cells per ml of 
R10, supplemented with 10% T-STIM (BD Biosciences) or 2.5% Cellkines (Helvetica 
Healthcare, Geneva) and 200 lU/ml IL-2 was made and y-irradiated (30Gy). Cells to be 
cloned were added to the cloning mix at a concentration of 1 cell per 600 pi mix, then 
plated out at 200 pi per well of a round-bottom 96 well plate (i.e. 0.3 cells per well). Control
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wells at 10 and 100 cells per well were also set up. Plates were cultured at 37°C/5% C02 and 
after 14-21 days examined for clones. Clones were re-stimulated as necessary, transferring 
them first to a 48 well plate, then at a second restimulation to a 24 well plate. Since the 
discontinuation of T-STIM in 2007, all CD8+ T cell clones and lines were subsequently 
cultured in CK media.
2.4 Bacterial cell-based techniques
2.4.1 Bacterial culture media and strains 
2.4.1a LB low salt media
1% Bacto-tryptone (Difco), 0.5% NaCI (Sigma Aldrich), 0.5% yeast extract (Difco).
2.4.1b TYP media
1.6% yeast extract (Difco), 1.6% Bacto-tryptone (Difco), 0.5% NaCI, 0.25% K2 HP04 (Sigma 
Aldrich).
All media was autoclaved on a liquid cycle at 121°C for 60 minutes, and supplemented with 
100 pg/ml ampicillin/carbanicillin (Fisher Scientific) prior to use.
2.4.1c Agar plates
15 g Bacto-agar/litre (Fisher Scientific) supplemented with 100 pg/ml ampicillin/carbanicillin 
(Fisher Scientific).
2.4.Id  Bacterial strains
Strain Description/Application Antibiotic resistance Supplier
ToplO Plasmid amplification for 
transformation, sequencing or 
transfection.
Ampicillin/Carbanicillin Invitrogen
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BL21(DE3) High stringency expression in Ampicillin/Carbanicillin Invitrogen
pLysS bacterial cell culture under the
control of the T7 promoter.
2.4.2 Making competent bacterial cells
Bacterial cells were streaked out onto an LB agar plate and incubated overnight at 37°C. 200 
ml of LB low salt media was inoculated with a single colony and grown to an ODeoo of 0.5- 
0.7. Cells were pelleted by centrifugation at 1590 x g for 20 minutes in a Beckman J2-MC 
centrifuge with a JA 10 rotor at 4°C. The pellet was resuspended in 40 ml of ice cold TFB1 
(30 mM KOAc, 50 mM MnCI2/100 mM KCI pH5.8,10 mM CaCI2, and 15% v/v glycerol). After 
pelleting by centrifugation as above, the bacterial cells were resuspended in 20 ml ice cold 
TFB2 (10 mM Na-MOPS pH7# 75 mM CaCI2, 10 mM KCI and 15% v/v glycerol). Cells were 
then aliquoted into pre-chilled eppendorf tubes and stored at -80°C.
2.4.3 Transformation of competent bacterial cells by heat shock method
Aliquots of competent bacteria, prepared as instructed above were thawed slowly on ice. 
50-100 ng of plasmid DNA (quantified by absorbance at 260 nm) was added to 50 pi thawed 
competent bacteria, kept on ice for 15 minutes, before being transferred to 37°C for 2 
minutes, and replaced on ice for 1 minute. Following this heat shock procedure, 100 ml of 
SOC media (Invitrogen) was added to the bacteria, and the mixture placed in a 37°C shaker 
set to 220 rpm for 30 minutes. Cells were then streaked out on LB agar plates supplemented 
with 100 pg/ml ampicillin/carbanicillin (Fisher Scientific) and incubated overnight at 37°C. A 
negative control tube containing bacteria alone was plated out for every transformation.
2.4.4 Target gene expression in bacterial cell culture
A single colony from a plate of freshly transformed BL21 bacteria was used to inoculate 50 
ml of TYP media supplemented with 100 pg/ml ampicillin/carbanicillin and agitated 
overnight at 220 rpm, 37°C. The following morning 1 litre of TYP media (supplemented with 
100 pg/ml ampicillin/carbanicillin) was inoculated with 2-5 ml of the starter culture and 
agitated at 37°C until the OD6oo reached between 0.4 and 1 (ideally 0.6). A 1 ml pre­
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induction sample was collected, microcentrifuged at 15600 x g (Centrifuge 5415D; 
Eppendorf) for 1 minute and the pellet stored at -20°C. Protein expression was induced by 
adding dioxin free isopropyl-l-thio-p-D-galactopyranoside (IPTG; Melford Laboratories) to 
make a final concentration of 0.5 mM. Flasks were agitated for a further 4-6 hours post 
induction. A 1 ml post-induction sample was taken and stored as for the pre-induction 
sample. The remaining culture was centrifuged at 1725 x g for 20 minutes at 4°C in a 
Beckman JE-6B centrifuge and the supernatant discarded. The bacterial pellet was either 
resuspended in lysis buffer for immediate inclusion body preparation (section 2.7.1), or in 
10-15 ml d.H20 and stored at -20°C.
2.5 Molecular Biology
2.5.1 DNA-based techniques 
2.5.1a Mini-prep of plasmid DNA
A single transformed bacterial colony was grown overnight under agitation at 220 rpm in 5 
ml LB media supplemented with 100 pg/ml ampicillin/carbanicillin at 37°C. Bacterial cells 
were pelleted by centrifugation at 1,333 x g (Sorvall RT 6000D centrifuge; Dupont 
Instruments) for 10 minutes at RT and the supernatant discarded. Plasmid DNA was 
extracted using a commercially available miniprep kit (Miniprep 250 kit; Qiagen) based on 
the alkaline lysis method. Extracted DNA was resuspended in warm (50°C) d.H20 and stored 
a -20°C.
2.5.1b Maxi-prep of plasmid DNA
A single bacterial colony previously transformed with plasmid DNA was used to inoculate a 
starter culture of 5 ml LB media (supplemented with 100 pg/ml ampicillin/carbanicillin) and 
shaken for 8 hours at 220 rpm at 37°C. 0.5-2 ml of starter culture was used to inoculate 
100-200 ml LB media (for high-copy plasmids) and 250-500 ml LB media (for low-copy 
plasmids), which was subsequently shaken overnight at 220 rpm, 37°C. The cultures were 
centrifuged at 1,333 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) for 20 minutes 
at 4°C and the supernatant discarded. The bacterial pellet was treated using a commercial
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endotoxin-free maxi-prep kit (Qiagen and Invitrogen) to extract the plasmid DNA. In the 
final step of the protocol the ethanol precipitated and dried DNA pellets were resuspended 
in 200-500 pi TE buffer and the concentration of eluted DNA quantified as outlined below. A 
maxi-prep typically yielded 700 pg of plasmid DNA.
2.5.1c Quantification of DNA
2 pi of DNA eluted following a mini- or maxi-prep procedure was diluted in 198 pi d.H20  
(milliQ). The absorbance of this solution was then measured on a spectrophotometer set to 
record at 260 nm wavelength. MilliQ d.H20 was used as a blank reference. An absorbance of 
1 at 260 nm was assumed to indicate a DNA concentration of 50 ng/pl (after the extinction 
coefficient for DNA, and the dilution factor were taken into account).
2.5.1d DNA sequencing
Sequencing was performed after each cloning step or PCR site directed mutagenesis (see 
sections 2.5.If) to verify the construct. For a construct containing the final TCR alpha-2A- 
beta sequence, three sequencing reactions were set up:
1) To check the pUC plasmid-TCR alpha junction.
2) To check the pUC plasmid-TCR beta junction.
3) To check the alpha-2A-beta junction.
500 ng of DNA template, 1 pi forward or reverse primer (MWG) (primer stock at 25
pmol/pl), 1 pi ABI BigDye enzyme and 3 pi of the corresponding sequencing buffer, made up
to a final volume of 15 pi. DNA was denatured at 95°C for 15 seconds, primers allowed to 
anneal at 50°C for 30 seconds, and DNA allowed to elongate at 60°C for 4 minutes for a total 
of 25 cycles. The sequencing reaction was cooled to 4°C before ethanol precipitation was 
performed (section 2.5.le).
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2.5.le  Ethanol precipitation
To the 15 pi of the sequencing PCR reaction (above), 35 pi of 100% ethanol (Sigma Aldrich) 
was added, and the mixture incubated at RT for 10 minutes. The reaction was centrifuged at
13,400 x g (Microcentaur, MSE) for 10 minutes and the supernatant was carefully aspirated 
and discarded. 50 pi of 70% ethanol was used to resuspend the DNA pellet for washing. The 
same centrifugation step was repeated and the supernatant again discarded. The pellet was 
allowed to dry before being sequence analysed at the central biotechnology services (CBS, 
Cardiff University) facility.
2.5.I f  PCR site directed mutagenesis (PCR-SDM)
To perform site directed mutagenesis of the N-glycosylation sites on the HLA A2 restricted 
SL9 epitope-specific 868 TCR, the alpha-2A-beta construct was supplied in a pUC (University 
of California) background. Five point mutations were made in the alpha chain and two in the 
beta chain using oligonucleotide pairs designed to insert the desired mutation. The resulting 
asparagine to glutamine substitutions alleviated the target sites for enzymes involved in the 
N-glycosylation process. The PCR reaction (30 ng DNA template, 10 pi forward primer and 
10 pi reverse primer (both at 100 pmol/pl; MWG), 1 pi 10 mM dNTPs (Promega), 1 pi Pfu 
polymerase (2.5 U/pl; Stratagene), 5 pi Pfu lOx buffer (Stratagene), and 22 pi d.H20 was 
placed in a sterile 0.2 ml PCR tube. DNA was denatured at 95°C for 30 seconds, primers 
allowed to anneal at 55°C for 1 minute, and DNA allowed to elongate at 68°C for 14 minutes 
for a total of 25 cycles. PCR tubes were cooled by placing on ice. The Dpnl endonuclease is 
specific for methylated and hemimethylated DNA (target sequence: 5'-Gm6ATC-3'). The 
parental DNA template was digested by adding 10 U Dpnl endonuclease (Promega) for each 
tube and incubating at 37°C for 2 hours. Competent DH5a bacteria were transformed with 
10 pi of the Dpnl treated PCR reaction mix (section 2.5.If) and the bacteria grown overnight 
at 37°C. The next day 5 colonies were randomly selected from each plate, grown overnight, 
and had their DNA extracted (section 2.5.1a). All the constructs were verified to contain the 
desired mutations by sequencing (section 2.5.Id).
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2.5.2 RNA-based techniques 
2.5.2a In vitro transcription (IVT)
RNA was synthesized using the mMessage mMachine T7 kit (Ambion) in line with the 
manufacturer's instructions. One 20 pi reaction required: 1 pig pure linear template DNA, 10 
pi 2x NTP/CAP, 2 pi lOx reaction buffer, 2 pi enzyme mix, made up to 20 pi with nuclease 
free water. The reaction was incubated for 2.5 hours at 37°C, followed by enzyme 
inactivation (5 minute incubation at 70°C) and DNase treatment to remove the DNA 
template (15 minute incubation at 37°C with 1 pi TURBO DNase (Ambion), 30 pi nuclease 
free water, and 30 pi LiCI). The synthesized RNA was precipitated by centrifugation at
13,400 x g (Microcentaur, MSE) for 30 minutes at 4°C. The supernatant was removed and 
replaced with 1 ml of nuclease free 70% ethanol before another centrifugation step (13,400 
x g for 10 minutes at 4°C). The supernatant was again discarded and the pellets dried at 
room temperature, and resuspended in 20 pi nuclease free water. The polyA tail was made 
by adding the following components to the 20 pi reaction mixture; 36 pi nuclease free 
water, 20 pi 5x E-PAP buffer, 10 pi 25 mM MnCI2, 10 pi ATP solution, and finally 4 pi E-PAP 
enzyme. The 100 pi reaction incubated at 37°C for 15-20 minutes. The RNA was recovered 
using the RNAeasy kit (Quigen). The concentration of RNA was quantified from absorbance 
at 260 nm wavelength using a spectrophotometer and on an RNA TBE gel (Invitrogen), and 
stored at -80°C. A typical 20 pi reaction yielded 20-30 pg RNA.
2.5.2b Transient transfection (Electroporation of IVT mRNA)
Jurkat cells were adjusted to a concentration of 7.5xl06/ml in R10. The counted cells, 0.4 cm 
cuvettes (Biorad), and mRNA were pre-chilled on ice for 5 minutes prior to electroporation. 
5 pg of IVT mRNA and 400 pi of cell suspension (3xl06 cells) were applied to one pre-chilled 
cuvette, while the control cuvette contained cells only. Using the Gene Pulsar II 
electroporator (Biorad), the cells were electroporated at 0.270 kV and 975 pF. The 
electroporated cells were immediately transferred to 6 ml of pre-warmed (37°C) R10 into a 
well of a 6-well tissue culture plate, and incubated for 24 hours at 37°C/5% C02 before 
carrying out flow-cytometric analysis for target protein expression levels.
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2.6.1 Viral assembly 
2.6.1a initial method1
The transfection reagent was prepared by mixing 150 pi CaCI2 and 1300 pi dH20, to which 
the three plasmids were added in the following amounts: 
pA8.9115 pg 
pMD2G 10 pg
pDNA (containing the construct of interest) 20 pg
The mixture of DNA and diluted 10 mM CaCI2 was then added drop by drop to 1500 pi 2x 
HEPES pH7.1 (Calcium phosphate transfection kit, Sigma Aldrich), as it was being bubbled 
using a 5 ml serological pipette to encourage formation of viral particles. The solution was 
incubated at RT for 20 minutes.
2.6.1b method2
174 pi of Express-ln transfection reagent (Thermo Scientific) was slowly added to 3 ml of 
DMEM-10/10 mM HEPES pH7.1 in a 15 ml falcon tube. The tube was inverted 4 times and 
incubated at RT for 20 minutes. Meanwhile, the DNA mix was prepared by combining the 
three plasmids in the following amounts: 
pA8.9118 pg 
pMD2G 7 pg
pDNA (containing the construct of interest) 15 pg
1 ml of the DMEM/Express-ln mix was then slowly added to the DNA, mixed and transferred 
to the remainder of the transfection reagent solution, inverted 4 times to mix and left to 
incubate for a further 30 minutes at RT.
2.6.2 Transfection of packaging cell line and processing of viral supernatant 
2.6.2a Initial method1
Following a 20 minute incubation at RT, the transfection reagent was applied directly to 
293T cells (ideally 80% confluent), cultured in a T175 flask in 30 ml of DMEM-10 media.
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Transfection was allowed to proceed for 48 hours, after which the cell culture supernatant 
was aspirated, centrifuged at 1,000 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) to 
remove any cell debris, and loaded onto Ultra-Clear 38.5 ml thin-wall centrifuge tubes 
(Beckman Coulter) for concentration of the viral supernatant in the ultracentrifuge (Optima 
I -100 XP Ultracentrifuge, SW 28.1 rotor, Beckman Coulter) at 129463 x g for 2 hours. The 
supernatant was discarded and the viral pellet resuspended in 500 pi PSG, before being 
either stored at -80 °C or used in transduction of cell lines.
2.6.2b Revised method2
3 ml of the DMEM/Express-ln/DNA mix was then applied to 293T cells (just exceeding 50% 
confluency) in a T175 culture flask, from which all DMEM-10 media has been aspirated. The 
reagent was left to cover the cells for 1 minute, before 22 ml of fresh DMEM-10 were added 
to the cells, and the flask was incubated at 37°C, 5% C02 for 48 hours. The viral supernatant 
was harvested and processed as described in the initial method except for the following 
changes: After centrifugation at 1,000 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) 
to remove the cell debris, the viral supernatant was syringed through a 0.45 p nylon filter 
(Nalgene), and the concentrated virus was resuspended in 2 ml of CK media.
2.6.3 Transduction of lymphocytes 
2.6.3a Initial method1
For transduction of Jurkat cell line, 1-128 pi of 1/50 diluted viral supernatant were applied 
to 2x 105 cells per well of a 24 well plate, initially to establish the multiplicity of infection 
(MOI) for a particular virus. 128 pi was typically sufficient to cause 100% transduction of 2x 
10s Jurkat cells.
For primary CD8+ T cells, the entire 500 pi of the concentrated viral supernatant was 
administered to 106 cells in a well of a 24 well plate, from which all the media was removed. 
The cells and virus were incubated together for 4 hours, at 37°C, 5% C02, before 2 ml CK 
media was added to the cells, and they were left to express the protein of interest for a 
further 70 hours.
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In both cases, the efficiency of transduction was assessed by following target protein 
expressing using flow cytometry.
2.6.3b Revised method1
24 hours prior to transduction, the CD8+ and CD4+ T cells were isolated from PBMC using 
anti-CD8, anti-CD4 MACS beads, MACS separation columns and a MACs magnetic cell sorter 
(all from Miltenyi Biotech) as described in section 2.3.4.106 CD8+ and CD4+ cells were mixed 
in a 1:1 ratio in CK media, applied to a well of a 24 well tissue culture plate, and stimulated 
to divide by addition of 6x 106 pre-washed (3 times, using RIO) anti-CD3/anti-CD28 antibody 
coated microbeads (Dynabeads T cell expander, Invitrogen) at a 1:3 cell: bead ratio. 
Following a 24 hour incubation at 37°C, 5% C02, 1 of 2 ml of CK media was aspirated and 1 
ml of viral supernatant added onto the cell-bead mix. Efficiency of transduction was
assessed by flow cytometry after a 72 hour culture period.
1 Lentiviral production protocol obtained courtesy of Dr. P. Brennan, Cardiff University, UK.
2 An adaptation of the lentiviral production protocol obtained through a collaboration with 
the University of Pennsylvania, USA.
2.6.4 Titering viral supernatant and calculating multiplicity of infection (MOI)
2x10s Jurkat cells in 1 ml of RIO were placed in each of 9 wells of a 24 well plate. The
concentrated virus supernatant was diluted 1/50 in RIO and the following amounts of 
diluted virus were added to the Jurkat cell-containing wells; 0 pi, 1 pi, 2 pi, 4 pi, 8 pi, 16 pi, 
32 pi, 64 pi, and 128 pi. The cells were then allowed to incubate with the virus for 28 hours 
at 37°C.
Multiplicity of infection (MOI) is the number of infectious viral particles per number of cells. 
We have to assume that each particle infects a cell (this of course isn't the case but accurate 
enough for calculating MOI). For example, if 10 pi of GFP viral supernatant was added to 106 
Jurkat cells and 26% became infected, 10 pi of viral supernatant would contain 26% of 106 
(260,000) particles of virus, meaning 1 pi contains 26,000 particles. Plotting the percentage 
of GFP positive cells at each amount of viral supernatant added against the amount of viral
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supernatant added produces a titration curve (Figure 6.8). The MOI is then estimated from 
values on the linear range of the curve as after the curvilinear and plateau phase the virus 
saturates the system and MOI estimates become inaccurate. Knowing the average number 
of cells infected in the linear portion of the titration curve, it is possible to calculate the 
number of particles of virus per pi assuming each particle infects a single cell. As an 
example, if 1 pi of viral supernatant contains 792,000 particles we assume it infects 792,000 
cells, giving an MOI of 1.
2.7 Protein Chemistry
2.7.1 Inclusion body preparation
Biotin-tagged MHCI heavy chains (wild type and Q115E mutant) and (wild type and 
K58E mutant) were expressed under the control of the T7 promoter as insoluble inclusion 
bodies in the Escherichia coli strain BL21 (DE3) pLys (Invitrogen) as described in section 
2.4.4. Inclusion bodies were released from IPTG-induced E. coli as follows. The bacterial 
pellet from 1 litre culture was re-suspended in 20 ml of lysis buffer (10 mM Tris pH8.1 
(Sigma), 10 mM MgCI2 (Sigma), 150 mM NaCI (Sigma) and lysozyme (Fisher Scientific)) were 
added both to a final concentration of 0.2 mg/ml. Finally, a cocktail of 5 protease inhibitors: 
500 pM AEBSF, 1 pg/ml Aprotinin, 1 pM E-64, 500 pM EDTA and 1 pM Leupeptin 
(Calbiochem) was added and bacterial suspension stirred at RT for 60 minutes. The bacterial 
suspension was then transferred to a 50 ml centrifuge tube (Falcon) and lysed by three 
repeated freeze/thaw cycles or by sonication to release the inclusion bodies. Inclusion 
bodies were purified by adding 5 volumes of Triton wash buffer (0.5% Triton X-100 (Sigma), 
50 mM Tris pH8.1 (Sigma), 100 mM NaCI (Sigma), 10 mM EDTA (Sigma), 2 mM DTT (Sigma)), 
pelleted by centrifugation at 1,333 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) 
for 20 minutes at 4°C and the supernatant containing the bacterial cell debris discarded. 
This step was repeated 2-3 times (a homogenizer was used each time to resolubilise the 
pellet in the Triton buffer) or until the inclusion body preparation was clean enough on the 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Once clean, 
the inclusion body pellet was denatured in 8 M urea or guanidine buffer (8 M urea or
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guanidine, 50 mM Tris pH8.1,100 mM NaCI, 10 mM ethylenediaminetetraacetic acid (EDTA) 
pH8 and 10 mM dithiothreitol (DTT), all from Sigma), the concentration estimated as 
described in section 2.7.5 and then stored in 1 ml aliquots at -80°C.
2.7.3 Fast protein liquid chromatography (FPLC)
The table on the next page outlines some of the properties of the Amersham Pharmacia 
columns used in the next section. All the columns were used by attaching them to an 
automated FPLC system (Amersham Pharmacia). Protein levels were continuously 
monitored by UV at 280 nm.
Column Description Use(s) Column
volume
(ml)
Volume of 
sample 
added 
(ml)
Flow
rate
(ml/min)
Volume of 
Fractions 
collected 
(ml)
Hi Trap Q Anion
Exchange
Purification 
of pMHCI 
monomers 
or TCR
5 500-
1000
5 1
Hi Trap Q 
desalting
Gel
Filtration
Removal 
of salt prior 
to biotiny- 
lation
5 0.5 0.5 0.5
Superdex 
HR 75
Gel
Filtration
Removal 
of excess 
biotin 
after bioti- 
nylation
23 2 0.5 0.5
2.7.3 Production of soluble human biotinylated peptide-MHC class I monomers
For the manufacture of pMHCI monomers, 30 mg of HLA A2 heavy chain with a biotin tag 
and 30 mg of inclusion body preparations were denatured separately in 10 ml 8 M urea 
or guanidine buffer (8 M urea (Sigma), 50 mM Tris pH8.1 (Sigma), 100 mM NaCI (Sigma), 10 
mM EDTA pH8 (Sigma) and 10 mM DTT (Sigma)) for 30 minutes at 37°C. Refolding was
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initiated by adding (in the order described) 1 ml peptide (4 mg/ml in DMSO), 30 mg 
denatured p2m, 30 mg denatured heavy chain in 1 litre of a pre-chilled |3- 
mercaptoethylamine/cystamine redox buffer (100 mM Tris pH8.1 (Sigma), 400 mM L- 
arginine HCL (Sigma), 2 mM EDTA (Sigma), 6.5 mM p-mercaptoethylamine (Sigma) and 3.7 
mM cystamine (Acros organics) at 4°C while stirring vigorously. After stirring for 4 hours at 
4°C the refold was transferred into 12 KDa dialysis tubing (Sigma), and dialysed against 12 
litres of d.H20 overnight then against 12 litres 10 mM Tris pH8.1 for 8 hours. Following 
equilibration of a 5 ml anion exchange column (Hi Trap Q HP; Amersham Pharmacia) with 10 
mM Tris pH8.1, the refold was loaded onto the column and the protein eluted with a salt 
gradient (0-500 mM NaCI in 10 minutes/10 mM Tris pH8.1). Figure 2.1 A shows a typical 
anion exchange trace where peak 1 contains refolded monomer and peak 2 contains the 
misfolded protein. The fractions containing peak 1 were collected, protease inhibitors 
added to prevent biotin tag cleavage, stored at 4°C and analysed by SDS-PAGE. If fractions 
contained the correctly refolded pMHCI, the SDS-PAGE gel showed two main bands (with 
some impurities after this ion exchange phase): a band at ~37 KDa (pMHCI heavy chain) and 
a band at ~12 KDa (P2m) (Figure 2.IB). The pMHCI band was typically more prominent than 
the p2m band. After analysis of the collected fractions on the SDS-PAGE gel, the fractions 
containing the two correctly folded proteins were pooled, concentrated down to 500 pi 
using 10 KDa cut off Ultrafree centrifugal filter (Millipore) and desalted using a 5 ml Hi Trap 
desalting column (Amersham Pharmacia) equilibrated with 10 mM Tris pH8.1 (Sigma). 
Desalted pMHCI monomer fractions were collected and biotinylated in a 2 ml biotinylation 
reaction (10 mM Tris pH8.1 (Sigma), 0.1 mM Tris HCI/1 mM biotin (Sigma), 8 mM MgCI2 
(Sigma), 5 mM ATP (Sigma), 2.5 pg Bir A enzyme (Invitrogen) (O'Callaghan C et al. 1999) 
overnight at room temperature. The removal of excess biotin and buffer exchange into PBS 
was performed by gel filtration (size exclusion) chromatography using a Superdex HR 75 
10/30 column (Amersham Pharmacia) equilibrated in PBS. Figure 2.2 shows a typical gel 
filtration profile, where peak 1 is the biotinylated pMHCI monomer and peak 2 is excess 
biotin. The excess biotin was concentrated and recycled for use in further biotinylation 
reactions. The peak 1 fractions were concentrated down to a 300 pi volume and stored at - 
80°C.
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Figure 2.1: Purification of pMHCI monomers by anion exchange. A. A typical anion 
exchange trace for pMHCI monomer refolds eluted with a salt gradient (the conductivity 
and concentration of which is shown as green and brown traces, respectively). Peak 1 is the 
correctly refolded pMHCI monomer and peak 2 is the misfolded protein. Peaks were 
subsequently analysed by SDS-PAGE analysis. B. 1 pg of pMHCI monomer loaded onto each 
of the six lanes (corresponding to the collected fractions) and separated by SDS-PAGE.
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Figure 2.2: Gel filtration to remove excess biotin from biotinylated pMHCI monomers.
Removal of excess biotin following the biotinylation reaction involved loading the 
biotinylated monomers onto a Superdex HR 75 10/30 size exclusion column, previously 
equilibrated in PBS. The graph shows the typical size exclusion profile, where peak 1 is the 
biotinylated monomer and peak 2 is the excess biotin.
2.7.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins were separated by SDS-PAGE using the Biorad Protean II electrophoresis system. 
Glass plates were wiped down with ethanol, assembled and the space between the plates 
was filled with resolving gel (125 mM Tris pH8.8, 0.1% SDS, 2 pl/ml of 25% AMPS solution, 
0.55 pl/ml TEMED, 12-15% acrylamide (all from Sigma)) to a height of 1 cm from the top of 
the plates, covered with a thin layer of dH20 and allowed to polymerise for 30 minutes. 
Excess water was removed and the denser stacking gel solution (125 ml Tris pH6.8, 0.1% 
SDS, 7.5 pl/ml 25% AMPS solution, 0.625 pl/ml TEMED, 6% acrylamide (all from Sigma)) 
applied gently to the top of the plates. The comb was inserted into the stacking gel, and the 
gel left to polymerise for a further 40 minutes. After removal of the comb, the gel was 
transferred into an electrophoresis tank and submerged in running buffer (192 mM glycine, 
50 mM Tris pH8.8, 350 pM SDS). Samples were prepared by diluting 1:5 in 6x sample buffer 
(125 mM Tris pH6.8, 4% SDS, 10% 0-mercaptoethanol, 20% glycerol, 20 pg/ml bromothenol 
blue) and heating to 95°C for 4 minutes. The samples and the molecular weight marker 
(Seeblue Plus2 marker, Invitrogen) were loaded into separate lanes on the gel. Gels were 
run at 80 mA for 45 minutes, and stained by agitating them for 1 hour with Coomasie Blue
11 14 17
Volume (ml)
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staining solution (40% methanol (BDH), 7% acetic acid (BDH), 0.025% Brilliant Blue G). The 
gels were destained by further agitation for a minimum of 1 hour with destain solution (10% 
methanol (BDH), 10% acetic acid (BDH)).
2.7.5 Estimating protein concentration by UV spectrophotometry
Inclusion bodies were diluted 1 in 100 in either 8 M urea or 6 M guanidine buffer, 
depending on the original solvent. The refolded pMHCI monomer samples were diluted 1 in 
10 in PBS. Using either the urea/guanidine buffers (for inclusion bodies) or PBS (for refolds) 
as reference blanks, readings at 280 nm wavelength were recorded. Protein concentration 
was calculated using the extinction co-efficient for each protein previously calculated from 
the amino acid sequence using Vector NTI suite (Microsoft). For example the extinction co­
efficient for monomeric pMHCI is 0.46.
2.8 pMHC multimer technology
2.8.1 Manufacture of pMHCI tetramers
Streptavidin (SA) has four binding sites for biotin therefore pMHCI tetramers can be 
constructed by adding streptavidin to a solution of biotinylated pMHCI monomers in a 1:4 
molar ratio. Tetramers were conjugate to R-phycoerythrin (PE) (Molecular Probes) and 
Allophycocyanin (APC) (Caltag) for use in flow cytometry, or Alexa Fluor-488 and Alexa 
Fluor-594 (both from Molecular Probes) for use in fluorescence microscopy. The volume of 
conjugated streptavidin required for each tetramer preparation was calculated and added 
in 5 aliquots of equal volume at 20 minutes intervals at 4°C, mixing the contents well each 
time. By adding streptavidin in aliquots as described the complete saturation of all four 
biotin binding sites for streptavidin is ensured with each addition. The tetramers were 
stored at 4°C for a period of up to four weeks, or until the tetramer showed signs of 
disintegration.
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2.8.2 pMHCI tetramer decay experiments
106 CD8+T cells were stained in 100 pi azide buffer (PBS, 0.1% NaN3/0.5% FCS (Sigma)) for 
20 minutes on ice with a concentration of tetramer, previously determined by titration that 
gave a starting fluorescence intensity (MFI) of 200 (+/- 50). After washing with 1-2 ml of 
azide buffer, the CD8+ T cells were resuspended in 110 pi azide buffer. A 10 pi aliquot was 
placed in a separate FACS tube to act as a control without the addition of competing 
unconjugated HLA A2-specific antibody. To the other tube containing the remaining 100 pi 
of cell suspension, 10 pi of unconjugated anti-HLA A2 mAb (clone BB7.2, Serotec, UK) at 100 
pg/ml was added to block tetramer re-binding. Aliquots of 10 pi were taken at the following 
time points after addition of the antibody; 0, 2, 5, 8,10, 15, 18, 20, and 30 minutes, added 
to FACS tubes containing 100 pi of PBS, and analysed on a FACSCalibur flow cytometer (BD). 
The control sample without any HLA A2 antibody added was analysed at 30 minutes.
2.8.3 pMHCI tetramer association experiments
106 CD8+ T cells were pelleted and resuspended in 200 pi PBS. A specific concentration of 
pMHCI tetramer was applied to the cell suspension, and 10 pi aliquots were taken out and 
placed in individual FACS tubes containing 100 pi PBS. The aliquots were removed from the 
master mix at the following time points; 0, 1, 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 28, and 30 
minutes, and were analysed on the FACSCalibur (BD).
2.8.4 Assembly of pMHC dextramers
Dextramers are composed of a dextran backbone decorated with streptavidin bound to 
biotinylated pMHC molecules (as in a pMHC tetramer), and several copies of a 
fluorochrome. The dextran backbones (obtained from Immudex, Denmark) were available 
with three types of fluorochrome attached: PE, APC, and FITC. The method of dextramer 
assembly with all three types of backbone was essentially the same, but the ratios of 
backbone to pMHC varied slightly. To prepare 500 pi (50 tests) of dextramer reagent with 
pMHCI monomers (Mr= 48.5 KDa) if the monomer is for instance at a concentration of 1.95 
mg/ml is outlined below:
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1) Dextramer-PE: 2 pi of dextran backbone is required for each 10 pi test of assembled 
dextramer reagent. Therefore for 50 tests, 100 pi of dextran-PE backbone and 7.9 pi 
of pMHCI monomer (at 1.95 mg/ml) were incubated together for 30 minutes at RT in 
the dark. The reagent was made up to 500 pi with 392.1 pi assembly buffer (0.05 M 
TRIS-HCL, 15 mM NaN3, pH7.2).
2) Dextramer-APC: 100 pi of dextran-APC and 4.4 pi of pMHCI monomer were 
incubated together for 30 minutes at RT in the dark. 395.6 pi of assembly buffer was 
added to make up the volume to 500 pi.
3) Dextramer-FITC: Two different types of FITC dextramer were made. For flow
cytometry a reagent with 1 pMHC monomer per streptavidin molecule was 
assembled as follows: 100 pi of dextran-FITC and 5.6 pi of pMHCI monomer were 
incubated for 30 minutes at RT in the dark. Subsequently, 394.4 pi of assembly 
buffer was added to the pMHC monomer backbone mix. For microscopy work, a 
dextramer containing 3 pMHC molecules per streptavidin was made up as follows: 
100 pi of dextran-FITC and 16.8 pi of pMHCI monomer were incubated together for 
30 minutes at RT in the dark. 383.2 pi of assembly buffer were added to complete 
the process.
The final concentration of dextramer in the preparations was 3.2xl0'8 M, and a 10 pi volume 
was typically used per stain. The concentrations of monomeric pMHC in a 10 pi preparation 
of each type of fluorochrome-conjugated dextramer reagent are outlined below:
1) Dextramer-PE : 6.6 Streptavidin (SA) molecules/ dextramer, 3 pMHC/SA.
Total pMHC per dextramer: 19.8
Amount of pMHC (n) = 3.2xl0"8/100000 (for 10 pi)
= 3.2xl0'13 moles of dextramer in 10 pi
19.8 MHC per dextramer so 19.8 x (3.2xl013) = 6.33xl0'12 moles (or 0.3 pg)
Therefore dextramer-PE contains 6.3xl0'12 moles (or 0.3 pg) pMHC monomer per 10 
pi staining volume.
2) Dextramer-APC: 2.9 SA/dextramer, 3 pMHC/SA.
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Total pMHC per dextramer: 8.7 
n = 3.2x10 8/100000 (for 10 pi)
= 3.2xl0'13 moles of dextramer in 10 pi
8.7 pMHC per dextramer-APC so 8.7 x (3.2xl013) = 2.78xl0*12 moles (or 0.13 pg) 
Therefore dextramer-APC contains 2.8xl0'12 moles (or 0.13 pg) pMHC monomer per 
10 pi staining volume.
3) Dextramer-FITC (MHC High version): 14.25 SA/dextramer, 3 pMHC/SA.
Total pMHC per dextramer: 42.75 
n = 3.2x 10'8/100000 (for 10 pi)
= 3.2xl013 moles of dextramer in 10 pi
42.75 pMHC per dextramer so 42.75 x (3.2xl013) = 13.68xl0'12 moles (or 0.65 pg) 
Therefore dextramer-FITC contains 13.7xl0'12 moles (or 0.65 pg) pMHC monomer 
per 10 pi staining volume.
For comparison, the calculation for determining the concentration of monomeric pMHC in 
each 0.5 pg pMHC tetramer preparation is shown below:
Tetramer-PE/APC/FITC: 1 SA/tetramer, 4 pMHC/SA.
Total pMHC per tetramer: 4
Amount (n) = mass (m)/ Molar mass (Mr)
n = 0.5x10 6g/48 KDa (average Mr of pMHCI)
= 1.04x1011 moles (or 0.5 pg) of MHC
Therefore 0.5 pg of tetramer preparation contains 1.04xl0'n moles pMHCI 
monomer.
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2.9 Treatment of cells with dasatinib and neuraminidase
2.9.1 Dasatinib treatment
Dasatinib was synthesized according to the published procedure (Lombardo et al. 2004). 
After initial optimization, CD8+T cells were incubated with 50 nM drug for 30 minutes at 37 
°C.
2.9.2 Neuraminidase treatment
5x10s CD8+ T cells were treated with 0.011 U of vibrio cholerae neuraminidase in a total 
volume of 500 pi of PSG medium for 15 minutes at R.T. The cells were subsequently washed 
with R10, as the FCS also inactivates neuraminidase. The cells were stained with FITC- 
conjugated peanut agglutinin (PNA) for 20 min at 4 °C to verify the desialylation status of 
the neuraminidase treated and untreated cells.
2.10 Flow cvtometrv
2.10.1 pMHC tetramer staining of T ceil clones, lines and PBMC
Unless otherwise stated ~105 CD8+ T cells specific for an antigen of interest were re­
suspended in 50 pi PBS and stained with 1 or 0.5 pg PE (Molecular Probes) or APC (Caltag) 
conjugated pMHCI tetramer for 15 minutes at 37°C or 20 minutes on ice, washed in PBS and 
centrifuged at 500 x g (Sorvall RT 6000D centrifuge; Dupont Instruments) for 5 minutes and 
resuspended in 50 pi PBS. The cells were then stained with 3 pi of an antibody (eg. anti-CD3 
FITC, clone SK7; BD) and 5 pi 7-Aminoactinomycin D (7AAD) (Viaprobe; BD) for 30 minutes 
on ice. After washing in PBS, cells were resuspended in 200 pi PBS or FACSfix (4% 
formaldehyde), and analysed using a FACSCalibur or a Canto II (both BD) flow cytometer 
(when using fluorochromes other than FITC, PE, and PerCP).
2.10.2 pMHC dextramer staining of T cell clones, lines and PBMC
Unless otherwise stated ~105 CD8+/CD4+ T cells specific for an antigen of interest were re­
suspended in 40 pi PBS and stained with 10 pi PE, APC, or FITC-conjugated pMHCI
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dextramer (Immudex, Denmark) for 30 minutes at RT. The unbound dextramers were 
removed by performing three washes with PBS, and the cells resuspended in 50 pi PBS prior 
to staining with cell surface antibodies as in section 2.10.1 above.
2.10.3 Gating strategy for phenotyping PBMC
When performing flow cytometric analysis it is important to employ a stringent gating 
strategy to exclude artefacts that may be contaminating the data. This is especially 
important in experiments when the cells of interest are present in very low frequencies in 
the sample. Figure 2.3 exemplifies the sort of gating strategy that was employed to 
phenotype CD4+ T cells from a PBMC sample. In order to get to the final CD4+ population, 
the following steps were taken: 1) FSC-H vs. SSC-H gating on the live lymphocyte population;
2) FSC-A vs FSC-H to eliminate any doublets; 3) Dead cells and CD14+ and CD19+ cells were 
excluded in the dump channel, and the gate placed around CD3+ cells; 4) and finally CD4+ 
cells. The CD4+ population was separated further into effector memory, central memory, 
and naive subsets according to their differential expression of CD27 and CD45RO 
phenotypic markers. Variations of this gating strategy were used for other cells types such 
as CD8+T cells, B cells, and y6 T cells. The gating strategy can be made even more stringent 
by performing a Boolean gating step after the first lymphocyte gate was drawn. Boolean 
gating serves to eliminate outliers that may occur due to fluorochrome spreading between 
FL channels.
2.11 CP8*T cell effector function assays
2.11.1 Enzyme linked immunospot (ELISpot) assay for interferon-y (IFNy)
96-well PVDF-backed plates (Millipore) were coated with IFNy capture antibody 1-DIK 
(Mabtech) at 15 pg/ml overnight at 4°C. Plates were washed twice in PSG and blocked with 
RPMI containing 10% FCS for 3 hours at 37°C. For target cell ELISpots: 2.5xl02-5xl02 CD8+T 
cells/well and 2.5xl04 CIR B cells expressing HLA A2/well +/- peptide were applied to 
duplicate wells of pre-coated plates in a total volume of 200 pi in PSG and incubated for 4- 
12 hours at 37°C. For tetramer ELISpots: 2xl03 CD8+T cells +/- various concentrations of
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Figure 2.3: Gating strategy for phenotypic analysis of PBMC. In order to eliminate artefacts, 
variations of this basic gating strategy were adhered to for flow cytometric analysis of PBMC. 
Gating steps 1-4 in addition to Boolean gating were followed before phenotypic analysis of a 
specific cell population (in this case CD4+ cells) was performed. Flow plot outlines in the  
bottom left portion of the figure depict the different phenotypic subsets of CD4+ and CD8+ T 
cells that can be viewed using a CD27 /CD45RO antibody co-staining.
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pMHCI tetramer (starting at 1 pg/ml) were applied to duplicated wells of pre-coated plates 
in a total volume of 200 pi PSG and incubated for 4-12 hours at 37°C. Plates were washed 6 
times with PBS at RT and incubated for 90 minutes with 1 pg/ml anti-IFNY-mAb-7B6-l biotin 
(Mabtech). After 6 further washes, a 1:1000 dilution of alkaline-phosphatase (AP)- 
conjugated streptavidin (Mabtech) was added and incubated at RT for 40 minutes. After 
further washes, chromogenic AP substrate (Bio-Rad) was added for 10-15 minutes and the 
development stopped by rinsing twice with H20. Spots were counted using an ELISpot 
reader system ELR02 (Autoimmun Diagnostika; Strassberg). The mean of the two duplicates 
was plotted.
2.11.2 Enzyme linked immunosorbent assay (ELISA) for macrophage inflammatory 
protein-13 (MIP-10)
CD8+T cells were washed twice in PSG and rested overnight (for CD8+T cell clones) and for 3 
days for cultured CD8+ T cells and TCR-transduced CD8+ cells. The next day CD8+T cells were 
adjusted to a concentration of 2.5x10s CD8+T cells/ml in PSG. Serial 1/10 dilutions (in PSG) 
of a specific peptide were made, starting at the highest peptide concentration of 100 pM. 
1x10s C1R target cells were then pulsed in a 50 pi volume of each peptide concentration for 
1 hour at 37°C. After washing with PSG, target C1R cells were counted and adjusted to 
2.5x10s cells/ml. 2.5xl04 CD8+T cells were placed into each well of a 96-U bottom plate with 
or without 2.5xl04 pulsed C1R target cells in a final volume of 200 pl/well. Plates were 
incubated for 4-12 hours at 37°C. Supernatants was removed and assayed for MIP-10 using 
a Quantikine ELISA kit (R&D systems). Alternatively the supernatant from the ELISA was 
assayed for other cytokines and chemokines using the cytometric bead assay (CBA) (see 
section 2.11.3).
2.11.2a MIP-10 ELISA for combinatorial peptide library screening
Background
The measurement of TCR cross-reactivity in a laboratory setting employs the combinatorial 
library screening technique. Combinatorial peptide libraries consist of all possible peptides 
of a defined length that can be synthesized from the 20 natural L-amino acids (Figure 2.4). 
Since the typical ap TCR recognizes peptides 9-11 amino acids in length, a 9mer library is a
113
Chapter 2
sensible place to begin. For a 9mer library, each mixture contains 1.7xl010 different 9mer 
peptides. When used at 1(30 pg/ml, the concentration of each peptide in each mixture is 
very low (5.3xl0‘14 M). In order to measure even the slightest CD8+T cell responses, a highly 
sensitive MIP-lf$ ELISA has become the method of choice for assessing TCR cross-reactivity 
of a human CD8+ T cell line or clone.
Position: 1 2 3 4 5 6 7 8 9
o x x x x x x x x
x o x x x x x x x
x x o x x x x x x
x x x o x x x x x
x x x x o x x x x
x x x x x o x x x
x x x x x x o x x
x x x x x x x o x
x x x x x x x x o
Figure 2.4: A nanomer (9mer) peptide library layout.Libraries are ordered in a position- 
scanning format. The 9mer library consists of 180 different peptide mixtures, each having 
one of the 20 L-amino acids in a defined fixed position (O) and all the other amino acids 
except cysteine at the remaining positions (X). Using this system the amino acids are entered 
into the fixed position (0) in alphabetical order according to their single letter code, the first 
mixture would contain peptides that all have an alanine (A) fixed at position one, and all the 
other possible amino acid combinations in the remaining positions. Whilst, the peptides in 
mixture 180 would all terminate in a tyrosine (Y).
The assay
The effector CD8+T cells were 'rested' in R2 media (2% FCS) for three days prior to the date 
of experiment to reduce the background cytokine levels. 5 pi of each 1 mM (1000 pM) 
peptide mix was added per well of a 96 well plate to C1R target cells (60,000 cells/well in 45 
pl/well volume), giving a final peptide concentration of 100 pM. 5 pi of PSG was added to 
the zero wells, and 5 pi of the relevant index peptide (at a final concentration of 1 pM) was 
used as a positive control. The target cells were incubated with the peptides for 2 hours at
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37°C, before the addition of effector CD8+T cells at a concentration of 30,000 cells per 50 pi. 
The assembled assay was incubated for 12-20 hours at 37°C. 50 pi of supernatant was 
collected from each well and either diluted 2.4x in assay diluent to be developed according 
to the standard ELISA protocol (section 2.11.2a) or frozen at -20°C for future analysis. All 
assays were performed in duplicate and averaged.
2.11.3 Cytometric bead array (CBA)
Peptide-pulsed C1R target cells were incubated with CD8+ T cells (in a 3:1 target: effector 
ratio) for 4-12 hours at 37°C. The supernatant was assayed using the human Thl/Th2
Cytokine kit (BD) according to the manufacturer's instructions. The sample acquisition was 
performed on a FACSCalibur (BD) flow cytometer, and the results analysed using standard 
curves constructed with the aid of CBA software (BD).
2.11.4 TCR/CD8 downregulation assay
HLA A2-expressing C1R cells were either pulsed with 1 pM peptide for 1 hour or incubated 
in PSG media alone. After two washes with PSG, 6xl05 pulsed or unpulsed targets were 
incubated with 3xl05 effector CD8+T cells for 4-12 hours at 37°C. Following the incubation, 
the cells were pelleted and the supernatant removed or analysed for cytokines in ELISA or 
CBA assays. The cell pellets were stained with anti-TCRFITC (Clone BMA 031; Serotec) and 
anti-CD8APC (clone RPA-T8; BD Pharmingen) for 30 minutes on ice, washed twice, and 
resuspended in PBS. Data was acquired using a FACSCalibur (BD) flow cytometer and 
analysed using FlowJo software (Treestar Inc., Ashland, OR, USA).
2.11.5 Intracellular cytokine staining (ICS) for CD8+T cell effector functions
This procedure enables quantification of various CD8+ T cell effector functions by flow 
cytometry. The assay set up was identical to a MIP-lp ELISA (section 2.11.2a and b), and the 
E:T ratio was typically 2:1, but 90,000 (instead of 60,000) CD8+ effectors were used per well 
of a 96 well plate (100 pi assay volume). Once the effector and target cells were placed in 
the wells, 1 pl/ml of BFA (stock at 10 mg/ml, Sigma-Aldrich), 0.7 pl/ml Monensin (Golgi- 
stop, BD), and 3 pl/well anti-CD107a (optional) were added. The assay was incubated for 6-
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12 hours at 37 °C, 5% CO2. After the desired incubation period, the assay plate was 
centrifuged at 667 x g for 3 minutes (Sorvall RT 6000D centrifuge; Dupont Instruments), and 
the supernatant discarded. The samples were washed once by application of 200 pi of PBS 
and centrifuged at 667 x g for 3 minutes (Sorvall RT 6000D centrifuge; Dupont Instruments). 
Once the supernatant was once again discarded, the pelleted cells were stained with a 
mixture of surface antibodies (typically binding the surface molecules CD3, CD8, CD4, CD14, 
and CD19) in a 50 pi volume for 20 minutes at RT. The cells were washed twice using the 
washing procedure with PBS, and resuspended in 100 pi lx cytofix/cytoperm solution (BD), 
and incubated for 20 minutes at RT, protected from light. The samples were then washed 
twice with 150 pi perm wash buffer (BD) diluted 1:10 with d.H20 and centrifugation at 733 x 
g for 3 minutes (Sorvall RT 6000D centrifuge; Dupont Instruments). The cell pellets were 
subsequently resuspended in 100 pi intracellular antibody mix (typically targeting activation 
markers IL-2, MlP-lfJ, TNF, and IFNy), and incubated for 20 minutes at RT, protected from 
light. The cells were finally given a further two washes with the perm wash buffer, and 
resuspended in 100 pi perm wash or PBS. The samples were analysed by flow cytometry 
using the FACS Canto II (BD) and FlowJo software (Tree Star Inc.).
2.11.6 Infection of TO and primary CD4+ T cells with HIV-1 and intracellular staining for the 
HIVgag p24 protein
Intracellular staining for the p24 protein is used to assess the extent of HIV infection by flow 
cytometry. TO cells are very permissive to infection with HIV-1. To infect, ~106T0 cells were 
pelleted by centrifugation at 500 x g for 5 minutes (Sorvall RT 6000D centrifuge; Dupont 
Instruments) and the pellet incubated with 100 pi HIV-1 (Strain HTLV-IIIB/H9 (NIH), which is 
CXCR4-dependent T cell-tropic) supernatant for 1 hour at 37 °C, 5% C02. The cells were then 
resuspended in 10 ml R10 media and placed in a T75 flask for culture. The cells were 
maintained in culture and remained infected with HIV for prolonged periods (up to several 
months), but the percentage of infected cells generally declined if cells remained in culture 
in excess of this culture period. Supernatant from the infected TO cells containing HIV-1 
particles and was used to infect new batches of TO cells, as well as primary CD4+ T cells. For 
this, CD4+ T cells were MACS-sorted from fresh PBMC isolated from HLA A2 positive blood
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donors (see section 2.3.4). 106 CD4+T cells per well of a 24 well plate were stimulated with 
anti-CD3/anti-CD28 coated microbeads in ratio of 1:3 cells: beads for a period of 48 hours in 
RIO media containing 200 lU/ml IL-2 (IL-2 media). 1 ml of viral supernatant (depleted of TO 
cells by centrifugation at 1,000 x g for 10 minutes (Sorvall RT 6000D centrifuge; Dupont 
Instruments)) was applied to the pre-activated CD4+ T cells in the presence of 200 lU/ml IL-2 
and incubated for 3 days at 37 °C, 5% C02. Following this incubation with the virus, the 
beads were magnetically removed and the cells placed in IL-2 media for further expansion.
Both TO and primary CD4+ T cells were tested for HIV infection by intracellular staining for 
the p24 protein, which forms part of the HIV capsid. Cells were pelleted in 5ml FACS tubes 
and incubated with AquaAmcyan viability dye, washed 3 times in 1 ml PBS, resuspended in 250 
pi cytofix/ cytoperm solution (BD), and incubated for 20 minutes at 4 °C in the dark. The 
cells were then washed again (3 times with 1 ml perm/wash buffer (BD)) and stained with 
the following antibodies: CD3 APC'H7/ CD8 PE Cy7/ and p24FITC for 20 minutes at 4 °C in the dark. 
Unbound antibodies were washed off (three times with 200 pi perm/wash buffer) and the 
cells resuspended in 200 pi of PBS. The cells were acquired on a FACS Aria flow cytometer 
(BD) and the data analysed using FlowJo (Treestar). Figure 2.5 shows the gating strategy 
typically used to assess the success of HIV infection.
2.11.7 Fluorometric assessment of T lymphocyte antigen-specific lysis (FATAL)-CD8+T cell 
killing assay
3xl04 of either pulsed (with antigenic or control peptide, for 1 hour) or unpulsed (incubated 
in media alone) target cells (typically C1R, TO or T2 cells) were stained with two different 
concentrations of CFSE (1 pl/ml and 10 pl/ml of 1/375 pre-diluted 10 mM stock) for 10 
minutes (and protected from light) to distinguish the antigen-presenting and internal 
control populations, prior to application of both population to a well of a 96-well U-bottom 
plate. 15x10s CD8+T cells (giving an E:T ratio of 5:1) were applied to the same plate (either 
specific for the antigenic peptide presented by targets or in conjunction with an ImmTAC/V 
reagent specific for the peptide) in a final of 200 pi. The assay was incubated for 4-12 hours
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Figure 2.5: Assessment of the extent of HIV infection by intracellular staining for p24 
expression. 106 HIV-infected (bottom right plot) or uninfected (bottom left plot) TO cells 
were treated with the viability dye Aqua followed by an intracellular stain with anti-CD3, - 
CD8, and -p24 antibodies. Although TO cells are CD4+, no anti-CD4 stain was included as 
the HIV infection induced downregulation of the CD4 coreceptor, and an intracellular CD4 
stain (unlike intracellular anti-CD3 and anti-CD8 stains) was not effective. The efficiency of 
TO cell infection with HIV ranged between approximately 90 and 100%, and a p24 stain 
was routinely performed prior to using the cells in functional assays.
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at 37°C and the cells harvested following removal of the supernatant. If PBMC were used as 
effector cells in this assay, the cells were typically stained with the following antibodies: 
Anti-CD3CyPE, anti-CD4Cy5PE, anti-CD8a705, pan-TCRy6PE, anti-CD69 APC, anti-CD45ROECD(Texas 
Red), anti-CD19APGCy7, and VividPac,flc Blue all purchased from Pharmingen, BD Biosciences (San 
Jose, CA).
The FACS dot plots in Figure 2.6 give an example of how specific lysis of target cells is 
determined using a FATAL assay.
2.12 Fluorescence microscopy
105 CD8+ T cells were treated stained with 4',6-diamidino-2-phenylindole (DAPI) nuclear 
stain (Invitrogen) and either Alexafluor-488 conjugated (Molecular Probes) peptide-MHC 
tetramers (at a final concentration of 12.5 pg/ml) or FITC-conjugated dextramers (Immudex, 
Denmark) (at a final concentration of 16.25 pg/ml) for 30 minutes at RT. Following three 
washes with PBS, each sample was fixed in 2% paraformaldehyde. After fixing, the CD8+ T 
cells were re-suspended in 100 pi of 2% FCS/PBS and then spun onto a microscope slide at 
550 rpm for 5 minutes using a cytospin III centrifuge (Harlow Scientific). Samples were 
subsequently analysed on a Leica DM LB2 (Leica Microsystems) fluorescence microscope.
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Figure 2.6: An example of a FATAL assay layout. Peptide-pulsed target cells were stained 
with one concentration of CFSE dye, while unpulsed control cells were stained with a 
different concentration of the same dye. The target and control populations were combined 
in the same FATAL assay and can each be identified by flow cytometry by their different 
CFSE signal intensities in the FL1 channel. In the absence of any peptide-specific ImmTAC 
reagent and effector CD8 +T cells, both populations remain intact (left panel), while in the 
presence of sufficient reagent and CD8 +T cells, the peptide-pulsed population disappears as 
the CD8 +T cells in the assay are being redirected to lyse target cells presenting the cognate 
peptide.
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The interaction between the TCR and peptide-MHC is central to T cell recognition of 
infected and dysregulated cells. Exploiting the high degree of specificity, afforded by the 
TCR/pMHC interaction, through the use of soluble pMHC molecules to target T cells bearing 
cognate TCRs, presents an attractive prospect for the detection of specific T cells in ex vivo 
samples. However, the monomeric TCR/pMHC interaction is classically weak and lasts only a 
matter of seconds at physiological temperatures, rendering the use of monomeric pMHC 
inadequate for such purposes. A solution was provided by Altman et al, who in 1996 
published a landmark paper describing the generation of tetrameric forms of pMHC 
molecules (Altman et al. 1996). As a result of the avidity effect which arises on 
multimerization, the half life of the TCR/pMHC interaction was increased from seconds to 
hours, permitting the use of specific fluorochrome-conjugated pMHC tetramers to detect T 
cells of interest by flow cytometry. Over a decade later, the uses of pMHC tetramers, still 
the most favoured form of pMHC multimer, have grown dramatically (see section 1.6 of the 
main Introduction for a few examples) and with it so too has our knowledge of T cell 
responses. It is no longer enough to simply highlight a select population of T cells and report 
its presence. Immunologists, my group included, are increasingly interested in 
characterising and grading the quality of specific T cell responses. The majority of these T 
cell responses are studied due to their involvement in diseases such as cancer, chronic 
infection, and autoimmunity. For the reasons described in more detail in section 1.7 of the 
Introduction of this thesis, the TCRs on many of these T cells display very low affinities for 
their cognate antigen. The low affinity of some TCR/pMHC interactions means it is not 
possible to use conventional pMHC tetramer technology to detect T cells bearing such TCRs. 
As part of my investigations into optimising TCR/pMHC interactions for targeting disease, I 
have developed a number of 'tricks' aimed at improving the detection and characterisation 
of low avidity T cells using multimeric pMHC molecules (Chapters 3-5). In this chapter I 
report the use of pMHCI tetramers with enhanced CD8  binding. I will begin by laying out key 
aspects of research generated by members of my group, which have provided a basis for my 
own studies.
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3.1.1 CD8 coreceptor dependence of CD8+ T cell activation and pMHCI tetramer binding
As described in section 1.4 of the main Introduction, the CD8  coreceptor is a key player in
the process of antigen recognition by CD8 + T cells. Understanding how CD8  influences the
dynamics of the TCR/pMHCI interaction and thus CD8 + T cell function represents a major
focus of the T  cell modulation group'. At the heart of this investigation were two important
questions: i) What range of TCR/pMHCI affinities is required for the detection of antigen-
specific CD8 + T cells by pMHCI tetramers? and, ii) How does the CD8  coreceptor influence
this process? My colleague Bruno Laugel proceeded to address these questions by studying
the efficiency of cell staining with a set of altered pMHCI tetramers, assembled from
monomeric pMHCI molecules which exhibited impaired CD8  binding (Laugel et al. 2007).
These 'CD8 -nuir pMHCI tetramers were constructed from HLA A2 monomers containing a
double D227K/T228A substitution in the a3 domain (Purbhoo et al. 2001), which completely
abrogated binding to the CD8  coreceptor whilst leaving the TCR/pMHC interaction
unperturbed. Data obtained with these CD8 -null pMHCI tetramers indicated that the CD8
coreceptor was required for binding of antigenic ligands that display suboptimal TCR/pMHCI
affinities. Furthermore, the extent of coreceptor dependence appeared to be inversely
correlated with TCR/pMHCI affinity (Laugel et al. 2007). In order to obtain a quantitative
measure of the contribution of CD8  binding to the engagement of soluble tetrameric pMHCI
molecules, a CD8 + T cell clone that recognises the HLA A2-restricted human telomerase
reverse transcriptase (hTERT)540-548 peptide (ILAKFLHWL, ILA from hereon), called ILA1
(Laugel et al. 2007; Purbhoo et al. 2007), was stained with a panel of pMHCI molecules
displaying: i) varying affinities for CD8 ; and, ii) a number of biophysically characterised
altered peptide ligands (APLs). The APLs used in this study were selected from a peptide
library of ~50 monosubstituted ILA peptides, based on their divergent abilities to stimulate
the ILA1 clone. The activation results, measured by IFNy ELISpot are summarised in Figure
3.IB. From this initial ILA variant peptide screen, the number of APLs was narrowed down to
six: 8 E, 5Y, 4L, 3G8T, 3G, and 8 Y. The 3G, 3G8T and 8 Y high affinity binders can be referred
to as 'superagonists' relative to the index peptide, whist 5Y, 8 E and 4L represent weak
agonists. Together with the index ILA peptide, these ligands span a wide range of binding
affinities for the ILA1 TCR. The dissociation constant (KD), which is determined by surface
plasmon resonance (SPR) binding equilibrium experiments, is a measure of TCR/ligand
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Figure 3.1: Kinetic and functional characteristics of the ILA epitope variants recognized by 
ILA1 CD8 * T cells. A. Table of Kq values calculated from kinetic parameters determined by 
surface plasmon resonance (SPR). B. An IFNy ELISpot screen of the peptide positions 
recognized by the ILA1 CD8 * T cell clone. The height of the peaks represents the strength of 
the IFNy signal quantified as the number of spot-forming cells per 200 ILA1 T cells added 
per well of the assay. The left-most peak represents the IFNy response exerted by the ILA 
index peptide, which was used as a reference. The number labels on the x-axis refer to the 
positions of the amino acids in the index ILA (ILAKFLHWL) peptide, which are indicated by 
the single letter code. Positions 2 and 9 are anchor residues and were thus kept the same 
as in the index sequence. (Data kindly provided by B. Laugel).
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affinity. The KD values for the monomeric ILA1 TCR/APL ligand interactions are summarised 
in Figure 3.1A. ILA1 TCR-binding to the weakest variant 8 E has an estimated KD value of ~2 
mM. However, because the affinity of this ligand lies on the threshold of detection by SPR, 
we can only confirm its KD as being > 500 pM with certainty.
To assess the influence of the monomeric TCR/pMHCI affinity and presence of a pMHCI/CD8  
interaction on pMHCI tetramer staining of CD8 +T cells, the APLs summarised in Figure 3.1A 
were complexed with MHCI molecules (either wildtype or CD8 -null) and assembled into 
fluorochrome-conjugated pMHCI tetramers. The two panels of pMHCI tetramers were then 
tested for their ability to stain the ILA1 clone under different staining conditions (4°C versus 
37°C). Figure 3.2 illustrates the differences in brightness intensity of the ILA1 CD8 + T cell 
clone when labelled with either wildtype (Figure 3.2A) or CD8 -null (Figure 3.2B) pMHCI 
tetramers refolded around several ILA APLs, at 37°C or 4°C (Figure 3.2 C and D, respectively). 
The results indicate that a functional wildtype pMHC/CD8  interaction is essential for the 
visualisation of CD8 + T cells in cases where the pMHCI tetramer used to stain these cells 
incorporated a low affinity APL. From the pMHCI tetramer staining data, it was deduced 
that under 'normal' staining conditions (staining with 10 pg/ml tetrameric pMHCI at 37°C 
for ~ 15 minutes) a TCR/pMHCI interaction of KD £ 40 pM was required for good pMHCI 
tetramer staining of CD8 + T cells. Importantly, the only variant in these clonal studies is the 
antigenic peptide used. Thus, the level of TCR and CD8  expression on the T cell surface are 
constant within any given experiment. The findings from this study set a basis for the work 
presented in this chapter.
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Figure 3.2: Staining of ILA1 CD8+ T cell clone with tetramerised cognate pMHCI 
molecules. The figure shows the staining of the ILA1 CD8 + T cell clone with seven different 
hTERT^u^gvariants, as indicated, refolded with wildtype (WT) HLA A2 (A) or D227K/T228A 
(CD8 -null) HLA A2 (B) at 37°C. The mean fluorescence intensity (MFI) values observed with 
pMHCI tetramer staining were plotted versus the TCR/pMHCI interaction KD values for 
experiments conducted at 37°C (C) and 4°C (D) with WT HLA A2 (circles) and CD8 -null HLA 
A2 (squares) molecules for each variant added at a final concentration of 220 nM (10 
pg/ml). Colour codes in C and D correspond to those shown in A and B. Staining with the 
set of altered peptide ligands refolded with each type of heavy chain was performed at 
least three times. Representative data are shown. Curves are the best fit of the model 
described under Experimental Procedures of (Laugel e ta l. 2007). (Data kindly provided by 
B. Laugel).
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3.1.2 The Q115E mutation and the pMHC/CD8 interaction
Following the work with CD8 -null pMHCI tetramers reported by Laugel et al, I became 
interested in investigating what effect enhancing the pMHCI/CD8  interaction would have on 
pMHCI tetramer staining of CD8 + T cells. CD8 -enhanced pMHCI molecules can be generated 
by subjecting the a2 domain of the HLA A*0201 allele to a glutamine/glutamic acid (Q/E) 
substitution at position 115 (Wooldridge et al. 2005; Wooldridge et al. 2007). Molecular 
dynamic modelling had predicted that this mutation would manifest itself by shortening a 
key hydrogen bond, which plays an important role in the interaction between the CD8 a 
subunit and the a2 domain of HLA A2. Figure 3.3 provides a structural representation of the 
pMHCI/CD8  interface, highlighting the positions of the Q.115 residue before and after the 
substitution. SPR measurements of CD8 -enhanced (Q115E-substituted) and CD8 -wildtype 
interactions with monomeric HLA A2, confirmed that the Q115E substitution increased the 
strength of CD8  binding by a factor of ~1.5 compared to wildtype pMHCI (KD ~85 pM for 
CD8 -enhanced and KD ~130 pM for CD8  wildtype) (Wooldridge et al. 2005; Wooldridge et al. 
2007). In compliance with these findings, C1R cells presenting the Q115E-substituted HLA 
A2-associated antigens were substantially better recognised by CD8 + T cells in functional 
assays. Furthermore, CD8 + T cells showed vast improvements in antigen-specific activation 
and cytotoxicity in response to target cells presenting cognate peptide in the context of 
Q115E HLA A2 molecules (Wooldridge et al. 2005; Wooldridge et al. 2007). Importantly, just 
like the D227K/T228A mutation, the Q115E substitution was not accompanied by changes in 
TCR/pMHCI specificity (Wooldridge et al. 2007). This enabled the influence of the CD8  
coreceptor on antigen recognition by CD8 + T cells to be assessed independently of 
TCR/pMHCI binding.
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Figure 3.3: The CD8alR4 guanidinium moiety forms a stronger electrostatic interaction 
with the HLA A*0201 Q115E mutant carboxylate than with the wildtype Q residue. HLA- 
A2 heavy chain is shown in yellow complexed with (32m (red) and CD8  (green). The inset 
shows the location of the key residues Q 1 1 5  in HLA A2 and R4  in CD8 a l.  For clarity, the right- 
hand-side close up is rotated about the vertical relative to the standard view. The wildtype 
Q 1 1 5  residue is shown for comparison (yellow). The Qn 5 /R 4  0 £ l..N r |l distance in the HLA 
A2 CD8 aa  crystal structure (Gao et al. 1997) is 3.18 A. This distance is predicted by the 
molecular dynamics simulation to shorten to an average of 2.56 A with Qn5E (shown as 
broken line) and enables these moieties to form a strong electrostatic interaction.
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3.1.3 Aims
The development of soluble recombinant pMHC molecules conjugated in multimeric form 
to fluorescent labels has enabled the physical enumeration, isolation, and characterisation 
of antigen-specific T cell populations by flow cytometry. Several factors determine whether 
a pMHCI tetramer will bind a cognate CD8 + T cell population, the monomeric affinity of the 
TCR/pMHCI interaction being of particular significance. A study by Laugel et al. had 
succeeded in quantifying the minimal affinity of a TCR/pMHCI interaction required for a 
pMHCI tetramer to bind a CD8 + T cell expressing a cognate TCR as KD < 40 pM (Laugel et al. 
2007) when using conventional technology. Significantly, this study demonstrated that the 
TCR/pMHC threshold required for regular pMHC tetramer staining is considerably higher 
than that required for T cell activation. This difference in threshold represents a significant 
problem when using pMHC tetramer technology for the detection of cancer-specific, 
autoimmune or MHC class ll-restricted T cell responses as these are typically dominated by 
weak TCR/pMHC interactions (Cole et al. 2007). At the outset of my project there was an 
urgent need to address this problem so as to develop technology that could be used to 
visualise all antigen-specific T cells using pMHC multimers and flow cytometry. The major 
aim of this work was to address this deficiency and therefore extend the diagnostic use of 
pMHC multimer technology and make it relevant in other important disease states. Since 
the CD8  coreceptor is involved in stabilising the TCR/pMHC interaction (Wooldridge et al. 
2005), CD8 -null pMHCI tetramers, which do not benefit from this stabilisation effect, were 
only successful in staining CD8 + T cells displaying high affinities for cognate antigen (Laugel 
et al. 2007). The principle aim of my investigation was thus to determine whether enhancing 
the pMHCI/CD8  interaction would have the opposite effect of lowering the threshold 
required for pMHCI tetramer staining of CD8 + T cells, without incurring a loss in TCR/pMHCI 
specificity. The specific aims of this work were to:
i) Manufacture wildtype and CD8 -enhanced HLA A2 monomers refolded around a set 
APLs, and assemble these into tetramers.
ii) Determine if pMHCI tetramers constructed from CD8 -enhanced (Q115E-substitued) 
peptide-HLA A2 monomers engineered to have ~1.5 fold higher affinity for CD8  are
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better able to detect cognate CD8 + T cell populations than wildtype pHLA A2 
tetrameric reagents, using the well characterised ILA1 system as a model.
iii) Provide a mechanistic explanation for the observations in ii).
iv) Assess whether the findings with the I LAI system extend to other systems, by 
studying the ability of wildtype and CD8 -enhanced pMHCI tetramers to stain low 
avidity CD8 + T cells (displaying a number of different antigen specificities) directly ex 
vivo.
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3.2.1 CD8-enhanced pMHCI tetramers stain CD8* T cells with avidities for cognate antigen 
that lie below the threshold of detection with corresponding wildtype reagents
To determine the binding threshold of wildtype and CD8 -enhanced pHLA A2 tetramers with
respect to monomeric TCR/pMHCI ligand affinity, I constructed two sets of pMHCI
monomers specific for the CD8 + T cell clone ILA1. This was done by refolding either wildtype
or CD8 -enhanced (Q115E-substituted) HLA A2 heavy chains with a set of six ILA APL (8 E, 5Y,
4L, 8 Y, 3G8T, and 3G) or the ILA index peptide (Figure 3.1 A). The refolding process and
pMHCI tetramer assembly are described in Sections 2.7 and 2.8 of Materials and Methods.
The two sets of HLA A2 tetramers were used to stain the cognate CD8 + T cell clone, ILA1. To
enable direct tetramer staining comparisons limited solely to differences in CD8  binding
properties, pMHCI tetramer concentration (10 pg/ml), staining temperature (37 °C),
incubation period (15 minutes), and staining volumes were standardised for each staining
procedure. As shown in Figure 3.4, the mean fluorescence intensity (MFI) of staining for the
I LAI clone with both sets (wildtype versus CD8 -enhanced) of variant MHCI tetramers
correlated with the affinity (KD) of the monomeric TCR/pMHC interaction (Figure 3.1 A). The
CD8 -enhanced pMHCI tetramers conserved the staining positions of the APLs relative to
each other, but resulted in a significant enhancement of tetramer staining when compared
to the wildtype reagents (Figure 3.4 A and B). This shift in the recognition spectrum in
favour of low affinity ligands is more clearly demonstrated on a mathematically fitted curve
of MFI versus KD values for the two sets of tetramers (figure 3.4 D). According to the curve,
coreceptor-enhanced pHLA A2 tetramers refolded with APLs that exhibited low monomeric
TCR/pMHCI binding affinities in surface plasmon resonance (SPR) experiments (KD >100 pM)
stained ILA1 CD8 + T cells with greater intensities compared to the corresponding wildtype
reagents. This effect was most marked with APLs displaying mid-range K0 values such as the
4L (Kd~117 pM; Figure 3.4 C) and 5Y (KD~242 pM; Figure 3.4 and (Laugel et al. 2007))
APL/HLA A2 tetramers. No significant staining differences between wildtype and CD8 -
enhanced tetramers were observed with lower monomeric TCR/pMHCI affinities (KD> 500
pM, variant 8 E) or with high affinity ligands 8 Y, 3G8T, and 3G (K0  ^ 20 pM) (Figure 3.4).
Importantly, since the experiments were conducted using a monoclonal CD8 + T cell system
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Figure 3.4: Tetrameric complexes of pHLA A2 containing the heavy chain a2 domain 
Q115E substitution bind low avidity CD8+ T cells. The ILA1 CD8 + T cell clone was stained 
with wildtype (A) and Q115E-substituted (B) pHLA A*0201 tetramers bearing different APL 
at a final concentration of 10 pg/ml with respect to the monomeric pMHCI component. 
The TCR/pMHCI affinities measured by SPR for the APL interactions shown are summarised 
in Figure 3.1 A. C. Affinity and binding kinetics of the ILA1 TCR/4L HLA A*0201 interaction; 
SPR experiments were performed as described previously (Laugel et al. 2007). Standard 
deviation from the mean dissociation constant (K0) of 3 separate experiments is shown. D. 
Staining intensities shown in (A) and (B) were plotted against TCR/pMHCI binding affinity 
(Kd) for wildtype (circles) and Q115E (squares) pH LA A2 tetramers; APL colour codes match 
those shown in A and B. Curves were fitted as described previously (Laugel et al. 2007). 
(The data in C was kindly provided by D. Cole.)
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(ILA1 clone), cellular factors that can influence pMHCI tetramer binding (see section 1.6 of 
the main Introduction), such as TCR and CD8  density, membrane flexibility and cell surface 
molecular topography, were standardised.
3.2.2 The extended avidity threshold for CD8-enhanced pMHCI tetramer staining is 
mediated primarily by a disproportionate increase in TCR/ pMHCI association rate
The CD8  coreceptor stabilises TCR/pMHCI interactions at the cell surface by approximately 
two-fold through an effect on dissociation rate that is consistent across a range of ligand 
affinities (Wooldridge et al. 2005). The Q115E mutation in the a2 domain of HLA A2 served 
to increase CD8  binding to pHLA A2 by approximately 1.5 fold (Wooldridge et al. 2005; 
Wooldridge et al. 2007). However, the Q115E mutation has such a minimal effect (2-5%) on 
the overall stabilisation of TCR/pMHCI dissociation, that its ability to enhance sensitivity to 
antigen cannot be explained by a difference in TCR/pMHCI off-rate (Wooldridge et al. 2005). 
Thus, the observation that Q115E pHLA A2 tetramers extend the avidity threshold of 
detection for cognate CD8 + T cells by a factor of approximately two-fold at the level of the 
corresponding monomeric TCR/pMHCI affinity (Figure 3.4) suggests an effect mediated via 
the association rate. To test this possibility, I compared the rate at which ILA1 CD8 + T cells 
bound identical concentrations of wildtype and Q115E-substitued pHLA A2 tetramers from 
solution. From the panel of tetramers, three pairs of wildtype and CD8 -enhanced tetramers 
were chosen: i) refolded around a high affinity (3G8T); ii) intermediate affinity (ILA index); 
and, iii) low affinity (4L) ligands (Figure 3.5 A, B, and C, respectively). In all cases, Q115E 
pHLA A2 tetramers exhibited more rapid uptake in these association assays (see section
2.8.3 of Material and Methods for assay details). Notably, however, this effect was more 
pronounced for the 4L APL/HLA A2 complex, which displays low/intermediate monomeric 
affinity for the ILA1 TCR (Figure 3.5 C), consistent with the staining data in Figure 3.4. Thus, 
mechanistically, the enhanced detection of low avidity CD8 + T cells afforded by Q115E CD8 - 
enhanced pHLA A2 tetramers is mediated primarily by a disproportionate increase in the 
TCR/pMHCI association rate.
133
Chapter 3
A B C
100 100 100
o>
80 80 80
60 60
40
index
30 IS 305 10 IS 20 25 30 S 10 IS 20 2S S 10 20 2S
Time (min)
Figure 3.5: WT and Q115E tetramer on-rates for the index ILA peptide and two variants.
The figure shows cognate pMHCI tetramer capture from solution by ILA1 CD8 * T cells. 
Concentrations of tetramer were titrated in an attempt to achieve a maximum 
fluorescence intensity of ~200. This level of staining could not be achieved for the wildtype 
4L ligand, and staining only reached an MFI of ~60 in this case. From left to right, panels 
show % maximal binding over 30 minutes for ILA1 cells stained with 0.2 Mg/nM 3G8T (A), 1 
pg/ml ILA index (B) and 5 pg/ml 4L (C) wildtype (circles) and Q115E (squares) tetramers. 
Representative data of 3 separate experiments shown.C urves represent least squares fit to 
equation 20 in (van den Berg et al. 2007).
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3.2.3 CD8-enhanced pMHCI tetramers enable direct ex vivo detection of low avidity 
antigen-specific CD8* T cells that cannot be visualised under identical conditions with 
wildtype tetramers
I sent reagents I had made to collaborators with access to patient samples. The resultant 
data have extended my findings with CD8 -enhanced tetramers to an ex vivo setting, 
demonstrating the capacity of these reagents to identify low avidity anti-tumour CD8 + T 
cells in patients' bone marrow. To this end, wildtype, Q115E, and CD8 -null D227K/ T228A 
HLA A2 tetramers were refolded with viral (CMV PP6 5 495-503; NLVPMVATV) and leukaemia 
antigen-associated (LAA) PR1 (proteinase3 i69- i77; VLQELNVTV) peptide epitopes, and were 
used to stain ex v/Vo-derived PBMC samples. In contrast to pathogen-specific responses, 
CD8 + T cell populations directed against tumour-derived epitopes generally exhibit low 
avidities for antigen and bear TCRs with weaker monomeric affinities for cognate pMHCI 
(Molldrem et al. 2003; Cole et al. 2007). Consistent with these properties, PRl-specific CD8 + 
T cell populations showed variable staining with different tetrameric reagents (Figure 3.6 A). 
Thus, while a minute number of high avidity PRl-specific CD8 + T cells could be identified 
with D227K/T228A pHLA A2 tetramers in some individuals with myeloid leukaemias, larger 
populations were generally defined with the corresponding wildtype reagents. The number 
of PR1/HLA A2 tetramer positive cells was larger still when staining was performed with 
Q115E tetramers. The number of cognate Q115E-substituted cells was consistent with the 
number of PR1 peptide-responding cells in the sample detected by ELISpot (Melenhorst et 
al. 2008), thereby indicating the existence of specific CD8 + T cell populations below the 
threshold of detection with wildtype tetramers (Figure 3.6 A). In contrast, higher avidity 
anti-pathogen CD8 + T cell populations specific for the CMV pp65495-so3 epitope were defined 
in mononuclear cell preparations at similar magnitudes with all three forms of the 
corresponding cognate tetramer (Melenhorst et al. 2008). This suggests that the increase in 
cellular events detected by pMHCI tetramers bearing the Q115E mutation does not simply 
correlate with an increase in non-specific background staining. However, a small increase in 
aberrant binding events was detected by performing phenotypic analysis of the cognate 
tetramer positive population. Figure 3.6 B shows how the majority of 'true' PR1/Q115E HLA 
A2 tetramer-binding events, which carry the memory phenotype (CCR7' CD45RA'/CD27+
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Figure 3.6: Coreceptor-enhanced pHLA A2 tetramers can identify low avidity antigen- 
specific CD8+ T cells that are not visible with the corresponding wildtype tetramers 
directly ex vivo. A. The upper panels show the gating strategy used to identify antigen- 
specific CD8 + T cells. First, doublets were distinguished from single cell events on the basis 
of their forward scatter-area (FSC-A) vs. forward scatter-height profile (FSC-H). Live CD3+ T 
cells were then distinguished from dead cells (ViVid+); monocytes (CD14+) and B cells 
(CD19+). Subsequently, fluorochrome aggregates were gated out in two consecutive 
bivariate plots and lymphocytes were further identified according to forward scatter (FSC) 
vs. side scatter profile (SSC). Histograms were then transformed at the level of the CD4 vs. 
CD8  plot. The frequencies of D227K/T228A, WT and Q115E PR1/HLA A2 tetramer-positive 
and background events, calculated within the CD8 +an d CD8  populations respectively, are 
shown as a percentage of the total live CD3+ lymphocyte population (lower panels).B . Cells 
staining brightly (yellow) and dimly (red) with the Q115E PR1/HLA A2 tetramer exhibit 
similar phenotypes based on expression of CCR7, CD27, CD45RA and CD57;t he tetramer- 
positive events are almost exclusively CCR7' memory cells, although a few naive events 
consistent with background staining are apparent as the gate is extended towards the CD8 + 
tetramer-negative population. The phenotypic distribution of these PRl-specific CD8 + T 
cells differs considerably from that of the overall CD8 + T cell population (grey density plot). 
(Data kindly provided by J. Melenhorst)
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CD57) can be differentiated from the naive (CCR7+ CD45RA+/CD27+ CD57+) tetramer 
positive CD8 +T cell population, which represents background staining.
3.3 Discussion
The ability to quantify and characterise antigen-specific T cells by flow cytometry using 
fluorochrome-conjugated multimeric pMHC complexes has transformed our understanding 
of cellular immune responses over the past decade. However, our understanding of T cell 
responses will not be complete if T cells displaying low affinities for antigen (such as CD8 + 
tumour- and auto-reactive T cells, and the majority of CD4+ T cells (Cole et al. 2007)) 
continue to 'fly under the radar' because they cannot be detected using conventional pMHC 
multimers staining procedures. The importance of developing better ways to visualise these 
low avidity T cell subsets becomes especially apparent when we consider that T cells that 
recognise the same pMHC antigen are known to differ in their sensitivity to this antigen by 
several orders of magnitude (Alexander-Miller et al. 1996; Alexander-Miller 2000). In view 
of this, it is becoming increasingly accepted that the quality of a T cell response may be just 
as important as its quantity, and that pMHC multimers can be used as invaluable tools for 
'grading' the quality of an antigen-specific T cell population. In this chapter I investigated 
the properties of tetrameric pHLA A2 complexes containing a Q115E mutation in the a2 
domain of the heavy chain (Figure 3.3), to engage CD8  with enhanced affinity without 
affecting the integrity of the TCR binding platform. The principal findings are:
i) CD8  coreceptor-enhanced Q115E pHLA A2 tetramers bind antigen-specific CD8 + T 
cells with avidities that lie below the detection threshold for wildtype tetramers 
(Figure 3.4).
ii) This effect is achieved through a disproportionate enhancement of the TCR/pMHCI 
association rate (Figure 3.5).
iii) The CD8 -enhanced tetramers retain their cognate binding properties in direct ex vivo 
applications (Figure 3.6).
iv) Background staining of the CD8 + T cell subset can be distinguished phenotypically as 
a mixture of naive and memory cells (Figure 3.6).
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By experimenting with Q115E-substituted HLA A2 tetramers presenting a collection of ILA 
APLs (Figure 3.1), I have quantified the ability of these CD8 -enhanced reagents to detect 
significantly weaker TCR/pMHCI (approximate KD > 250 pM) interactions than wildtype 
reagents (approximate KD £ 80 pM), without significant increases in background levels. 
Furthermore, using the well characterised ILA system, I have succeeded in proving that the 
ability of CD8 -enhanced tetramers to stain low avidity T cells arises from a disproportionate 
increase in TCR/pMHC association rate. So while a single Q115E mutation in the heavy 
chain of HLA A2 stabilises the cognate TCR/pMHCI by only ~50%, the combined avidity of 
this effect can substantially increase tetramer on-rate and impact on tetramer staining. 
Extending the findings from the well characterised ILA system to an ex vivo setting highlights 
a novel use of CD8 -enhanced pMHCI tetramers for the physical detection, quantification 
and characterisation of low avidity antigen-specific CD8 + T cell populations by flow 
cytometry, a task that would otherwise not be achieved with wildtype reagents. While there 
are concerns that as the CD8 -enhanced tetramers lower the affinity threshold for the 
TCR/pMHCI interaction, increases in background level of staining would become inevitable 
for some ex vivo specimens, background staining can be reliably distinguished from cognate 
staining on the basis of phenotypic characteristics. Naive populations displaying a low level 
of fluorescence are a typical indication of non-specific tetramer uptake. Thus, is it highly 
recommended that CD8 -enhanced pMHCI tetramers are used in conjunction with 
polychromatic flow cytometric platforms for optimal evaluation of antigen-specific immune 
responses. In addition, where the staining of intermediate/high avidity T cells is concerned, 
low concentrations of Q115E HLA A2 tetramers can be used as a substitute for wildtype 
tetramers in order to conserve reagent.
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The low affinity of some TCR/pMHC interactions means it is not possible to use conventional 
pMHC tetramer technology to detect T cells bearing such TCRs. In the previous chapter I 
have demonstrated how pMHCI tetramers displaying an enhanced interaction with the CD8  
coreceptor are able to stain low avidity T cells, which remain undetected by conventional 
pMHCI tetramer technology. In this chapter I report the use of an alternative 
multimerization scaffold (dextran) to increase pMHC and fluorochrome valency, with the 
ultimate aim of improving the detection of CD8 + and CD4+ T cells bearing low affinity TCRs.
4.1.1 pMHC dextramers
The design of pMHC dextramers arises from the same principles as other pMHC multimers: 
the multimerization of pMHC allows several pMHC molecules to interact simultaneously 
with multiple TCRs on a single T cell, greatly prolonging the half-life of interaction, and thus 
enabling specific T cell detection. Dextramers differ from tetramers in three ways: i) each 
dextramer contains 8-12 pMHC molecules instead of the four found in a pMHC tetramer; ii) 
the pMHC molecules are organised around a dextran polymer backbone (instead of a single 
streptavidin molecule used to make pMHC tetramers) in an orientation that enables optimal 
TCR/pMHC contact; and, iii) the dextran backbone of dextramers carries a larger number of 
conjugated fluorochrome molecules than a pMHC tetramer (Batard et al. 2006). 
Theoretically, these features act to increase the dextramers' avidity for specific T cells and 
enhance their staining intensity, thereby increasing the resolution and signal to noise ratio. 
Figure 4.1 shows a schematic of a pMHC dextramer alongside a pMHC tetramer.
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Figure 4.1: Comparison of dextramer and tetram er structures. A pMHC dextramer is 
composed of a dextran (polymer of glucose) backbone decorated with numerous 
streptavidin molecules which in turn bind 1-4 pMHC molecules (via their biotin tags), and 
several fluorochrome molecules.T he numbers of each type of component varies between 
different dextramers. A pMHC tetramer is composed of a streptavidin molecule, around 
which 4 pMHC molecules and a fluorochrome are arranged.
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4.1.2 Aims
For the reasons described in more detail in section 1.7 of the main Introduction of this 
thesis, many TCRs of interest to translational immunologists display very low affinities for 
their cognate antigen. The detection of T cells bearing these TCRs using conventional pMHC 
tetramer staining procedures is inefficient, and a search for better pMHC-based reagents is 
under way. The principal aim of this chapter was to evaluate how a novel type of pMHC- 
based reagent, called a dextramer, compares to a tetramer (constructed using identical 
monomeric pMHC) in its ability to stain a cognate population of T cells. The specific aims of 
this work were to:
i) Optimise staining protocols for a novel type of pMHC multimeric molecules called 
dextramers.
ii) Compare pMHC dextramers and tetramers in their ability to stain low avidity CD8 + 
and CD4+T cells.
iii) Provide a mechanistic explanation for pMHC dextramer action based on 
observations in ii), if time-permitting.
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4.2.1 pMHCI dextramers show improved staining of low avidity CD8+ T cells over 
corresponding pMHCI tetramers
In addition to my investigation into the influence of the CD8 coreceptor on pMHCI tetramer 
staining of CD8+ T cells, I was given the opportunity to test a novel type of pMHC multimeric 
reagent called a dextramer. The well documented ILA system was ideal for the initial part of 
the investigation into whether pMHCI dextramers would hold an advantage over pMHCI 
tetramers in staining specific CD8+ T cells. HLA A2 monomers were refolded around the ILA 
index peptide and four APLs (8E, 5Y, 4L and 3G) displaying a wide range of affinities for the 
ILA1 TCR (Kd ~2000-3.7 pM, Figure 3.1 A in Chapter 3). An additional HLA A2 monomer was 
refolded around the HIV309-317 epitope (ILKEPVHGV), designed to act as a negative control 
for monitoring background staining with each type of pMHCI multimeric reagent. The 
pMHCI monomers were assembled into either tetramers or dextramers (Figure 4.1, and 
sections 2.8.1 and 2.8.5 of Material and Methods), both conjugated to the same R- 
phycoerythrin (PE) fluorochrome for detection by flow cytometry. Initially, a titration of 
tetramers and dextramers incorporating ILA index/HLA A2 and non-cognate HIV 
epitope/HLA A2 was performed to establish the amount of each type of reagent required to 
stain the ILA1 clone with the highest signal to noise ratio (Figure 4.2). From this preliminary 
titration experiment it was decided that the optimal staining amounts for each reagent 
were: 10 pi for dextramer and 0.5 pg for tetramer. Since tetramers and dextramers are 
different types of reagents it was possible that by performing a titration, the increase in 
staining MFI demonstrated by dextramers over tetramers was simply due to a 10 pi 
dextramer preparation containing more monomeric pMHC than found in 0.5 pg of tetramer 
preparation. By calculating the amount of monomeric pMHC in 10 pi dextramer and 0.5 pg 
tetramer preparations I was able to establish the concentration of pMHC monomer present 
per dextramer or tetramer staining. Because dextramers conjugated to each of three 
fluorochromes (PE, APC, or FITC) have been optimised to comprise different quantities of 
streptavidin (SA) or pMHC monomer, the amounts of monomeric pMHC within each type of 
dextrameric reagent varies (see section 2.8.5 of Materials and Methods). When carried out 
in a 40 pi final staining volume, each 0.5 pg tetramer-PE stain corresponds to a
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Figure 4.2: Establishing optimal amounts of pMHC tetram er and dextramer reagents to  
use per test. 105  ILA1 cells were stained with different quantities of ILA index/ HLA A*0201  
dextramer (A) and tetramer (B), or a non-cognate HIV epitope/ HLA A*0201 dextramer (C) 
and tetramer (D), all conjugated to the R-phycoerythrin (PE) fluorochrome, and recorded by 
flow cytometry. The histograms show staining mean fluorescence intensity (MFI) obtained 
with titrated amounts of pMHCI tetram er/ dextramer. The optimal amount of each type of 
pMHC multimeric reagent (highlighted in red) was determined by looking at staining 
profiles with the highest signal to noise ratios. The data is representative of 2 separate 
experiments.
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concentration of 12.5 pg/ml, whilst each 10 pi dextramer-APC stain corresponds to a 
concentration of 7.5 pg/ml. Thus, despite using nearly 2 fold more tetramer than 
dextramer, the dextramer still achieves higher staining intensities (Figure 4.2).
Figure 4.3 A illustrates the staining profiles of the ILA1 clone with HLA A2 tetramers and 
dextramers presenting ILA peptides of varied affinities. As for the CD8 -enhanced Q115E 
pHLA A2 tetramers (Figure 3.4 in Chapter 3), the staining profiles for ILA APLs presented by 
tetramers and dextramers correlated with their monomeric TCR/pMHC affinities. However, 
the MFIs of ILA1 cells stained with dextramers were significantly higher than for tetramers 
assembled from the same pHLA A2 monomer. The most dramatic shift in MFI (15 fold 
increase) was observed with the 5Y variant (K0~ 242 pM). Interestingly, a ~400% increase in 
staining was observed for the 8 E variant when present as part of a dextramer versus a 
tetramer. The 8 E variant has a KD of >500 pM, which lies on the threshold of detection by 
SPR, and does not stain the ILA1 clone when presented by tetrameric HLA A2. If the staining 
seen with the 8 E variant is indeed real, it represents one of the weakest TCR/pMHCI 
interactions ever detected by a relatively insensitive technique of flow cytometry. Finally, 
although there was some increase in background staining with non-cognate dextramers 
over tetramers, this corresponded to a very small percentage of the dramatic increase in 
specific staining signal and was therefore deemed to be acceptable in terms of signal to 
noise ratio.
To test how the pMHCI tetramer and dextramer reagents performed in a more physiological 
setting, I set up a 'spiking' experiment by staining PBMC (isolated directly ex vivo) which 
have been mixed (spiked) with a small percentage (1%) of ILA1 CD8 + T cells. Figure 4.3 B 
shows the ability of each ILA APL/HLA A2 tetramer (top panel) and dextramer (bottom 
panel) to pick out the ILA1 population amongst the PBMC. Consistent with the results from 
ILA1 staining alone (Figure 4.3 A), the 5Y dextramer was able to stain the target ILA1 
population, whilst the 5Y tetramer failed to separate the ILA1 clone from the bulk PBMC 
CD8 + population. Clearer separation of the ILA1 target population (from bulk PBMC) was 
seen with the 4L dextramers compared to 4L tetramers. Slight increases in MFI were also
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Figure 4.3: Comparison of pHLA A2 tetram er and dextramer staining profiles of ILA1CD8+ 
T cells and PBMC spiked with ILA1. A. The ILA1 CD8 * T cell clone was stained with 
tetram er (left panel) and dextramer (right panel) reagents made with pHLA A2 monomers 
bearing different variants of the index hTERT5 4 0 _5 4 8  peptide (ILAKFLHWL), or the non­
cognate HIV3og.3 1 7  peptide (ILKEPVHGV), conjugated to the R-phycoerythrin (PE) 
fluorochrome. TCR/pMHCI affinities measured by SPR for the ILA variants has been 
previously documented (Laugel et al. 2007). B. 106  human PBMC were spiked with 104  ILA1 
cells and stained with the ILA variant tetramers (top panel) or dextramers (bottom panel) 
and a combination of antibodies against the surface markers CD3, CD4, CD8 , CD14, CD19, 
and the viability dye Aqua. Staining with dextramers and tetramers (in A and B) was 
performed using optimal conditions for each type of reagent (section 2.10 of Materials and 
Methods). Representative data of 3 separate experiments shown.
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observed with dextramers displaying higher affinity ILA index and 3G antigens, when 
compared to tetramers bearing the same antigens.
4.2.2 pMHCII dextramers show improved staining of CD4+ T cells over corresponding 
pMHCII tetramers
The CD8  coreceptor enhances the on-rate of the TCR/pMHCI interaction (Figure 3.5 and 
(Laugel et al. 2007; Wooldridge et al. 2007; Wooldridge et al. 2009)). The combination of 
avidities arising from TCR/pMHCI and pMHCI/CD8  interactions can substantially impact on 
tetramer staining (Choi et al. 2003; Pittet et al. 2003; Laugel et al. 2007). However, the 
strength of the human pMHCII/CD4 interaction remains too weak to be reliably measured 
by techniques such as SPR (Bakker et al. 2005; Wooldridge et al. 2009). The current 
consensus is that the CD4 coreceptor does not play a role in stabilising the TCR/pMHCII 
interaction and thus in the binding of pMHCII tetramers (Boniface et al. 1998; Crawford et 
al. 1998). An in house study of 14 different TCR/pMHC interactions showed that TCR/pMHCI 
interactions were of significantly higher affinity than TCR interactions with MHCII-restricted 
peptides (Cole et al. 2007). In light of this, CD4+ T cells are notoriously more difficult to 
detect using pMHC tetramer technology. To determine whether the staining advantage of 
pMHC dextramers over tetramers was true for the MHC class II system, I stained a CD4+ T 
cell clone (Flu2-5), specific for the HLA DR*0101 (HLA DRl)-restricted influenza virus A 
HA307-319 epitope (PKYVKQNTLKLAT), with tetramers and dextramers assembled from 
HA/HLA DR1 monomeric pMHCII. The Flu2-5 T cell clone was also stained with non-cognate 
tetramers and dextramers containing MAGE-A327i-279 (FLWGPRALV)/HLA A*0101 (HLA Al) 
monomeric pMHCI to monitor differences in background staining for the two types of 
pMHC multimeric reagent. Figure 4.4 (A) shows the MFI profiles for the tetramer- and 
dextramer-stained Flu2-5 T cell clone. The HA dextramer stained the Flu2-5 clone with 5- 
fold higher intensity than the HA tetramer, with an insignificant increase in background 
staining. When the HA tetramer and dextramer reagents were used to stain PBMC which 
had been 'spiked' with the Flu2-5 clone (comprising 1% of total PBMC), the HA dextramer 
was able to specifically distinguish the target CD4+T cell clone from the rest of the PBMC,
147
Chapter 4
Unstained MAGETet HATet Unstained MAGE Dex HA Dex
B
749 161 d 160100- 161 1 0 0 . 3810
so. 8 0 .
Xm
5 6 0 -
**-oNp
4 0 -
2 0 -
W ,n u 
> 1W 101
Tetramer-PE
10* 10* io» 10» 
Dextramer-PE
N oTet/D ex +MAGE Tet +MAGE Dex
+HA Dex 3091+HATet 388
10* 1 0 ' 1 0 ‘ 10* 10* 10* 1 0 '  10> 1 0 s 10*
Tetramer/Dextramer-PE
Figure 4.4: Dextramers made with pHLA DR*0101 bind CD4+T cells substantially better 
than tetramers made with equivalent monomeric pMHC. A. The Flu2-5 CD4+ T cell clone 
was stained with tetramer (left panel) and dextramer (right panel) reagents made with 
pH LA DR*0101 monomers bearing the cognate influenza virus A HA3 0 7 . 3 1 9  (PKYVKQNTLKLAT) 
peptide (red line) and MAGE-A3271_279 (FLWGPRALW)/ HLA A*0101 (blue line) as a negative 
control, all conjugated to the R-phycoerythrin (PE) fluorochrome. The numbers next to 
each histogram correspond to the staining MFI with each tetramer/dextramer reagent and 
unstained cells (black line). B .106 human PBMC were spiked with 104  Flu2-5 CD4+T cells 
and stained with cognate Flu HA or non-cognate MAGE tetramers or dextramers and a 
combination of antibodies against the surface markers CD3, CD4, CD8 , CD14, CD19, and the 
viability dye Aqua. Numbers in red correspond to the staining MFI of the Flu2-5 T cells 
population. Staining with dextramers and tetramers (in A and B) was performed using 10 
pg/m l of each type of reagent with respect to monomeric pMHC content. Representative 
data of 2  separate experiments shown.
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while the HA tetramer failed to do so (Figure 4.4 B).
4.2.3 The increase in intensity of pMHCi dextramer versus tetramer staining cannot be 
explained by a disproportionate increase in TCR/pMHCI association rate
The avidity effect that arises from the multimerization of pMHC molecules is the result of 
the cooperative interactivity of each pMHC with a TCR. For a pMHC tetramer bound to the 
surface of a T cell, once one pMHCi 'arm' becomes dissociated from its cognate TCR, the 
other arms remain associated and enhance the probability that the dissociated 
interaction(s) will re-associate. In this way, the avidity effect extends the half-life of the 
TCR/pMHC interaction from seconds to several hours (Laugel et al. 2005). Since both 
tetramers and dextramers have pMHC valences > 4, they are predicted to have very long 
TCR/pMHC dissociation rates. Therefore, the ability of pMHC dextramers to extend the 
avidity threshold of detection for cognate CD8 + and CD4+ T cells might be explained by 
dextramers displaying a faster association rate than tetramers. To test whether this was 
indeed the case, I compared the rate at which ILA1 CD8 + T cells adsorbed tetramers and 
dextramers (assembled from 4L/HLA A2 monomers) from solution over a 20 minute period 
at room temperature (Figure 4.5). Although the 4L-dextramer stained the ILA1 clone with an 
MFI four times higher than observed with 4L-tetramer (Figure 3.4), surprisingly its 
association rate was considerably (~ 6  fold) lower than for the corresponding tetramer. And 
while the tetramer stained the ILA1 population at its maximum fluorescence intensity after 
only 7 minutes, the dextramer required >20 minutes to reach its maximum level of staining 
(Figure 4.5). The fact that the efficiency of dextramer staining was not a result of high 
association rates, proved somewhat surprising. Perhaps the explanation to the dextramers' 
mode of action was more to do with the structure of these molecules, than with the binding 
kinetics of the individual pMHCs. When pMHC tetramers are used to stain a specific T cell 
under physiological temperatures, they are readily internalised into endocytic vesicles 
(Whelan et al. 1999). Thus, any tetramer that can associate with the T cell surface for just a 
few minutes at 37°C will be internalised and subsequently unable to dissociate from the cell 
during an experiment. The endocytosis is a consequence of TCR ligation by its cognate 
pMHC antigen, and results in the downregulation of TCR/pMHC tetramer complexes from 
the cell surface. Once inside the endocytic vesicles, the tetramers cannot dissociate
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Figure 4.5: A comparison of pMHCI dextramer and tetramer association rates. 4L/ HLA
A*0201 dextramer (circles) and tetramer (squares) capture from solution by the ILA1 CD8 + 
T cell clone over a period of 20 minutes at room temperature. The concentrations of both 
reagents were titrated to achieve a maximal fluorescence intensity of ~2000. The pMHC 
association curves are representative of 2  separate experiments.
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from the cell during an experiment. Another consequence of TCR/pMHC internalisation into 
vesicles is that any bound tetramers are enzymatically degraded, which leads to a reduction 
in the fluorescence signal over time (Whelan et al. 1999). In addition to endocytic 
degradation, pMHC tetramer-mediated TCR downregulation reduces the TCR concentration 
on the T cell surface. As described in section 1.6 of the main Introduction, TCR 
concentration constitutes an important parameter of pMHC tetramer staining efficiency. 
We hypothesised that the sheer size of dextramers, composed of the bulky dextran 
backbone in addition to a multitude of pMHC and fluorochrome entities, may simply 
prevent the internalisation of these molecules into endocytic vesicles following TCR 
engagement. To this end, I performed fluorescence microscopy with tetramers and 
dextramers under identical staining conditions (as described in section 2.12 of Materials and 
Methods) (Figure 4.6 B). ALW/HLA A2 Alexa-488 conjugated tetramers and ALW/HLA A2 
FITC-conjugated dextramers were used to stain the 3F2 CD8 + T cell clone, which recognises 
the HLA A2-restricted epitope of the preproinsulin (PPI15-24; ALWGPDPAAA) antigen, called 
ALW. The staining intensities for the two types of ALW/HLA A2 multimer were verified by 
flow cytometry prior to performing microscopy (Figure 4.6 A). The presence of multitudes of 
small fluorescent vesicles in the microscopy images (Figure 4.6 B) confirmed that 
dextramers, like tetramers, were being internalised from the T cell surface. The only marked 
difference was the fact that dextramer staining delivered a consistently brighter 
fluorescence signal compared to tetramers, when measured by both flow cytometry and 
fluorescence microscopy (Figure 4.6).
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Figure 4.6: pMHC tetramers and dextramers are internalised by T cells at 37°C.A . FACS 
plot showing the differences in mean fluorescence staining intensities (MFIs) between 
tetramer- and dextramer-stained CDS* T cell clone, ALW, specific for the HLA A*0201- 
restriced epitope of preproinsulin, ALW (PPI1 5 -2 4 ; ALWGPDPAAA). The cognate ALW-specific 
tetramers and dextramers were assembled using ALW/HLA A2 monomers conjugated to 
the fluorochrome Alexa-488, and FITC, respectively. Both fluorochromes, fluoresce in the 
same channel (FL-l).B . Fluorescence microscopy images of ALW cells stained with cognate 
ALW/pHLA A2 tetramers (left panels) and cognate dextramers (right panels). The staining 
was performed at 37°C and as described in section 2.12 of Materials and Methods, and is 
representative of at least 3 replicates. Nuclei are shown in blue, and the tetramers/ 
dextramers in green. Although the pattern observed using fluorescence microscopy does 
not guarantee the presence of pMHC multimer inside cells, evidence for internalisation of 
tetramer into early-endocytic vesicles at 37°C has previously been documented by Whelan 
etal. 1999 using confocal microscopy.
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In this chapter I investigated the functionality of a novel type of pMHC multimeric reagent, 
called a dextramer, by conducting a direct comparison with tetramers assembled using 
identical pMHC. I have shown that:
i) Dextramers offer a substantial staining advantage over tetramers in the detection of
both CD8 + and CD4+T cell populations (Figures 4.3 and 4.4).
ii) The difference in staining intensity between dextramers and tetramers was most 
dramatic for lower affinity monomeric TCR/pMHC interactions, echoing the 
observations with CD8  coreceptor-enhanced versus wildtype tetramers summarised 
earlier (Figures 4.3 and 4.4).
iii) Dextramers do not manifest their effects by displaying increased TCR association-
rates or by evading internalisation into early endosomes from the cell surface
(Figures 4.5 and 4.6).
The dextran polymer backbone stabilises the conformation of the attached proteins, the 
MHC-peptide complexes and fluorochromes in a way that aims to maximise the number of 
successful TCR/pMHC contact points. In contrast, only three out of the four pMHC 
molecules are thought to be capable of engaging a cell-surface TCR in a pMHC tetramer 
(Wooldridge et al. 2009). Initially, these structural differences pointed towards dextramers 
manifesting their effects via a faster rate of association. However, dextramers took >3 times 
longer than tetramers to attain their maximum staining potential (Figure 4.5). Confronted 
with this result, we considered the possibility that perhaps the sheer size of dextramers, 
compared to the much smaller tetramers, prevented the internalisation of these reagents 
into endocytic vesicles when the staining was performed under physiological temperatures. 
My microscopy data showed that this was not the case (Figure 4.6). And although it would 
have been interesting to provide a mechanistic explanation for the fact that dextramers 
hold an advantage over conventional tetramers in staining low avidity T cells, it was not a 
principal aim of this study and was not pursued further. We can however speculate that the 
size of dextramers is responsible for the slow rates of uptake observed (Figure 4.5). While
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compact tetramers can diffuse between cells with relative ease, bulky dextramers may take 
longer to do so. The most likely reason that dextramers are better than conventional 
tetramers at staining low avidity T cells may be due to something as simple as dextramers 
having a brighter signal due to the large number of fluorochrome molecules per reagent 
compared to tetramers. Irrespective of their mode of action, the data presented in this 
chapter provide validation of dextramers as a novel and valuable tool for the physical 
detection of low avidity CD8 +and CD4+ T cell populations by flow cytometry.
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5.1.1 What is dasatinib?
Dasatinib is a dual Bcr-Abl/Src kinase inhibitor, which entered the clinic for the treatment of 
chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), and is a second 
generation drug designed to benefit cancer patients that have become resistant to its 
predecessor imatinib (common name Glivec, Novartis)(Shah et al. 2004; Weichsel et al. 
2008). Since Src kinases are known to play an important physiological role in T cell 
activation, Weichsel et al. conducted an elegant study into the role of the protein tyrosine 
kinase inhibitor (PKI) dasatinib on T cell function, to assess its toxicity to the immune system 
compared to the promiscuous PKI staurosporine. The authors examined the effects of 
dasatinib and staurosporine on T cells, and discovered that both reagents exerted an 
inhibitory effect on multiple T cell effector functions including proliferation, activation, 
cytokine production, and degranulation. Importantly, this was mediated by the disruption of 
early T cell signal transduction events and was not due to a reduction in T cell viability. 
Despite reducing T cell functionality, the inhibitory effect of dasatinib (unlike staurosporine) 
was entirely reversible following withdrawal of the drug. Indeed, T cell clones incubated in 
50 nM dasatinib for 24 hours were able to regain responsiveness to antigen within 1 hour of 
drug removal.
5.1.2 T cell signalling and dasatinib
Many of the inhibitory effects of dasatinib can be attributed to its action on the signalling 
molecule Lck. Lck is a key player in the TCR-mediated signalling cascade, which is initiated 
when a T cell makes contact with cognate antigen. Together with another kinase from the 
Src family, Fyn, Lck is closely associated with coreceptors CD4 and CD8  (Zamoyska et al. 
2003). As described in more detail in section 1.4.4 of the main Introduction, recognition of 
an antigenic stimulus by the TCR results in the activation of Lck and Fyn, which in turn 
phosphorylate tyrosine motifs located within the  ^ chains of the TCR/CD3 complex. The 
signalling cascade eventually culminates in the activation and proliferation of the T cell. By 
inhibiting Lck and Fyn kinases, dasatinib is able to shut down signal transduction, resulting in 
T cells with defective effector functions. Because dasatinib is ~1000 times more potent than
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imatinib (dasatinib IC50, 0.5 nmol/L; imatinib IC50, 0.6-0.8 pmol/L), its effect on Lck and 
Fyn, and ultimately T cell function is likely to be more pronounced (Carter et al. 2005; 
Weichsel et al. 2008). The T cell modulation group collaborated with Weichsel and 
colleagues to investigate whether this increase in potency displayed by the new anti-cancer 
drug was associated with a reduction in T cell activity, and thus immunosuppression that 
could prove detrimental in a clinical setting. During these studies we noticed that dasatinib 
treatment of T cells resulted in increased surface expression of both TCR and CD8 .
5.1.3 Dasatanib increases levels of TCR and CD8 on the T cell surface
The idea that dasatinib may be used as a reagent to enhance tetramer staining stemmed 
from the observation by Weichsel et al. that dasatinib increased TCR and CD8  expression on 
the surface of CD8 + T cells (Weichsel et al. 2008). EBV-C, ILA1, and Mell3 CD8 +T cell clones 
(specific for the HLA A2-restricted: EBV-derived epitope GLCTLVAML; human telomerase 
reverse transcriptase epitope ILAKFLHWL; and, Melan-A epitope ELAGIGILTV, respectively) 
were treated with either dasatinib or the promiscuous PKI staurosporine at 0, 2,10, or 100 
nmol/L concentrations for 3 hours. Following incubation with either PKI, cells were stained 
with anti-a^TCR and anti-CD8  antibodies, and the percentage increase (above untreated 
CD8 + T cells) in apTCR and CD8  cell surface expression was recorded. All three CD8 + T cell 
clones experienced increases in surface TCR and CD8  expression on treatment with 
dasatinib and staurosporine, predominantly when these reagents were used at 50 nM/L 
(Figure 5.1). The observation that dasatinib was able to increase the TCR and CD8  
concentrations without appearing toxic to T cells at concentrations of <100 nM (Weichsel et 
al. 2008) opened up the question of whether this anti-cancer drug could be used as a tool 
for improving pMHC tetramer-mediated detection of T cells. However, since staurosporine 
was also shown to increase cell surface expression of TCR and CD8 , a selection of PKIs on T 
cells would have to be assessed to determine which PKI had the best effect on pMHC 
tetramer staining with minimal T cell toxicity. This data is presented in section 5.2.1.
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Figure 5.1: Effects of dasatinib and staurosporine on antigen-specific CD8+ T cell clones.
Cells (1 x i(£) of the CD8 +T cell clones EBV-C, MEL13, or ILA1 were either left untreated or 
treated with either dasatinib or staurosporine at concentrations of 2, 10, or 50 nmol/L for 
3 hours at 37°C. The samples were analyzed for ap TCR and CD8  expression by flow 
cytometry using flurochrome-conjugate surface antibody staining. (Data kindly provided by 
L. Wooldridge (Weichsel et al. 2008)).
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5.1.4 Aims
As described in section 1.6 of the main Introduction, pMHC multimers have transformed the 
study of antigen-specific T cells by enabling their visualisation, enumeration, phenotypic 
characterisation and isolation from ex vivo samples. However, these reagents are far from 
ideal for the study of interactions where TCR/pMHC interactions are weak such as those 
that predominate in anti-tumour and autoimmune T cell responses. Current technology is 
also rather poor for MHCII-restricted T cells because their TCRs bind with lower affinity than 
MHCI-restricted T cells (Coif et al. 2007). Furthermore, unlike CD8 , the CD4 coreceptor does 
not help stabilise TCR/pMHC interactions (Wooldridge et al. 2003; Wooldridge et al. 2006; 
Wooldridge et al. 2009) to mean that over half of pMHCII-restricted T cells fail to stain with 
cognate pMHCII tetramer using conventional technology. The fortuitous discovery by our 
laboratory that a short treatment with the non-toxic PKI dasatinib results in increased 
expression of both TCR and CD8  lead to speculation that we might be able to use this effect 
for diagnostic benefit by enhancing pMHC tetramer staining. The aims of this work were to:
i) Study the effects of short-term treatment with a selection of PKIs on pMHCI 
tetramer staining and determine which PKI had the best effects.
ii) Examine whether dasatinib treatment could be used to enhance pMHCII 
tetramer staining without a concomitant increase in background staining.
iii) Examine if dasatinib treatment could also be beneficial for pMHC tetramer 
staining of murine T cells.
iv) Explore whether dasatinib could help pMHC tetramer staining where TCR/pMHC 
affinity was low and 'beyond the reach' of current technologies.
v) Test whether dasatinib treatment could bring autoimmune T cells within the 
range of pMHC tetramer staining.
vi) Determine whether dasatinib could prevent the problem of pMHC tetramer- 
induced cell death.
vii) Assess whether dasatinib treatment could improve pMHC tetramer staining of ex 
vivo samples.
viii) Delineate the mechanism by which dasatinib improves pMHC tetramer staining.
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5.2 Results
5.2.1 The effect of PKI treatment on pMHC tetramer staining of CD8* and CD4+ T cells
Initially, the effect of multiple different PKIs on cognate and non-cognate pMHCI tetramer 
staining was determined by treating ILA1, a CD8 + T cell clone specific for the HLA A2- 
restricted epitope hTERT54o-548 (ILAKFHWL), with titrated amounts of each PKI (Figure 5.2). 
Pre-incubation with the PKI PP2 (Calbiochem) resulted in a moderate increase in tetramer 
staining; however, no significant enhancement was observed when ILA1 CD8 + T cells were 
pre-treated with herbimycin, PP3, genestein (Calbiochem) or staurosporine (Biomol) (Figure 
5.2). Incubation of ILA1 CD8 +T cells with the PKIs dasatinib or 3-(2-(lH-benzo[d]imidazol-l- 
yl)-6-(2-morpho-linoethoxy) pyrimidin-4-ylamino)-4-methylphenol (Lck inhibitor II; 
Calbiochem) resulted in a 3-10 fold increase in pMHCI tetramer staining intensity (Figures
5.2 E and 5.3 A). The variations in pMHCI tetramer staining were likely a result of natural 
fluctuations in TCR and CD8  expression on the surface of CD8 + T cells during different stages 
of the grown cycle. Importantly, PKI inhibitor treatment did not enhance staining with non­
cognate pMHCI tetramer (Figures 5.2 F and 5.3 B). The enhancement of pMHCI tetramer 
staining following dasatinib treatment was highly dose dependent (Figure 5.3 C). Maximal 
effect was achieved by exposing CD8 +T cells to 50 nM dasatinib for 1 hour, which resulted in 
an 89% increase in pMHCI tetramer staining intensity (Figure 5.3 C). Unexpectedly, pre­
incubation of CD8 +T cells with 50 nM dasatinib for as little as 30 seconds resulted in a 60% 
increase in pMHCI tetramer staining (Figure 5.3 D). Furthermore, incubation with 50 nM 
dasatinib for 30 minutes significantly enhanced the staining of both ILA1 and Mell3 CD8 +T 
cell clones over a wide range of pMHCI tetramer concentrations (Figure 5.3 E&F). Pre­
incubation with dasatinib also enhanced pMHCI tetramer staining of the naive murine F5 
CD8 + T cells directly ex vivo (Figure 5.3 G) and pMHCII tetramer staining of a HLA DR1- 
restricted CD4+ T cell clone (Figure 5.3 H). Thus, pre-incubation with 50 nM dasatinib for 30 
minutes provides a quick and easy way to enhance pMHC tetramer staining efficiency in 
both human (CD4+ and CD8 + T cells) and murine systems. These effects were highly specific; 
increased pMHC tetramer binding only occurs in the presence of a cognate TCR/pMHC 
interaction (Figure 5.3 B&H).
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Figure 5.2: Testing the effects of other PKIs on tetramer staining. 10s ILA1 CD8 * T cells 
were re-suspended in 40pl of PBS and pre-treated with various concentrations of protein 
kinase inhibitors; genestein (A), PP2 (B), herbimycin (C), and PP3 (D) prior to staining with 
cognate HLA A2/ILAKFLHWL-PE (ILA-PE) tetramer at a final concentration of 10 pg/ml for 20 
minutes at 37°C. In each case, the mean fluorescence intensity (MFI) of ILA-PE tetramer 
staining at each concentration of PKI was compared to untreated ILA-PE stained ILA1 CDS* T 
cells as a reference. Untreated ILA1 cells stained with a non-cognate tetramer-PE (irr tet) 
were used as a negative control. E. ILA1 CD8 + T cells were treated with optimal 
concentrations of each PKI (determined from A-D) and 50 nM dasatinib, or left untreated, 
and stained with ILA-PE tetramer. Dasatinib increased ILA1 CD8 + T cell staining with ILA-PE 
tetramer by 127%, with the Lck II and PP2 reagents coming second and third, with 125% 
and 70% enhancement in staining, respectively. The increases in MFI afforded by dasatinib, 
Lck II inhibitor, and PP2 were determined as significant (p < 0.001 for dasatinib and Lckll, 
and p<0.05 for PP2). F. The same panel of PKIs as in (E) was used to pre-treat ILA1 CD8 * T 
cells prior to staining with non-cognate tetramer-PE to show no significant increase in 
background fluorescence.
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Figure 5.3: Dasatinib substantially improves pMHC tetramer staining intensity.
B
100 ■  Irr.Tct
■  Tet only
■  Das + Tet
■  Lck II + Tet
I 0 0  io l  102 103
A2 ELA only 
A2 ILA only 
50nM D + A2 ILA 
lOnM D + A2 ELA 
20nM D + A2 ELA
■ 30nM D + A2 ELA 40nM D + A2 ELA 50nM D + A2 ELA 
lOOnM D + A2 ELA
Tetramer-PE
100 i o l  102 103
Tetramer-PE
500
400
300
0  20 3 0  4 0  50
Dasatinib conc. (nM)
700
600
500
400
300
200
100
0
■  - Dasatinib
■  + Dasatinib
0 20 30 4010
Tetramer conc. (pg/ml)
104
io3
102
IO1
10°*
.V
400
200
100
10 20  30 4 0  50  600
Incubation with 50 nM 
dasatinib (mins)
450  
14. 400
5  350  
i -  300  
<¥ 250
m 200  
2  150
50
•  -
■  - Dasatinib
1---------
■  + Dasatinib
0  10 2 0  30  40
Tetramer conc. (pg/ml)
H
' i t
MR = 156
m
•
.
MR = 234
n
r -/fe .
100 io l  102 103 100 |0 l  102 103
100
Tet +D 
ITet-D  
I -ve + D 
l -ve-DU
100 101 102 103
Murine F5pMHCI-PE pMHCII-PE
162
Chapter 5
Figure 5.3: Dasatinib substantially improves pMHC tetramer staining intensity. A. 105 ILA1 
CD8 +T cells were re-suspended in 40 pi of PBS ±50 nM dasatinib or Lck inhibitor II, then 
incubated at 37°C for 30 minutes. Cells were then stained with cognate HLA 
A2/ILAKFLHWL-PE tetramer at a final concentration of 10 pg/ml for 20 minutes at 37°C, 
washed twice in PBS and analyzed on a FACSCalibur (BD) flow cytometer. A >10-fold 
increase in median fluorescence intensity (MFI) was observed after treatment with 50 nM 
dasatinib (blue) or 50 nM Lck inhibitor II (red) compared to staining without PKI pre­
treatment (green line). B. 10^  ILA1 CD8 +T cells were treated with various concentrations of 
dasatinib for 30 minutes at 37°C, then stained with either HLA A2/ILAKFLHWL tetramer or 
the non-cognate HLA A2/ELAGIGILTV tetramer for 20 minutes at 37°C before washing with 
PBS. C. 105 ILA1 CD8 +T cells were resuspended in 40 pi of PBS ± the indicated concentration 
of dasatinib and incubated for 60 minutes at 37°C. Cells were then stained with cognate 
HLA A2/ILAKFLHWL-PE tetramer at a final concentration of 10 pg/ml for 20 minutes at 37°C 
and washed twice in PBS prior to flow cytometric analysis. D. As (A), but ILA1 CD8 +T cells 
were incubated with 50 nM dasatinib for various times prior to staining with pMHCI 
tetramer. For this experiment the drug was washed off prior to staining. E. As (A), but 
tetramer concentration was varied to stain CD8 +T cells pre-treated ± 50 nM dasatinib for 30 
minutes. F. 105 Mell3 CD8 * T cells were stained with various concentrations of HLA 
A2/ELAGIGILTV tetramer following incubation ± 50 nM dasatinib for 30 minutes. G. 5x10s 
splenocytes from an F5 TCR transgenic Rag+ mouse were resuspended in PBS ± 50 nM 
dasatinib and incubated for 30 minutes at 37 °C. Cells were subsequently stained with H2- 
Db/ASNENMDAM-PE tetramer for 20 minutes at 37°C followed by anti-CD8-Cy5.5 for 30 
minutes on ice prior to two washes in PBS and analysis by flow cytometry. H. 105 cells of 
the HLA DR*0101-restricted, influenza virus A HA307-319 PKYVKQNTLKLAT-specific CD4+ 
clone C6  were incubated with PBS ±50 nM dasatinib for 30 minutes at 37°C, then stained 
with cognate PE-conjugated tetramer for 20 minutes at 37°C. Samples were washed with 
PBS before flow cytometric analysis. Irrelevant tetramer was used as a negative control in 
all cases.
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The best results were observed with the PKIs dasatinib and Lck II. Because the two reagents 
exhibited such similar functionality, I was interested to see if one of the reagents had an 
advantage over the other with relation to its stability. To compare the stability of the drugs, 
dasatinib and Lck II inhibitor, which are typically stored at -20°C and thawed on the day of 
experiment, were left at room temperature for a maximum period of 14 days. At several 
time points during this period, both reagents were tested for their ability to enhance 
staining of ILA1 CD8 + T cell clone with cognate HLA A2 tetramers refolded around ILA 
peptide variants (Table 5.1). The results are summarised in Figure 5.4. Over the two week 
period that dasatinib and Lck II inhibitor were kept at RT, both reagents had retained their 
functionality and were able to enhance tetramer staining with the ILA variant tetramers in 
each case. On closer observation, dasatinib lost some of its activity after days 7, 10 and 14 
at RT. This was especially visible with the low avidity 5Y and 8 E ILA tetramers. However, the 
overall difference in stability was not considered important enough to warrant using one 
reagent rather than the other.
Compared to the less well characterised (at least with respect to T cell function) Lck II, 
dasatinib is an FDA approved drug (commercial name Sprycel, manufactured by Bristol- 
Myers Squibb) and is non-toxic to patients (Lombardo et al. 2004; Weichsel et al. 2008). 
Furthermore, when tested for stability, Lck II did not perform substantially better than 
dasatinib (Figure 5.4). In order to avoid an inundation of requests for us to manufacture and 
provide dasatinib to other laboratories, Professor Sewell informed several drug companies 
that there might be a new market for the substance as a research reagent. Dasatinib (>99% 
purity) can now be purchased for £80.00 for 10 mg (Axon Medchem) (pure reagent was not 
commercially available when I undertook the experiments described herein). 1 0  mg of 
dasatinib is sufficient for 107 pMHC tetramer stains. Due to the low cost of dasatinib and its 
low toxicity as evidenced by its use in patients (Lombardo et al. 2004; Weichsel et al. 2008) 
we decided to take dasatinib forward as our PKI of choice for subsequent studies of pMHC 
tetramer staining.
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LIGAND 8E 5Y 4L Index 8Y 3G8T 3G
KolLAlTCR Binding (pM) >500 242 117 36.6 2 2 .6 4.04 3.7
Table 5.1: Affinity measurements of the interaction between the ILA1 TCR and hTERT540- 
548 pMHCI variants. Summary of the results obtained by nonlinear analysis of surface 
plasmon resonance binding equilibrium experiments as detailed in (Laugel et al. 2007) and 
(Melenhorst et al. 2008). K0 values were determined by analyzing the data in nonlinear 
curve fittings to the equation AB=BxABmax/(K0+B) assuming 1:1 Langmuir binding.
165
Chapter 5
8E -
5 Y -
C
• 2  4L -t
re 
>
index­
es
□
□
□
□
untreated 
dasatinib (d ay l) 
dasatinib (day3) 
dasatinib (day7) 
dasatinib (day 10) 
dasatinib (day 14) 
Lckll (d ay l)
Lckll (day3)
Lck II (day7)
Lck II (day 10) 
Lck II (day 14)
---------- 1----------1---------- 1 • • i
1 10 100 1000 10000
Tetramer-PE (MFI)
Figure 5.4: The stabilities of dasatinib and Lck II PKIs are closely matched. 10s ILA1 CDS* T 
cells were re-suspended in 40 pi of PBS and pre-treated with 50 nM dasatinib or 50 nM Lck 
II inhibitor prior to staining with cognate HLA A2 tetramers refolded around variants of the 
ILA (ILAKFLHWL) peptide (Table 5.1) at a final concentration of 10 Mg/ml for 20 minutes at 
37°C.T o test the stability of the PKIs relative to each other, an aliquot of dasatinib and Lck II 
inhibitor were left at RT for period of 1-14 days (indicated by the fading red and blue bars, 
respectively). ILA-PE variant tetramer staining of untreated ILA1 CDS* T cells (black bars) 
was used as a reference.
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5.2.2 Dasatinib preferentially enhances pMHCI staining of T cells bearing low affinity TCRs
In order to dissect further the effects of dasatinib, I examined pMHCI tetramer staining 
using several well-characterised APLs (encountered in Chapters 3 and 4) for the ILA1 CD8 +T 
cell clone that differ in their binding affinity for the ILA1 TCR by >100-fold (Table 5.1). Pre­
incubation with dasatinib enhanced staining efficiency with all variant pMHCI tetramers 
(Figure 5.5 A). The percentage increase in tetramer staining afforded by pre-incubation with 
dasatinib for 8 E, 5Y, 4L, ILA index, 3G8T and 3G pMHCI tetramers was 675%, 1825%, 324%, 
111%, 75% and 26%, respectively. Thus, the benefits of dasatinib pre-treatment in terms of 
enhanced tetramer staining intensity are greater for peptide variants that exhibit weaker 
interactions with the ILA1 TCR. The intensity of pMHCI tetramer staining in the presence 
and absence of dasatinib treatment was plotted against the monomeric TCR/pMHCI 
dissociation constants (Figure 5.5 B). The data demonstrate that in the absence of dasatinib 
there is a sharp reduction in tetramer staining intensity for ligands with TCR/pMHCI KD >35 
pM; this is consistent with previous observations (Laugel et al. 2007). In the presence of 
dasatinib however, the TCR/pMHCI affinity threshold for this sharp drop-off did not occur 
until the KD exceeded 200 pM. In fact, dasatinib treatment allowed detectable staining of 
the ILA1 clone even when the agonist TCR/pMHCI KD exceeded 500 pM. Dasatinib treatment 
therefore enables the physical detection of CD8 + T cells bearing TCRs with low affinity for 
the cognate pMHCI ligand that would otherwise be undetectable using pMHCI tetramer 
staining alone.
5.2.3 Dasatinib reduces pMHCI tetramer-induced cell death
Previous studies have shown that soluble pMHCI tetramer-induced signalling can trigger cell 
death (Purbhoo et al. 2001; Guillaume et al. 2003; Cebecauer et al. 2005). This can reduce 
the number of live cells that remain after pMHCI tetramer staining. Activation-induced cell 
death (AICD) represents a huge impediment for pMHC multimer guided sort-cloning of 
antigen specific T cells. At best, such sort cloning is only ~2% efficient (unpublished 
observations). This low frequency drops further when TCR/pMHC interactions are of high 
affinity or for staining times longer than 10 minutes. Consequently, methodologies for 
preventing pMHC multimer-induced cell death are highly desirable. Since dasatinib blocks
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Figure 5.5: Dasatinib treatment preferentially increases the ability of pMHCI tetramers to 
stain T cells bearing low affinity TCRs. A. 105 ILA1 CD8+ T cells were stained with 10 pg/m l 
PE-conjugated HLA A2 tetramer folded around the 8E, 5Y, 4L, index (ILAKFLHWL), 3G8T or 
3G peptides for 20 minutes at 37°C following incubation ± 50 nM dasatinib for 30 minutes 
at 37°C. For all samples, data were acquired with a FACSCalibur flow cytometer (BD) and 
analyzed using FlowJo software.Ir relevant tetramer was used as a negative control.B . The 
MFI of tetramer staining for all of the variants in the presence and absence of dasatinib 
displayed in (A) were plotted against the monomeric affinity of TCR/pMHCI interactions 
previously measured for each of these variants expressed as the dissociation constant 
(KD)(Table 5.1). Curves were fitted as described in the Materials and Methods. FACS 
staining data is representative of 2 separate experiments.
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antigen-specific signalling and subsequent T cell effector functions (Weichsel et al. 2008), 
we hypothesised that treatment with the drug may reduce tetramer-induced cell death. 
Indeed, the percentage of tetramer-positive cells that died when PBMCs were stained 
directly ex vivo with pMHCI tetramers representing epitopes derived from cytomegalovirus 
(CMV) and Epstein-Barr virus (EBV), was reduced in the presence of dasatinib (Figure 5.6). 
Therefore, dasatinib exerts three beneficial effects: i) it increases the intensity of pMHCI and 
pMHCII tetramer staining; ii) it preferentially enhances pMHCI tetramer staining of T cells 
bearing low affinity TCRs; and, iii) it reduces pMHCI tetramer-induced cell death.
5.2.4 Substantial improvements in the detection of antigen-specific CD8+ T cells directly ex 
vivo
The above findings suggest that dasatinib treatment might enable the identification of low 
avidity antigen-specific CD8+ T cells directly ex vivo that cannot be 'seen' in the absence of 
treatment. To test this idea, I first examined the staining of CD8+T cell lines in the presence 
or absence of 50 nM dasatinib. Staining improvements were observed in three different 
CD8+ T cell lines raised against the Melan-A/MART-l26-35 epitope (ELAGIGILTV) and three 
different CD8+T cell lines stimulated with the influenza matrix Mi58^ 6 epitope (GILGFVFTL), 
all derived from HLA A2+ individuals. Representative data are shown in Figure 5.7 A. In all 
cases, dasatinib treatment substantially enhanced the staining intensity of cognate CD8+ T 
cells without concomitant increases in the tetramer-negative population. In accordance 
with the results above, CD8+ T cells that stained poorly with pMHCI tetramer received the 
greatest benefit from dasatinib treatment. The staining intensity of all cognate CD8+ T cells 
increased by at least 2-fold after dasatinib treatment, but T cells that bound tetramer 
weakly exhibited increases of >20-fold in their fluorescence intensity. In many cases, larger 
populations of cells that stained with the corresponding pMHCI tetramer were detected 
after dasatinib treatment. This increase in tetramer-positive cells after dasatinib treatment 
likely reflects the combined effects of a lower detection threshold in terms of TCR/pMHCI 
affinity and the fact that dasatinib reduces pMHCI multimer-induced cell death (Figure 5.6). 
Subsequently, collaborators with access to patient PBMC samples examined whether 
dasatinib could enhance pMHCI tetramer staining of cognate CD8+ T cells directly ex vivo 
and enable the detection of antigen-specific CD8+ T cells that are 'invisible' with routine
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Figure 5.6: Dasatinib reduces pMHCI tetramer-induced cell death. Increased tetramer 
staining in the presence of dasatinib appears to be due partly to reduced cell death. Cell 
death induced by tetramer staining was assessed using the amine-reactive viability dye 
GrViD at the end of the staining procedure, which is spectrally distinct from ViViD. PBMC 
were stained with ViViD to identify and allow exclusion of dead and dying cells prior to the 
addition of pMHCI tetramer; GrVID staining was performed after pMHCI tetramer and 
surface antibody staining. Data were acquired on a BDLSR II flow cytometer and analyzed 
using FlowJo software. ViViD+/ CD14+ and CD19* cells were excluded from the analysis and 
the frequency of GrViD* cells was assessed in the tetramer*C D3*CD8* T cell populations. 
Representative flow profiles are shown here for CDS* T cells specific for the HLA A2- 
restricted epitopes CMV PP6 5 4 9 5 . 5 0 3  (NLVPMVATV) and EBV BMLFI2 5 9 - 2 6 7  (GLCTLVAML). The 
frequencies of dead cells varied depending on the tetramer used, but the frequency of 
GrViD-positive dead cells within the tetramer* population was always lower in the presence 
of 50 nM dasatinib.( Data kindly provided by K. Ladell).
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staining procedures. Indeed, a substantial increase in both pMHCI staining intensity and the 
percentage of antigen-specific CD8 + T cells was observed at both 4°C and 37°C in PBMC 
samples stained with HLA A2 tetramers specific for antigens derived from CMV, EBV and 
Melan-A (Figure 5.7 B).
5.2.5 pMHCI staining of functional autoimmune CD8*T cells following dasatinib treatment
Collaborators in King's College London, who have access to PBMC samples from patients 
with type I diabetes, next examined pMHCI tetramer staining of IE6 , a preproinsulin (PPI15- 
24)-specific H L A  A2-restricted autoreactive CD8 +T cell clone isolated from one such patient. 
This CD8 +T cell clone produces TNF, IFNy and MIPlfS on stimulation with target cells pulsed 
with cognate PPI-derived peptide antigen (Figure 5.8 A), but does not stain with cognate 
pMHCI tetramer using conventional staining procedures (Figure 5.8 B). Dasatinib treatment 
allowed the IE6  CD8 + T cell to bind cognate tetramer without affecting staining with non­
cognate tetramer (Figure 5.8 B). In keeping with these findings, dasatinib treatment allowed 
the identification of a P P I1 5 .2 4 /H L A  A2 tetramer-positive population directly ex vivo from a 
type I diabetic patient, consistent with a corresponding IFNy ELISpot response to PPI peptide 
of 13 responder cells per 106 PBMCs (Figure 5.8 C). Dasatinib did not increase direct ex vivo 
PPI/HLA A2 tetramer staining in healthy H L A  A2-matched control subjects (Figure 5.8 C). A 
seven-fold increase in the percentage of autoreactive CD8 +T cells was observed when short­
term lines expanded from two type I diabetic patients were stained in the presence of 
dasatinib (Figure 5.8 C). Thus, dasatinib treatment allows the detection of functional 
autoreactive CD8 +T cells that are otherwise undetectable with standard staining conditions.
5.2.6 How does dasatinib exert its beneficial effects on pMHC tetramer staining?
Previous studies have demonstrated that incubation with Src kinase inhibitors results in 
enhanced TCR and CD8  expression at the cell surface (Luton et al. 1994; D'Oro et al. 1997). 
Consistent with these observations, Weichsel et al. have recently demonstrated that 
increased levels of TCR and CD8  are seen at the cell surface following incubation with 
dasatinib for 4 hours (Weichsel et al. 2008). Initially, therefore, I investigated this increase in 
TCR and CD8  levels as a possible mechanism for the observed effects on tetramer binding.
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Figure 5.7: Dasatinib enhances the visualization of antigen-specific CD8* T cells in mixed 
cell populations. A. Staining of HLA A2-restricted CD8 +T cell lines expanded from PBMC by 
one round of stimulation with the influenza matrix peptide (GILGFVFTL) or the
Melan-A/MART-1 2 6 - 3 5  peptide (ELAGIGILTV). Lines were stained with cognate tetram er ± 
pre-treatment with 50 nM dasatinib for 30 minutes at 37°C. B. Flow cytometric profiles of 
live CD3+ lymphocytes stained with HLA A2 tetramers folded around the EBV BMLF1 2 5 9 . 2 6 7  
(GLCTLVAML), CMV pp65495.503 (NLVPMVATV) or M el a n-A/M A R T - ( E L A G I G I L T V )  
peptide epitopes. 2X106  PBMC were stained with the amine-reactive viability dye ViViD, 
then stained with tetramer ( lp  g in minimal staining volume) ± pre-treatment with 
dasatinib for 30 minutes at 37°C. Cells were then stained with cell surface markers as 
described in the Materials and Methods; a dump channel was used to exclude dead cells, 
CD14+ and CD19+ cells from the analysis. Data were acquired with a BD LSR Ilf low 
cytometer and analyzed using FlowJo software.(D ata in B. kindly provided by K.L adell).
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Figure 5.8: Dasatinib allows detection of autoreactive CD8* T cells. A. CD8 +T cell clone 
IE6 , specific for the HLA A2-restricted epitope PPI1 5 -2 4 , was activated with either 
CMVpp654955o3 or PPI1 5 . 2 4  peptide for 6 hours at 37°C and then assayed for TNFa 
production by intracellular cytokine staining (ICS) as detailed in the Materials and Methods 
section 2.11.5. B. Staining of CD8+ Tcell clone IE6 with either an irrelevant or PPI15-24/HLA 
A2 tetramer ± pre-treatment with 50 nM dasatinib for 30 minutes at 37°C. C. 
Representative stainings with PPI/HLA A2 tetramer ± pre-treatment with 50 nM dasatinib 
for 30 minutes at 37°C. Left panels: control subject PBMC; middle panels: type I diabetic 
patient PBMC; right panels: a short-term line expanded by one round of peptide 
stimulation from a type 1 diabetic patient.( Data kindly provided by A.S kowera)
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The beneficial effects of dasatinib on pMHCI tetramer staining were observed within 
seconds of dasatinib treatment (Figure 5.3 D); whereas significant increases in TCR and CD8 
levels were not observed until >30 minutes (Figure 5.9). Therefore, this time-dependent 
accumulation of TCR and CD8 at the cell surface cannot explain the effects of dasatinib on 
tetramer binding. I next investigated whether the mechanism of PKI action operates 
through TCR- or CD8-mediated effects. Dasatinib treatment enhanced pMHCI tetramer 
staining of the HLA A2-restricted ELAGIGILTV-specific Melc5 CD8+T cell clone and a CD8+T 
cell line raised against the Melan-A/MART-l26-35 epitope (ELAGIGILTV) with both wildtype 
and CD8 null (DT227/8KA) tetramers (Figure 5.10), thereby demonstrating that PKIs can 
exert their effects in the absence of a pMHCI/CD8 interaction. Thus, consistent with effects 
on pMHCII tetramer binding (Figure 5.3), dasatinib does not enhance pMHCI tetramer 
binding via CD8-mediated effects.
I therefore decided to focus on what happens to the TCR on treatment with a PKI such as 
dasatinib. TCR expression levels are not static and TCRs are constantly being down- 
regulated from the cell surface (Krangel 1987). TCR internalisation is thought to be 
mediated by three different mechanisms: i) constitutive recycling of the TCR between 
intracellular compartments and the plasma membrane in resting cells by an unknown 
mechanism (Dietrich et al. 2002); ii) protein kinase C activation (Minami et al. 1987; Dietrich 
et al. 2002); and, iii) Lck-mediated tyrosine phosphorylation following TCR ligation by 
specific pMHC ligand. Dasatinib has been shown to target Lck and therefore has the 
potential to inhibit the latter pathway of TCR downregulation (Carter et al. 2005; Weichsel 
et al. 2008). Indeed, dasatinib treatment was found to block antigen-induced TCR 
downregulation from the CD8+ T cell surface (Figure 5.11 A). pMHC tetramers are rapidly 
internalised under normal staining conditions (Whelan et al. 1999), and therefore I 
hypothesised that dasatinib might exert its beneficial effects by blocking this process. To 
this end, I performed fluorescence microscopy in the presence and absence of dasatinib 
(Figure 5.11 B). ILA/HLA A2 Alexa488-conjugated tetramer capping and internalisation was 
blocked in the presence of dasatinib and remained on the cell surface, where it formed a 
ring that was visibly brighter than tetramer that had been internalized (Figure 5.11 B). Thus, 
by preventing TCR downregulation, PK inhibition acts to drive the system towards
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Figure 5.9 Dasatinib results in a time dependent increase in TCR and CD8  expression 
levels at the CD8 + T cell surface. The ILA1 CD8 * T cell done was treated with PBS ± 50 nM 
dasatinib at 37°C and 105 CD8 + T cells were removed from the medium at 0, 10, 30, 60,180 
and 250 minutes. ILA1 CD8 + T cells were subsequently stained with anti-CD8  FITC or anti- 
TCR FITC for 30 minutes on ice, washed twice and resuspended in PBS. Data were acquired 
on a FACS Calibur flow cytometer (BD) and analyzed using FlowJo software. Representative 
data of 3 separates experiments shown.
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Figure 5.10: Beneficial effects of dasatinib are not CD8-mediated. A. Melc5 CD8+ T cells 
were pre-treated with PBS ± 50nM dasatinib for 30 minutes at 37°C, then stained with HLA 
A2 DT227/8KA cognate tetramer for 20 minutes at 37°C. After washing twice, data were 
acquired on a FACSCalibur flow cytometer (BD) and analyzed using FlowJo software. B. 
Staining of HLA A2-restricted CD8  ^ T cell lines expanded from PBMC by one round of 
stimulation with the Melan-A/MART-1 2 6 - 3 5  peptide (ELAGIGILTV). Lines were stained with 
either wildtype or CD8 null cognate tetramer ± pre-treatment with 50 nM dasatinib for 30 
minutes at 37°C.(D ata kindly provided by M. Clement).
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Figure 5.11: Dasatinib blocks antigen-induced TCR downregulation and tetramer 
internalization from the cell surface. A. M e ll3  CD8* T cell clone was pre-treated with PBS ± 
50 nM dasatinib and exposed to C1R-A2 B cells previously pulsed with 10"6 M ELAGIGILTV 
peptide or medium alone for 4 hours at 37°C. Cells were subsequently stained with anti- 
TCR-FrrC and anti-CD8-APC antibodies for 30 minutes on ice, washed twice and 
resuspended in PBS. Data were acquired on a FACSCalibur flow cytometer (BD) and 
analyzed using FlowJo software. B. 105 ILA1 CD8+ T cells were pre-treated with PBS (i & ii) 
or PBS+ 50 nM dasatinib (iii & iv) for 30 minutes at 37°C, then stained with 20 pg/ml 
ILAKFLHWL/HLA A2-Alexa488 tetramer for 15 minutes at 37°C. Representative data of 2 
replicates (for A) and >3 replicates (for B) shown. Fluorescence microscopy was performed 
as described in the Materials and Methods.A Ithough the pattern observed in B (i & ii) using 
fluorescence microscopy does not guarantee the presence of tetramer inside cells, 
evidence for internalisation of tetramer into early-endocytic vesicles at 37°C has previously 
been documented by Whelan eta l. 1 999 using confocal microscopy .
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a higher number of surface TCRs and a higher number of potential productive engagements 
with pMHC tetramer. This has the effect of increasing tetramer on-rate, at least in pMHCI 
systems (Figure 5.12).
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Figure 5.12: Dasatinib enhances pMHCI tetramer association-rate. Rate of hTERT540^ 48 
(ILAKFLHWL)/HLA A2 tetramer recruitment to the cell surface of CD8 + T cell clone ILA1 is 
substantially enhanced following treatment with 50 nM dasatinib for 30 minutes at 37°C. 
Curves represent the following on-rate estimates: fast rate 0.14/min, slow rate 0.04/min 
(tetramer only); fast rate 0.42/min, slow rate 0.06/min (dasatinib + tetramer). (Data kindly 
provided by M. Clement).
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pMHC tetramer technology has revolutionised the study of antigen-specific T cells. 
However, one major limitation of this technique is that pMHC multimer staining is 
dependent on a distinct TCR affinity threshold that lies well above that required for T cell 
activation (Laugel et al. 2007). Consequently, pMHC tetramers fail to identify functional T 
cells that express TCRs with low affinity for cognate antigen. Such low affinity interactions 
characterise TCR/pMHCI binding in tumour-specific and autoreactive CD8 + T cells (Cole et al. 
2007). In this chapter I demonstrate that a short incubation with a reversible PKI such as 
dasatinib results in three major benefits in terms of pMHC tetramer staining. Firstly, 
substantial improvements in pMHC tetramer staining intensity are observed. This effect 
applies to both CD4+ and CD8 + T cells (Figure 5.3). Indeed, the beneficial effects are so 
striking even at low pMHC tetramer concentrations that dasatinib treatment could be used 
to conserve reagent. Secondly, dasatinib treatment reduces tetramer-induced cell death 
that has been previously reported to be an issue with pMHC multimer staining protocols 
(Purbhoo et al. 2001; Guillaume et al. 2003; Cebecauer et al. 2005). Thirdly, the benefits of 
dasatinib treatment are greater for TCR/pMHCI interactions of low affinity. This effect is 
particularly important in the setting of tumour-specific and autoreactive CD8 + T cell 
populations. Such effects are also likely to apply to CD4+ T cells, which typically bind cognate 
pMHCII antigens with affinities lower than those reported for pMHCI systems (Cole et al. 
2007). Importantly, no increase in background staining was seen in any of the systems 
tested here (Figures 5.2 F, 5.3 B, 5.3 H, 5.9 B and 5.9 C). Similarly, positive staining of PBMC 
in the presence of dasatinib only ever coincided with a positive ELISpot result to the 
relevant peptide and never accompanied by an increase in background staining. Dasatinib 
proved to be a particularly powerful tool in the detection of autoreactive CD8 + T cells from 
type I diabetic patients. No increase in the PPI tetramer positive population was observed in 
healthy donors and staining was only ever seen if a functional response to the preproinsulin 
peptide was evident.
I next examined the mechanism by which dasatinib enhances staining with cognate pMHC 
tetramers. Experiments with CD8 -null tetramers (Figure 5.10) supported data
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demonstrating that treatment enhanced pMHC staining of CD4+ T cells (Figure 5.3 H), ruling 
out the possibility that staining enhancement was dominated by a CD8-dependent 
mechanism. Further experiments showed that the positive effects of dasatinib treatment 
were almost immediately evident (Figure 5.3 D) and were not reliant on the increased 
expression levels of TCR (and CD8) that are seen over a much longer timeframe (Figure 5.9). 
Dasatinib treatment also induced a substantially faster pMHC tetramer on-rate (Figure 
5.12). Microscopic analysis of pMHC tetramer staining confirmed that staining was 
considerably brighter in the presence of dasatinib and that the tetramer was not 
internalised by dasatinib treated cells. The above data caused us to conclude that the 
enhanced staining observed was a direct result of preventing TCR downregulation.
When an individual pMHC molecule in a pMHC tetramer engages a cell surface TCR, this 
engagement can be described as either 'productive' or 'non-productive' in terms of whether 
it finally results in the capture of the tetramer from solution (Figure 5.13). A productive 
engagement requires a second pMHC in the tetramer to bind a second TCR before the first 
pMHC dissociates. As a result, the main factor that determines whether a pMHCI tetramer 
exhibits stable binding is likely to be the duration of the primary monomeric TCR/pMHC 
interaction. 'Non-productive' engagements are more likely to occur for low affinity, rapidly 
dissociating ligands. We hypothesise that dasatinib acts to prevent TCR downregulation 
after 'non-productive' engagement thereby maintaining TCRs at the cell surface where they 
are available for future interactions with pMHC. In simple terms, regular pMHC tetramer 
staining affords each initiating TCR/pMHC engagement just a single attempt to capture a 
tetramer from solution before it dissociated and the TCR is downregulated. The presence of 
dasatinib prevents this downregulation and in doing so allows the TCR further serial 
attempts at tetramer capture. Dasatinib treatment may also have a secondary effect as it is 
likely to block the internalisation of non-triggered TCRs that has been shown to occur at the 
same time as the internalisation of pMHC-engaged TCRs (Niedergang et al. 1997; San Jose et 
al. 2000). Dasatinib and other effective PKIs prevent TCR downregulation, acting to maintain 
surface TCRs and enabling a higher number of potential productive engagements with 
pMHC tetramer as indicated by the red arrows in Figure 5.13. Increased TCR availability at
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Tetramer binding
ProductiveNon-productive
v_y
dasatinib
TCR downregulation
>|r dasatinib ^  dasatinib
TCR downregulation
Figure 5.13: Dasatinib prevents downregulation of 'empty' TCRs.P roposed model for the 
mechanism by which dasatinib enhances cognate tetramer staining. Dasatinib treatment 
prevents TCR and coreceptor downregulation and maintains these receptors at the cell 
surface, thereby increasing molecular availability for further capture of pMHC tetramer 
from solution.
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the T cell surface would increase the likelihood of a 'productive engagement' for low affinity 
ligands. This effect would be less obvious for higher affinity ligands, where slow TCR/pMHCI 
off-rates already increase the likelihood that a second pMHCI 'arm' in a tetramer can bind 
before dissociation of the first monomeric TCR/pMHCI interaction. As described above, the 
beneficial effects observed do not involve significant contribution from the CD8 coreceptor 
suggesting that CD8 availability at the T cell surface must be sufficient for pMHCI tetramer 
staining in the absence of dasatinib treatment.
In summary, I have demonstrated that a short incubation with reversible PKIs such as 
dasatinib affords a number of important benefits including:
i) Enhancement of the mean fluorescence intensity during any pMHCI tetramer 
staining.
ii) Conservation of valuable pMHC tetramer reagent as the amount required is 
significantly reduced in the presence of dasatinib.
iii) Detection of T cell populations that exhibit low affinity TCR/pMHC interactions. 
This effect will be of particular importance for researchers and clinicians studying 
diseases characterised by T cells of this phenotype such as chronic viral infection, 
autoimmune and neoplastic disease. The beneficial effects of this reagent also 
extend to MHCII tetramers, with which staining is often very poor or not visible 
at all.
iv) Inhibition of activation-induced cell death during staining. This affect results in a 
greater number of tetramer positive cells and is likely to be extremely useful 
when using pMHC tetramers to sort-done antigen-specific T cells.
Importantly, these benefits are restricted to cognate T cells and are not accompanied by 
concomitant increases in background staining. More recent results obtained in collaboration 
with the Peakman group at Kings College have extended our findings that dasatinib 
treatment can expose concealed antigen-specific T cells that bear low affinity TCRs within a 
large cohort of Type 1 diabetics. Similar increases in staining were not observed in a group 
of healthy controls (manuscript in preparation).
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I conclude that the use of PKIs such as dasatinib during pMHC multimer staining is a cheap, 
easy and effective way to improve results that can be applied to pMHCI and pMHCII 
reagents in both human and murine systems. My supervisor has recently heard that the 
benefits of pMHC multimer staining in the presence of dasatinib also extend to Macaque 
systems. The conservation of Src kinases (Yadav et al. 2008) makes it likely that the 
immense benefits of dasatinib during pMHC staining listed above will extend to any 
mammalian system. I therefore recommend a PKI such as dasatinib should be included 
when conducting any pMHC multimer staining.
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At the start of my project, the T cell modulation group was particularly interested in 
exploring whether modified TCRs could be useful in the clinic. Specifically, our interest was in 
TCRs with enhanced affinity for cognate antigen and TCRs with altered glycosylation (Chapter 
7). Obviously, these approaches cannot be readily applied to natural endogenous TCRs. These 
studies therefore necessitated that we establish optimal TCR gene transfer protocols in 
Cardiff. I took the lead on these optimisation studies. As described in section 1.8.3 of the 
main Introduction, TCR gene transfer provides an efficient and relatively rapid way of 
generating large numbers patient-autologous T cells of required specificity that can be used 
for subsequent adoptive transfer. As described below, I considered several different 
strategies for the transfer of TCR genes to recipient primary T cells before I finally settled on 
a lentiviral system. We currently regularly achieve 60-90% transduction of primary T cells 
using my methodology. I will begin by summarising the various methodologies that can be 
used to introduce and express 'foreign' genes in mammalian cells.
6.1.1 Gene transfer into mammalian cells
There are several different ways of delivering genes of interest (GOI) for expression inside 
mammalian cells. Before choosing a method for gene delivery into cells, or transfection, two 
other factors should be considered:
1) The source of genetic material: The source of genetic material can be either DNA or RNA. 
Since mRNA does not require nuclear localisation for expression, transfecting mRNA has 
several advantages over DNA transfection (Yamamoto et al. 2009). These advantages include 
no risk of integration into the host genome, cell cycle-independent transfection efficiency, 
and adjustable and rapid expression (Yamamoto et al. 2009). Because transfection of mRNAs 
bypasses the need for translocation into the nucleus and transcription, expression of GOIs 
can be achieved within minutes of delivery into host cells (Job et al. 2001; Yamamoto et al.
2009). In contrast, transfected DNA must carry a host cell-specific promoter to be 
transcribed into mRNA, and the period between transfection and expression is considerably 
longer. Furthermore, the expression level is determined by strength of this exogenous
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promoter. Matured mRNA consists of five significant structures: i) the cap; ii) 5' untranslated 
region (5'UTR); iii) open reading frame (ORF); iv) 3' untranslated region (3'UTR); and, v) poly-A 
tail (Elango et al. 2005). The efficiency of mRNA translation depends on the integrity of these 
structures, which can be affected by exposure to RNA-enzymes (RNAses). As a result, the in 
vitro preparation of mRNA is a laborious process that demands more caution than the 
preparation of DNA constructs (Elango et al. 2005).
2) Stable or transient transfection: Mammalian cells can be transfected transiently or stably 
(Recillas-Targa 2006). For transient transfection, the delivered genes are only expressed for a 
limited period of time as they are not integrated into the genome and their expression is lost 
with cell division (Recillas-Targa 2006). In order to achieve stable transfection, the foreign 
genetic material is integrated into the host cell genome and the resultant transgene 
expression is sustained even after host cells replicate (Glover et al. 2005). Since transient and 
stable transfection offer different durations for GOI expression, the choice between the two 
techniques depends on the objective of the experiment.
Many transfection methods have been developed. These can be classed into one of three 
categories: i) biological; ii) chemical; and, iii) physical.
i) Biological transfection: Biological transfection comprises virus-mediated transfection, also 
known as transduction. Viral transduction is highly efficient and represents the most 
commonly used method in clinical research (Pfeifer et al. 2001). Retroviruses such as the 
murine leukaemia virus (MLV) were used to make the earliest gene delivery vectors. More 
recently, retroviral vectors have been superseded by lentiviral vectors, which are largely 
based on the genome of the human immunodeficiency virus (HIV). Both retroviral and 
lentiviral vectors have been used to establish sustainable transgene expression in humans 
(Hacein-Bey-Abina et al. 2002; Woods et al. 2003). Once the virus gains access to a cell, its 
DNA is integrated into the host genome, so that as the host cell replicates the viral DNA 
segregates into each daughter cell. The advantages of viral-mediated transfection include: 
ease and high efficiency of transfection, sustained stable transfection, and transgene 
expression in vivo. The major drawbacks are immunogenicity, cytotoxicity, insertional
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mutagenesis due to the random mature of viral genome integration, and a limit on the size of 
the foreign gene that can be inserted into the vector whilst preserving infectivity (Hacein- 
Bey-Abina et al. 2003; Woods et al. 2003).
ii) Chemical transfection: Chemical transfection represents the first method to be used to 
introduce foreign genes into mammalian cells. Chemical methods commonly use cationic 
polymer (one of the oldest chemicals used), calcium phosphate, cationic lipid (the most 
popular method) and cationic amino acid (Schenborn et al. 2000a; Schenborn et al. 2000b; 
Schenborn et al. 2000c). The underlying principles of gene delivery are similar for all types of 
chemical transfection. Essentially, a positively charged chemical adheres to intrinsically 
negatively-charged nucleic acids and masks their negative charge. The resultant positively- 
charged nucleic acid/chemical complexes bind to the negatively charged cell membrane of 
the host cell, and are believed to be internalised by endocytosis or phagocytosis. The 
advantages of chemical transfection methods are relatively low cytotoxicity, no mutagenesis, 
no extra-carrying DNA and no size limitation on the packaged nucleic acid. The major 
drawback however is that the techniques achieve low transfection efficiency, and are 
generally not applicable in vivo.
iii) Physical transfection: Physical transfection is the most contemporary group of 
transfection methods, which rely on the use diverse physical tools to deliver exogenous 
genetic material into mammalian cells. Physical transfection methods include 
electroporation, direct microinjection, biolistic particle delivery, laser-based transfection, 
sonoporation and the use of magnetic nanoparticles (Mehier-Humbert et al. 2005). 
Electroporation is the most widely used physical method (Mehier-Humbert et al. 2005; Kim 
et al. 2010). Although the exact mechanism of electroporation is not fully understood, it is 
presumed that a short electrical pulse causes perforations in the cell membrane through 
which nucleic acids can enter (Inoue et al. 2001; Mehier-Humbert et al. 2005; Kim et al.
2010). The advantages of physical transfection include their ease, the ability to transfect a 
large number of cells in a short time, and the ability to transfect a wide range of cell types. 
The disadvantages are the requirement for expensive instruments, and cell cytotoxicity due 
to the invasive nature of the techniques.
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To summarise, although a wide range of transfection methodologies are available, each one 
has its own advantages and disadvantages. Therefore the selection of the best method 
depends upon the experimenter's objectives.
6.1.2 Methods for transferring more than one gene to cells
Many gene transfer applications require vectors that express more than one protein. 
Introduction of multiple genes into the same host cell and equimolar expression of these 
genes cannot be efficiently achieved by co-transduction with multiple vectors each carrying a 
single GOI. In such circumstances, a gene co-expression system is required. The co-expression 
of more than one gene from a single plasmid can be performed using a number of 
mechanisms: splicing, internal promoters, fusion proteins, internal ribosome entry sites 
(IRES), and ribosome skipping mechanisms (de Felipe et al. 1999; Vang et al. 2008). One of 
the challenges facing viral-assisted TCR transfer is that the TCR is composed of 2 chains that 
must be expressed in equal amounts for assembly. The most commonly used strategy in the 
construction of vectors for TCR expression is the insertion of an internal ribosome entry site 
(IRES) between the TCR alpha and beta chains (Ngoi et al. 2004). Thus, while translation of 
one chain (typically alpha) is initiated at the promoter, translation of the second chain 
(typically beta) is initiated through the IRES sequence. In such vectors however, the 
expression efficiency of the second chain is somewhat lower, resulting in inefficient cell 
surface TCR expression (Yang et al. 2005). This problem can be overcome by borrowing 
technology that is employed naturally by picornaviruses for the production of polyproteins 
from a single open reading frame (ORF) (Palmenberg 1990). This is orchestrated by a 
relatively short (17-20 amino acids long, depending on the virus) 2A peptide sequence, which 
causes the ribosome to skip a peptide bond between the last and second last amino acid of 
the 2A peptide sequence (Yang et al. 2008). Insertion of the 2A peptide between TCRa- and 
TCR -^encoded sequences allows translation of the alpha chain without causing an arrest in 
beta chain synthesis. As a result, near equimolar amounts of both TCR chains are produced 
from a single open reading frame (Szymczak et al. 2004). Since the peptide-bond skipping 
event occurs after a portion of the 2A sequence has undergone translation, the first section 
of the peptide remains attached to the C-terminus of the TCR alpha chain, while the N-
188
Chapter 6
terminus of the TCR beta chain gains a proline residue. The presence of these additional viral 
residues does not seem to affect the function or assembly of the TCR chains (Ryan et al. 
1994; de Felipe et al. 1999; Donnelly et al. 2001; Yang et al. 2008). The expression of both 
genes from the same small construct offers several advantages and ensures that TCR 
cassettes are small enough to be carried efficiently by retroviral and lentiviral constructs.
6.1.3 The retroviral genome, virion structure and replication cycle
Retroviruses are single stranded RNA viruses that replicate via a double-stranded DNA 
intermediate (Temin et al. 1970). The retroviral RNA encodes the gag and pol genes that are 
expressed from an unspliced transcript, the env gene that is expressed from a spliced version 
of the genome, in addition to the u5, u3 and r regions located on either end of the genome 
(Figure 6.1). Retroviruses replicate by reverse-transcribing this RNA construct into a DNA 
form of the genome that is able to integrate into the chromosomal DNA of the host cell, 
where it is thereafter referred to as a provirus. On reverse transcription the ends of the 
genome undergo structural changes leading to the formation of 5' and 3' long terminal 
repeats (LTRs). This change permits appropriate expression of the viral genes gag, pol and 
env. The gag gene encodes structural proteins that make up the viral core: matrix, capsid and 
nucleocapsid. The pol gene encodes viral replication enzymes: protease, reverse 
transcriptase and integrase. Then env gene encodes the envelope glycoprotein (Env), which is 
processed into transmembrane (TM) and surface (SU) subunits. The TM and SU fragments 
assemble together with components of the lipid bilayer derived from the host cell to form 
the viral envelope around the core (Buchschacher 2001).
The infection of a cell by a retrovirus begins with recognition of a specific cellular receptor by 
the viral envelope glycoprotein and the fusion of viral and cellular membranes to permit the 
release of the viral core into the cytoplasm of the cell. Once inside, the RNA strands of the 
viral genome are uncoated and reverse transcribed into DNA using viral reverse transcriptase 
and the cellular tRNA molecule as a primer that recognises a sequence on the 5'LTR on the 
viral RNA. The viral DNA gains entry to the nucleus after nuclear envelope breakdown that 
occurs during cell division, and integrates itself into the chromosomal DNA. The resultant 
provirus simply hijacks the cellular transcription machinery to replicate its genome and form
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Figure 6.1: Structure of the retroviral genome and retroviral vector. The viral RNA is 
represented by the black line at the top of the figure (A), with the locations of the open 
reading frames (ORFs) gag, pol and env strung out along it. The genomic RNA (B)b egins 
with r (repeat) and u5 (unique 5' region) segments, and terminates with the u3 (unique 3' 
region) an r (repeat) region, and a poly-A tail. Reverse transcription of the RNA initiates a 
set of structural rearrangements of the genome termini, resulting in formation of long 
terminal repeat (LTR) structures. A retroviral vector (C) is constructed by replacing the 
retroviral gag, pol and env genes by a foreign gene of interest (GOI), and supplying the 
genes essential for formation of virions on separate plasmids. Full length retroviral 
transcripts and the retroviral vector also encode a packaging signal (W) upstream of 
gag/GOI start codon, enabling full length transcripts to be encapsidated into newly formed 
viral particles.
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the proteins that together assemble into new viral progeny, which can bud out of the cell. 
The events of the retroviral replication cycle are summarised in Figure 6.2 (Scherer et al. 
2007).
6.1.5 General concepts of retro/lentiviral vector design
The unique property of retroviruses to deliver and integrate their genomes into a cell has 
been exploited for the delivery of GOIs to cellular targets by engineering retroviral vectors; 
derivatives of viruses capable of specific gene transfer (Demaison et al. 2002). Lentiviruses 
are a genus of retroviruses that are characterised by their association with 'slow' diseases 
that have long latent periods. The most well known example of a lentivirus is the human 
immunodeficiency virus (HIV). Although all retroviruses are capable of acting as vectors to 
deliver genetic information to the nucleus of a cell, lentiviruses have the unique ability 
among retroviruses to replicate in non-dividing cells and have therefore superseded other 
classes of retroviruses as tools for gene delivery (Lewis et al. 1994). More recent studies 
however, have highlighted the importance of cytokine-induced activation (but not 
necessarily division) of human T cells as a prerequisite for efficient infection with lentiviruses. 
Without cellular activation, the infection appears to be blocked at a pre-integration state by 
an incompletely understood mechanism (Unutmaz et al. 1999; Schumacher 2002).
The basic backbone of the vector (outlined in Figure 6.1) is constructed by removing the viral 
genes gag, pol, and env from the viral genome, freeing up space for insertion of a GOI and a 
number of elements which function to increase or regulate the expression of that gene. For 
instance, the viral LTRs flanking the GOI are often unsuitable for efficient expression, and are 
replaced by a stronger promoter from another virus such as CMV or SV40. Other design 
features include: i) a cassette of enzymatic restriction sites to facilitate insertion of several 
genetic elements into a single vector; ii) enhancers for optimal expression; iii) internal 
ribosome entry sites (IRES) for expression of more than one GOI; and, iv) post-transcriptional 
regulatory elements for regulation of protein production (Adam et al. 1991; Zufferey et al. 
1998; Demaison et al. 2002). More recently, a range of self-inactivating (SIN) vectors, in 
which the U3 region of the 3'LTR has been truncated or deleted, have been developed. When
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Figure 6.2: The retroviral replication cycle. 1. Binding of viral envelope glycoproteins to 
cell surface receptors (CD4, and CXCR4 or CCR5 in the case of HIV-1). 2. Fusion. 3. 
Unraveling of the viral RNA genome. 4. Reverse transcription of the RNA into DNA by the 
reverse transcriptase enzyme (RT). 5. Formation of pre-integration complex (PIC). 6 . 
Nuclear import of PIC. 7. Integration of viral DNA into host genome to form a provirus. 8 . 
Transcription of multiply spliced mRNAs. 9. Translation of Tat and Rev, the early regulatory 
proteins. 10. Nuclear import of Tat and Rev. 11. Export of singly spliced and unspliced 
mRNAs from the nucleus, mediated by Rev. 12. Translation of viral structural proteins 
occurs in the cytosol. 13. Assembly of viral RNA genome, proteins, and cellular factors 
including the cellular primer tRNA (essential for reverse transcription) into a virion occurs 
at the cell membrane. 14. Budding. 15. Viral maturation. (Figure taken from Scherer et al. 
2007).
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the defective U3 region is reverse transcribed it results in an inactive promoter in the 5'LTR, 
rendering this type of vector less capable of spontaneous recombination and replication than 
traditional retroviral vectors (Zufferey et al. 1998). In the context of TCR gene transfer, the 
sole purpose of a viral vector is gene delivery. Thus, for safety reasons viral vectors are 
engineered to be replication-defective, with the ability to complete only a single round of the 
retroviral replication cycle. Replication-defective retroviral and lentiviral vectors are 
commonly generated by transient transfection of a producer cell line with several plasmids 
(typically three or four) in order to separate the c/s-acting elements; required for optimal 
packaging, reverse transcription and integration of the GOI, from trans-acting elements; 
proteins that make up the structure of the virion and perform enzymatic functions (Naldini et 
al. 1996). A vector that is produced by this method of trans-complementation, during which 
the likelihood of recombination between the viral genes is greatly minimised, can be used to 
transduce (infect and express a foreign gene in) target cells.
6.1.6 The Lenti-SxW lentiviral vector and the three plasmid packaging system
The lentiviral vector used to deliver the HLA A*0201 restricted HIV-1 Gag77-85 (SLYNTVATL) 
specific TCR (868 TCR) genes to target cells for the purpose of this study was based ironically 
on the very virus the TCR was engineered to recognise, HIV-1. This lenti-SxW vector (also 
called pHR'SINcPPT-SFFV-x-WPRE) was developed and kindly donated by Qasim Waseem and 
others at the Molecular Immunology Unit, University College London. The design and 
development of the lenti-SxW vector is fully documented in (Demaison et al. 2002), and its 
various components are depicted in Figure 6.3. Since the vector was originally designed for 
gene delivery into non-dividing hematopoetic cells, which are notoriously problematic to 
transduce, it incorporates several additional elements geared towards enhancing gene 
expression: LTR sequences from the spleen focus forming virus (SFFV), post-transcriptional 
elements from the Woodchuck hepatitis virus (WPRE), and the central polypurine tract 
(cPPT) sequence of HIV-1. The authors found that the incorporation of these elements into 
the vector backbone resulted in between 20- and 73-fold increase in transgene expression in 
engrafted cell lineages compared to basic lentiviral vectors containing the CMV promoter 
(Demaison et al. 2002). Lenti-SxW is a self-inactivating vector, as the U3 region of its HIV- 
3'LTR has been deleted for additional safety.
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Figure 6.3: The lentivirus is assembled from three plasmids: pA8.91, pMD2.G, and lenti- 
SxW. The lentiviral vector used in this study, Lenti-SxW encodes the genes of interest (the 
868 TCR alpha and beta chains, separated by 2A peptide), and several transduction- 
enhancing elements. The packaging plasmids pA8.91 (coding for matrix and transcription 
proteins) and pMD2.G (coding for envelope proteins) supply the other proteins required for 
viral assembly in trans.
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As previously mentioned, replication-defective vectors are generated by co-transfection of a 
producer cell line with a number of additional plasmids carrying the trans-acting 
components. In the three-plasmid system used for this study, these comprise the envelope 
plasmid pMD.2G and the packaging plasmid pA8.91 (Figure 6.3) (Zufferey et al. 1998).
6.1.7 Aims
Adoptive transfer of ex-vivo cultured lymphocytes is emerging as a promising technology for 
the treatment of cancers and chronic viral infections. However, for the reasons outlined in 
the main Introduction, a major limitation of this approach is the low frequency and/or TCR 
affinity of the antigen-specific T cells selected for adoptive transfer therapy, coupled with the 
laborious process of expanding and maintaining the T cells in culture. Genetic manipulation 
of the recipients' own T cells by transduction with exogenous TCR genes specific for a 
cancer/viral epitope of choice alleviates many of these drawbacks. The primary aim of this 
work was to establish and optimise TCR gene transfer at Cardiff University School of 
Medicine. At the outset, I was set the goal of routinely achieving at least 50% transduction of 
primary T cells with a TCR of choice. I chose to pioneer these studies with the well- 
characterised HIV-specific 868 TCR. This TCR recognises the HLA-A*02-restricted, HIV pl7 
Gag-derived (amino acids 77-85) antigen SLYNTVATL (SL9). The CD8+ T cell line 868 from 
which the 868 TCR originated no longer exists, adding to my interest in investigating whether 
the transduction of primary polyclonal T cells with the 868 TCR would generate T cells with 
similar properties to the 868 line (Sewell et al. 1997; Wilson et al. 1998). The ultimate aims of 
this chapter were thus to select the best system for the delivery of 868 TCR genes into 
primary CD8+ T cells, optimise this process, and assess the ability of recipient CD8+T cells to 
respond to the SL9 antigen (both artificially pulsed on, and presented naturally by HIV- 
infected cells). As previously mentioned, one of the potential problems of introducing T cell 
receptors into cells that already have an endogenous TCR is the formation of mispaired TCR 
a|3 dimers. For this reason, an additional goal was to assess whether TCR chain mispairing 
was an issue for the 868 TCR system.
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6.2.1 Efficiency of gene delivery by transient transfection techniques of DNA and mRNA 
electroporation is very poor
Electroporation involves the introduction of genes into cells using one of two sources of 
genetic material: a recombinant bacterial plasmid or in vitro transcribed (IVT) messenger RNA 
(mRNA) molecules, and a pulse of electricity. The pDNA or IVT mRNA can gain access to the 
cytoplasm of the cell by entering through pores in the cell membrane, generated by the 
electric pulse (Weaver 1993; Zhao et al. 2006). In the earliest days of this investigation, I 
experimented with these transient transfection techniques by using either a pUC plasmid 
containing a green fluorescent protein (GFP) construct or in-vitro transcribed GFP mRNA 
(prepared as described in section 2.5.2a) as markers of transfection efficiency, and a CD4+ 
Jurkat T cell line as targets for transfection (Figure 6.4). 3xl06 Jurkat cells were 
electroporated in the presence of 10 pg GFP pDNA, 2 pg GFP mRNA, or RIO media (as a 
negative control), and analysed for expression of the GFP transgene 19 hours post 
transfection. The efficiency of transfection with GFP-mRNA (39%) was substantially higher 
compared to that with the GFP-encoding plasmid (11%). Despite this initial success, IVT RNA- 
transfection had many drawbacks: the laborious and expensive process of mRNA 
preparation, low RNA yield (typically only 20-30 pg of mRNA per reaction), and a low 
theoretical probability of cells being transfected with both TCR a and p chains in the eventual 
TCR transfection experiments. In addition, the process of electroporation, and bacterial 
lipopolysaccharide (LPS) contaminants in plasmid preparations resulted in extensive cell 
death, with a 50-70% reduction in live cells. The extent of cell death is predicted to be even 
greater for the less robust primary T cells (Beebe et al. 2003), which are the ultimate target 
for transfection with the 868 TCR. Finally, the transient nature of transgene expression 
imposes a strict time window on any functional assays that are to be carried out with 
transfected cells, and thus the information that can be gathered from such experiments. For 
all the above reasons, I decided to explore an alternative method for delivery of the 868 TCR 
into cells.
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Figure 6.4: Transient transfection of Jurkat cells with plasmid GFP DNA versus in vitro 
transcribed (IVT) GFP mRNA under similar electroporation conditions. 3xl06 Jurkat cells 
were either left untransfected (A), transfected with 10 pg plasmid GFP DNA (B),o r 
transfected with 2 pg GFP mRNA (C). The samples were analysed by flow cytometry 19 
hours post transfection. The total number of cells recorded was kept constant for all 
samples. Figure shows representative data of 2 separate experiments.
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Figure 6.4: Transient transfection of Jurkat cells with plasmid GFP DNA versus in vitro 
transcribed (IVT) GFP mRNA under similar electroporation conditions. 3xl06 Jurkat cells 
were either left untransfected (A), transfected with 10 pg plasmid GFP DNA (B),o r 
transfected with 2 pg GFP mRNA (C). The samples were analysed by flow cytometry 19 
hours post transfection. The total number of cells recorded was kept constant for all 
samples. Figure shows representative data of 2 separate experiments.
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6.2.2 Construction of a lentivirus vector to deliver a HLA A*0201 restricted HIV-1 Gag77-85 
(SLYNTVATL) specific TCR (868 TCR)
The 868 TCR was isolated from an SL9-specific CD8+ T cell line, grown from HIV-infected 
individual 868 in April 1996. This subject made a sustained and robust CD8+T cell response 
against the immunodominant HLA-A*02-restricted, HIV p l7  Gag-derived (amino acids 77-85) 
epitope SLYNTVATL (SL9) (Sewell et al. 1997; Wilson et al. 1998). Repeated attempts to 
generate T cell clones from the 868 line by limiting dilution were unsuccessful. Instead, an 
immunodominant SL9-specific TCR (868 TCR) was isolated from the line by phage display, a 
technique which is suitable for isolation of antigen-specific TCRs from polyclonal T cell 
populations and which bypasses the need for a T cell clone {Varela-Rohena, 2008a #882}. The 
dominant nature of the 868 TCR was determined by SL9/HLA A2 tetramer sorting of 
peripheral blood from the HIV-infected individual whom the CD8+ T cell line was originally 
derived from, with 8 out of 10 tetram er positive T cells expressing a TCR with the 868 TCR 
beta chain (TRBV5-6 by IMGT nomenclature, or V(35.2 by Arden classification) (Wilson et al. 
1998). The 868 TCR has a naturally unusual alpha chain (part TRAV12-2*01 part TRAV12-1, or 
Va2). Codon-optimised full length constructs of the TCRa and TCRp chains for mammalian 
expression were constructed by GeneArt AG (Regensburg, Germany). The 868 TCR binds to is 
cognate antigen with a dissociation constant (KD) of <150 nM as measured by SPR {Varela- 
Rohena, 2008a #882}. As a result, this TCR binds with the highest affinity ever seen to date by 
some margin as the second strongest interaction described to date is that of the HTLV-I- 
specific TCR A6 which binds with a K0 of ~ 1 pM  (Cole et al. 2007).
After the poor success of transient transfection techniques, I diverted my focus to the 
generation of stable transductants using a lentiviral vector system. Modified lentiviruses 
have shown great promise in the delivery of T cell receptor and other genes into various cell 
types. As previously discussed, the success of lentiviral transduction is determined by many 
factors, including the promoter and enhancer elements, and the nature of the envelope 
which coats the virus. The key feature of the HIV-based self-inactivating lenti-SxW vector 
used in this study, are outlined in section 6.1.6.
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Prior to insertion into the lentiviral vector, the components of the 868 TCR construct were 
assembled in a pUC19 shuttle vector (Figure 6.5). The pUC plasmid was especially adapted for 
cloning of TCR alpha and beta genes by incorporating a cassette with additional restriction 
enzyme cleavage sites and the SGSG-2A region separating the TCR alpha and beta insertion 
sites. The 2A peptide used in this study is an 18-amino acid long fragment derived from the 
Thosea asigna virus ((Yang et al. 2008) and Appendix 1C). For the ribosome-skipping 
mechanism of 2A to function, the TCR alpha and beta chains must be part of the same open 
reading frame (ORF). It is thus essential that the stop codon on the C-terminus of the alpha 
chain is removed, to allow translation to proceed through the entire ORF. In vitro studies 
have estimated a cleavage of ~85% when 2A is used on its own, or ~95% if preceded by the 
amino-acid spacer sequence SGSG, which was incorporated into the 868 TCR a-2A-|3 
construct (Yang et al. 2008).
The 868 TCR alpha chain was inserted into the modified pUC vector using Xbal and Xhol 
restriction sites, while the beta chain was cloned in using Kpnl and Not I (Figure 6.5). The fully 
assembled 868 TCR a-SGSG-2A-(3 construct was subsequently excised from the pUC vector 
with a single BamHI digestion for transfer into the lenti-SxW vector (Figure 6.6), which was 
treated with the same enzyme. Following ligation of vector and insert, the construct was 
checked for presence of the 868 TCR insert by a further BamHI restriction digest (Figure 6.7) 
and sequenced in the region of the TCR insert to check for directionality (Appendix 4).
6.2.3 Successful transduction of CD4+ Jurkat T cell line and primary CD8+ T lymphocytes 
with the 868 TCR using a lentiviral vector system
To investigate the transduction efficiency of the lenti-SxW lentiviral vector, Jurkat cells were 
initially transduced with a version of the vector encoding GFP, which was kindly provided 
together with the lentiviral vector by Qasim Waseem et al. at the Molecular Immunology 
Unit, University College London. The GFP-encoding gene insert was chosen for optimisation 
of transduction because of its small size and ease of detection of its emission band (511nm) 
in transduced cells by fluorescence microscopy and flow cytometry. The GFP-expressing virus 
was initially generated by calcium phosphate transfection of the 293T packaging cell line,
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2763 bp
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Figure 6.5: Schematic of the pUC19-x-SGSG-2A-y shuttle vector. The 2A peptide sequence 
and spacer sequence SGSG were cloned into th£ vector using the EcoRI and Hindlll 
restriction sites. The 868 TCR alpha was cloned into the pUC19-x-SGSG-2A-y vector in 
position of Y , using the Xbal and Xhol restriction enzymes. The 868 TCR beta chain was 
inserted into the same vector in position of V  using the Kpnl and Notl restriction enzymes. 
The assembled 868 TCR alpha-SGSG-2A-beta construct was excised from the pUC vector 
using a single BamHI digestion (positions of BamHI restriction sites are highlighted in 
yellow), for transfer into the lentiviral vector (Figure 6.6).
200
Chapter 6
Lenti-SxW 
9064 bp
S V 40
promoter-enhancer
W PR
3'HR'SIN seq primer 
TCR a-SGSG-2A-P * pnI(8257
ASP718 (8253'
Xhol (8241) 
5 a m H I(8 2 3 i )
5'HR'SIN seq primer 
3' SFFV LTR 
cPPT 
RRE ^
LTR-HIVdelU3
gpt (OFR-frame shift)
*
Figure 6.6: Schematic of the lentiviral Lenti-SxW vector. In the Lenti-SxW abbreviation, S 
refers to the SV40 promoter, x stands for any gene of interest, and W refers to the 
woodchuck hepatitis virus post-transcriptional element (WPRE). The SV40 promoter- 
enhancer, LTR sequences from the spleen focus forming virus (SFFV), the WPRE and the 
central polypurine tract (cPPT) sequence of HIV-1 act as enhancers of transduction 
efficiency.T he 868 TCR alpha-SGSG-2A-beta construct was excised from the pUC bacterial 
vector (Figure 6.5), and inserted into the Lenti-SxW vector in place of V  (red arrow) via the 
BamHI restriction site.
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Figure 6.6: Schematic of the lentiviral Lenti-SxW vector. In the Lenti-SxW abbreviation, S 
refers to the SV40 promoter, x stands for any gene of interest, and W refers to the 
woodchuck hepatitis virus post-transcriptional element (WPRE). The SV40 promoter- 
enhancer, LTR sequences from the spleen focus forming virus (SFFV), the WPRE and the 
central polypurine tract (cPPT) sequence of HIV-1 act as enhancers of transduction 
efficiency.T he 868 TCR alpha-SGSG-2A-beta construct was excised from the pUC bacterial 
vector (Figure 6.5), and inserted into the Lenti-SxW vector in place of Y  (red arrow) via the 
BamHI restriction site.
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Figure 6.7: Cloning of the 868 TCR into the lentiviral vector, Lenti-SxW. A. A BamHI 
restriction digest of the pUC-868 TCR construct showing the pUC vector (larger band) and 
868 TCRa-SGSG-2A-P insert (smaller band). B. BamHI restriction digest of Lenti-868 TCR 
construct after ligation of the product from A and BamHI-cleaved Lenti-SxW vector, 
showing that the ligation was successful.
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using the 3-plasmid system of expression, comprising lenti-SeW, pMD2G, and pA8.91. 
Following a 24-48 hour incubation period, the viral supernatant was harvested, depleted of 
cell debris by centrifugation and applied to Jurkat cells in increasing amounts. The extent of 
GFP expression was determined by flow cytometry. Figure 6.8 illustrates the steady increase 
in GFP expression with increasing addition of GFP viral supernatant to a constant number of 
Jurkat cells. The multiplicity of infection (MOI), which is a measure of the number of 
infectious viral particles per cell for a particular batch of viral supernatant, was estimated 
from values on the linear range of the curve. For calculation of MOIs refer to section 2.6.4 of 
Materials and Methods.
Although application of > 30 pi of crude viral supernatant (MOI 3-10) caused GFP expression 
in 55-90% of 2 -10x l05 Jurkat cells, application of 1 ml of the same virus to MACS-sorted 
primary CD8+ T cells delivered a mere 0.5-1% GFP expression (Figure 6.9). At this point, 
several reasons for the low transduction efficiency of primary T cells were proposed: the low 
concentration of viral particles in the crude supernatant preparations applied to the cells, the 
toxicity of calcium phosphate contaminants, and the need for primary cells to be activated 
prior to infection. The first condition to be manipulated was the concentration of viral 
particles, which was increased by ultracentrifugation of the crude viral supernatant for 
several hours. Infection of primary CD8+T cells with 30 pi concentrated GFP-expressing virus 
resulted in 10-15% of the cells expressing GFP (figure 6.10 A). The efficiency of transduction 
of primary CD8+T cells with 868 TCR-virus (generated by the same method as the GFP virus) 
correlated directly with that for the GFP-virus, with 10-15% of cells exhibiting surface 
expression of the 868 TCR as determined by an HLA A2 tetram er refolded around the SL9 
peptide (Figure 6.10 B). The modified TCR-negative Jurkat cell line (J.RT3.T3.5; (Weiss et al. 
1984)) was used for subsequent 868 TCR-transduction experiments, as TCR expression can be 
assessed by analysis of rescued CD3 surface expression in addition to specific SL9/HLA A2 
tetram er staining. The unusually high affinity of the 868 TCR for its cognate SL9/HLA A2 
antigen (KD <150 nM) ensured that cells expressing this TCR stained well in the absence of 
CD8 expression. The TCR negative Jurkat cells used to test the lentiviral expression system 
did not express CD8. This knowledge was factored in when I made the decision on which TCR 
to use for developing TCR gene transfer.
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Figure 6 .8 : Determining the multiplicity of infection (MOI) of the concentrated lentiviral 
supernatant carrying the GFP construct, on the Jurkat cell line. Assuming that each viral 
particle infects a single cell and a constant number of cells is used for each transduction, it 
is possible to calculate the number of infectious particles/pl of supernatant.A n average of 
the values in linear part of the curve (ie. 1 pl,2 pi ,a nd 4 pi virus added) is taken.F rom the 
average number of cells infected it is possible to calculate the num ber of particles of virus 
per pi viral supernatant, assuming that 1 particle infects 1 cell.
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Figure 6.9: Transduction of CD4+ Jurkat T cell line and primary CD8 + T cells with a GFP- 
encoding lentiviral construct. 106 Jurkat cells (bottom panel) and 10  ^ MACS-sorted CD8+ 
lymphocytes (top panel) were treated with 1 ml crude viral supernatant encoding the GFP 
construct. Following a 48 hour incubation with the virus, the cells were tested for GFP 
expression by flow cytometry. The numbers in the upper-right quadrants refer to the 
percentages of GFP+ transduced cells.
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Figure 6.10: Transduction of primary CD8 + primary T cells using concentrated lentivirus.
The transduction efficiency with a lentiviral vector carrying the GFP construct (A)a nd that 
of the lentiviral vector with the 868 TCRa-2A-p insert (B) using two different concentrations 
of lentivirus. In each case, the virus was concentrated by ultracentrifugation. The 
percentages indicate the proportions of cell expressing the gene interest for each 
transduction.
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Although ultracentrifugation of the viral supernatant had made viral transduction of primary 
CD8+T cells possible, the efficiency of the technique did not increase above 15% with further 
addition of the concentrated viral supernatant (Figure 6.10). Meanwhile, other groups 
working on TCR gene transfer reported much higher transduction rates for primary T 
lymphocytes, indicating that my current protocol required improvement. Next, I tested the 
hypothesis that calcium phosphate was exerting a toxic effect on the primary CD8+ T cells by 
substituting for a commercially available transfection reagent called Express-ln. When used 
in combination with ultracentrifugation of the viral supernatant, significant increases in 
transfection efficiency were observed. In addition to these changes in conditions, I 
investigated the effect of culturing the packing 293T cell line in R10-HEPES instead of DMEM- 
10 media, and introducing a CD4+ T cell co-culture. I also prepared the lymphocytes for 
transduction by adding anti-CD3 and anti-CD28 antibody-coated microbeads prior to viral 
infection, as pre-activation of cells was reported to be a requirement for efficient 
transduction by some groups (Xue et al. 2005; Jones et al. 2009).
As illustrated in Figure 6.11, the protocol achieved 70-99% transduction efficiency of primary 
CD8+T cells with GFP-virus. This high level of transgene expression was replicated using the 
868 TCR-expressing virus (Figure 6.12), alleviating the need for any cell-sorting of the 
tetramer-specific population following subsequent transductions with the 868 TCR. The 
efficiency of transduction was significantly reduced when the 293T cells were cultured in the 
recommended R10-HEPES media compared to DMEM-10 (Figure 6.11), meaning all further 
transductions were carried out using DMEM-10 media. Co-culturing CD8+T cells with CD4+T 
lymphocytes produced a slight increase in the level of transduction, but this was not 
significant enough for the effort taken up by additional MACS separations, and this 
requirement of the protocol was deemed unnecessary for future transductions.
6.2.4 Primary CD8+ T cells transduced with a lentiviral vector encoding the 868 TCR 
maintain a stable level of exogenous TCR expression in culture, and acquire specificity for 
the SL9 epitope
After transduction with the 868 TCR-lentivirus, primary CD8+ T cells were expanded and 
maintained in culture for up to two months. During this time, the percentage of cells
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Figure 6.11: Optimisation of the lentiviral transduction protocol; Differences in
transduction of CD8 +T cells with GFP-lentivirus using the recommended R10-HEPES and 
DMEM-10 media, and combinations of CD8 + and CD4+ T cells. 106 of either MACs-selected 
CD8+ cells, CD4+ cells, or 106 each of CD8+ and CD4+ were pre-activated with anti-CD3 and 
anti-CD28 antibody-coated microbeads prior to addition of 1 ml concentrated GFP- 
encoding lentivirus, manufactured using the 293T packaging cell line cultured in either 
DM EM -10 (top panel), or R10-HEPES (bottom panel), as recommended in the revised 
protocol. The uppermost plot (grey) shows CD8+ and CD4+ T lymphocytes that have not 
been infected with GFP-virus.
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Figure 6.12: Transduction of primary CD8 * T lymphocytes with a lentiviral vector
expressing the 8 6 8  TCR, using the revised and optimised TCR transduction protocol. 106
MACS-sorted CD8+ T cells isolated from two donors, were pre-activated with anti-CD3 and 
anti-CD28 antibody-coated microbeads prior to addition of 1 ml concentrated lentivirus 
encoding the 868 TCR.T he lentivirus was generated using 293T packaging cell line cultured 
in DMEM-10 media. Surface expression of the 868 TCR was determined 72 hours post 
infection with the lentivirus by SL9/HLA A2 tetramer staining.
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expressing the 8 6 8  TCR, and the level of TCR expression determined by SL9/HLA A2 tetramer 
staining did not change. The cells were used in activation and killing assays to test their 
functionality. The 8 6 8  TCR-transduced CD8 +T cells exhibited specific activation and killing in 
response to target cells presenting SL9 peptide in a concentration-dependent manner (Figure 
6.13). Untransduced CD8 +T cells, isolated from the same donor, did not produce significant 
levels of MIP-lp or induce target lysis in response to SL9-pulsed targets.
The 8 6 8  TCR-transduced CD8 +T cells were also subjected to a combinatorial peptide library 
screen to determine the amino acid preference exhibited by the 8 6 8  TCR-transduced CD8 + T 
cells at each position of the peptide (Figure 6.14). A 9mer peptide library was chosen for the 
screening, based on the length of the index SL9 (SLYNTVATL) peptide. Figure 6.15 summarises 
the extent of MIP-ip release by 8 6 8  TCR-transduced cells in response to a fixed amino acid at 
each of the nine positions. Despite some background activation, the transduced cells 
collectively responded to the index SL9 peptide, with the highest responses to index amino 
acids at positions 1, 3, 4, and 6 . All of the residues located in the index peptide elicited a 
detectable response. Flowever, on replicating the assay numerous times, a clear preference 
was seen for a proline at position 7.
5.2.5 Primary CD8+ T cells transduced with a lentiviral vector encoding the 868 TCR are 
polyfunctional and are capable of killing HIV-infected cells.
Polyfunctionality, or the ability to produce high levels of several soluble factors 
simultaneously, has been shown to be a key feature of a successful immune response in both 
human and murine systems (Almeida et al. 2007; Darrah et al. 2007; Precopio et al. 2007). In 
a study, focusing on the factors associated with successful targeting of HIV-1 infected cells by 
CD8 + T cells, Almeida et al. demonstrated that CD8 + T cells that achieve optimal control of 
HIV-1 replication also display polyfunctionality. In keeping with this work, if TCR-transduced 
CD8 + T cells are to be successful in the clinic, they would need to make a polyfunctional 
response to their target antigen. I investigated whether CD8 + T cells transduced with the 8 6 8  
TCR possessed this desired quality by measuring five effector functions of these cells in 
response to activation by target cells presenting cognate SL9 peptide. Figure 6.16 shows
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Figure 6.13: Primary CDS* T cells transduced with the 8 6 8  TCR are capable of specific 
activation and killing in response to SL9 peptide-pulsed targets. A. A MIP-1|3 ELISA 
conducted with 95% SL9/HLA A2 tetram er positive CD8+ T cell line and C1R HLA A2- 
expressing target cells pulsed with different concentrations of SL9 peptide. B. A FATAL 
killing assay conducted with the same 868 TCR-transduced cells, SL9 peptide-pulsed HLA 
A2 positive TO cell as targets, and unpulsed TO cells as controls. Untransduced CD8+T cells 
from the same donor were used as negative controls for both assays. Error bars represent 
s.d. from the mean of two replicates. Data in is representative of >2 separate experiments.
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Figure 6.14: A 9-mer combinatorial peptide library screen of CD8+ T cells transduced with the 868 TCR. The CD8+ T cells 
screened in this assay were 95% positive for 868 TCR expression, determined by cognate SL9-tetramer staining. The P1-P9 
refer to the positions of each of the 20 amino acid residues in the 9mer peptide. Responses to amino acids which are 
present in the index SL9 peptide are highlighted in red. 10~6 M index SL9 peptide was used as a positive control. Error bars 
represent s.d. from the mean of 2 replicates. Data is representative of 2 separate experiments.
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Figure 6.16: 868 TCR-transduced CD8+ T cells display specific activation to express 
multiple effector functions in response to target cells presenting cognate antigen. Target 
T2 cells pulsed with a range of SL9 peptide (SLYNTVATL) concentrations or mock-pulsed 
with medium alone were incubated with 868 TCR-transduced (~95% SL9/HLA A2 tetram er 
positive) CD8+ T cells or untransduced CD8+ T cells from the same donor for 12 hours at 
37°C, in the presence of a directly conjugated aCD107a mAb and secretion inhibitors as 
described in section 2.11.5 of Materials and Methods. After incubation, cells were initially 
stained with the amine viability dye Aqua, and then with directly conjugated mAbs specific 
for the surface markers CD3 and CD8. After subsequent fixation and permeabilisation, 
intracellular staining for specific cytokines was performed. Surface mobilisation of CD107a 
(green), and intracellular production of the cytokines TNF (red), M IP -lp  (purple), IFNy 
(yellow), and IL-2 (turquoise) are shown. The line plots depict dose-response relationships 
between the SL9 peptide concentration and the percentage of CD8+ T cells activated to 
express each individual function. Error bars represent s.d. from the mean of 2 replicates.
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Figure 6.17: 8 6 8  TCR-transduced CD8 + T cells are highly polyfunctional. Pie chart 
representations of ICS data (from the same experiment as in Figure 6.16) depicts the 
percentages of 868 TCR-transduced CD8+ T cells exhibiting 0-5 of each of the five effector 
functions: CD107a, TNF, M IP -lp , IFNy, and IL-2. The labels on the upper-left side of each 
pie chart correspond to  the concentrations of SL9 peptide presented on target cells. 
Experimental details are outlined in Figure legend 6.16,a nd section 2.11.5 of Materials and 
Methods.
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Figure 6.18: 8 6 8  TCR-transduced CD8 + T cells are capable of killing target cells infected 
with HIV-1. A FATAL killing assay conducted with 868 TCR-transduced CD8+ T cells and 
either HIV-1 infected (right panels) or uninfected (left panels) TO cells as targets. The HIV* 
TO population was shown to be ~100% infected with HIV-1 by means of a p24 intracellular 
FACS stain prior to the experimental setup. Both HIV+ and HIV' TO populations were 
stained with the cellular dye CFSE to distinguish them from the CD8+ effector population, 
as infection with HIV-1 causes downregulation of the CD4 coreceptor (right panels). The 
assay was also conducted with untransduced CD8+T cells from the same donor to assess 
the level of background lysis. Data is representative of >2 separate experiments.
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Figure 6.19: TCR V0 antibody screen of 8 6 8  TCR-transduced and untransduced primary 
CD8 * T cells, distinguished by SL9 tetramer staining. 106 MACS-sorted CD8+ cells were 
transduced with 300 pi of concentrated 868 TCR-lentiviral supernatant and stained with a 
combination of SL9/HLA A2 tetramer-APC and a panel of TCR Vp antibodies, before analysis 
by flow  cytometry.
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very positive initial result highlighted a possibility that mispairing of TCR chains abrogated 
tetramer binding, and thus SL9 tetramer staining did not provide an accurate representation 
of the TCR-transduced cell population. In further experiments, the transduced and 
untransduced populations were instead differentiated by staining with the TCR Va2 antibody, 
specific for the 8 6 8  TCR alpha chain. Since a proportion of primary CD8 + T cells naturally 
express a TCR a2 chain, any cells staining with the Va2 antibody were MACS-depleted prior 
to transduction. Figure 6.20 shows the pattern of VP antibody staining for 8 6 8  TCR- 
transduced cells using PBMC taken from 3 donors. The transduced cells were identified by 
Va2* staining. Although each donor showed a different pattern of vp antibody staining of 
untransduced cells, their 8 6 8  TCR-transduced cells all stained predominantly with the V05.2 
antibody (>90% frequency). Unlike in the previous example (Figure 6.19), identifying the 
transduced population with the Va2 antibody instead of tetramer exposes a small number of 
cells staining with TCR Vp antibodies other than vp 5.2. Since the tests for TCR mispairing 
were carried out on SL9 TCR-transduced cell lines (and not clones), it is possible that some of 
these vp responses are due to background staining of untransduced cells, and may not 
necessarily signify TCR chain mispairing.
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Figure 6.20: TCR Vp antibody screen of 8 6 8  TCR-transduced and untransduced primary CD8 4 T cells in three donors, 
distinguished by TCR Va2 staining. 106 MACS-sorted CD8+ T cells isolated from 3 different donors were each either 
transduced with 1 ml of concentrated 868 TCR-lentiviral supernatant ( ~95% transduction efficiency) or remained 
untransduced. Both sets were stained with a combination of TCR Va2 antibody and a panel of TCR Vp antibodies, before 
analysis by flow cytometry. The transduced graph shows results from the TCR Va2+gate, while the untransduced graph 
shows Vp staining patterns for the Va2 population.
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Adoptive transfer therapy uses T cells isolated and cultured from patients to treat cancers 
and chronic viral infections. Although the technique has shown some initial success, it has a 
number of limitations, the most significant being the low frequency of antigen-specific T cells 
and the labour-intensive cell expansion process {Xue, 2005 #889;Kessels, 2002 #833;Varela- 
Rohena, 2008a #881;Schumacher, 2002 #869;Mansoor, 2005 #842;Heemskerk, 2006 #822}. 
Altering the specificity of a T cell by transfer of TCR genes bypasses some of these 
requirements, equipping T cells of varied specificities with the ability to target a desired 
antigen.
In this chapter I have evaluated and compared several methods available for the introduction 
of genes into T cells; pDNA and mRNA electroporation techniques to achieve transient 
transfection and a lentiviral vector for stable transduction. Electroporation of a Jurkat cell 
line with a GFP-encoding bacterial pUC plasmid resulted in GFP expression in 11% of the cells 
(Figure 6.4). Substituting the plasmid DNA for in vitro-transcribed (IVT) GFP mRNA raised the 
transfection efficiency to 39%. Although the IVT mRNA transfection technique was deemed 
successful, the cells expressing the foreign gene would have to be physically sorted in order 
to obtain a pure GFP-positive population for use in functional assays. Unfortunately, the 
transient nature of the technique results in the dilution of transgene expression with each 
cell division, meaning that any transfected cells have to be assayed immediately. Such a 
limited time frame would not allow for incorporation of a cell sorting step into the protocol. 
In addition, both DNA and mRNA electroporation techniques resulted in a considerable 
amount of cell death. With only ~30% of Jurkat cells remaining viable after the 
electroporation process, very large quantities of cells and mRNA would be consumed by this 
process. Typically only 20-30 pg of mRNA are generated by each IVT reaction, rendering this 
technique very expensive and time-consuming. Furthermore, it is predicted that the extent 
of cell death following the electroporation procedure would be even greater when using 
primary CD8 * cells as targets, as these are reputedly less robust than Jurkat cell lines (Beebe 
et al. 2003). My results using mRNA electroporation contrasted with those obtained by 
Hofmann et al. (Hofmann et al. 2008). The problems I encountered with mRNA
221
Chapter 6
electroporation and the success of lentiviral vectors reported by other groups meant that I 
did not pursue further optimisation of this technique.
The use of lentiviral vectors for the genetic modification of primary lymphocytes has 
improved enormously in recent years {Zhao, 2005 #1128;Morgan, 2006 #845;Varela-Rohena, 
2008a #882;Schaft, 2003 #865}. The gene transduction experiments carried out in this 
chapter were performed using the pHR'SINcPPT-SFFV-x-WPRE (lenti-SxW) lentiviral vector, 
specifically designed for the transduction of non-dividing hematopoetic cells, which are 
notoriously difficult to transduce (Demaison et al. 2002). I began experimenting with the 
lentiviral system using a version of the lenti-SxW vector housing a gene encoding GFP (lenti- 
SeW). Infection of a TCR-negative Jurkat cell line with >30 pi crude lentiviral supernatant 
generated using the lenti-SeW construct, resulted in GFP expression in up to 98% of cells 
(Figures 6 .8 , 6.9). Applying viral supernatant with the same MOI to primary CD8 + human T 
lymphocytes resulted in a much lower frequency (0.5-1.0%) of GFP positive cells (Figure 6.9). 
Although this confirmed other groups' findings that primary CD8 +T cells require substantially 
higher MOIs than Jurkat cells for transduction (Toscano et al. 2004), the efficiency of 
transduction was much too low even at MOIs as high as 100.
A revised and optimised protocol for transduction finally produced the desired levels of 
transgene expression (70-99%) in primary CD8 * T cells treated with anti-CD3/anti-CD28 
antibody-coated microbeads and concentrated GFP-encoding lentivirus (Figure 6.11). 
Interestingly, although the infection of non-dividing cells is deemed to be a feature of 
lentiviruses, activation of primary lymphocytes was required for efficient infection. It appears 
lentiviruses are inefficient at infecting quiescent cells, whilst lentiviral vectors are even less 
so. Several groups have investigated the factors that permit lentiviruses but not lentiviral 
vectors to integrate into non-dividing cells. Agosto et al. have attributed the inefficient 
integration of conventional HIV-based lentiviral vectors to the presence of the VSV-G 
envelope (Agosto et al. 2009). Replacing the VSV-G envelope in the lentiviral vector construct 
with the natural CXCR4-tropic HIV env gene element increased the efficiency of transgene 
delivery to resting CD4* T cells (Agosto et al. 2009). Yamashita and colleagues undertook a 
different approach by mutating all the HIV proteins known to be involved in nuclear envelope
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entry (including Vpr) both individually and together, but found that this did not prevent HIV 
infection of non-dividing cells (Yamashita and Emerman 2006). Based on their data Yamashita 
et al. hypothesised that the efficiency of lentiviral integration is somehow related to the 
action of the capsid protein, which facilitates uncoating of the virion (Yamashita et al. 2006). 
It is possible that the uncoating of the capsid represents a rate-limiting step in the infection 
process. Interestingly, while lentiviruses like HIV exhibit inefficient infectivity of quiescent 
cells in vitro this is not the case in vivo (Ravot et al. 2002; Yamashita et al. 2006). However, 
the complexity of the in vivo setting may continue to obstruct our understanding of the true 
mechanism of HIV infection of quiescent cells for years to come.
The transduction efficiency of primary CD8 * T cells with a lentiviral vector encoding the HLA 
A2-restricted HIV gag-specific 8 6 8  TCR correlated directly with the transduction efficiency 
using the GFP-encoding virus (Figures 6.10 and 6.12). This was very encouraging as the 
efficiency of expressing two TCR chains that have to refold, pair, and be exported to the T cell 
surface was expected to be lower than a simple cytosolic GFP molecule. The high level of 
transduction achieved can be at least partially attributed to the design of the lentiviral vector 
itself. As described in Demaison et al, the incorporation of a strong SV40 promoter, SFFV and 
WPRE enhancer elements, and an amphotropic VSV-G envelope, all contribute to the success 
of this expression system (Demaison et al. 2002). In addition, the presence of the all- 
important 2A peptide and the SGSG spacer sequence function to express high quantities of 
each TCR chain, enabling efficient assembly of the chains into a functional TCR.
To test whether 8 6 8  TCR-transduced CD8 + T cells could be functionally re-programmed with 
the specificity for the SL9 epitope SLYNTVATL, the TCR-transduced or untransduced cells 
were stimulated with TO target cells loaded with various concentrations of SL9 peptide. The 
8 6 8  TCR-expressing cells were capable of SL9 peptide specific activation demonstrated by 
MIP-lp release, and specific cytotoxic activity in a FATAL assay (Figure 6.13). The 8 6 8  TCR- 
transduced cells also displayed polyfunctionality (Figures 6.16 and 6.17). In addition to 
recognising the index SL9 peptide, the 8 6 8  TCR-transduced cells showed a high level of 
specificity in a combinatorial library peptide screen. The transduced cells responded to 
residues present at each position in the index peptide amongst mixtures of peptides
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composed of thousands of different amino acid combinations (Figures 6.14 and 6.15). Most 
importantly, the 8 6 8  TCR-transduced CD8 * T cells achieved their ultimate functional goal of 
lysing target cells infected with HIV-1 (Figure 6.18). Finally, the TCR-transduced cells retained 
their TCR expression and functionality throughout the period for which they were maintained 
in culture (typically 2  months).
Despite maintaining a high level of TCR expression, the activation and lytic threshold of the 
transgenic 8 6 8  TCR-expressing cells was higher than for the parental 8 6 8  line from which the 
8 6 8  TCR originated (Sewell et al. 1997). A similar decrease in antigen sensitivity was observed 
in other TCR transduction studies (Schaft et al. 2003; Hofmann et al. 2008). There are a 
number of possible explanations for this phenomenon. It has been observed that the highly 
differentiated nature of a CD8 +T cell clone or line means only a low concentration of target- 
peptide is sufficient to trigger their effector functions (Kimachi et al. 2003). In contrast, the 
MACS-sorted CD8 * cells transduced for these experiments harbour a whole range of 
phenotypes, amongst some of which are naive cells with high stimulation thresholds. 
However, since the cells are activated with anti-CD3/anti-CD28 coated beads prior to 
transduction, the percentage of cells that have not acquired the effector phenotype should 
be very low. A more plausible explanation is that the introduction of an exogenous TCR into a 
T cell population already expressing a range of endogenous receptors may lead to mispairing 
between the various native and introduced TCR a and (3 chains.
The inefficient expression of introduced TCR a and (3 chains in T lymphocytes can be one of 
the rate-limiting steps for TCR gene therapy. Once the lentiviral vector has integrated the TCR 
genes into the chromosomal DNA, the TCR a and 3 chains must be expressed in equimolar 
ratios, refolded, and assembled together with the CD3 y, 6 , e, and £ subunits on the cell 
surface. TCR chain mispairing and competition between the exogenous and endogenous 
TCRs for the CD3 complex may dilute the expression of relevant TCR a(3 heterodimers on the 
surface of TCR-transduced cells. As mentioned in the introduction to this chapter, several 
strategies have been employed to limit the mispairing of TCR chains, and enhance the 
preference of exogenous TCR chains for each other and the CD3 molecules (Boulter et al. 
2003; Cohen et al. 2006; Cohen et al. 2007; Kuball et al. 2007; Sebestyen et al. 2008;
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Okamoto et al. 2009). Although the 8 6 8  TCR used in this study was not subject to any such 
dramatic modifications, primary CD8 * T cells transduced with the receptor did not display a 
significant amount of TCR chain mispairing (Figures 6.19 and 6.20). There can be a number of 
explanations for why we did not observe mispairing of the 8 6 8  TCR chains with the 
endogenous TCR chains. First, our system is likely to express the transduced TCR chains at 
much higher levels than the endogenous chains as the 8 6 8  TCR chains were codon optimised 
for mammalian expression and expressed under a very strong promoter. A number of groups 
have demonstrated that codon modification of TCR genes leads to enhanced functional 
expression of the TCR in transduced T cells (Heemskerk 2006; Scholten et al. 2006; Thomas et 
al. 2007; Bendle et al. 2009). In addition, an elegant theory proposed by Heemskerk et al. 
suggests there may exist a hierarchy of TCR chain-pairing events, with each chain exhibiting 
'strong" or 'weak' TCR chain properties. The theory implies that 'strong" TCR chains will 
preferentially pair with each other and out-compete any endogenous TCRs for CD3- 
association, if these happen to display 'weaker" properties.
The T cell modulation group has attempted to manufacture over 70 different TCRs by 
refolding bacterially-expressed extracellular domains of the TCRa and [3 chains using dilution
of denaturing conditions (Boulter et al. 2003). The efficiency of refolding varies widely. Some 
TCRs refold extremely well, while about 30% fail to refold at all. All the TCRs that we work 
with regularly, including the 8 6 8  TCR, fall at the high end of the refolding spectrum. We 
hypothesise that this is because they comprise TCRa and (3 chains that preferentially pair
with each other. Indeed, our collection of HLA A2-restricted TCRs that fold well included a 
very limited number of a(3 TCR chain pairings. We therefore speculate that TCR chain pairings
that refold very well in vitro will act as 'strong" TCRs whereas 'weak" TCRs will neither refold 
well nor compete well for cell surface expression. Marleen van Loenen of Leiden University in 
the Netherlands has recently been awarded a travelling fellowship and will come to Cardiff to 
test this hypothesis during 2011 using a spectrum of strong and weak TCRs that recognise the 
same HLA A2-restricted CMV-derived antigen. For the time being this idea remains 
conjecture. The discovery of means to predict whether a particular TCR will have a 'strong" or 
'weak" phenotype with respect to competition with an endogenous TCR could aid TCR gene 
transfer strategies.
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As discussed in the previous chapter, the transfer of defined TCR genes into human T cells 
appears to be a promising new strategy for redirecting T cells against a number of antigens 
implicated in disease. However, many TCRs recognising antigens associated with cancer, 
autoimmunity, or rapidly evolving persistent pathogens are characterised by low affinities, 
making them ineffective candidates for TCR gene transfer therapy. Chapter 8  of this thesis 
deals with this issue, by addressing how the affinity of TCRs can be enhanced significantly by 
performing directed molecular evolution of soluble TCRs, by phage display. However, in 
addition to using laborious (albeit effective) surface display techniques (Holler et al. 2000; Li 
et al. 2005; Zhao et al. 2007), other strategies for increasing TCR affinity (Cohen et al. 2006; 
Kuball et al. 2007) should be explored. Glycosylation affects the flexibility, movement, and 
interactions of surface molecules, and is known to naturally regulate antigen sensitivity 
during T cell development (Demetriou et al. 2001; Baum 2002; Pappu et al. 2004). It is thus 
entirely plausible that manipulating the glycosylation status of a T cell may improve antigen 
recognition. In this chapter, I investigate whether reducing the level of T cell, and more 
specifically TCR glycosylation could provide an alternative strategy for enhancing TCR 
affinity and/or T cell sensitivity to cognate antigen. I assess the impact of: i) removing 
terminal sialic acid residues from the T cell surface; and, ii) individually silencing conserved 
N-glycosylation sites in the constant regions of TCR a or p chains; on the antigen sensitivity 
of T cells. I will begin by introducing how proteins become glycosylated in the first place, 
and what roles glycosylation plays in the T cell-mediated immune response.
7.1.1 Synthesis and function of N> and O- linked glycans on cell surface proteins
Nearly all mammalian cell surface proteins are terminally modified by glycosylation. The 
process of glycosylation is initiated in the cytosol and progresses through the lumen of the 
ER and the Golgi apparatus, where nucleoside-diphosphate-activated sugars are 
sequentially connected to branched polysaccharide chains by a complex set of enzyme- 
mediated reactions. The attachment of glycans to proteins can occur in a number of ways, 
but the initial step typically involves a glycosidic link to the amide nitrogen of asparagine
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residues located within N-glycosylation motifs [N-X-S/T] (asparagine, followed by any amino 
acid other than proline, followed by serine or threonine) to form N-linked glycans. The 
resulting N-glycosylated proteins traverse the ER and Golgi apparatus, undergoing a further 
level of modification termed 'trimming' (Varki 2009); a process whereby glucose and 
mannose residues are cleaved off and replaced by N-acetylglucosamine, galactose, fucose, 
and sialic acid derivatives. O-linked glycosylation occurs at a later stage during protein 
processing, in the Golgi apparatus. This involves the addition of N-acetyl-galactosamine to 
serine or threonine residues, followed by other carbohydrates such as galactose and sialic 
acid (Varki 2009). Figure 7.1 illustrates the typical sugar composition and spatial 
distributions of N- and O-glycans.
The majority of proteoglycans are terminally decorated by sialic acids, a group of 
monosaccharides derived from neuraminic acid. These sugar molecules carry a carboxylate 
group at the 1-carbon position, which is normally ionized at physiological pH, giving it a 
characteristic negative charge (Varki 2009). The presence or absence of this negatively 
charged and highly hydrated glycan on cell surface proteins greatly influences the 
interaction of these proteins with each other and their environment (Varki 2009). Sialic 
acids are now known to have important roles in cell proliferation, protection of 
glycoproteins from the actions of proteases, and shielding of epithelial surfaces from 
infection, mechanical and enzymatic damage (Corfield et al. 1992; Rutledge et al. 1996; 
Fujita et al. 2000).
7.1.2 Removal of sialic acid from cell surface glycoproteins on T cells results in increased 
sensitivity to antigen
Sialic acid is a key molecule in cell-cell interactions and is involved in regulating: i) lateral 
mobility of proteins in the plasma membrane; ii) protein interactions with each other and 
their environment; and, iii) the organization of proteins into ordered domains (Kelm et al. 
1997; Rudd et al. 1999; Sacchettini et al. 2001). However, sialyl-glycans only became of 
interest to immunologists, when it was shown that the high sialylation status of a T cell 
correlated with reduced sensitivity to antigen (Demetriou et al. 2001; Baum 2002). Around
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Figure 7.1: A schematic highlighting the differences between N -and O-linked 
glycosylation. A. The distribution of N- and O-linked glycans on a cell surface glycoprotein, 
in this case the protein tyrosine phosphatase CD45. The membrane proximal region 
contains multiple N-glycans, while the membrane distal region contains some N-glycars 
and abundant O-glycans. B. Examples of N- and O-glycan structures, both of which are 
typically terminated by addition of the negatively charged sialic acid (diamond symbols). 
Core 1 O-glycans can be modified by both a2.3 and a2,6 sialic acid, while core 2 O-glycars 
can be modified by a2,3 sialic acid at the ternrini of both branches. The termini of N-glycars 
can be modified by either a2,3 or a2,6 sialic acid. Figure reproducec from (Hernandez et al. 
2007).
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the same time, several groups reported that the formation of the immunological synapse 
was to some extent regulated by the glycosylation state of the proteoglycan agrin (Khan et 
al. 2001), and by the addition of branched N-glycans to cell surface glycoproteins such as 
CD8 , CD45, CD43, and the TCR (Demetriou et al. 2001; Lowe 2001; Baum 2002). 
Furthermore, work by Pappu and Shrikant demonstrated that removal of sialic acid residues 
from naive T cells enhanced early activation events and reduced the duration of antigen- 
TCR engagement required to initiate proliferation and differentiation of these T cells (Pappu 
et al. 2004). They expanded on their initial findings by showing that desialylation of naive T 
cells augmented the cytotoxic response to tumour-associated antigens (TAAs). This 
represented an important achievement, considering that due to their low surface pMHCI 
expression and lack of costimulatory molecules, tumours are notoriously poor stimulators of 
naive T cells (Pappu et al. 2004).
7.1.3 The key glycoproteins involved in T cell-antigen recognition
T cell recognition of antigen-presenting cells (APCs) comprises several stages: i) TCR 
engagement of pMHC antigen; ii) formation of a junction between the two cells known as 
the immunological synapse; and, iii) signal transduction by the TCR-associated machinery 
(Grakoui et al. 1999; van der Merwe 2000). Since most of the proteins implicated in this 
complex set of events are modified by glycosylation, individual glycans are likely to play 
important roles. For instance, it is not a mere coincidence that oligosaccharides found on 
proteins involved in the formation of supramolecular activation clusters (SMACs), the 
hallmark of immunological synapses established by T cells, are conserved across species 
(Dustin, 1997a #2369). These glycans are likely to function by positioning cell surface 
receptors and coreceptors, thus dictating the alignment of T cell and target cell surfaces 
(Dustin, 1997a #2369). As mentioned in the previous section, both desialylation and 
deglycosylation (removal of entire N-linked glycans) can enhance T cells sensitivity to 
antigen (Demetriou et al. 2001; Baum 2002; Pappu et al. 2004). However, T cell SMACs are 
complex molecular lattices comprising a multitude of receptors, coreceptors, and regulatory 
molecules (Grakoui et al. 1999). Pin pointing the key players, changes in whose glycosylation 
status can bring about these effects, becomes a veritable challenge. To date, the list of
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suspects has been narrowed down to four: CD8 , CD43, CD45, and the TCR. I will briefly 
summarise the evidence to support the involvement of varying glycosylation states of each 
of these molecules in controlling antigen recognition:
i) CD8 coreceptor glycosylation and T cell activation
Of the four main candidate molecules suggested to play a role in controlling the effects of T 
cell glycosylation status on antigen sensitivity, CD8  has been by far the best studied. Two 
independent studies by Moody et al. and Daniels et al. simultaneously published 
observations that immature CD8 * CD4* double positive (DP) thymocytes were able to bind 
MHCI tetramer loaded with non-cognate peptides. Binding of non-cognate pMHC required 
the CD8  coreceptor (Daniels et al. 2001; Moody et al. 2001). The reason non-cognate MHCI 
tetramer binding was observed with DP and not single-positive (SP) mature CD8 + 
thymocytes was attributed to the presence of sialic acid on the terminal glycans of mature 
but not immature thymocytes. The standard method for differentiating sialylated and 
unsialylated glycans is by exploiting their differential abilities to bind a plant lectin called 
peanut agglutinin (PNA). PNA recognizes all carbohydrates containing terminal galactose 
residues, but it binds with highest affinity to the disaccharide sequence Gal01,3GalNAc 
((Lotan et al. 1975; Wu et al. 1996) and Figure 7.1 B), which forms part of a common O- 
linked oligosaccharide structure present on several glycoproteins including CD8 , CD45 and 
CD43 (Gillespie et al. 1993; Wu et al. 1996). PNA preferentially binds 'naked' unsialylated O- 
linked glycans, so on addition of sialic acid by the sialyltransferase enzyme its binding sites 
are obscured, resulting in a loss of PNA binding (Gillespie et al. 1993; Priatel et al. 2000). 
Importantly, the sialyltransferase enzyme is expressed by mature but not immature 
thymocytes (Gillespie et al. 1993; Priatel et al. 2000). It follows, that treatment of mature 
thymocytes with a bacterial neuraminidase to remove the sialic acid residues restores 
tetramer binding to the levels observed with immature thymocytes, implying that sialic acid 
somehow interferes with the pMHCI/CD8  interaction (Daniels et al. 2001; Moody et al. 
2001). Although no detailed investigation into the mode of action of this small negatively 
charged glycan was conducted, the group proposed a number of theories for the enhanced 
pMHCI tetramer binding seen in the absence of sialic acid moieties. Sialic acid may
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somehow affect the rigidity of the CD8  stalk, or the lateral mobility of CD8  within the lipid 
bilayer. Perhaps more plausibly, electrostatic repulsion between sialic acid moieties could 
affect the accessibility of CD8  to MHCI (Moody et al 2001, Daniels et al 2001). Since the CD8  
coreceptor is involved in stabilising the TCR/pMHCI interaction (Wooldridge et al. 2005), 
increasing the affinity of pMHC/CD8  binding through removal of sialic acid would in turn 
results in enhancing the stability of the TCR/pMHCI complex. Although these publications 
by Moody et al. and Daniels et al. have been critical in exploring the question of how 
changes in glycosylation affect antigen recognition, their focus on CD8  alone failed to 
explain some key observations, such as the enhanced antigen recognition by T cells with 
aberrant pMHCI/CD8  interactions or those lacking the CD8  coreceptor altogether.
ii) CD45 and CD43 glycosylation and T cell activation
PNA also binds the protein tyrosine phosphatase CD45, and the heavily sialylated anti­
adhesion molecule, CD43 on immature but not mature thymocytes. These molecules 
regulate T cell activation leading some groups to speculate that these molecules may be the 
most likely to mediate the enhanced sensitivity of T cells to antigen after removal of sialic 
acid (Wu et al. 1996; Hernandez et al. 2007). It has been reported that sialylation regulates 
the dimerisation and activity of CD45 (Xu et al. 2002). Dimerisation of CD45 is believed to 
interfere with its cytoplasmic associated phosphatase domains so that the dimer exhibits 
vastly reduced activity compared to the two monomers (Bilwes et al. 1996). Thus, 
desialylation of CD45 may reduce its negative effect on T cell signalling and increase T cell 
sensitivity to antigen.
Hi) TCR glycosylation and T cell activation
More recently, the focus of investigation has shifted towards the molecule central to T cell 
antigen recognition, and common to all T cells, the TCR. Major evidence for how changes in 
the glycosylation status of the TCR impact on T cell-antigen recognition has come from an 
elegant study by Demetriou et al, who demonstrated that genetic disruption of the normal 
N-glycosylation pathway, more specifically a deficiency in the enzyme 1,60 N- 
acetylglucosaminyltransferase V (Mgat5) in mice resulted in enhanced antigen recognition
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(Demetriou et al. 2001). The enhancement in T cell antigen recognition was attributed to 
improved TCR engagement (of pMHC), clustering and downregulation. In fact, the increase 
in TCR affinity was so dramatic that the mice developed autoimmunity (Demetriou et al. 
2001). The fact that Mgat5 directly reduces the mobility of TCRs displaying Mgat5-modified 
glycans means that any disruption to its function would increase TCR mobility and 
subsequent clustering. As a result, the need for CD28-mediated costimulation is bypassed, 
with a subsequent reduction in the activation threshold for all T cells, irrespective of their 
specificities. Enhanced antigen recognition and loss of immune tolerance was therefore 
explained by enhanced TCR clustering at the site of antigen presentation and a reduced 
need for costimulation by CD28 (Demetriou et al. 2001).
7.1.4 T cell glycosylation and crossreactivity
The observations of Daniels et al. 2001 and Moody et al. 2001 showed that immature 
thymocytes can recognize non-cognate pMHC molecules (Daniels et al. 2001; Moody et al. 
2001). This broader recognition profile of immature thymocytes is believed to be regulated 
by CD8  glycosylation and may represent a critical mechanism that allows immature 
thymocytes to gain a positive selection signal from self pMHCI molecules. My laboratory 
have recently shown that the strength of the pMHCI/CD8  interaction can control T cell 
crossreactivity in mature CD8 * T cells (Wooldridge et al. 2010). The binding affinity and/or 
half-life of TCR/pMHC engagement is believed to be the critical parameter that determines 
whether or not a T cell responds to a given pMHC antigen. As described above, there is 
some evidence to indicate that TCR glycosylation can alter pMHC binding. Given the 
suggested role for TCR and CD8  glycosylation in T cell activation in response to cognate and 
non-cognate peptide ligands, I decided that it would be interesting to examine whether the 
T cell glycosylation status could alter T cell crossreactivity. I will begin by introducing this 
subject.
The rearrangement and recombination of genetic elements encoding a functional TCR
18achieves an astounding level of diversity and can theoretically produce over 1 0  different 
human ap TCRs (Davis et al. 1988; Venturi et al. 2008). Such a vast number of combinations
233
Chapter 7
would in theory support a one TCR to one peptide specificity hypothesis, until we are 
reminded that there are only 5xl013 cells of human origin in the average human body. To 
put this into perspective, if 109 cells approximates to a gram of human tissue, then 1018 T 
cells would weigh a colossal 106 Kg or 1000 tons (Mason 1998). Thus, in order for T cell 
immunity to work as it does, theoretical considerations dictate that each individual T cell 
must be capable of recognising over a million different peptides (Mason 1998). More recent 
estimates suggest that there are only 2.5 x 107 TCRs in the human naive T cell pool (Arstila 
et al. 1999), a number that is dwarfed by the potential magnitude of foreign peptide-MHC 
complexes that could be encountered and which it appears the body can mount a successful 
immune response to (Mason 1998). Thus, in theory at least, an extremely high level of T cell 
crossreactivity, sometimes referred to as polyspecificity, is an essential feature of T cell 
recognition. As described above, the questions of how T cells achieve crossreactivity, and 
how this property can be regulated (for instance by the CD8  coreceptor) form a major 
interest for members of my group. Their findings confirm that a high level of TCR 
crossreactivity is essential for effective T cell immunity (Mason 1998; Wooldridge et al. 
2010). Given that the strength of the TCR/pMHC interaction is correlated with TCR 
crossreactivity, it will be extremely interesting to see if the glycosylation status of a T cell, 
and in particular its TCR, can influence T cell crossreactivity by affecting the stability of the 
TCR/pMHC antigen interaction.
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7.1.5 Aims
Several groups have demonstrated the impact of differential sialylation of CD8  on 
modulation of TCR affinity during thymocyte selection (Daniels et al. 2001; Moody et al. 
2 0 0 1 ), while others have attributed the increase in antigen sensitivity, observed on 
desialylation, to changes in oligomerisation state and activity of costimulatory molecules 
CD45, and CD43 (Wu et al. 1996; Hernandez et al. 2007). Thus, the major question as to 
which glycoconjugates are responsible for the observed increase in antigen sensitivity which 
results from T cell deglycosylation, remains unanswered. As part of my study into 
optimisation of TCR-antigen interactions I aim to investigate how the sialylation state of a T 
cell and the N-glycosylation state of a TCR impacts on antigen recognition. Since 
glycosylation influences the structure of proteins and their interactions with each other and 
the environment, removal of sialic acid and/or glycosylation residues from the TCR may 
increase its antigen recognition capacity. In addition to carrying out global T cell 
desialylation I aim to investigate how the mutation of individual N-glycosylation sites on a 
specific TCR impacts on the antigen sensitivity and crossreactivity of the host CD8 + T cells. 
The specific aims for this chapter were to:
i) Assess whether a functional pMHCI/CD8  interaction is a prerequisite for increasing 
CD8 *T cell-mediated antigen recognition on desialylation.
ii) Determine whether the increase in antigen sensitivity on removal of cell surface 
sialic acid by the neuraminidase enzyme is experienced by T cell subsets other than 
CD8 *T cells.
iii) Subject sialylated and desialylated CD8 * T cells of known specificity to a 
combinatorial peptide library screen, to assess the impact of glycosylation on TCR 
crossreactivity.
iv) Investigate the role of TCR surface glycosylation in antigen recognition by 
performing site directed mutagenesis (SDM) of individual glycosylation sites and 
evaluating the functionality of T cells transduced with these TCR glycosylation 
mutants.
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7.2.1 Desialylation increases antigen sensitivity of three T cell subsets irrespective of CD8 
coreceptor involvement
The standard method for differentiating sialylated and unsialylated O-linked glycans is by 
exploiting their differential abilities to bind peanut agglutinin (PNA). As mentioned in 
section 7.1.3 i), the sialylation status of a T cell can be verified by cell staining with PNA 
molecules that are conjugated to a fluorescent dye and analysed by flow cytometry 
(Gillespie et al. 1993; Priatel et al. 2000). In order to remove the sialic acid, T cells were 
subjected to treatment with neuraminidase (section 2.9.2 of Materials and Methods), a 
promiscuous enzyme derived from vibrio cholerae. As an example, the sialylation status of 
neuraminidase-treated and untreated tumour antigen-specific ILA1 CD8 +T cell clone, which 
recognises the HLA A2-restricted ILA peptide (hTERTs4o-54s; ILAKFLHWL), was examined by its 
ability to bind PNA as a test to verify the success of the enzymatic reaction (Figure 7.2).
Removal of terminal sialic acid moieties from another tumour-reactive Melan-A-derived HLA 
A2-restricted Melan-A26 3s; ELAGIGILTV (ELA) peptide-specific Mell3 CD8 + T cell clone 
enhanced its sensitivity to peptide antigen when presented on C1R cells (Figure 7.3). The 
M ell3 clone was either treated with neuraminidase or left untreated, and the success of 
the enzymatic reaction was verified by PNA-FITC staining. The PNA+ and PNA” fractions were 
subsequently used as effectors in a cytometric bead array (CBA) to measure their levels of 
activation in response to titrated cognate ELA peptide presented on C1R target cells 
expressing three types of surface HLA A2 molecule: 227/8 K/A (Purbhoo et al. 2001; Laugel 
et al. 2007), wildtype (WT), and Q115E (Wooldridge et al. 2005; Wooldridge et al. 2007). 
The HLA A2 molecules differ in the strength of their interactions with the CD8  coreceptor: i) 
227/8 K/A mutant shows abrogated CD8  binding (CD8 -null); ii) WT displays a normal 
physiological interaction with CD8 ; and, iii) Q115E binds CD8  with ~1.5 fold higher affinity 
than wildtype (CD8 -enhanced). With all three targets, cytokine release from desialylated 
cells was observed at peptide concentrations a factor of 1 0  and even 1 0 0  fold
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Figure 7.2: Desialylated T cells bind PNA. ILA1CD8 + T cell clone was treated with 0.011U of 
neuraminidase enzyme (from vibrio cholerae) as described in section 2.9.2 of Materials and 
Methods. The FACS histogram shows neuraminidase treated (red peak) and untreated 
(green peak) ILA1 cells incubated with FITC-conjugated peanut agglutinin (PNA), which 
binds desialylated but not sialylated glycans.
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Figure 73: Neuraminidase treatment enhances antigen sensitivity of CDfT T cells 
irrespective of CD8 involvement. M e ll3  CD8* T cell clone was incubated with titrated 
cognate Melan-A26r3 5 (ELAGIGILTV; ELA) peptide-pulsed C1R cells bearing surface HLA 
A*0201 molecules of three forms: CD8-null 227/8 K/A mutants (top panel), CD8
wildtype/normal (middle panel), or CD8-enhanced Q115E mutants (bottom panel). The 
M e ll3  clone and C1R cells were incubated together for 4 hours at 37°C and the extent of 
TNF, IFNy, and IL-2r elease was determined using a cytometric bead array (CBA) kit, 
recorded by flow cytometry on a FACSCalibur, analysed using FlowJo software and plotted 
using Prism graphpad software. The coloured data points indicate cytokine release by 
M e ll3  cells that were pre-treated with neuraminidase, while the black data points show 
cytokine release by untreated cells. Representative data of 2 replicates shown.
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lower than from untreated cells, and the strength of the readout signal was enhanced by as 
much as seven fold for some concentrations of peptide (Figure 7.3). In addition to 
investigating the effect of desialylation on CD8 + T cell activation with target cells presenting 
cognate peptide, I examined how neuraminidase treatment influences pMHCI tetramer 
staining. For this role I decided to use the well characterised ILA system encountered in 
Chapters 3, 4, and 5. Neuraminidase treated and untreated 1LA1 CD8 + T cell clone was 
stained with HLA A2 tetramers refolded around three cognate ligands displaying a range of 
affinities for the ILA1 TCR, and a non-cognate ligand to evaluate any concomitant increases 
in background staining (Figure 7.4). Desialylation of ILA1 CD8 +T cells had the most profound 
effect on staining with HLA A2 tetramers, presenting the low affinity 5Y ligand, with a two 
fold increase in MFI. Desialylation also increased the staining of ILA1 CD8 + T cells with ILA 
index/HLA A2 tetramers. However, no difference in tetramer staining with the high affinity 
3G/HLA A2 tetramers was observed between desialylated and sialylated ILA1 CD8 +T cells.
The increase in antigen sensitivity observed on removal of sialic acid in the experiment with 
Mell3 CD8 * T cells (Figure 7.3) was not affected by differences in CD8  binding. In fact, a 
substantial increase in antigen sensitivity was still observed even in the absence of a 
pMHCI/CD8  interaction (227/8 K/A targets). Based on the published data (Daniels et al. 
2001; Moody et al. 2001), this finding was unexpected. If the effect of desialylation is 
observed in the absence of a pMHCI/CD8  interaction I reasoned that this might be apparent 
with CD8 -negative T cells. I therefore decided to examine whether other T cell types, that 
do not rely on CD8  for antigen recognition, experienced increases in antigen sensitivity on 
desialylation. A CD4* T cell line (JF-HA) and clone (Flu2-5) were rendered more sensitive to 
their cognate antigen, an HLA DR*0101 (HLA DR1 from hereon)-restricted epitope of 
influenza hemagglutinin (HA)307-3i9; PKYVKQNTLKLAT (PKY), on treatment with 
neuraminidase (Figure 7.5). Staining of the CD4* JF-HA T cell line with the PKY/HLA DR1 
tetramer (Figure 7.5A) demonstrated how a population of low avidity cells, that is normally 
undetected by conventional pMHCII tetramer staining methods, becomes 'visible' on 
desialylation. An improvement in cognate PKY/HLA DR1 tetramer binding by the CD4+ Flu2-5
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Figure 7.4: Neuraminidase treatment preferentially enhances staining of CD8+ T cells with 
pMHCI tetramers presenting low affinity cognate ligands. 1(£ ILA1 CD8 * T cells , either 
treated with neuraminidase (unfilled bars) or untreated (filled bars), were stained with 1 0  
pg/ml PE-conjugated HLA A2 tetramers refolded around the index ILA peptide (K0 ~ 37 
pM), the low affinity ILA altered peptide ligand (APL) 5Y (Kq ~ 242 pM), the high affinity ILA 
APL 3G (Kq ~ 3.7 pM), and a non-cognate peptide ligand (negative control), for 20 minutes 
at 37 °C. Data were acquired with a FACSCalibur flow cytometer (BD) and analysed using 
FlowJo software. The MFI of tetramer staining for each APL was presented in graphical form 
for ease of comparison. Data are representative of 2 replicates.
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Figure 7.5: CD4* T cells become more sensitive to antigen on desialylation. A. Cognate 
PKY/HLA DR*0101 tetram er staining of a CD4* T cell line, JF-HA, specific for the influenza 
hemagglutinin (H A ^ t^ ;  PKYVKQNTLKLAT (PKY) peptide, after incubation with 
neuraminidase (right panel) and untreated (left panel). The numbers in upper right 
quadrants refer to the percentage of tetramer positive T cells. B. A cognate PKY/HLA 
DR*0101 tetram er staining profile of a CD4+ T cell clone, Flu2-5, specific for the same 
peptide as the CD4+ T cell JF-HA line (A), in the presence (blue) and absence (black) of 
neuraminidase (N). C. CBA measurement of IFNy release by the Flu2-5 CD4+ T cell clone 
either treated with neuraminidase (blue unfilled bars) or untreated (black filled bars) on 
activation with titrated PKY peptide, presented on HLA DR*0101 positive target cells. Data 
in B and C are representative of 2 separate experiments.
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T cell clone was also observed on removal of terminal sialic acid moieties by neuraminidase 
(Figure 7.5B). This result was important for two reasons. Firstly, it demonstrates that 
desialylation can improve antigen engagement in the absence of the CD8  coreceptor; and, 
secondly it restricts the increase in antigen sensitivity to antigen engagement. Neither CD45 
nor CD43 are thought to engage antigen. Collectively these statements suggest that the 
improvement in antigen engagement by desialylated T cells may be due to the direct effects 
of the TCR.
In accordance with the CD8 * T cell results in Figure 7.3, desialylation of CD4* T cells also 
resulted in increased cytokine release (Figure 7.5C). Neuraminidase-treated Flu2-5 CD4+ T 
cells secreted almost twice as much IFNy in response to HLA DR1 positive targets cells 
presenting 10 7M PKY peptide, compared to untreated cells. However, the effect was not as 
pronounced as for CD8 + T cells, suggesting that the glycosylation of CD8  may still play some 
role in regulating antigen sensitivity. Neuraminidase treatment also enhanced the 
recognition of isopentenyl pyrophosphate (IPP) antigen by y6  T cells (Figure 7.6). A y6  T cell 
line (AJH), and a y6  T cell clone (Bob) showed increased TNF production in response to IPP. 
We have previously reported that recognition of aminobisphosphonates (nBPs) and IPP by 
human y6  T cells requires contact with cells of human origin (Green et al. 2004). The 
activation assays were therefore performed in the presence of C1R cells. The increase in 
antigen sensitivity was strongest for the AJH y6  line, which showed a two fold increase in 
cytokine production at 10^M IPP on desialylation.
In addition to documenting the effect of neuraminidase treatment on T cells by cytometric 
bead array activation assays and tetramer staining, I looked at how the sialylation status of 
a T cell impacts on pMHC tetramer association and dissociation rates. Figure 7.7A shows 
that a neuraminidase-treated Jurkat cell line transduced with the HLA A2-restricted, HIV pl7  
Gag-derived (amino acids 77-85) antigen SLYNTVATL (SL9)-reactive 8 6 8  TCR (introduced in 
Chapter 6 ) is able to capture cognate SL9/HLA A2 tetramer from solution at a faster rate 
than untreated 8 6 8  TCR Jurkat transductants. The SL9/HLA A2 tetramer dissociation curves 
in Figure 7.7B illustrate that desialylated 8 6 8  TCR+ Jurkat cells display a slightly slower
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Figure 7.6: Desialylation of y6 T cells enhances their recognition of isopentenyl 
pyrophosphate (IPP) antigen. Cytometric bead array (CBA) measurement of TNF release 
by a y6  T cell line, AJH (left panel) and a y6  T cell clone (right panel), in response to titrated 
IPP antigen and in the presence of C1R cells. Unfilled bars represent y6  T cells treated with 
the enzyme neuraminidase before assaying. Filled bars refer to untreated y6  T cells. Error 
bars show s.d. from the mean of two replicates. Data are representative of 2 separate 
experiments.
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Figure 7.7: Desialylation of 868 TCR-transduced Jurkat cells enhances cognate SL9/HLA 
A2 tetramer association and dissociation rates. A. Tetramer association curves recorded 
over a 20 minute period for neuraminidase-treated (white squares) and untreated (black 
squares) 868 TCR-transduced Jurkat cells, stained with 10 pg/ml SL9/HLA A2 tetramer. B. 
Dissociation curves of SL9/HLA A2 tetramer (10 pg/ml) from sialylated/desialylated 868 
TCR-transduced Jurkat cells over a 30 minute time period, in the presence of a competing 
anti-HLA A2 antibody. Representative data from 2 experiments shown. Assay details can be 
found in sections 2.8.2 and 2.8.3 of Materials and Methods.
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tetramer off-rate than their sialylated counterparts. The difference in tetramer off-rates for 
the sialylated and desialylated 868 TCR-transduced Jurkat cell subsets appears to be less 
pronounced than the difference in on-rates.
7.2.2 Desialylation of CD8* T cells enhances the crossreactivity of their TCRs
The fact that desialylation of T cells enhances their sensitivity to antigen implies that 
glycosylation may control the ability of T cells to recognize many different antigens, in other 
words their crossreactivity. To test this hypothesis, ILA1 CD8+ T cells were treated with 
neuraminidase to remove any surface sialic acid residues and subjected to a 9mer 
combinatorial peptide library screen. The screen was also performed in parallel with un­
manipulated ILA1 cells, which had not undergone neuraminidase treatment. The 
organisation of the 9mer combinatorial peptide library and the details of the assay are 
described in section 2.11.2b of Materials and Methods. A comparison of MIP-lp release 
profiles for both neuraminidase-treated and untreated cell subsets in response to the 9mer 
peptide mixtures is summarised in Figure 7.8. Although the strongest responses made by 
desialylated cells (red bars) were observed at the same residue positions as for the 
sialylated cells (black bars), the magnitude of these responses was higher for the cells that 
had undergone neuraminidase treatment. In addition, the number of peptide sequences 
that induced MIP-10 release was greater for desialylated ILA1 cells. The differences in 
combinatorial library results for the sialylated and desialylated subsets are more clearly 
illustrated by Figure 7.9. The box summary representation highlights the residues that are 
preferred by the ILA1 TCR at each position of a 9mer peptide. Each box represents one of 
the 9 positions in the 9mer peptide, and the letters correspond to the residues that induce a 
MIP-10 response at each of these positions. Both sialylated (top panel) and desialylated 
(bottom panel) ILA1 cells show strong preference for amino acids leucine and glycine at 
positions 1 and 3, as well as the conserved FLH motif present in the index ILA (ILAKFLHWL) 
peptide at positions 5, 6, and 7, respectively. However, the number of amino acid residues 
recognised at each position of the screen, and subsequently the overall number of peptides 
that were recognised by the ILA1 clone was significantly higher for desialylated cells than 
sialylated cells.
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Figure 6: Desialylation of the I LAI CD8+ T cell clone increases the magnitude of responses 
In a combinatorial peptide Ifcrary screen. A. The ILA1 clone, either treated (white bars) or 
untreated (black bars) with neuraminidase enzyme was used to screen a nonamer 
combinatorial peptide library (CPL). Each graph in the figure represents a scan on a single 
amino acid position to determine the preference of the ILA1 TCR for a particular amino acid 
residue at that position. The responses were quantified by measuring the level of MIP-ip 
release by the ILA1 done. The position index on the x-axis refers to the single letter amino 
acid code for the amino acid residue found in the fixed position of each peptide in the 
mixture. Error bars show s.d. from the mean of two replicates. Representative data from 2 
separate experiments shown.
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Figure 7.9: Box summary representation of the ILA1 CD8* T cell clone 9mer peptide library 
screen data (shown in Figure 7.8). The hierarchy of the responses to various residues at 
each position in the nonamer screen was constructed by categorizing the level of M IP-13 
production by the ILA1 clone into 5 distinct bands. MIP-13 responses below 500 pg/ml 
were excluded from this summary. Each box represents an amino acid position of a 
nonamer peptide, while the size and colour of the letters within each box indicate the 
amino acid residues preferred by the ILA1 TCR at that position. The letters underneath the 
box summaries refer to the residues found in the index peptide (ILAKFLHWL) at that 
position in the nonamer.
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The combinatorial libraries are manufactured in such a way as to ensure that each peptide 
is present at the same concentration in every mixture. When the peptide mixtures are 
assayed at 100 pg/ml, the concentration of an individual peptide is 5.3x10 14M. In order to 
investigate how the removal of sialic acid from the surface a T cell impacts on recognition of 
a peptide antigen over a range of concentrations, I used 17 randomly generated peptides of 
the format XLXKFLXXL (where X refers to an amino acid residue apart from cysteine 
randomly selected from the 20 available). The leucine anchor residues at positions 2 and 9 
were fixed, ensuring that no discrimination between peptides would occur at the level of 
peptide-MHCI binding. Figure 7.10 illustrates MIP-1{3 release by sialylated (panel A) and 
desialylated (panel B) ILA1 cells in response to C1R cells presenting each of the 17 'KFL- 
fixed' peptides over a range of concentrations. In accordance with the combinatorial 
peptide library screen results (Figure 7.8), desialylated ILA1 cells were able to recognize a 
greater number of peptides then sialylated cells.
7.2.3 Silencing of individual conserved N-glycosylation sites present on the 868 TCR does 
not increase its sensitivity to antigen
In Chapter 6 , I described the process of engineering T cells specific for the HLA A2-restricted 
SL9 antigen derived from HIV-1 (HIV pl7 Gag77 8s SLYNTVATL), by transducing Jurkat and 
primary CD8 * T cells with the 8 6 8  TCR. Due to the success of the 8 6 8  TCR transduction, I 
decided to use this system to test the hypothesis that the removal of certain N-glycosylation 
sites located in the TCR constant region increases its sensitivity to antigen. The N- 
glycosylation sites in the 8 6 8  TCR were located by scanning 8 6 8  TCR a and (3 chain amino 
acid sequences (Appendix 2 A and B) for N-X-[S/T]-Y (where N denotes an asparagine, S/T 
denote serine/threonine, and X and Y represent any amino acid other than proline) motifs 
using the ExPASy (Prosite) software. The scan retrieved seven N-glycosylation motifs; two in 
the 8 6 8  TCR (3 chain, and five in the a chain (Appendix 2). Figure 7.11 highlights the 
positions of these glycosylation motifs on a human a(3 TCR. To abrogate glycan attachment 
at these sites, I designed a set of primers to mutate the asparagine (N) residues in the N-X- 
[S/T]-Y N-glycosylation sequence to glutamine (Q) (Appendix 3).
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Figure 7.10: Titration profiles for 17 randomly generated ILA1 TCR-specific XLXKFLXXL 
peptides conducted with sialylated and desialylated ILA1 CDfT T cell clone. A shows MIP- 
1|3 procuction by sialylated (neuraminidase untreated) ILA1 CD8~ T cell clone. B shows MIP- 
1P procuction by cesialylated (neuramini-dase treated) ILA1 CD8V T cell clone. The peptides 
assayed here w ere randomly selected from all the possible combinations o* amino acids 
found in the 9m er peptide library. The leucine anchor residues at positions 2 and 9, and 
central conserved KFL m otif were fixed. All other positions (shown as X) were varied. For 
cell numbers and assay details refer to section 2 .11.2b of Materials and Methods.
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Figure 7.11: The front (A) and side (B) views of a human a(3 TCR with highlighted N- 
glycosylation motifs. A total of seven sites of glycan attachment are highlighted (yellow 
and circled): two in the beta chain (blue), and five in the alpha chain (green). The labels 
next to each glycosylation m otif denote the glycosylation mutant ID, the residue number of 
the asparagine that was mutated to silence the glycosylation site, and whether this residue 
is located in the variable (v) or constant domain (c) of the TCR (see Appendix 3). The a5 
glycosylation site is not shown here as it is located in the stalk region of the TCR alpha 
chain, and is thus absent from the crystal structure. The approximate contract regions for 
the pMHC, CD8 and CD3 are indicated by the red arrows.
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Glutamine was selected for the substitutions because its physico-chemical properties 
closely resemble those of asparagine, ensuring that the structure of the TCR was not altered 
by the amino acid substitutions themselves. The conditions for the N/Q site directed 
mutagenesis (SDM) of the glycosylation sites is described in section 2.5.If  of Materials and 
Methods. The SDM for each of the seven glycosylation TCR mutants was performed in the 
pUC (See Figure 6.5 of Chapter 6 ) vector background, since the sheer size (~9000 basepairs, 
without the insert) and looped secondary structure of the lentiviral vector made it 
unsuitable for this technique. The success of SDM was verified by automated sequencing of 
each of the SL9-specific glycosylation mutant TCR a and p chains, and aligning these with 
the 8 6 8  TCR wild type sequence (Appendix 4).
Once I was satisfied that the SDM of each glycosylation site had worked, the a or 3 TCR 
chains that contained a mutation were excised from the pUC vector and slotted into the 
Lenti-SxW lentiviral vector (Figure 6 . 6  of Chapter 6 ) in place of the existing wildtype a or p 
TCR chain.
Experiments with Jurkat transductants:
The resultant lentiviral constructs were used to make lentiviral supernatants with the 
methodology developed in Chapter 6  and described in section 2.6 of Materials and 
Methods. The multiplicity of infection (MOI) of each lentiviral preparation was determined 
by titering the viral supernatants on TCR negative Jurkat cells and monitoring the surface 
levels of CD3 expression with addition of virus using an anti-CD3 antibody (Figure 7.12 A). 
From the MOIs determined using these viral titration curves, volumes of viral supernatant 
containing the same number of infectious particles were calculated for each 8 6 8  TCR 
mutant. This ensured that the levels of surface TCR expression on transduced cells did not 
vary with each viral preparation, enabling a direct comparison between the antigen binding 
properties of the 8 6 8  TCR glycosylation mutants. Figure 7.12 B shows the differences in 
cognate SL9/HLA A2 tetramer staining levels of Jurkat cells transduced with lentiviruses (of 
equal MOIs) encoding the wildtype 8 6 8  TCR and seven 8 6 8  TCR glycosylation mutants. 
Lentiviral supernatants encoding glycosylation mutants G(32 and Ga5 did not lead to surface
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Figure 7.12: Testing transduction of Jurkat TCR-negative T cell line with 868 TCR 
glycosylation mutants. A. Titering of concentrated (but 1 /50 diluted) lentiviral supernatant 
encoding each of the 868 wildtype (WT) TCR and the 868 TCR glycosylation mutants (G(3l, 
G|32, G a l, Ga2, Ga3, Ga4, and Ga5) on 2x10s TCR negative Jurkat cells. Surface TCR 
expression with each addition of virus was determined by flow cytometry, with anti-CD3 
antibody staining 72 hours post infection. B. SL9/HLA A2 tetramer staining of Jurkat cells 
transduced with lentivirus preparations of equal multiplicities of infection (MOIs, see 
section 2.6.4 of Materials and Methods), expressing the full panel of 868 TCR glycosylation 
mutants. No anti-CD3 or SL9 tetramer staining was detected for Jurkat cells transduced 
with G02 and Ga5 glycosylation mutants. Representative data of >2 separate experiments 
shown.
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TCR expression. To rule out the possibility that this was a result of faulty viral production, 
the procedure was repeated several times, each time with the same conclusion. It is 
therefore highly likely that eliminating the glycosylation motifs at these sites interferes with 
the stable cell surface expression of the TCR. In view of this, G(32 and Ga5 mutants were 
dropped from further investigation. The differences in SL9 tetramer staining for Jurkat cells 
transduced with the other 8 6 8  TCR glycosylation mutants were not immense. I therefore 
decided to study the TCR/pMHCI binding kinetics for each 8 6 8  TCR transductant in more 
detail by performing tetramer association and dissociation assays. Measuring tetramer on- 
and off-rates can reveal differences in TCR affinity that may not be apparent by simply 
examining steady-state mean fluorescence intensity after a typical 30 minute stain at 
physiological temperatures. Figure 7.13 depicts SL9 tetramer association and dissociation 
curves conducted with Jurkat cells transduced with the 8 6 8  TCR glycosylation variants. 
Unfortunately, the Ga4 variant was omitted from this experiment due to poor growth of the 
transduced cells. Although there was some increase in tetramer association rates for all the 
glycosylation mutants compared to WT, Ga2 and Ga3 displayed the highest rates. Their 
tetramer dissociation rates were not substantially dissimilar to that of WT 8 6 8  TCR- 
transduced Jurkat cells. The increase in tetramer on-rates observed with Ga2 and Ga3 
glycosylation mutants, however, gave hope that this increase in antigen sensitivity might 
correlate with increased functional activity, as reported in the next section. I therefore 
proceeded to examine TCR-induced functional responses.
Experiments with primary CD8* T cell transductants:
As mentioned in the previous paragraph, no substantial increase in SL9 tetramer staining 
(above MFI of wildtype 8 6 8  TCR transductant) level was observed for any of the 
glycosylation mutants. A possible reason is that Jurkat cells do not express the CD8  
coreceptor, which is a key molecule implicated in TCR-antigen recognition. Amongst its 
various roles, CD8  stabilises the TCR/pMHCI interaction by approximately ~2 fold 
(Wooldridge et al. 2005). It is therefore possible that the differences in pMHCI tetramer 
staining between the wildtype 8 6 8  TCR and the glycosylation mutants would become more 
apparent if these TCRs were to be expressed on CD8 * T cells. A further reason for using
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Figure 7.13: SL9/HLA A2 tetramer association and dissociation rates for Jurkat T cells 
transduced with the 868 TCR and 868 TCR glycosylation mutants. A shows % maximal 
binding over 30 min for the various 868 TCR-transduced Jurkat T cells stained with 10 pg/ml 
SLYNTVATL index MHC tetramer. B. Dissociation curves performed with same concentration 
of SL9/HLA A2 tetram er as in A, from 868 TCR CD8+ T cell transductants over 30 min, in the 
presence of a competing anti-HLA A2 antibody. The assays were performed with 95-100%  
pure 868 TCR-transductants, and representative data are shown here. The protocols for 
pMHC tetram er association and dissociation assays can be found in sections 2.8.2 and 2.8.3 
of M aterials and Methods. Representative data of 2 separate experiments shown.
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primary CD8 * T cells as targets for lentiviral transduction is that, unlike Jurkat cells, these T 
cells are capable of eliciting a plethora of effector functions and cytotoxicity on stimulation 
with cognate antigen. Lentiviral transduction of polyclonal primary CD8 + T cells (MACS- 
sorted from fresh PBMC) was previously described in Chapter 6  and further details can be 
found in section 2.6.3 of Materials and Methods. A high degree of transduction efficiency 
(~90%) was generally achieved when each of the 8 6 8  TCR-encoding lentiviruses was used to 
infect primary CD8 *T cells (Figure 7.14). SL9/HLA A2 tetramer staining of these cells (Figure 
7.15) revealed a similar pattern of MFIs as observed with transduced Jurkat cells (Figure 
7.12 B). Again, although the Ga2 mutant displayed the highest level of SL9 tetramer 
staining, this was not substantially greater than the MFI for the wildtype 8 6 8  TCR- 
transduced cells. As demonstrated by the exceptionally high tetramer staining MFIs in 
Figure 7.15, the interaction between the 8 6 8  TCR and its cognate SL9/HLA A2 tetramer (in 
the presence of CD8 ) is already of very high affinity. As a consequence, any increase in TCR 
affinity, which may be afforded by removal of a particular glycosylation site may not 
manifest itself by means of tetramer staining. In view of this, I decided to look for any 
apparent functional differences between the transductants. After all, even if removal of 
certain glycosylation sites translated into increased pMHCI tetramer binding, proof that 
these cells performed better in target cell recognition and elimination than wildtype 
transductants would be required to justify their use in adoptive transfer therapy. To this 
end, I examined the functionality of the CD8 +T cells transduced with the variant 8 6 8  TCRs in 
activation assays by using two readouts: i) release of MIP-10 cytokine in response to target 
cells presenting the SL9 peptide, detected using a MIP-10 ELISA (Figure 7.16A); and, ii) killing 
of SL9 peptide-pulsed target cells, measured using the FATAL assay (Figure 7.16B). Although, 
all 8 6 8  TCR transductants exhibited highly specific MIP-10 release and cytotoxicity in 
response to target cells presenting the cognate SL9 peptide, none of the glycosylation 
mutants performed substantially better than the wildtype 8 6 8  TCR.
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Figure 7.14: Transduction of polyclonal CD8 + T cells with the 8 6 8  TCR and 8 6 8  
glycosylation mutant TCRs. 10  ^ MACS-sorted polyclonal CD8* T cells were activated with 
anti-CD3 and anti-CD28 antibody-coated microbeads prior to infection with 1ml of 
concentrated lentiviral supernatant, encoding the wildtype (WT) 868 TCR and five 868 TCR 
glycosylation mutants. Untransduced cells, and CD8+ T cells transduced with the 868 TCR 
and the following glycosylation mutants G(31, G a l, Ga2, Ga3, and Ga4 were stained with 
cognate SL9/HLA A2 tetram er 72 hours post infection. The efficiency of lentiviral 
transduction was determined by flow cytometry, and analysed using FlowJo software. The 
numbers in the upper left quadrants refer to the percentage of CD8+ SL9/HLA A2 tetramer* 
cells.
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Figure 7.15: SL9/HLA A2 tetramer staining of primary CD8* T cells transduced with 
lentiviral vectors encoding the 868 TCR and 868 TCR glycosylation mutants. Six lots of 106 
MACs-sorted CD8+ T cells, isolated from the same blood donor were each transduced with 
lm l concentrated lentiviral supernatant of similar MOI (determined by titration on Jurkat 
cells) encoding the 868 TCR and the 868 TCR glycosylation mutants (G(31, G a l, Ga2, Ga3, 
and Ga4). The transductants were stained with 10 pg/m l SL9/HLA A2 tetramer 72 hours 
post infection. Untransduced CD8+ T cells isolated from the same donor were also stained 
with SL9 tetram er, as a negative control. Representative data of 2 separate experiments 
shown.
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Figure 7.16: Primary CD8* T cells transduced with the 868 TCR and 868 TCR glycosylation 
mutants are capable of specific activation and killing in response to SL9 peptide-pulsed 
targets. A. A M IP-lp ELISA conducted with 92-95% SL9/HLA A2 tetramer positive 868 TCR 
transductants and HLA A2-expressing C1R target cells pulsed with different concentrations 
of SL9 peptide. B. A FATAL killing assay conducted with the same glycosylation mutant 868 
TCR transduced cells, SL9 peptide-pulsed HLA A2 positive T2 cell as targets, and unpulsed 
T2 cells as controls. Untransduced CD84 T cells from the same donor were used as negative 
controls. Error bars depict s.d. from the mean of 2 replicates. Representative data from 2 
separate experiments shown.
258
7.3 Discussion
Chapter 7
Many TCRs implicated in targeting disease-associated antigens such tumour-derived 
epitopes, self-peptides and viral escape mutants, are weak. This low affinity for cognate 
antigen makes them suboptimal candidates in adoptive T cell therapy. Various methods to 
increase TCR affinity in the laboratory, mostly centring around yeast or phage display, have 
been developed (Li et al. 2005; Dunn et al. 2006; Zhao et al. 2007). However, despite being 
capable of achieving >106 fold increases in TCR affinity, these techniques are labour 
intensive (Li et al. 2005). Furthermore, they target the highly variable CDR loops, and must 
therefore be individualised for each TCR (Li et al. 2005; Dunn et al. 2006; Zhao et al. 2007). 
The glycosylation levels of a T cell have previously been reported to affect T cell function 
(Grigorian et al. 2007; Lau et al. 2007). Moreover, T cells in distinct differentiation states 
exhibit different levels of glycosylation (immature/mature and naive/memory) which relate 
to their sensitivity to antigen (Moody et al. 2001; Pappu et al. 2004). In view of this, I 
decided to investigate the potential therapeutic benefit of glycosylation as a TCR affinity 
regulator, initially by studying the effect of desialylation on T cell antigen sensitivity, and 
later by silencing individual glycosylation sites on a TCR. Since only the invariable constant 
regions of the TCR are glycosylated, the prospect of increasing TCR affinity by abrogating 
key glycans could represent a universal method for enhancing T cell antigen sensitivity, 
irrespective of intrinsic TCR specificity. My key findings are:
i) Desialylated CD8 * T cells are rendered substantially more sensitive to antigen than
their sialylated counterparts (Figure 7.3). Importantly, removal of sialic acid from the
T cell surface exerts the same effect on antigen recognition irrespective of the 
strength of the pMHCI/CD8  interaction, which suggests that the co-receptor is not 
responsible for the majority of this phenomenon.
ii) Desialylation of CD8 * T cells enhances cognate pMHCI tetramer staining. The
enhancement of pMHCI tetramer staining afforded by desialylation correlates with
TCR/pMHCI affinity (Figure 7.4).
259
Chapter 7
iii) Desialylation of other T cell subsets (CD4+ T cells and y6  T cells) also increases 
sensitivity to antigen, both in terms of cytokine release and tetramer staining (for 
CD4* T cells only) (Figures 7.5 and 7.6).
iv) Removal of terminal sialic acid from the surface of 8 6 8  TCR-transduced CD8 + T cells 
specific for the HLA A2-restricted, HIV-derived SL9 antigen increases cognate 
SL9/HLA A2 tetramer association, and decreases tetramer dissociation rates (Figure 
7.7).
v) Desialylation of a CD8 * T cell clone increases its TCR crossreactivity (Figures 7.8-7.10).
vi) Silencing of individual N-glycosylation sites present in the constant domains of the 
8 6 8  TCR a and p chains does not correlate with increased antigen sensitivity (Figures 
7.11-7.16).
As I was nearing completion of the second part of this study, investigating whether the 
glycosylation state of a TCR could be used as an affinity regulator, a paper was published by 
Kuball et al. in the Journal of Experimental Medicine (Kuball et al. 2009). The title of this 
publication: 'Increasing functional avidity of TCR-redirected T cells by removing defined N - 
glycosylation sites in the TCR constant domain' suggested that the authors had found results 
that were contrary to my own. The authors reported that silencing of one key glycosylation 
site in the constant domain of two murine and one human anti-tumour TCR resulted in 
increased sensitivity to cognate antigen, without concomitant increases in non-specific 
recognition (Kuball et al. 2009). The key mutations reported were: i) an N/Q substitution in 
the constant domain of the murine TCR alpha chain at position 90 (c-90 mutant); and, ii) an 
N/Q substitution in the constant domain of the human TCR alpha chain at position 36 (c-36 
mutant). Since my own work was carried out on a human TCR, I will focus on how their 
findings with human WT-1 TCR relate to the 8 6 8  TCR. The constant domain of the human 
TCR alpha chain has three conserved glycosylation motifs: NVS, NKS, and NNS. The TCR 
affinity-enhancing mutation c-36 involves an N/Q substitution in the first NVS motif, thus 
silencing this glycosylation site. In the 8 6 8  TCR, the c-36 mutation corresponds to the N/Q 
substitution at position c-31 resulting in the Ga2 mutant (see Appendix 2). The Ga2 mutant 
did not exhibit a substantially increased sensitivity to antigen either in terms of cognate
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tetramer staining (Figures 7.12 and 7.15), or in functional assays (Figure 7.16). Since the 
work with the c-36 mutant reported by Kuball et al. opposed my own claims, I speculated 
that perhaps our findings did not agree due to the different affinities of the TCRs we 
experimented on. The 8 6 8  TCR that I used in my study has the highest affinity of a natural 
TCR (K0  ~ 100 nM) ever described using the biophysical technique of choice for such weak 
protein-protein interactions, SPR (Varela-Rohena, 2008a #882}, whilst the TCRs used in the 
rival study are both lower affinity anti-tumour TCRs: i) two murine TCRs specific for epitopes 
of human p53 and MDM2 antigens; and, ii) a human TCR specific for a WT-l-derived epitope 
(Kuball et al. 2009). It was thus possible that an increase in TCR affinity afforded by 
deglycosylation of the 8 6 8  TCR only corresponded to a minute fraction of its overall affinity.
Meanwhile, in search for new technologies to increase TCR affinity, collaborators at 
Adaptimmune Ltd. decided to reproduce the affinity-enhancing c-36 mutation (in the 
conserved NVS glycosylation motif) reported by Kuball et al, in the 1G4 TCR, specific for a 
cancer testis antigen expressed in a wide range of cancers, NY-ESO-I157-165 
(SLLMWITQC/HLA A*0201). The 1G4 TCR binds to its cognate antigen with a KD ~ 32 pM 
(Zhao et al. 2007). In accordance with my own studies, this mutation did not increase 
antigen sensitivity of recipient CD8 + T cells after TCR transduction. Thus, the two attempts 
to repeat the data seen by Kuball et al, and reported in just one experiment using a human 
TCR (Kuball et al. 2009), have both failed to reproduce this promising result.
In summary, I demonstrate that the removal of cell-surface sialic acid increases T cell 
sensitivity to antigen (irrespective of the CD8  involvement). Further studies focusing on 
removing complete sugars by mutating conserved N-glycosylation sites on the TCR chains 
failed to demonstrate that T cells bearing any of these molecules were substantially more 
sensitive to antigen than those bearing the wildtype TCR. Overall, my studies confirm that 
the glycosylation of the T cell surface can play a substantial role in T cell sensitivity to 
cognate antigen. Unfortunately, my attempts to examine the role of individual N-linked 
glycans on the TCR in this phenomenon failed to reveal a hoped for 'global' solution that 
could be applied to any TCR being considered in TCR gene therapy and adoptive T cell
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transfer therapy. Further studies will be required in order to understand how the 
glycosylation of T cell surface proteins regulates cellular antigen sensitivity.
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In Chapter 6 , I described how the transfer of TCR genes, specific for an antigen of choice, 
into recipient host T cells offers a practical approach for redirecting T cell immunity. This 
was achieved by transduction of polyclonal CD8 * T cells with a natural (albeit codon- 
optimised) HIV gag-specific 8 6 8  SL9 TCR. The 8 6 8  SL9 TCR binds to its cognate antigen with a 
dissociation constant (K0) of £150 nM as measured by SPR (Varela-Rohena, 2008a #882). As 
a result, this TCR binds its antigen with the highest affinity recorded to date for a natural 
TCR. However, using natural TCR genes is not always a viable option for TCR gene therapy. 
For instance, the vast majority of natural anti-tumour TCRs exhibit too weak an affinity for 
effective tumour eradication, whilst many natural anti-viral TCRs are inefficient at 
recognising viral escape mutants. The advancement of soluble TCR technologies (Molloy et 
al. 2005), to which my colleague Jonathan Boulter made a tremendous contribution (Boulter 
et al. 2003; Li et al. 2005), has revolutionised T cell immunotherapy. The transduction of T 
cells with affinity-enhanced TCRs generated by soluble TCR technologies has the potential to 
dramatically improve T cell-antigen recognition in a setting where naturally occurring TCRs 
would fail. In addition to using soluble TCR technology for advancing the success of TCR 
gene transfer therapy, soluble TCRs can themselves act as therapeutic agents, bypassing the 
need for laborious and costly cell culture systems. In this chapter, I evaluate the therapeutic 
potential of a novel class of soluble TCR reagents called Immune mobilising monoclonal 
TCRs Against Cancer/Virus (ImmTAC/Vs), targeting common cancer and HIV epitopes, 
respectively.
8.1.1 Soluble antibody- and TCR-based immunotherapies
The adaptive immune response is equipped with two main types of antigen-specific 
molecules: antibodies and TCRs. Antibodies recognise non-self aspects of circulating and 
cell-surface proteins, whereas apTCRs monitor cells for the surface presentation of peptides 
complexed with MHC molecules (Chaplin 2010). Both of these immune receptors offer a 
unique potential for novel, highly specific, targeted therapeutics. Kohler and Miller were 
amongst the first to successfully harness the therapeutic potential of antibodies, and were
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awarded a joint Nobel Prize in 1984 for their work. They developed a technique to generate 
monoclonal antibodies (mAbs) against any given antigen by fusing a line of myeloma cells, 
which exhibited impaired antibody production, with healthy antibody-producing B cells and 
successfully selected the fused hybridoma cells (Kohler et al. 1975). 35 years on, mAbs and 
their derivatives are the fastest growing class of therapeutic molecules, with more than 30 
mAb products currently registered as approved drugs and hundreds being tested in clinical 
trials (Brekke et al. 2003; Casadevall et al. 2004; An 2010; Nelson et al. 2010). There are 
three categories of antibodies generated for use in therapeutics: i) 'naked' mAbs; ii) 
conjugated mAbs; and, iii) bi-specific mAbs.
i) 'Naked' mAbs:
'Naked' antibodies function as therapeutic agents by eliciting an antibody-dependent cell- 
mediated cytotoxicity (ADCC), whereby effector cells, primarily NK cells but also 
macrophages, lyse target cells that have been bound by specific mAbs by engaging the Fc 
portion of a mAb by their Fc receptors (most commonly CD16/FcyRIII) (Clynes et al. 2000).
ii) Conjugated mAbs:
In oncology, conjugated mAbs have been developed to deliver various 'payloads' to the 
target tumour cells in vivo, effectively acting like 'magic bullets'. The payloads are designed 
to enhance the ADCC process by inducing toxicity via agents such as cytotoxic drugs, 
prodrugs, or radioisotypes (Sievers et al. 2001; Wiseman et al. 2002; von Mehren et al.
2003). These antibody-drug conjugates (immuno-conjugates) are composed of a 
recombinant antibody covalently bound via a synthetic linker to a cytotoxic agent (Chari 
2008). The main objective of immuno-conjugates is to combine the pharmacological 
potency of the cytotoxic drug and the high specificity of mAbs for tumour-associated 
antigen targets. The incorporation of anti-neoplastic drugs into mAb-based immunotherapy 
has demonstrated their ability to kill cancer cells (Bailly, 2009). However, the success of 
such immuno-conjugates as therapeutic molecules has been limited compared to 'naked' 
mAb therapies (Haeuw et al., 2009). To date, only one drug, namely gemtuzumab 
ozogamicin (Mylotarg; anti-CD33 mAb conjugated to calicheamycin, Pfizer/Wyeth) has been 
approved by the FDA in 2000 for the treatment of patients with acute myeloid leukaemia
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(AML) (Poison et al. 2009). Shortly after being given the 'go ahead' by the FDA, gemtuzumab 
ozogamicin was voluntarily withdrawn from distribution. The reasons for the withdrawal 
included high levels of off-target toxicity due to protease-mediated degradation of the 
linker joining the mAb to the cytotoxic drug. Efforts are currently being made to improve 
both the antibody function (by enhancing the affinity and specificity of the Fv antibody 
portions) and limiting the off-target toxicity of the cytotoxic conjugates (for example by 
improving the stability of linkers so that their hydrolysis only occurs within the target cell 
cytoplasm) (Junutula et al. 2008; Beck et al. 2010).
iii) Bi-specific mAbs:
An alternative and increasingly powerful approach is to harness the high cytotoxic potential 
of T cells through the use of T cell-engaging bi-specific antibodies (Clynes et al. 2000; 
Cartron et al. 2002; Muller et al. 2007). Conventional antibodies lack the ability to recruit T 
cells because these cells are not equipped with Fey receptors. T cell-engaging bi-specific 
mAbs have been designed to target a desired antigen with one binding site and polyclonally 
activate T cells via the CD3 complex with the other binding site (Withoff et al. 2001; Wolf et 
al. 2005). Amongst this class of mAbs, the most successful therapeutic candidates are Bi­
specific T cell Engaging (BiTE) antibodies (Wolf et al. 2005; Baeuerle et al. 2009). The BiTE 
construct blinatumomab (MT103), which has a dual specificity for CD19 and CD3 molecules, 
represents the most advanced bi-specific antibody to date (Loffler et al. 2000; Bargou et al. 
2008). Blinatumomab has the ability to elicit lysis of tumour cells and has shown promising 
results in Phase I (non-Hodgkin's lymphoma) and Phase II (acute lymphoblastic leukaemia, 
ALL) clinical trials by instigating CD3+ T cells to lyse CD19* lymphoma and leukaemia cells 
(Bargou et al. 2008; Baeuerle et al. 2009; Nagorsen et al. 2009). The enormous potency 
difference between BiTE antibody blinatumomab and a conventional antibody may be 
mainly due to two factors. Firstly, while a conventional mAb engages NK cells by binding 
myriads of Fc receptors, a BiTE antibody can activate cytotoxic CD8 +T cells by engaging very 
few CD3 molecules. Secondly, cytotoxic T cells exhibit a higher lytic potential and serial 
mode of lysis (engaged by BiTE antibodies) than NK cells triggered by conventional mAbs 
(Bargou et al. 2008). Taking into consideration that normal B cells also express CD19, it is
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encouraging that blinatumomab has thus far exhibited minimal side effects, at most 
resembling flu-like symptoms.
Despite showing great promise in certain situations, the success of therapeutic mAbs is 
limited by the nature of antigens that antibodies are designed to recognise. The majority of 
therapeutic antibodies target intact cell-surface proteins (Figure 8.1 and (Chaplin 2010)), the 
likes of which represent only a small fraction of the total antigen repertoire that 
distinguishes tumours and virally infected cells from normal cells. These tumour-associated 
and viral antigens are intracellular and are only displayed on the surface of cells after being 
processed into peptides and complexed with MHC molecules (Davis et al. 1998; Rudolph et 
al. 2006; Coif et al. 2007). Peptide antigens presented in the context of MHC class I (MHCI) 
are of particular interest for targeting applications because they are derived from the total 
pool of endogenously expressed proteins within a given cell. A number of attempts have 
been made to tap into this vast resource of disease-associated antigens by developing mAbs 
against various peptide-MHCI complexes. Wittman et al. succeeded in generating a murine 
lgG2a mAb called 3.2G1, capable of recognising the tumour-associated GVL peptide 
(GVLPALPQV) derived from human chorionic gonadotropin beta (CGB) presented in the 
context of HLA A2 (Wittman et al. 2006). The 3.2G1 mAb was able to recognise the 
endogenously-processed GVL/HLA A2 complex with TCR-like specificity. They designated 
this class of antibodies as TCR mimics (TCRm) to reflect this role (Wittman et al. 2006). 
Impressively, the 3.2G1 TCRm exhibited Ab-dependent cellular cytotoxicity of a human 
breast carcinoma line known to express the GVL antigen in vitro, and inhibited in vivo 
tumour implantation and growth in mice (Wittman et al. 2006). However, while this study 
elegantly demonstrates that generation of mAbs targeting peptide-MHC complexes is 
possible, it remains very difficult and to this day only a handful of TCRm Abs exist. In 
contrast to antibodies, TCRs are specifically designed to recognise endogenously processed 
peptides presented on the cell surface in the context of MHC (Figure 8.1 and (Davis et al. 
1998; Rudolph et al. 2006; Coif et al. 2007)), making this type of antigen ideal for soluble 
TCR targeting. Like mAbs, soluble TCRs can now be engineered to deliver 'pay loads' such as 
radioisotopes, toxins or immunomodulatory molecules to their targets. In one of the earliest 
successful soluble TCR immunotherapy studies, Card et al. reported the production of a
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Figure 8.1: The differences in antigen recognition displayed by antibodies and TCRs.
Cytoplasmic proteins, in this case tumour-associated antigens (TAAs) comprise intracellular 
proteins (pink), cell-surface-bound proteins (red), and secreted proteins (green). These 
proteins are degraded into short peptides by the proteasome. The peptide fragments are 
transported to the lumen of the endoplasmic reticulum where they can bind MHC class I, 
whereupon the complex cycles to the cell surface. The MHC molecules are shown on the 
surface of the cell with their intracellularly derived peptide fragments (red, pink and green). 
Whilst antibodies can only bind secreted or surface bound antigens typically in the form of 
whole proteins, TCRs have access to all antigens, regardless of cellular localisation, when 
these antigens are presented in complex with MHC on the surface of cells. Since the 
majority of TAAs and other pathogenic antigens are intracellular (i.e. not surface displayed, 
except in the context of HLA-peptide), soluble TCRs (when armed with cytotoxic agents or 
immune stimulators) are ideal candidates for immunotherapy (Figure taken from Molloy et 
al. 2005).
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single-chain TCR-interleukin- 2  (IL-2 ) fusion protein specific for an epitope of the p53 
tumour suppressor protein (Card et al. 2004). This fusion protein, designated 264scTCR/IL-2, 
was capable of reducing lung metastases in an experimental HLA A2+ mouse tumour model, 
and inhibited the growth of primary tumours derived from the A375 (p53+/HLA A2+) human 
melanoma cell line in these 'humanised' mice (Card et al. 2004; Belmont et al. 2006). Other 
immunomodulatory molecules that have shown great promise when fused to mAbs, can 
also be fitted to TCRs. These candidates include the cytokines interleukin-12 (IL-12) and 
tumour necrosis factor (TNF) (Halin et al. 2003; Dela Cruz et al. 2004), MHC class I (Lev et al.
2004), or a CD3 antibody (Davol et al. 2004; Gao et al. 2004). Collectively, these molecules 
share the function of redirecting T cells to target tumours or virally infected cells, and thus 
make ideal fusion partners for soluble TCRs.
The success of mAbs in soluble immunotherapy stems from the fact that antibodies: i) are 
naturally secreted by B cells and thus already exist as soluble molecules; and, ii) display 
naturally high affinities for antigen (0.1-10 nM KD) (An 2009). On the contrary, naturally 
occurring TCRs: i) are exclusively expressed on the surface of T cells, where they are 
tethered to the cell surface via their insoluble transmembrane regions; and, ii) have low 
affinities for antigen (1-100 pM KD) (van der Merwe et al. 2003) imposed by the processes 
of positive and negative selection in the thymus. The narrow range of affinities displayed by 
natural TCRs translates into antigen binding half-lives of 1-10 seconds (van der Merwe et al. 
2003) at 25°C and considerably shorter at physiological temperatures (Willcox et al. 1999a). 
The short binding half-lives of natural TCRs are simply too low to enable soluble TCRs to 
localise to their target antigens and deliver a payload. Monoclonal antibodies on the other 
hand display much longer binding half-lives in the range of minutes to hours (Einhauer et al. 
2001; Gerstner et al. 2002). If soluble TCRs are to rival mAbs as therapeutic agents, they 
must undergo a significant increase in affinity. This can be achieved by in vitro evolution 
techniques such as phage display, which require that the TCR is expressed in a suitable 
recombinant format. However, whilst 'affinity maturation' of mAb had become routine 
practice (Boder et al. 2000; Hanes et al. 2000), the poor stability of the TCRs meant that 
initial efforts to generate soluble high affinity TCRs for use as therapeutic agents were 
unsuccessful. The next section of this chapter describes how significant breakthroughs in
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the manufacture of soluble TCRs has enabled the generation of TCRs with antibody-like 
binding properties, broadening our understanding of TCR-antigen interactions and making 
the development TCR-based therapeutic targeting agents a feasible goal.
8.1.2 Production of soluble monoclonal TCRs with enhanced affinities
Unlike antibodies, TCRs are not naturally expressed as soluble proteins but instead reside on 
the T cell surface. The extracellular domains of the TCR a and p chains are held together via 
a single membrane-proximal disulphide bond, the presence of which is required for TCR 
stability. Attempts to generate soluble TCRs containing this natural disulphide bond have 
been unsuccessful (Garboczi et al. 1996). In view of this failure, different means of 
stabilising TCR a-p heterodimeric pairing were attempted. The success of 'single-chain' TCR 
constructs, analogous to antibody scFv fragments (Va-linker-vpcp, where V=variable 
domain, C=constant domain), was limited and unpredictable (Plaksin et al. 1997). A more 
fruitful approach involved stabilising the extracellular TCR subunits by fusion to jun-fos 
leucine zippers (Willcox et al. 1999b). Although this innovation successfully yielded 
functional soluble TCRs, these TCRs had two significant drawbacks. Firstly, the flexibility of 
the leucine zippers interfered with the crystallisation process, and, secondly, the 'foreign' 
nature of the required linkers carried with it the potential for immunogenicity if the 
reagents were to be used in the clinic (Willcox et al. 1999b; Boulter et al. 2003). In 2003, my 
colleague Jonathan Boulter reported an alternative method for designing stable, soluble 
TCR constructs with a high degree of specificity and minimum sequence deviation from 
wildtype (Boulter et al. 2003). This involved the insertion of a non-native disulphide bond 
into the interface between the TCR constant domains, at a region distinct from where the 
native disulphide bond is naturally located. The approximate location of the new disulphide 
bond was predicted by molecular modelling of a known TCR crystal structure (Ding et al.
1998). Amongst several residues proposed for mutation to cysteines, threonine-48 in the 
TCR a constant domain (TRAC T48) and serine-57 in the TCR P constant domain (TRBC S57) 
were selected due to their orientation towards each other and close proximity (Boulter et 
al. 2003). With both of these residues mutated to cysteines, and the insoluble 
transmembrane regions truncated immediately N-terminal of the natural membrane 
proximal cysteines, the resultant disulphide-linked soluble (dsTCRs) (later designated
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monoclonal TCRs, mTCRs) refolded well and showed a high degree of stability (Boulter et al. 
2003). Importantly, the technique preserves the specificity and three-dimensional structure 
of the wildtype TCR, and yields soluble TCRs that are amenable to crystallisation (Boulter et 
al. 2003; Chen et al. 2005). Finally, because the disulphide bond is buried deep in the 
globular TCR <*P interface it presents a minimal risk of antigenicity and is thus suitable for 
therapeutic application (Boulter et al. 2003).
With the novel soluble mTCR manufacture system in place, Boulter et al. proceeded to 
increase the affinity of a number of monoclonal TCRs by displaying them on the surface of 
bacteriophage (Smith 1985; Li et al. 2005). Prior to the generation of stable mTCRs, 'phage 
display* to increase TCR affinity was not an option, as the TCR constructs were too unstable 
for presentation on the surface of phage. As an alternative, multimerization of TCRs 
(typically as TCR tetramers) was performed to take advantage of the 'avidity effect', the 
same effect that also allows pMHC tetramers to bind their target TCRs ((Subbramanian et al. 
2004; Laugel et al. 2005), and section 1.6 of the main Introduction). However, at the 
molecular level, this approach relies on a high probability of TCR-antigen encounter 
enabling more than once TCR in a TCR tetramer to bind cognate pMHC. In reality, the 
number of cognate pMHC molecules naturally presented equates to only £50 per cell 
explaining why this technology was only partially successful at staining target cells 
expressing natural levels of antigen (Subbramanian et al. 2004; Laugel et al. 2005).
The unique stability of dsTCRs made them highly suitable for phage display, a technique that 
is used for the high-throughput screening of protein interactions (Li et al. 2005). Holler et al. 
had already demonstrated the success of a similar yeast display approach by showing that 
generating mutations within the TCR a-chain complementarity determining region (CDR)3 
loop of the murine 2C TCR (expressed as a single-chain construct) increased its affinity by 
>100 to 9 nM K0. without incurring a loss in specificity in in vitro binding assays (Holler et al. 
2000). Display techniques such as yeast and phage display enable the study of protein- 
protein interactions (in this case the TCR and pMHCI antigen) by providing a connection 
between the genotype and phenotype of the proteins of interest. Production of high affinity 
dsTCRs that fall outside of normal in vivo constraints by phage display is a laborious process
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that involves: i) random mutagenesis of specific CDR loops within the individual TCR a and (J 
chains; ii) cloning of mTCR a and 0 genes into phagemid vectors; iii) fusion of the TCR P gene 
construct to gene III of M13 bacteriophage (downstream of the TCR ap sequence), the 
product of which will be eventually displayed on the phagemid surface as a bi-cistronic 
protein; iv) screening the mTCR-expressing phage by a phage ELISA using streptavidin- 
immobilised, biotin-tagged, pMHCI complexes as targets and detecting bound phage using 
anti-gene III protein antibodies (Smith 1985; Li et al. 2005); and, v) sequencing of the 
genomes of phage clones which produce a signal in the ELISA, and recording the TCR 
affinity-enhancing mutations in the CDR loops. The probability that a randomly introduced 
mutation enhances the affinity of a given TCR is very low. The success of phage display 
depends on millions of mTCR clones being generated. These are organised into phagemid 
libraries (comprising up to 1010 clones, Liddy et al. submitted). The phage libraries undergo 
several rounds of screening of decreasing concentrations of immobilised pMHCI in a process 
called 'molecular evolution'. The end product of molecular evolution is a handful of phage, 
expressing mTCRs displaying the strongest affinity for cognate pMHCI. To increase TCR 
affinity further still, second-generation libraries are constructed by combining several CDR 
loop mutations (discovered using first-generation phage display libraries) in a single TCR (Li 
et al. 2005; Dunn et al. 2006). Using directed molecular evolution, Li et al. demonstrated 
that the affinity of TCRs can be increased dramatically, by at least 106-fold (Li et al. 2005). 
For instance, the affinity of a TCR (1G4) specific for the HLA A2-restricted tumour associated 
antigen NY-ESO-Iismss (SLLMWITQC), which is expressed in a large variety of cancers, was 
increased from 11 pM to 26 pM. This increase in affinity translates into a shift in TCR/pMHCI 
binding half-life from 7 seconds to >15 hours at 25°C (Li et al. 2005). Importantly, the 1G4 
and other high affinity monoclonal dsTCRs (mTCRs) generated by phage display, bound 
cognate cell surface pMHCI even at very low levels of peptide and exhibited no 
crossreactivity to endogenously derived non-specific peptides (Li et al. 2005). The next 
section introduces a novel type of soluble TCR targeting reagents, generated using the 
advances just described.
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8.1.3 ImmTAC/Vs
The combination of advances in soluble TCR technology and molecular affinity evolution 
systems, have enabled the production of 'Immune-mobilising monoclonal TCRs Against 
Cancer/Viruses (ImmTAC/Vs) (Liddy et al. submitted). ImmTAC/Vs are TCR-based bi-specific 
immunotherapeutic molecules designed to redirect the lysis of target cells presenting a 
specific pMHCI antigen by engaging and recruiting polyclonal CD8+ T cells. While the soluble 
high-affinity TCR portion of the ImmTAC/V molecule targets a desired antigen, the anti-CD3 
single-chain (sc)Fv antibody fragment polyclonally activates T cells via the CD3 complex, 
effectively redirecting T cells to kill its target be it a tumour or a virally infected cell. 
ImmTACs, designed to target tumour associated antigens (TAAs), represent the more 
advanced of the two types of reagent to date, although a number of ImmTAVs recognising 
viral antigens are currently being optimised (one of which is described in Section 8.2.5). 
Figure 8.2 illustrates the ImmTAC mode of action when applied to the targeting of tumours. 
The four ImmTACs studied in this chapter were generated by firstly producing soluble 
monoclonal mTCRs from CD8* T cell clones (Boulter et al. 2003) with specificities for the 
following TAAs: i) gpl0028* 288 (YLEPGPVTA/HLA A*0201); ii) MAGE-A3i68-i76
(EVDPIGHLY/HLA A*0101); iii) Melan-A/MART-12635 (EAAGIGILTV/HLA A*0201); and, iv) a 
cancer testis antigen expressed in a wide range of cancers, NY-ESO-I15716S 
(SLLMWITQC/HLA A*0201) (see Table 1.2 of the main Introduction). The nomenclature for 
the four ImmTACs was devised according to the antigens the mTCR components were 
designed to recognise: ImmTAC-gplOO, ImmTAC-MAGE, ImmTAC-MEL and ImmTAC-NYE. 
Surface plasmon resonance (SPR) established that the wildtype mTCRs bound their 
respective antigens with K0 values of ~30 pM, ~248 pM, ~18 pM, and ~11 pM (Liddy et al. 
submitted). High affinity versions of the wild type mTCRs were subsequently generated by 
subjecting the TCR sequences to directed molecular evolution and phage display selection, 
as described in section 8.1.2 of this chapter ((Li et al. 2005; Dunn et al. 2006), and Liddy et 
al. submitted). The bi-specific ImmTAC molecules were then engineered by fusing a 
humanised anti-CD3 scFv to the high affinity mTCR 0 chain via a flexible linker (Liddy et al. 
submitted). The ImmTAC a and 0 chain were expressed separately in E. coli as inclusion 
bodies, and refolded in vitro (Boulter et al. 2003). The TCR/pMHCI antigen binding
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Figure 8.2: Re-directing T cell responses to kill tumour cells. A. The high affinity 
monoclonal TCR portion of the ImmTAC molecule binds a unique antigen on the tumour 
cell surface, while the anti*CD3 single-chain (sc)Fv antibody portion recruits T cells of all 
specificities to kill the tumour cell. B. Normal cells presenting a non-cognate melan A 
antigen do not bind the ImmTAC-NYE reagent specific for the NY-ESO-1 tumour antigen. C. 
Tumour cells presenting the cognate NY-ESO-1 antigen are decorated by ImmTAC-NYE 
molecules, which elicit activation of a polyclonal population of T cells, culminating in killing 
of the target cells. The action of the ImmTAC reagent can be quantified by monitoring 
cytokine production (panels B and C) or cell lysis.
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kinetics for the high affinity mTCRs and the corresponding ImmTAC molecules were 
determined by SPR, and are summarised in Table 8.1. As indicated, the biophysical 
parameters for the CD3 scFv-fused and unfused mTCRs were very similar, implying that the 
structure integrity of each mTCR was not altered by the fusion process.
A
ImmTAC
Target
Protein/Peptide HLA
TCR binding to peptide/HLA complex
Kon
fM -V 1)
*oH
(S1)
T >4 
(H)
K0
(pM)
ImmTAC-NYE NY-ES0-1157165
SLLMWITQC
HLA*0201 5.70x10s 2.72x10 s 12 26
ImmTAC-gplOO
Gpl0028O2M
YLEPGPVTA HLA’ 0201 5.25x10s 5.79x10-® 33.1 11
ImmTAC-MAGE Mage-A3i6s !76 EVDP1GHLY HLA*0101 3.17x10s 1.81x10s 10.5 57
ImmTAC-MEL
Melan A26.JS 
EAAGIGILTV HLA*0201
1.97x10s 3.62x10® 53 18
B
ImmTAC
Target 
Protein/Peptide HLA
TCR binding to peptide/HLA complex
| M ¥ )
K.«
(s1)
T Yt 
(h)
Ko
(pM)
ImmTAC-NYE ny-eso- i 1S7165
SLLMWITQC
HLA*0201 6.25x10s 1.13xlGs 17 18
ImmTAC-gplOO
G pl0028o 2M 
YLEPGPVTA HLA*0201 3.67x10s 1.80xias 15 33
ImmTAC-MAGE
Mage-A3iU 176 
EVDPIGHLY HLA*0101 4.54x10s 1.92x10s 12
44
ImmTAC-ME I
Melan A j^ jj 
EAAGIGILTV HLA*0201
1.33x10s 5.20x10® 37 39
Table 8.1: Biophysical characteristics of 'free' soluble TCRs and TCR portions of ImmTAC 
molecules with four different specificities. Kinetics and equilibrium binding properties of 
'free' TCRs (A) and the same TCRs incorporated into ImmTAC molecules (B) determined by 
SPR. Measurements were conducted by flowing soluble TCRs or ImmTACs over cognate 
peptide/MHC class I molecules immobilised via a biotin tag on the surface of streptavidin- 
coated CM-5 chips. In most cases, the heteroclitic peptide was used for SPR due to 
increased stability when complexed to relevant MHCI as a soluble molecule. (SPR 
measurements kindly provided by Immunocore Ltd.).
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8.1.4 Aims
A major breakthrough in the production of soluble mTCRs, and advances in directed 
molecular evolution by phage display represent two critical events which enabled the 
generation of high affinity TCRs suitable for use as immunomodulatory therapeutic reagents 
(Boulter et al. 2003; Li et al. 2005). In this chapter I present data obtained with a novel class 
of mTCR-based therapeutic agents called 'Immune-mobilising monoclonal TCRs Against 
Cancer/Viruses' (ImmTAC/Vs) as part of a collaboration with Immunocore Ltd (Oxford). 
Immuncore are experts in the production and molecular engineering of soluble versions of 
lymphocyte cell surface proteins such and pMHC and TCRs. The company has less expertise 
in T cell assays. I was delighted to be given the opportunity to help them test the effects of 
their reagents in a range of in vitro and ex vivo assays. The aims for this work were to:
i) Test the ability of ImmTAC reagents, targeting four common TAAs (gplOO, MAGE-3, 
Melan-A and NY-ESO-1), to specifically activate polyclonal CD8+ T cells.
ii) Evaluate the ability of ImmTACs to incite a specific polyfunctional CD8+ T cell 
response, and determine which CD8* T cell phenotypes are responding.
iii) Assess the ability of ImmTACs to redirect CD8+ T cells to lyse peptide-pulsed targets 
and tumour cell lines presenting the relevant TAAs.
iv) Preliminarily assess whether the presence of regulatory T cells (Tregs) affects 
ImmTAC function.
v) Determine whether ImmTACs are capable of inhibiting tumour growth in vivo.
vi) Explore whether an ImmTAV designed to target a common epitope derived from 
HIV-1, can redirect polyclonal CD8+ T cells to respond to this antigen.
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8.2.1 ImmTACs specifically target tumour cells and activate CD8* T cells
Initially, the in vitro biological activity of ImmTACs was assessed by measuring the activation 
of a polyclonal population of CD8 * T cells in the presence of tumour cell lines presenting the 
relevant antigen: i) NY-ESO-1 on IM9 EBV-transformed B-lymphoblastoid cells; ii) gplOO on 
Mel526 melanoma cells; iii) MAGE-3 on A375 melanoma cells; and, iv) Melan-A on Me!624 
melanoma cells. The CD8 * T cells were obtained by positive MACS selection using PBMC 
prepared from healthy donors, and kept in a cytokine-free environment for several days 
prior to assaying in order to minimise background activation. IFNy cytokine production 
(measured by IFNy ELISpot) was chosen as the readout for CD8 + T activation in the presence 
of tumour lines and titrated levels of ImmTAC. The number of IFNy-spot forming cells (SFC) 
per 106 CD8 + T cells was recorded at each concentration of ImmTAC. Representative data 
are shown in Figure 8.3 A-D. In all cases, CD8 + T cells were only activated in the presence of 
tumour cells and the ImmTAC reagent. The number of activated IFNy-producing CD8 + T cells 
correlated with the concentration of ImmTAC used. Furthermore, all four ImmTACs 
produced EC50 values within the same range as the KD values for the corresponding 
ImmTAC/pMHCI interactions determined by SPR (Figure 8.3 and Table 8.1). Tumour cells are 
renowned for expressing extremely low levels of surface pMHCI antigen. Epitope counting 
studies performed by Immunocore Ltd. using PE-labelled high-affinity TCRs show that there 
are '''10-50 copies of popular HLA A2-restricted TAA-derived peptides on the surface of an 
average tumour cell (unpublished and (Purbhoo et al. 2006)). In contrast, peptide-pulsed 
cells can present ~100-1000 peptide copies (unpublished and (Purbhoo et al. 2006)). 
Therefore, the fact that ImmTACs were able to redirect CD8 + T cells to recognise these 
tumour lines efficiently represents a remarkable degree of antigen sensitivity.
8.2.2 ImmTACs elicit polyfunctional responses in memory CD8+ T cells directly ex vivo
Clearly, if ImmTACs are to eventually fulfil their roles as therapeutic reagents, their actions 
would have to be assessed under more physiological conditions than used in the 
experiments described so far. The closest system to the use of ImmTACs in vivo is to
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Figure 8.B: Biological activity of ImmTAC molecules with different specificities. (A-D) IFNy 
ELISpot assays showing activation of purified CD8 + T cells mediated by titrated 
concentrations of ImmTAC molecules in the presence of tumour cells expressing 
endogenous levels of antigen. E=effector; T=target. ImmTAC molecules+ E + T (circle); E + T 
alone (triangle); E + ImmTAC alone (inverted triangle); T + ImmTAC alone (square). The 
numbers on the y-axis represent the number of spot forming cells (SFC) per 106 CD8 * T cells 
assayed. Error bars depict mean values ± s.e.m. A. ImmTAC-NYE and IM9 EBV-transformed 
B-lymphoblastoid cells; B. ImmTAC-gplOO and Mel526 melanoma cells; C. ImmTAC-MAGE 
and A375 melanoma cells; and, D. ImmTAC-MEL and Mel624 melanoma cells. (Figure 
kindly provided by Immunocore Ltd.).
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examine their behaviour using fresh ex vivo-derived PBMC instead of purified populations of 
CD8* T cells. To this effect, I set up in vitro activation assay comprising PBMC isolated from 
an HLA A2* healthy donor. In this experiment, the PBMC were either pulsed with 10 6 M NY- 
ESO-1 is7165 peptide or were incubated with media alone, in the presence of a titrated 
ImmTAC-NYE and unpulsed PBMC from the same donor acting as effectors. The cells and 
ImmTAC-NYE were incubated with a directly conjugated aCD107a mAb and secretion 
inhibitors as described in the Materials and Methods section 2.11.5. After incubation, the 
cells were initially stained with the amine viability dye ViViD, and then with directly 
conjugated mAbs specific for the surface markers CD3, CD4, CD8, CD27, CD45RO and CD57 
to enable phenotypic analysis of the CD8+ and CD4+ T cells in the assay. Intracellular staining 
for specific cytokines (IFNy, TNF, and IL-2) was then performed, following fixation and 
permeabilisation. Details of the typical gating strategy adopted for phenotyping PBMC can 
be found in section 2.10.3 of Materials and Methods. The extent of ImmTAC-mediated 
activation was determined for CD8\ CD4+ and y6 T cell subsets present within the PBMC 
sample. Although y6 T cells also express surface CD3, the level of ImmTAC-specific activation 
for these lymphocytes was negligible (data not shown). Figure 8.4 A shows the activation 
profiles of CD8+ and CD4* T cells in the presence of titrated ImmTAC-NYE. Based on the 
extent of degranulation (surface CD107a mobilisation) and production of cytokines (IFNy, 
TNF, and IL-2), CD8* T cells appeared to be substantially more sensitive to ImmTAC- 
mediated activation than CD4+ T cells (Figure 8.4 A). These findings were important for two 
reasons. They demonstrated that ImmTACs: i) preferentially engaged CD8+ T cells; and, ii) 
elicited a polyfunctional CD8+T cell response.
I was also interested in dissecting the ImmTAC-T cell response further to determine which 
phenotypes within the CD8* and CD4* T cell populations were being activated. The potential 
of the CD3 scFv portion of an ImmTAC to activate a naive T cell subset in the absence of a 
TCR signal could carry the risk of 'awakening* potentially autoreactive T cells. Phenotypic 
characterisation of activated CD8* T cells was performed by staining with antibodies 
directed against CD27 and CD45RO T cell differentiation markers. Superimposition of 
phenotypic profiles of activated CD8* T cells and the overall CD8+ T cell population revealed
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Figure 8.4:1 mmTACs target primarily CD8*T cells. Flow cytometry was used to measure 
extent of activation (determined by surface CD107a expression and intracellular cytokine 
release) of CD8* and CD4+ T cell subsets in a sample of ex v/Vo-derived human PBMC, in the 
presence of titrated ImmTAC-NYE reagent. The numbers assigned to each FACS gate, 
correspond to the percentage of activated CD4+ or CD8* T cells. A shows the dose-response 
relationship between ImmTAC-NYE concentration and the relative percentages of CD8+ 
(coloured bars) and CD4+ (black bars) T cells activated to express each of the four effector 
functions (CD107a, green;IF Ny, yellow;T NF, red;an d, IL-2, turquoise) in the presence of a 
sample of PBMC target cells pre-pulsed with cognate NY-ESO-1 peptide. B. Phenotypic 
profile of CD8* (upper panels) and CD4* (lower panels) T cells activated with l t f 11 M 
ImmTAC-NYE in the presence of NY-ESO-1 peptide-pulsed PBMC. Coloured dots depict 
individual cells that e lid t a distinct function, as indicated in A, superimposed on cloud plots 
showing the phenotypic profile of the overall CD8+ and CD4+T cell population^ he upper 
panels show events from the corresponding panels in A and are colour-coded to match. 
Representative data of >2 separate experiments shown.
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that the vast majority of responding CD8 + and CD4+ T cells belonged to the effector (CD27‘ 
CD45RO /effector memory (CD27 CD45RO+) subsets (Figure 8.4 B).
Based on the fact that ImmTACs preferentially activated CD8 + T cells, ImmTAC/V-mediated 
CD4* T cell engagement was not investigated further. Figure 8.5 shows ex v/Vo-derived 
PBMC activation results obtained with ImmTAC-gplOO, focusing on CD8 + T cells. Target 
PBMC pulsed with 10 6 M gpl0028o-288 heteroclitic peptide YLEPGPVTV (or unpulsed), or 
Mel526 melanoma cells, were incubated for 12 hours with fresh autologous (unpulsed) 
PBMC in the presence or absence of ImmTAC-gplOO at the indicated concentrations, a 
directly conjugated aCD107a mAb and secretion inhibitors as described in the previous 
paragraphs and in the Materials and Methods section 2.11.5. In the peptide-pulsed PBMC 
samples containing ImmTAC-gplOO, substantial numbers of CD8 + T cells were activated in a 
sensitive and dose-dependent manner to elicit multiple effector functions (Figure 8.5 A). In 
agreement with ImmTAC-NYE data presented in Figure 8.4 B, the vast majority of ImmTAC- 
gplOO-responding CD8 * T cells belonged to the effector memory (CD27 CD45RO+) subset 
(Figure 8.4 B). These effector memory CD8 + T cells also exhibited a terminally differentiated 
phenotype characterised by expression of the senescence marker CD57. T cells expressing 
this marker are associated with maximal lytic capacity (Chattopadhyay et al. 2009), a 
desirable feature for an immunotherapeutic agent designed to target tumour cells. 
Encouragingly, ImmTAC-gplOO was equally capable of eliciting a polyfunctional CD8 + T cell 
response with a similar phenotypic distribution when using the Mel 526 melanoma cell line, 
a natural tumour cell line that expresses very low levels of gplOO antigen, as targets (Figure 
8.5 B bottom panels), as when using peptide-pulsed PBMC (Figure 8.5 B top panels).
8.2.3 ImmTACs redirect T cells without tumour specificity to lyse tumour-transformed 
cells
In order to be effective therapeutic agents, ImmTAC/Vs must not only activate CD8 + T cells
in a polyfunctional manner, but also re-direct these effector cells to lyse the
+
tumour/infected target cells. To investigate whether polyclonal CD8  T cells were able to 
respond to ImmTACs in this way, I set out to optimise a flow cytometric cytotoxicity assay
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Figure 8.5: Efficient activation of multiple CD8+ T cell effector functions by ImmTAC- 
gplOO. A. Dose-response relationship between the concentration of ImmTAC-gplOO and 
the percentage of CD8* T cells activated to express each individual function in the presence 
of cognate gp-100 peptide-pulsed PBMC. Surface expression of CD107a (green), and 
intracellular production of the cytokines IFNy (yellow), TNF (red) and IL-2 (turquoise), are 
shown. Coloured bars represent activation in response to peptide-pulsed targets; black 
bars represent activation in response to unpulsed targets. B. Phenotypic profile of CD8+T 
cells activated with ImmTAC-gplOO at a concentration of 1 0 11 M in the presence of 
peptide-pulsed PBMC (upper panels) or Mel526 cells (lower panels). Coloured dots depict 
individual cells that elicit a distinct function, as indicated in A, superimposed on cloud plots 
showing the phenotypic profile of the overall CD8* T cell population; the upper panels 
show events from the corresponding panels in A and are colour-coded to match. 
Representative data of 2 experiments shown.
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otherwise known as a FATAL assay (Materials and Methods section 2.11.7). I experimented 
with two parameters: i) effector to target ratio (E:T) (Figure 8.6 A); and, ii) donor 
dependence (ie. whether CD8+ T cells isolated from different blood donors influenced the 
efficiency of ImmTAC function (Figure 8.6 B)). These optimisation assays were conducted 
with 1 nM ImmTAC-NYE, using CD8+ T cells, derived from PBMC by magnetic cell sorting, as 
effectors and NY-ESO-li57.i6s-peptide pulsed T2 cells as targets. Firstly, increasing the E:T 
ratio >5 : 1  did not correspond with higher levels of peptide-pulsed target cell lysis, 
indicating that the efficacy of ImmTACs was not limited by the number of responding CD8+ T 
cells. This observation implies that over the course of the assay, a single CD8+ T cell 
activated by a specific ImmTAC is capable of serially killing several targets. The speculation 
that ImmTACs are capable of causing individual CD8+T cells to serially kill their targets was 
confirmed using time lapse video microscopy footage of a single CD8+ T cell (of the EBV- 
specific clone 176.C4.1) lysing three Mel624 (gplOO 280-288 peptide-expressing melanoma cell 
line) target cells. Three screen capture images taken at 0, 1.5, and 5.5 hours illustrate the 
serial killing process (Figure 8.7). The fact that ImmTACs can elicit CD8+T cells to serially kill 
their targets is likely to contribute to their anti-tumour potency. In the second set of FATAL 
optimisation experiments (Figure 8.6 B), the source of CD8+ T cells did not significantly alter 
the efficiency of target cell lysis. This was welcome news, as it meant that further data 
generated using ImmTACs was not skewed by donor-dependent differences in CD8+ T cells. 
It also implied that ImmTACs were likely to function in most individuals, provided these 
individuals presented the target peptide in the context of an HLA allele to which the 
ImmTAC mTCR was restricted.
Since higher E:T afforded no advantage in terms of ImmTAC-mediated target cell lysis, 
further killing assays using pure CD8+ T cell populations as effectors adhered to a ratio of 5:1 
to conserve cells. Clearly, in experiments where PBMC were used as both targets and 
effectors, the E:T ratio was difficult to determine. Assuming that CD8+ T cells constitute 
~15% of total PBMC, 106 PBMC were typically used per assay condition. This corresponds to 
roughly the same number (~1.5xl05) of effectors used in a FATAL killing assay conducted 
with pure CD8* T cells. In experiments performed with PBMC isolated directly ex vivo, 
ImmTAC reagents induced specific lysis in a dose-dependent manner (Figure 8.8 A and B).
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Figure 8.6: Optim isation of the FATAL assay for measuring ImmTAC-mediated cytotoxicity.
A. 3X104 T2 cells pulsed with titrated concentrations of NY-ESO-l157.165 peptide were 
combined in a cytometric cytotoxicity FATAL assay with 1 nM ImmTAC-NYE and three 
different quantities of effector PBMC -derived CD8*T cells according to effector to target 
ratios (E:T) of 5:1, 10:1, and 20:1. Representative data of 2 experiments shown. B. 3X104 
NY-ESO-l157.165 peptide pulsed TO cells were assayed with In  M ImmTAC-NYE reagent 
combined with CD8+ T cells isolated from the PBMC of three different donors in an E:T ratio 
of 5:1. In each case the assays were performed over a 16 hour incubation period, and the 
target cell lysis was determined by flow cytometric quantification of labelled target cell 
elimination relative to an internal control.
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Figure 8.7: Visualisation of redirected lysis o f M el642 melanoma CD8* T cells in the  
presence of ImmTAC-gplOO. Time lapse video microscopy showing serial killing of three 
M el624 melanoma cells (orange) by a single CD8+ T cell (EBV-specific done 176.C4.1) 
without tumour specificity (green) in the presence of 10'10 M ImmTAC- gplOO. The pink line 
tracks the path of the single CD8+ T cell over a period of 5.5 hours. Melanoma cells were 
plated at 3 x 104 cell/well and the T cell done was plated at 8 x 103 cell/well. (Figure kindly 
provided by Immunocore Ltd.)
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Figure 8.8: Redirected lysis of tumour cells and peptide-pulsed targets by PBMC in the  
presence o f ImmTAC molecules. A. Redirected lysis over 16 hours of PBMC pulsed with 
(red circles) or without (black squares) gp l00 2 8 0 - 2 8 8  heteroclitic peptide YLEPGPVTV at a 
concentration of H I6 M in the presence of titrated doses of ImmTAC-gplOO and autologous 
PBMC.B . Redirected lysis over 16 hours of PBMC pulsed with various concentrations of the 
g p l0 0 28o 2 8 8  heteroclitic peptide YLEPGPVTV in the presence (blue circles) or absence (black 
squares) of l f r 9 M ImmTAC-gplOO and autologous PBMC. C. Redirected lysis over 16 hours 
of M el526 cells (green circles) or control (TO) cells (black squares) in the presence of 
titrated doses of ImmTAC-gplOO and PBMC. D. Redirected lysis over 16 hours of Mel624 
cells (mauve circles) or control (TO) cells (black squares) in the presence of titrated doses of 
ImmTAC-NYE and PBMC.Lysis was determined by flow cytometric quantification of labelled 
target cell elimination (FATAL assay). Representative data of >2 replicates shown.
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Furthermore, CD8  T cells present within these PBMC were effectively redirected to lyse 
tumour cells in dose titrations of ImmTAC-gplOO and ImmTAC-NYE (Figure 8 . 8  C and D).
8.2.4 ImmTAC function is not reduced in the presence of CD4+CD25'CD127Lo regulatory T 
cells (Tregs)
A small subset of a0 T cells called regulatory T cells (Tregs) is regarded as a major concern 
by tumour immunologists. The role of Tregs as their name suggests is to regulate the 
activities of other T cells such as CD8 * T cells, typically in an inhibitory capacity. There is 
increasing evidence to suggest that the recruitment of these inhibitory Tregs into the 
tumour environment constitutes one of the many mechanisms that tumours have 
developed to evade the cytotoxic immune response ((Turk et al. 2004; Wang et al. 2007), 
and section 1.7.2 of the main Introduction). For example, a recent study has confirmed that 
enrichment of Tregs in the tumour mass correlates with impaired CD8 + T cell function and 
poor prognosis of breast cancer (Xu et al. 2010). Most Treg subsets are characterised by a 
CD4*CD25H'profile, and constitutive expression of the transcription factor Forkhead box 
protein 3 (Foxp3). Tregs are capable of effectively suppressing the proliferation and activity 
of both CD4*CD25 and CD8 * T cells in a contact-dependent manner by inhibiting the 
production of immunostimulatory cytokine interleuking-2 (IL-2) (Annunziato et al. 2002; 
Curiel et al. 2004). Since Tregs also express surface CD3, activation of these cells by 
ImmTACs could result in a counterproductive inhibition of CD8 + T cell-mediated cytotoxicity. 
To investigate whether regulatory T cells did indeed have an inhibitory effect on ImmTAC- 
mediated cytotoxic activity, I conducted a killing assay in which autologous CD8 + T cells 
(present within the PBMC) were redirected to lyse PBMC pulsed with NY-ESO-1 peptide by 
ImmTAC-NYE, under three conditions: i) no Tregs (PBMC depleted of Tregs); ii) normal levels 
of Tregs (unmanipulated PBMC); and, iii) high numbers of Tregs (PBMC supplemented with 
Tregs in an effector to Treg ratio of 1:10). Although, there was a large difference in Treg 
numbers between the Treg-enriched PBMC and the unmanipulated/Treg-depleted PBMC 
samples, no significant difference in specific ImmTAC-redirected cytotoxicity was apparent 
(Figure 8.9 A, and Figure 8.10). To rule out the possibility that the Treg isolation process 
(performed using a human Treg isolation kit, Invitrogen) had somehow impaired Treg 
function, I analysed the supernatant from the killing assay depicted in Figure 8 . 8  A for
287
Chapter 8
-Tregs 
Normal 
+ Tregs
SO"u
40 "
2 0 -
10"
N
B
-Tregs 
-* •  Normal 
♦  + Tregs
£
"So 10000- 
Q.
CMI—I
0#
[ImmTAC-NYE] (Log10 M )
Figure 8.9: Assessing the effect o f regulatory T cells on ImmTAC-NYE redirected lysis. A.
The ability of ImmTAC-NYE to specifically redirect lysis of NY-ESO-l^.jgg peptide-pulsed 
PBMC (derived from an HLA A2* donor) by autologous CD8+ T cells (within the PBMC) was 
recorded in a FATAL assay under conditions where regulatory T cells (Tregs) were either 
depleted (black squares), supplemented (red squares), or left unmanipulated (grey 
squares).B . The supernatant taken from A was analysed for the release of IL-2 after the 16 
hour incubation period using a cytometric bead array (CBA). Tregs were isolated using a 
human Treg isolation kit (Invitrogen), and were tested for purity by FACS staining of T cells 
with the following staining profile CD4*CD25*CD127Lo. Error bars depict s.d.fro m the mean 
of 2 replicates.
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Figure 8.10: Assessing the effect of regulatory T cells on ImmTAC-NYE redirected lysis.
FACS plots depicting the lysis of target (P=PBMC pulsed with NY-ESO-l157.168 peptide) 
versus control (U=unpulsed PBMC) cell populations in a FATAL killing assay performed with 
autologous CD8 * T cells (within the PBMC) in the presence (of 1 nM, bottom panel) or 
absence (top panel) of ImmTAC-NYE reagent, under conditions where regulatory T cells 
(Tregs) were either depleted (left plots), supplemented (middle plots), or left 
unmanipulated (right plots). The numbers within each gate correspond to the percentage 
of cells present within each U or P population relative to each other. The U and P 
populations were distinguished by staining with two different concentrations of CFSE dye.
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various cytokines including IFNy, TNF and IL-2. Although the levels of IFNy and TNF were 
unperturbed for all three Treg conditions (data not shown), the level of IL-2 was significantly 
reduced in the Treg-enriched sample (Figure 8 . 8  B). This finding is consistent with the role of 
Tregs as 'IL-2 sinks', and confirms that the Tregs used in the killing assay (Figure 8.9 A and 
Figure 8.10) were functional in this respect. Although a more extensive study on the effect 
of Tregs on ImmTAC function may need to be performed, these initial data, implying that 
ImmTACs are effective even in the presence of large numbers of these inhibitory cells, are 
very encouraging and suggest that the presence of Tregs in tumours may not represent a 
major problem for ImmTAC-based therapies.
8.2.5 ImmTACs control tumour growth in vivo
To determine if ImmTAC reagents could affect tumour growth in vivo, a xenograft model 
was used. Immunocompromised NOD/SCID or Beige/SCID mice were engrafted with tumour 
cell lines (Mel526 or A375) and unstimulated PBMC on day 0, and the ImmTACs were 
administered intravenously (iv) an hour later and then every 24 hours for four-nine days. 
The size of the tumours was then measured by taking calliper readings in two perpendicular 
dimensions, and calculating the tumour volume using the formula: volume (mm3) = (length x 
width2)/2. Tumour volumes were recorded in this way three times per week, and plotted 
against the number of days post tumour engraftment to generate tumour growth curves 
(Figure 8.11). Figure 8.11 A presents data generated from mice that were engrafted with the 
Mel526 tumour cell line and treated intravenously with ImmTAC-gplOO. In this experiment, 
mice received the following doses of ImmTAC-gplOO: 0.1, 0.04, 0.01 and 0.004 mg/kg, post 
tumour engraftment. Dosing regimens were based on data derived from in vitro 
experiments (for example, 0.1-1 nM for ImmTAC-gplOO, Figure 8 . 8  C). All four doses of 
ImmTAC-gplOO in this schedule inhibited tumour growth over the study period of 32 days, 
with the highest doses (0.1, 0.04 and 0.01 mg/kg) exhibiting substantial tumour inhibition. 
No reduction in tumour growth was observed in mice receiving either no ImmTAC or no 
PBMC, indicating that the inhibition in tumour growth was dependent on the interaction 
between ImmTACs and presumably CD8 * T cells and possibly CD4+ T cells in the PBMC 
sample. In Figure 8.11 B, a similar assay set-up (to the ImmTAC-gplOO experiment) was 
used to test the effect of ImmTAC-MAGE on the growth of the engrafted A375 tumour cell
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Figure 8.11: In vivo efficacy of ImmTAC molecules in NOD/SCID and Beige/SCID xenograft 
models. A. Dose titration of ImmTAC-gplOO in a Beige/SCID xenograft model (n=8 mice). 
M el526 melanoma cells (2 x 10^) and PBMC (5 x 106) were engrafted subcutaneously (sc) at 
day 0. Treatment with ImmTAC-gplOO commenced one hour post-engraftment and was 
then administered every 24 hours from days 1-4 (indicated by *) at intravenous (iv) doses 
of 0.1 (green inverted triangles), 0.04 (purple diamonds), 0.01 (grey circles) and 0.004 
(brown squares) mg/kg. As controls, Mel526 cells were engrafted without (black squares) 
or with (blue triangles) PBMC and dosed with vehicle (PBS). B. A375 melanoma cells 
(2.5X106) were engrafted sc at day 0 with PBMC (2 .5x l06) in a NOD/SCID xenograft model 
(n=12 mice). ImmTAC-MAGE at 0.01 mg/kg (purple inverted triangles) or control ImmTAC 
at 0.01 mg/kg (blue cirdes) was administered iv one hour post-engraftment and every 
other day for an additional nine doses (indicated by *). As controls, A375 cells were 
engrafted without (black squares) or with (grey triangles) PBMC and dosed with vehicle 
(PBS). C. M el526 melanoma cells (106) were engrafted with PBMC (106) at day 0 in a 
NOD/SCID xenograft model (n=6 mice) and dosed iv at 0.04 mg/kg with ImmTAC-MEL 
(purple circles) one hour post-engraftment and then every day from days 1-4 (indicated by 
*). As controls, M el526 cells were engrafted without (black squares) or with (blue triangles) 
PBMC and dosed with vehicle (PBS). Error bars depict mean values ± s.e.m. (Figure kindly 
provided by Immunocore Ltd.)
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line. In this trial however, a MAGE antigen-specific ImmTAC was tested alongside a non­
specific control ImmTAC, both dosed at 0.01 mg/kg, and administered iv one hour post 
engraftment and every other day for a further nine doses. Over the 42 day data collection 
period, ImmTAC-MAGE substantially inhibited tumour growth, while administration of 
irrelevant ImmTAC did not coincide with a significant tumour grown reduction. Importantly, 
this investigation highlighted the fact that the scFv CD3 portion alone (albeit administered 
as part of an irrelevant ImmTAC) was not responsible for exerting the anti-tumour effects. 
The finding demonstrates that ImmTAC reagents need to bind both effector and target cells 
together in order to exhibit efficacy. Figure 8.11 C, summarises the results obtained with the 
third murine study, conducted with ImmTAC-MEL. Over a period of 40 days, a 0.04 mg/dose 
of ImmTAC-MEL completely inhibited tumour growth. This represented the strongest 
inhibitory response out of the three ImmTACs tested.
8.2.6 ImmTAVs for the eradication of HIV-infected cells
In addition to designing new therapeutic tools aimed at cancer eradication, immunologists 
are preoccupied with harnessing the power of the adaptive immune response to combat 
persistent viral infections. In particular, HIV-1 infection presents a tremendous challenge. 
Due to its many clever defences (see section 1.7.1 of the main Introduction), HIV-1 can 
evade the immune response to give it sufficient time to infect its target CD4+ T cells and 
severely immunocompromise its host, resulting in a fatal condition called Acquired 
Immunodeficiency Syndrome (AIDS). One of HIV's main evasion mechanisms is the rapid 
generation of 'escape mutants'; epitopes derived from the virus, which are not well 
presented to, or recognised by the majority of naturally occurring CD8 + T cells. As a result, 
the virus simply outpaces the CD8 + T cell response and leaves these cells 'exhausted' and 
unable to perform their immune functions {Barnes, 2004 #2312;Oxenius, 2002b #2313}. 
However, a recent study involving members of my research team, reported the control of 
HIV-1 immune escape by CD8 + T cells expressing an enhanced HIV-specific TCR {Varela- 
Rohena, 2008a #882). The high affinity TCR described in this study was capable of 
recognising all the HIV-1 escape mutants commonly generated by the virus. As a direct 
result of these findings and the ImmTAC data presented in this chapter, Immunocore 
generated a series of ImmTAV molecules designed to redirect CD8 + T cells to target common
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epitopes derived from HIV-1. Although these ImmTAV-HIV molecules are still at a relatively 
early stage of development, some preliminary data is presented in Figures 8.12 and 8.13. In 
the same way that ImmTACs mediate the lysis of target cells expressing tumour antigens, 
ImmTAV-HIV is able to redirect polyclonal CD8 + T cells to kill target cells presenting the 
cognate SL9 peptide (derived from pl7 HIV gag) in the context of HLA A2 (Figure 8.12 A and 
B). More importantly, ImmTAV-HIV can elicit CD8 * T cell driven lysis of HIV-infected CD4+ T 
cells, presenting naturally low levels of endogenously processed antigen (Figure 8.12 C and 
Figure 8.13). Although the body of data generated with HIV-specific ImmTAVs is nowhere 
near as extensive as that obtained with ImmTACs, these preliminary results are certainly 
encouraging.
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Figure 8.12: Redirected lysis of HIV-infected and SL9 peptide-pulsed target cells by primary CD8 + T cells in the presence 
of ImmTAV-HIV. A. Specific redirected lysis over 16 hours of T2 cells pulsed with 1 nM HIV01 gag77* 5, SL9 (SLYNTVATL) 
peptide in the presence of titrated doses of ImmTAV-HIV (blue circles) or ImmTAC-gplOO (black circles) negative control, 
and primary CD8* T cells (isolated from PBMC by MACS separation). B. A flow cytometric plot depicting the relative 
percentages of target (T2 cells pulsed with 1 nM SL9 peptide, right CFSE Hi population) and control (unpulsed T2 cells, left 
CFSELo population) in the presence of two concentrations of ImmTAV-HIV (bottom panels) or ImmTAC-gplOO (top panels), 
and primary CD8+ T cells. C. Specific redirected lysis over 16 hours of HIV-infected TO cells in the presence of titrated doses 
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Figure 8.13: ImmTAV-HIV redirects polyclonal CD8* T cells and PBMC to specifically kill 
HIV infected TO cells. Flow cytometric plots summarise data from a FATAL assay performed 
over 12 hours, using 3X104 of either HIV-1 infected (90-100% p24+ )o r uninfected TO cells 
as targets labelled with CFSE in the presence of In  M ImmTAV-HIV, ImmTAC-gplOO 
(negative control) or no ImmTAV/C and an effector population. In A, the effectors 
consisted of a pure population of 15X104 MACS-sorted polyclonal CD8+T cells. In B, 106 
unsorted PBMC were used as effectors giving a final E:T in the assay of approximately 
5:1.(as in A). The numbers within each FACS plot correspond to the percentages of CFSE- 
labelled target (T) TO cells relative to the CFSE-unlabelled effector (E) population.
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Harnessing the power of the adaptive immune response to combat cancer and persistent 
viral infections has been a long-term goal for immunotherapy. Since it is now widely 
recognised that the T cell response is required for the efficient in vivo elimination of 
tumour-transformed and virally-infected cells, inciting T cells to target known disease- 
specific antigens is of utmost clinical importance (Alexander-Miller et al. 1996; Zeh et al.
1999). Initial research, focusing on the use of bi-specific monoclonal antibodies (mAbs), has 
shown that redirecting the cytotoxic T cell response can achieve tumour clearance in vivo 
(Bargou et al. 2008; Baeuerle et al. 2009; Nagorsen et al. 2009). However, the success of 
mAbs is limited by the nature of antigens they are designed to recognise ((Chaplin 2010) 
and Figure 8.1).
In contrast to antibodies, TCRs can recognise any endogenously processed antigen in the 
form of pMHC class I molecules presented on the surface of all nucleated cells. Until 
recently, two issues have hindered the development of soluble TCR-directed therapy: the 
lack of soluble TCR production systems and the low affinities of TCRs for their antigen. A 
major advance in the production of soluble monoclonal TCRs (mTCRs) led by my colleague 
Jonathan Boulter, has yielded mTCRs which are sufficiently stable for expression on the 
surface of bacteriophage, and hence could be subjected to affinity maturation by phage 
display (Boulter et al. 2003; Li et al. 2005). Using this technique, directed molecular 
evolution of a number of mTCRs specific for common tumour associated antigens (TAAs) 
was performed, increasing the affinity of some of these wild type TCRs >106 fold to pM KDs 
((Li et al. 2005) and Liddy et al. submitted). The fusion of these high affinity mTCRs to 
humanised anti-CD3 single chain (sc) Fv antibody fragments, gave rise to a novel set of 
reagents called Immune mobilising monoclonal TCRs Against Cancer (ImmTACs) (Figure 8.2). 
The work presented in this chapter demonstrates that these ImmTACs can overcome the 
limitations of natural TCR-mediated recognition and redirect the full might of T cell effector 
functions to kill tumours expressing natural epitope numbers on the cell surface (as low as 
2-10 copies per cells, Liddy et al. submitted). The key features of ImmTAC design include: i) 
an anti-CD3 scFv moiety that activates T cells regardless of their TCR specificity; ii) a high
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affinity mTCR, which binds to its cognate pMHCI with an affinity and half-life several orders 
of magnitude higher than the anti-CD3 scFv/CD3 interaction; and, iii) the observation that 
mTCRs are not internalised on binding. It is likely that these features have collectively 
contributed to the success of ImmTAC molecules in the eradication of tumour cells, by 
effectively marking these cells for execution by bystander CD8 + T cells of any specificity.
The majority of the work presented in this chapter concerns the study of four ImmTACs 
(Table 8.1). I demonstrated that the ImmTACs used in this study are united by the following 
pertinent features:
i) The majority of lymphocytes activated by ImmTACs are CD8 + T cells (Figure 8.4).
ii) ImmTACs activate CD8 + T cells in a dose-dependent manner at cellular EC50 values in 
the low picomolar range, consistent with the K0 of the corresponding monomeric 
mTCR/pMHCI interactions (Table 8.1 and Figure 8.3).
iii) Polyclonal CD8 * T cell activation triggered by ImmTACs elicits a polyfunctional 
response that includes cytokine production and lytic activity (Figures 8.4 and 8.5).
iv) The majority of CD8 * T cells responding to ImmTAC stimulation display the effector 
memory phenotype (Figure 8.5).
v) ImmTAC-mediated effector cell activation and target cell lysis is specific and limited 
to cells that express cognate pMHCI molecules (Figures 8.3-8.10).
vi) The potency of ImmTACs is associated with their ability to elicit serial killing by CD8 + 
T cells (Figures 8 . 6  and 8.7).
vii) ImmTAC-driven target cell lysis is not inhibited by potential activation of bystander 
regulatory T cells (Tregs) (Figures 8 . 8  and 8.9).
viii) ImmTACs exhibit in vivo efficacy by significantly inhibiting tumour growth in 
xenograft tumour NOD/SCID and Beige/SCID mouse models (Figure 8.10).
Investigating the behaviour of these novel reagents both in vitro and in vivo lead us to 
speculate about their mode of action in the context of the adaptive immune response as a 
whole. For instance, the high levels of tumour growth inhibition observed with only 5 doses 
of ImmTAC in two out of three mouse models (Figure 8.10 A and C) could not be entirely 
enacted through redirected CD8 * T cells within the engrafted PBMC sample alone (Figure
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8.10 A and C). Further observations that ImmTACs possess the power to induce 
polyfunctional CD8 * T cell responses (comprising both lytic activity and the production of 
soluble factors) (Figure 8.5) and cause these effector cells to serially kill their targets (Figure 
8.7), support a scenario in which the initial redirection of CD8 + T cells acts as a catalyst that 
drives the recruitment of additional immune effectors to the tumour (Price et al. 1999). In 
simple terms, by targeting tumour antigens, ImmTACs serve to expose the tumour's 
identity, drawing in T cells that are naturally 'blind' to its whereabouts. The unmasking of 
the tumour thus represents the critical step, after which the interplay between activated 
redirected CD8 * T cells and other mediators of the adaptive immune response guides the 
remainder of the tumour eradication process. It is therefore entirely possible that the initial 
minimal dose of ImmTAC reagent is all that is needed to instigate an amplification of the 
primary CD8 * T cell response (potentially through epitope spreading), which could then 
serve to generate a self-sustaining tumour-specific immune reactivity. Further extensive 
work will be required to demonstrate that ImmTACs can induce a wider immune response 
via epitope-spreading.
In the final part of this chapter, I introduced a relative of ImmTACs, designed to target cells 
presenting viral antigens indicative of persistent viral infections. These molecules are called 
Immune mobilising monoclonal TCRs Against Viruses (ImmTAVs) to reflect this role. In 
particular, my studies focused on assessing the function of ImmTAV-HIV, a bi-specific 
immunomodulatory reagent comprising a high affinity mTCR specific for a common epitope 
of HIV-1. Although the optimisation of ImmTAV-HIV has not reached the same advanced 
stage as ImmTAC development, its ability to redirect polyclonal CD8 + T cells to kill target 
cells pulsed with the relevant peptide and later those infected with HIV-1 is very promising 
(Figures 8.11 and 8.12). Further ImmTAV-HIV experiments are underway. The lack of 
pathogen containment facilities at Immunocore Ltd. means that the experiments will be 
conducted at the Cardiff University School of Medicine.
To conclude, ImmTACs and ImmTAVs collectively represent an exciting new class of soluble 
mTCR-based immunotherapeutic reagents. These bi-specific molecules manifest their 
immunomodulatory effects by: i) utilising their high affinity mTCR components to target
298
Chapter 8
pMHCI molecules implicated in disease; and, ii) bringing them to the attention of polyclonal 
CD8 * T cells by anti-CD3 scFv-mediated targeting of CD3 molecules on these immune cells. 
The fact that ImmTAC/Vs can redirect CD8 + T cells to target any antigen, regardless of their 
intrinsic specificity, gives this strategy a considerable advantage over cell-based therapies 
(ACT and TCR gene transfer therapy, described in sections 1.8.2 and 1.8.3 of the general 
Introduction, and Chapter 6 ) that require extensive ex vivo lymphocyte manipulations on an 
individualised basis. Instead, ImmTAC/Vs can be formulated as "off-the-shelf" drugs for 
administration in defined dosing schedules to any patient with the relevant HLA allele and 
an antigen-positive tumour. These features all favour the advancement of ImmTACs into the 
clinic.
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9
GENERAL DISCUSSION
The work outlined in my thesis is linked by the common theme of optimising interactions 
between peptide-MHC molecules and the receptors that engages these ligands at the T cell 
surface (TCR and CD8/CD4 coreceptors). I have explored several translational aspects of this 
topic. The principal aims of this thesis were to develop strategies for enhancing the affinity 
of T cell/antigen interaction to:
i) Enable detection of T cells displaying low affinities for antigen with pMHC multimers;
ii) Explore means of increasing TCR affinity for antigen at the T cell surface; and,
iii) Investigate the use of soluble high affinity TCRs as therapeutic agents.
9.1 Enhancing TCR/pMHC affinity to improve T cell detection with pMHC multimers
pMHC multimer technology has transformed the study of antigen-specific T cell responses 
by enabling visualisation, enumeration, phenotypic characterisation and isolation of antigen 
specific T cells in direct ex vivo samples by flow cytometry. The technique has some specific 
advantages over other detection methods as it can identify antigen-specific cells without 
the need to activate them and alter their phenotype. pMHC multimers can also detect cells 
regardless of what effector function they possess. The extraordinary utility of such reagents 
is demonstrated by their use in over 7000 published studies in the last 15 years. A major 
obstacle standing in the way of efficient flow cytometric detection of T cells is the fact that 
pMHC multimer staining is dependent on a distinct TCR/pMHC affinity threshold that lies 
above that required for T cell activation (Laugel et al. 2007). As a consequence, conventional 
pMHC multimer staining procedures fail to identify functional T cells expressing low affinity 
TCRs that are characteristic of the majority of tumour-specific and autoreactive CD8+ T cells 
and the nearly all CD4* T cells (Cole et al. 2007). This problem had been identified as an 
urgent, unmet need when I started my studies and I was tasked with testing various 
strategies to reduce the TCR/pMHC binding threshold required for pMHC multimer staining
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and thereby open up these technologies to tumour-specific, autoimmune and MHC class II T 
cells.
Chapters 3, 4, and 5, comprising the first half of my thesis are united by the common theme 
of improving the detection of low affinity T cells using fluorochrome-conjugated pMHC 
multimers. Laugel et al. established that a Ko of £ 40 pM is required to observe a level of 
staining that allows clearly distinct tetramer positive populations of polyclonal T cells 
stained with conventional pMHCI reagents and 'standard' staining conditions (10 pg/ml 
pMHCI tetramer, for 30 minutes at 37°C) (Laugel et al. 2007). In the first part of my PhD, I 
aimed to reduce the TCR/pMHC affinity threshold that governs the detection of T cells with 
pMHC multimers. I began by investigating the properties of tetrameric pHLA A*0201 
complexes containing the Q115E mutation in the a2 domain of the heavy chain (Chapter 3). 
By adding one further hydrogen bond to the pMHCI/CD8 interface, the Q115E substitution 
enhances CD8 binding by ~50% (Wooldridge et al. 2005; Wooldridge et al. 2007). MHCI 
molecules containing the Q115E mutation are able to engage the CD8 coreceptor with 
enhanced affinity without affecting the integrity of the TCR/pMHCI interaction (Wooldridge 
et al. 2007). Using a well characterised HLA A2-restricted, telomerase-specific system with a 
wide range of biophysically characterised ligands as a model, I have quantified the ability of 
these CD8-enhanced pMHCI tetramers to detect T cells bearing substantially weaker 
TCR/pMHCI interactions (approximate Ko £ 250 pM) than wildtype reagents (approximate 
Ko £ 80 pM). I demonstrated that the effect is achieved through a disproportionate increase 
in the TCR/pMHCI association rate. I went on to demonstrate that the CD8-enhanced 
tetramers can stain functional derived CD8* T cells in direct ex vivo samples that remain 
undetected with wildtype pMHCI tetramers.
I then went on to investigate the importance of increasing pMHC and fluorochrome valency 
by using an alternative multimerization scaffold called a dextramer (Chapter 4). Whilst 
pMHC tetramers are assembled from four pMHC molecules, dextramers are higher valency 
structures comprising as many as ~40 monomeric pMHCs. Dextramers offer a considerable 
advantage over tetramers in the detection of both CD8* and CD4+ T cell populations and 
allow the staining of T cells bearing lower affinity TCRs than cannot be visualised by regular
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pMHC tetramer staining using identical pMHC monomer. My attempts to provide a 
mechanistic explanation for the staining advantage afforded by dextramers over
conventional tetramers were not entirely successful. Assessment of dextramer versus
tetramer association rates showed that increased valency did not translate into higher rates 
of TCR/pMHC association. In contrast, dextramer on-rates were substantially slower than 
the rapid association kinetics displayed by pMHC tetramers. Microscopic imaging of T cells 
stained with dextramers or tetramers at physiological temperatures showed that both
reagents were internalised into endocytic vesicles. Higher order pMHC multimers
(pentamers, octamers, dextramers and polymers) are predicted to have generally longer 
interaction half-lives at the cell surface than pMHC tetramers. However, at physiological 
temperatures, the potential advantage of longer multimer dwell times afforded by the 
higher valency of dextramers is rendered largely irrelevant due to rapid internalisation 
kinetics (Whelan et al. 1999). Eliminating the above possible explanations for the increased 
success with pMHC dextramers led us to speculate that that the answer might lie in the 
nature of the multimerization scaffold. Unlike pMHC tetramers, which are assembled 
around a single streptavidin molecule, the dextran scaffold of dextramers is a polymer of 
glucose. The large dextran scaffold can accommodate high valencies of streptavidin, pMHC, 
and fluorochrome moieties, analogous to beads on a string (Figure 4.1). Furthermore, the 
flexibility of the dextran polymer is likely to greatly affect the conformational freedom of 
the attached pMHC monomers. In view of these structural differences between tetramers 
and dextramers, we speculate that dextramers hold an advantage over tetramers in staining 
low affinity T cells by engaging TCRs which are located much further apart than the pMHC 
'arms' of the tetramer can extend to (pMHC multimer 'arm-span'). Therefore, while pMHC 
tetramer (short 'arm-span') binding relies on the close proximity of cognate TCRs (a high 
TCR concentration), dextramers (long 'arm-span') are able to stain cells displaying much 
lower TCR densities (Figure 9.1). During the course of pMHC multimer staining, the 
internalisation of pMHC-triggered TCRs from the T cell surface reduces the concentration of 
TCRs further. Since TCR density is a critical parameter in determining the efficiency of pMHC 
multimer staining, the 'arm-span effect' could explain why dextramers outperform 
tetramers in cell staining. Dextramers might be capable of continuing to bind to the cell 
surface long after the TCR cell surface density has gone below the threshold to allow
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Figure 9.1: Dextramer versus tetramer staining. Successful pMHC multimer staining of T 
cells requires the formation of two or more productive TCR/pMHC interactions. The figure 
illustrates how the 'arm span' effect permits pMHC dextramers (with a long arm span) to 
stain T cells displaying low surface TCR densities by productively engaging TCRs located far 
a p a rt Meanwhile, pMHC tetramers (with a short arm span) require a high TCR 
concentration to engage two or more TCRs, and fail to stain T cells with low TCR densities. 
In addition, the fluorescence signal resulting from dextramer staining is substantially 
brighter (than tetram er staining) due to the high valency of fluorochrome molecules 
present on the dextran backbone. Refer to Figure 4.1 for key.
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continued tetramer staining. In addition, compared to a single fluorochrome molecule 
conjugated to a pMHCI tetramer streptavidin scaffold, the dextran backbone is decorated 
by large numbers of fluorochrome molecules. Undoubtedly, the difference in fluorochrome 
valency between tetramers and dextramers accounts for a large part of the difference in the 
staining brightness that can be achieved with each reagent (Figure 9.1).
In Chapter 5, I demonstrate the importance of TCR (and CD8, where applicable) 
concentration in the pMHC-mediated staining of T cells. I show that the reversible protein 
kinase inhibitor (PKI) dasatinib improves the staining intensity of human (CD8+ and CD4+) 
and murine T cells without concomitant increases in background staining. Dasatinib 
enhances the capture of cognate pMHC tetramers from solution, produces higher intensity 
staining at lower pMHC concentrations, and substantially lowers the TCR/pMHC interaction 
affinity threshold required for cell staining. Accordingly, dasatinib permits the identification 
of T cells with very low affinity TCR/pMHC interactions, such as those indicative of tumour- 
specific responses and autoimmune conditions, which are not susceptible to detection by 
ordinary pMHC tetramer technology. Dasatinib has the additional benefit of reducing 
tetramer-induced cell death of the targeted cells. Although preliminary, my own experience 
of including dasatinib treatment in a sort-cloning protocol resulted in the growth of three 
CD8* T cell clones. In contrast, no T cell clones were generated following single-cell sorting 
of the same sample in the absence of the PKI. Dasatinib is now included in the majority of 
cell-sorting protocols performed in my laboratory to validate these findings.
Collectively, the findings summarised above represent novel 'tricks' aimed at increasing the 
detection of T cells displaying sub-optimal affinities for antigen. Whilst these 'tricks' share 
the goal of increasing the affinity of the TCR/pMHC interaction, they achieve this in different 
ways: i) CD8-enhanced pMHCI tetramers rely on the subtle increase in pMHCI/CD8 binding 
afforded by the Q115E substitution in the a2 domain of HLA A2; ii) dextramers owe their T 
cell staining efficiency to increased pMHC and fluorochrome valency, and a large, flexible 
multimerization scaffold; and, iii) the PKI dasatinib represents a universal way of enhancing 
the staining potential of CD8+and CD4* T cell subsets by increasing the TCR (and coreceptor) 
concentration on the T cell surface by preventing downregulation of triggered receptors.
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Combining the advantages of these 'tricks' can lower the TCR/pMHC threshold of detection 
even further. Therefore a combination of CD8-enhanced tetramers (or dextramers) at high 
concentration, high staining temperature (37°C) and in the presence of dasatinib would 
guarantee to stain the majority of antigen-specific T cells within the T cell repertoire. 
However, other factors in addition to TCR/pMHC affinity are likely to control the sensitivity 
of T cells to pMHC antigen on the target cell surface. Factors such as TCR expression, TCR 
valency, CD8 expression and TCR-coreceptor adduct levels are likely to affect both the 
sensitivity to antigen and pMHC tetramer staining in a similar direction. Other factors such 
as altered expression of costimulatory molecules or inhibitory phosphatases might be 
expected to alter the sensitivity of T cells without necessarily affecting their avidity for 
multimeric cognate antigen.
In addition to enabling the characterisation of T cell responses, pMHC multimers have the 
potential for use as therapeutic agents. pMHC multimers can be used to manipulate a 
specific T cell-mediated immune response both ex vivo and in vivo, be it either to boost 
desirable or suppress unwanted T cell responses. Several groups have demonstrated the use 
of pMHC multimers in the ex vivo depletion of undesired (e.g. graft-versus-host disease 
[GvHD]-associated) T cells from transplant material before transfer to the recipient (Yuan et 
al. 2004; Bakker et al. 2005) and in the in vivo inactivation of undesired (e.g. autoreactive) T 
cells for the prevention or treatment of autoimmune diseases such as type I diabetes 
(Casares et al. 2002; Masteller et al. 2003) and rheumatoid arthritis (Zuo et al. 2002). In 
addition to conventional pMHC tetramers, which rely on TCR engagement to elicit 
activation-induced cell death (AICD) of undesired T cell populations, a class of 'suicide 
tetramers' promises to deliver higher levels of cytotoxicity. Currently these reagents 
mediate their cytotoxic effects through incorporation of radioactive isotopes such as 225Ac 
(McDevitt et al. 2001; Yuan et al. 2004). However, the in vivo efficacy and off-target toxicity 
of 'suicide tetramers' remains to be confirmed.
Another important use of pMHC multimers is in the ex vivo detection and isolation of 
specific populations of T cells for use in adoptive therapy (Oelke et al. 2003; Barnes et al. 
2004; Casalegno-Garduno et al. 2010). The rationale behind adoptive therapy is the
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expansion and re-infusion of T cells with desired specificities into a patient (adoptive 
transfer) to enhance reactivity against defined tumour- or virus-associated antigens. 
Adoptive therapy has shown considerable promise in the treatment of infectious diseases 
(Haque et al. 2002; Heslop et al. 2010) and malignant tumours {Rosenberg, 2004a #382}. 
However, the viability and occasionally functional activity of pMHC multimer-enriched T 
cells is hampered by the persistence of TCR/pMHC interactions, subsequent signalling 
events, and ultimately TCR/pMHC complex internalisation (Whelan et al. 1999; Maile et al. 
2001; Xu et al. 2001). Knabel and colleagues have provided a clever solution to this problem 
by engineering 'reversible' pMHC tetramers (also called streptamers). Streptamers 
dissociate into their pMHC monomeric components in the presence of a competitor such as 
free biotin, resulting in rapid loss of T cell staining (Knabel et al. 2002; Neudorfer et al.
2007). My study with the reversible PKI dasatinib has not only demonstrated its ability to 
enhance the staining of low avidity T cells, but has shown promise in reducing pMHC 
tetramer-induced cell death. Work is currently ongoing to confirm these preliminary 
findings. If successful, I envisage that dasatinib will form a crucial aspect of pMHC multimer- 
mediated ex vivo T cell purification protocols.
9.2 Enhancing TCR/pMHC affinity to increase T cell sensitivity to antigen
Adoptive transfer of ex v/Vo-derived and in vitro-expanded specific T cell populations is 
becoming an increasingly desirable strategy for the treatment of patients with cancer or 
infectious diseases. Numerous studies have demonstrated that T cells with an inherent 
ability to recognise very low antigen densities are the most effective at eliminating tumours 
and viruses in vivo (Alexander-Miller et al. 1996; Yee et al. 1999; Zeh et al. 1999; Dutoit et al. 
2002). In view of this, it is becoming increasingly accepted that the quality of a T cell 
response may be just as important as its quantity. Studies of more than 30 TCR/pMHC 
interactions by members of my group have confirmed that the most sensitive T cells bear 
the highest affinity receptors and are also the most independent of CD8 engagement for T 
cell activation and pMHCI tetramer staining (unpublished and (Cole et al. 2007)). In 
compliance with these data, low TCR/pMHC affinity is often associated with poor clinical 
outcome, and strategies for increasing TCR affinity are urgently needed to improve the 
efficacy of adoptive T cell transfer therapies.
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T cells displaying low affinities for antigen are especially prevalent within T cell subsets 
targeting tumour-associated or self-antigens. Isolation of these cells can be achieved using 
pMHC multimers and the various 'tricks' outlined in the previous section of this discussion. 
The ex vivo purified T cells can be subsequently expanded for use in adoptive therapy. 
Alternatively, their TCR genes can be extracted and delivered to autologous primary T 
lymphocytes. Optimisation of TCR gene delivery using a replication-deficient lentiviral 
vector (described in Chapter 6) was a prerequisite for my investigation of modulation of TCR 
affinity. At the outset of my PhD I had hoped to use TCR gene transfer to study how altered 
glycosylation affected TCR expression and function (Chapter 7) and to examine the effects 
of enhanced TCR affinity for cognate antigen. I abandoned plans to investigate the effects of 
enhanced affinity TCRs as this study was overtaken by the work of our collaborators at the 
University of Pennsylvania {Varela-Rohena, 2008a #882}. My interest in investigating the 
impact of altered surface glycosylation on T cell antigen recognition stemmed from 
observations that the desialylation of T cells enhanced their sensitivity to antigen (Moody et 
al. 2001; Daniels et al. 2002; Starr et al. 2003; Pappu et al. 2004; Brennan et al. 2006). My 
own studies repeated and extended these observations. Various studies have attributed the 
affects of desialylation to four T cell surface molecules: TCR, CD8, CD43 and CD45. My initial 
experiments showed that pMHCI tetramer staining increased when T cells were 
desialylated. It is difficult to envisage how this effect could be attributed to CD43 or CD45 
when these molecules do not bind to pMHCI antigen. I next ruled out the involvement of 
the CD8 molecule in increased antigen engagement by showing that CD8-null tetramer 
staining was also enhanced by desialylation. I also showed that desialylation enhanced 
antigen engagement in the complete absence of the CD8 molecule using pMHCII and CD4+ T 
cells. Desialylation was also shown to enhance antigen recognition by both CD4+ T cells and 
y6 T cells. Collectively, these experiments strongly suggest that enhanced antigen binding 
and antigen recognition of desialylated T cells functions directly through events on the 
TCR/CD3 complex. This conclusion suggested that manipulation of TCR glycosylation might 
provide a universal means to enhance the antigen binding and antigen sensitivity of TCR- 
transduced T cells.
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I proceeded to silence the N-glycosylation sites within an HIV-specific 868 TCR by site 
directed mutagenesis. Expression of the resultant de-glycosylated 868 TCR mutants was 
achieved by transduction of T cells using the optimised transduction protocol described in 
Chapter 6. While I was undertaking these studies, a paper was published claiming that the 
silencing of a single glycosylation site in a transduced TCR could be used to enhance antigen 
sensitivity (Kuball et al. 2009). My own studies failed to repeat the findings of Kuball et al. 
(Kuball et al. 2009). Silencing of individual N-glycosylation sites, including the conserved Ga2 
N-glycosylation site analogous to the 'affinity-enhancing' c-36 site, did not result in 
increased antigen sensitivity. My negative findings were echoed by collaborators at 
Adaptimmune Ltd, who reproduced the c-36 mutation in another tumour-reactive TCR, 
specific for the NY-ESO-li57 i6s (SLLMWITQC) peptide antigen. Thus, whilst I have 
demonstrated that the removal of surface sialic acid increases antigen sensitivity of T cells, 
and that the effect observed is not CD8-dependent, abrogation of TCR glycosylation failed 
to increase the functional sensitivity of the recipient T cells. In view of this, I do not believe 
that the manipulation of individual TCR-specific N-glycosylation sites represents a universal 
way to increase TCR affinity and the antigen-sensitivity of T cells used in TCR gene transfer 
and adoptive T cell therapy.
TCR crystal structures such as shown in Figure 7.10 B reveal that the glycosylation motifs are 
strictly aligned, and are restricted to one face of the TCR. It is improbable that such ordering 
of glycans exists by chance. The presence of large sugar residues along one face of the 
TCR/pMHC complex is bound to affect how TCRs can come together. Further work will be 
required in order to establish how the TCR a  and (3 chains interact with the CD3 and 
£ components of the TCR before we can gain a picture of how TCRs might aggregate. I 
predict that glycosylation regulates T cell antigen recognition by limiting molecular 
interactions compared to the 'naked' glycan-free face of the TCR and by separating adjacent 
TCRs and components of the CD3 complex, both physically and electrostatically. Since the 
extent of TCR/TCR and TCR/CD3 cluster formation is an important parameter affecting T cell 
antigen recognition, glycosylation may regulate T cell antigen sensitivity by limiting the 
formation of these activation clusters. It is well documented that the TCR-TCR distance is a 
critical parameter in TCR-mediated signalling. TCRs fail to signal when they bind antigen but
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are held >80 A apart and exhibit progressively stronger signalling as this distance is 
shortened (Cebecauer et al. 2005). The increase in antigen sensitivity observed on removal 
of negatively charged terminal sialic acid moieties from the surface of a T cell could be 
explained by increased TCR clustering due to reduced electrostatic repulsion between 
individual TCRs.
Sialic acid forms a small component of the much bulkier glycan structures (Figure 7.1 B). We 
envisaged that silencing of entire N-linked glycosylation sites on a TCR would have a more 
dramatic effect on antigen recognition than sialylation, by allowing TCRs to come into even 
closer contact with each other. Although silencing of individual TCR N-glycosylation sites did 
not result in a substantial increase in antigen sensitivity, it is possible that the collective 
removal of glycans from the glycosylated face of the TCR would have a more favourable 
outcome. However, glycans have many important roles other than regulating T cell antigen 
sensitivity. My own experience has taught me that glycans at particular sites are essential 
for stable surface TCR expression. Furthermore, surface expression of a 'naked' TCR lacking 
glycosylation would leave it vulnerable to protease-mediated degradation. These obstacles 
are likely to impede further N-glycosylation knockout studies of the role of glycosylation in 
TCR-antigen recognition and rule this approach out as a way of universally increasing the 
efficacy of transduced TCRs. Further studies will be required in order to determine whether 
mechanisms that specifically target TCR sialylation could be useful in the setting of TCR gene 
transfer therapy.
9.3 High affinity TCRs as therapeutic agents
Soluble TCR-directed therapy has been made possible by the development of efficient 
soluble TCR production systems and TCR affinity maturation techniques. In Chapter 8 I 
evaluate the potential of soluble high affinity TCRs conjugated to immunomodulatory anti- 
CD3 scFv fragments to act as therapeutic molecules. These novel reagents called Immune 
mobilising monoclonal TCRs Against Cancer or Viruses (ImmTAC/Vs) overcome the 
limitations of natural TCR-mediated recognition by redirecting the polyclonal T cell immune 
response towards cells expressing various tumour-associated antigens and an 
immunodominant epitope of HIV-1. ImmTAC/Vs are designed according to the same
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principles as the Bi-specific T cell Engaging (BiTE) antibodies introduced in Chapter 8. Both 
therapeutic molecules employ lymphocyte receptors (ImmTAC/Vs: soluble TCRs; BiTE 
antibodies: soluble BCRs/mAbs) for antigen recognition, and an immunomodulatory 
antibody to redirect the polyclonal T cell response. ImmTAC/Vs and BiTE antibodies 
represent an alternative to TCR gene transfer therapy for the eradication of tumours, and 
virally-infected cells. The advantages and disadvantages of each therapeutic approach are 
summarised in Table 9.1. While ImmTAV development is still at a relatively early stage, 
ImmTACs have demonstrated very promising in vivo efficacy by inhibiting tumour growth in 
xenograft tumour mouse models. If the protein levels that have been used in mice were 
scaled up to human systems it might be possible to successfully treat a patient with just 
milligram quantities of ImmTAC. This extends the boundaries of protein therapeutics by 
several orders of magnitude (Liddy et al. submitted), in addition to making ImmTAC-based 
therapies potentially both cheap and easy when compared to adoptive T cell therapy 
approaches. Preliminary results have demonstrated that the encouraging in vivo tumour 
growth results extend to murine tumour regression models (Liddy et al. submitted). These 
exciting data have resulted in the initiation of human clinical trials of ImmTACs in the UK 
and USA this year; the outcome of these trials is eagerly anticipated by all involved. To 
conclude, ImmTACs and ImmTAVs represent a novel class of soluble TCR-based 
immunotherapeutic reagents. These therapeutic molecules are a testament to rational drug 
design and demonstrate just how much our understanding of the TCR/pMHC interaction has 
increased over the past decade.
9.4 Summary
During my PhD, I have contributed to development of several strategies aimed to enhance 
the TCR/pMHC interaction to improve the detection and characterisation of T cells 
displaying low antigen sensitivity using pMHC multimers, and enhance T cell sensitivity to 
cognate antigen. I am hopeful that as our knowledge of the TCR/pMHC interaction central 
to T cell immunology develops further, its manipulation will give rise to increasingly more 
sophisticated therapies for cancer and infectious diseases.
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Immunotherapy Advantages Disadvantages
TCR gene 
transfer
• Increases the frequency of T 
cells in the periphery specific 
for a desired disease- 
associated pMHC antigen.
• T cells for transduction can 
be selected based on 
advantageous qualities such as 
polyfunctionality, cytotoxicity 
and persistence in vivo.
• Transduction of different T 
cell subsets (eg. CD8+ T cells, 
CD4+ T cells, Tregs) to suit 
desired function.
• Long-term persistence of 
antigen-specific memory T 
cells.
• Requirement for expensive, 
sterile T cell culture systems.
• TCR gene therapy requires 
host conditioning by 
lymphodepletion, with toxic 
side effects.
•Transduced T cells often less 
effective then parent T cells 
(source of TCR used for 
transduction).
• Possible risks of TCR 
autoimmunity: TCR chain 
mispairing and reactivity 
against host MHC haplotypes.
Bi-specific 
T cell Engaging 
(BiTE) antibody
• mAbs are naturally soluble 
and are easy to manufacture.
• mAbs are naturally high 
affinity.
• BiTEs can engage T cells 
unlike conventional mAbs.
• Can be administered as 'off 
the shelf' drugs.
• No need for host 
conditioning.
• Difficulty in generating mAbs 
against pMHC antigen.
• Possible risk of 
immunpathology: host against 
BiTE, and BiTE against host (eg. 
mismatched MHC haplotypes).
Immune mobilising 
monoclonal TCR 
Against Cancer/ 
Virus (ImmTAC/V)
• Soluble TCRs produced in 
bacterial cell culture systems 
(easy and inexpensive).
• Higher affinity than BiTEs.
• Engage cytotoxic CD8* T cells 
preferentially.
• Low off-target cytotoxicity.
• Can be administered as 'off 
the shelf' drugs.
• No need for host 
conditioning.
• Possible risk of 
immunopathology: host against 
ImmTAC/V, and ImmTAC/V 
against host (eg. mismatched 
MHC haplotypes).
Table 9.1: Comparison of three immunotherapies.
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9.5 Future Directions
Protein Kinase Inhibitors
The use of PKIs like dasatinib in improving pMHC tetramer staining has been published 
(Lissina et al. 2009). It would be interesting, and potentially very useful, to further formally 
investigate the additional benefit of this PKI in reducing pMHC multimer-mediated AICD of 
the targeted cells. AICD is a metabolic phenomenon that arises due to the prolonged TCR 
triggering which accompanies pMHC-multimer staining. AICD is therefore a major problem 
affecting conventional flow cytometric cell sorting protocols. By blocking early T cell 
signalling events downstream of TCR/pMHC engagement, dasatinib is predicted to prevent 
AICD and improve the efficiency of flow cytometric cell sorting. Although this property also 
results in the inhibition of T cell effector functions including proliferation, activation, 
cytokine production and degranulation, the effects of dasatinib are said to be reversible 
(Weichsel et al. 2008). Indeed, members of my laboratory have shown that T cells can still 
respond to antigen after being incubated in 50 nM dasatinib for 24h and then washed. It 
would therefore be interesting to determine if there are additional benefits to including 
dasatinib in cell sorting protocols, and compare the functionality of T cells sorted in the 
presence and absence of the PKI. I have obtained some preliminary data showing that sort- 
cloning of T cells post-dasatinib treatment rescued cells from AICD, and that the 
proliferation capacity of the sorted cells was not impaired. In contrast, T cells sorted from 
the same sample in the absence of dasatinib perished. I would like to expand on these initial 
findings to determine whether the effect seen with dasatinib in tetramer sort-cloning is real 
and reproducible. Any means to prevent pMHC multimer-mediated AICD would be a huge 
benefit to the T cell research community and the pursuit of this aim is extremely 
worthwhile.
ImmTAC/Vs
Since my involvement in the project, ImmTAC development has progressed to the exciting 
stage of human clinical trials. Soluble TCR-based ImmTACs hold several advantages over 
adoptive T cell (ACT) therapeutic approaches (see Table 9.1). One of these advantages is the 
low cost of ImmTAC manufacture and treatment. The projected costs of 'off the shelf 
ImmTAC therapy (estimated at ~£5000/patient) are many times lower than those for ACT
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(estimated at ~£100,000/patient). Thus, ImmTACs might form a new weapon in the anti­
cancer armoury that will supersede current ACT efforts. However, there are areas where 
adoptive T therapy using TCR gene-transduced cells may have an advantage over 
ImmTAC/Vs. Introduction of specific TCR genes into a precisely defined cell permits the 
selection of cells with desired antigen specificity and required effector function (eg. 
improved cytotoxicity, cytokine production and persistence in vivo). For instance, the 
administration of IL-2, a cytokine produced by certain subsets of CD4+ T helper cells has 
been shown to improve the efficacy of effector CD8+ T cells transferred to patients 
undergoing ACT (Yee et al. 2000). In light of this, co-infusion of TAA-reactive TCR-transduced 
CD8* and CD4* T cells is predicted to result in a more effective anti-tumour response than 
infusion of each T cell subset alone. The limited number of characterised MHCII-associated 
TAAs has impeded the generation of pMHCII-restricted CD4+ T cells for use in adoptive 
therapy. However, Morris et al. have successfully demonstrated the use of IL-2-producing 
CD4+ T cells transduced with a high affinity pMHCI-restricted TCR to improve the in vivo 
clearance of melanoma in a murine xenograft tumour model (Morris et al. 2005). Since 
infusion of IFN-y-producing CD4+ T cells transduced with the same TAA-specific TCR failed to 
improve tumour clearance, the effective anti-tumour response was attributed to the ability 
of the previous subset of CD4* T cells to produce IL-2, thus providing help for CD8+ T cell- 
mediated anti-tumour cytotoxicity. Interestingly, although CD4+ T cells are not normally 
associated with high cytotoxicity themselves, adoptive transfer of CD4+ T cells transduced 
with a high affinity MHCI-restricted NY-ESO-1 antigen-specific TCR were recently shown to 
elicit tumour lysis and clinical remission of cancer in melanoma patients (Hunder et al.
2008). In addition to transduction of T cells to achieve cytotoxicity of target cells, several 
groups have investigated the use of Tregs as TCR recipients (Tsang et al. 2008; Hombach et 
al. 2009; Brusko et al. 2010). In this scenario, Tregs transduced with a TCR specific for a 
targeted self-epitope would act as antigen-specific suppressor cells. A recent study has 
demonstrated the effective use of Tregs transduced with TCRs specific for MHCII molecules 
in promoting transplantation tolerance in a mouse model (Tsang et al. 2008). Such 
redirected Tregs might be useful in clinical applications in the context of autoimmunity and 
transplantation.
313
Chapter 9
Another important attribute of ACT is that the infused T cells (unlike ImmTAC/Vs and other 
drugs) are retained within the host and can offer immune protection in cases of disease 
relapse. This is elegantly demonstrated by a long-term follow-up study on patients who 
received donor-derived EBV-specific CD8* T cells (Heslop et al. 2010). The transferred T cells 
were detected in the patients beyond a 9 year period, implying that they had entered the 
memory pool even though the infused cell lines were predominantly of the effector 
memory phenotype (Heslop et al. 2010). Taking the above points into consideration, it 
remains to be seen whether ImmTAC/Vs offer an overall therapeutic advantage over 
adoptive T cell therapy in the long term.
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APPENDICES 
Appendix 1: Sequences of 868 TCR a and 0 chains and SGSG-2A peptide 
A. 868 TCR a:
acgcgtgctagccgccaccatgatgaagagcctgagggtgctgctggtgatcctgtggctgcagctgtcctgggtgtggagccagcag
aaggaggtggagcagaatagcggccctctgagcgtgcccgagggcgccatcgccagcctgaactgtacctacagcgacagaggca
gccagagcttcttctggtacaggcagtacagcggcaagagccccgagctgattatgttcatctacagcaacggcgacaaggaggac
ggcagattcaccgcccagctgaacaaggccagccagtacatcagcctgctgatccgggatagcaagctgtccgacagcgccaccta
cctgtgtgccgtgagaaccaatagcggctacgccctgaatttcggcaagggcaccagcctgctggtgaccccccacatccagaatcct
gaccccgccgtgtaccagctgagagacagcaagagcagcgacaagagcgtgtgtctgttcaccgacttcgacagccagaccaacgt
gtcccagagcaaggacagcgacgtgtacatcaccgacaagaccgtgctggacatgaggagcatggacttcaagagcaacagcgcc
gtggcctggagcaacaagagcgacttcgcctgtgccaacgccttcaacaacagcatcatccccgaggacacctttttccccagccctg
agagcagctgtgacgtgaaactggtggagaagagcttcgagaccgacaccaacctgaacttccagaacctgagcgtgatcggcttc
agaatcctgctgctgaaggtggccggattcaacctgctgatgaccctgagactgtggagcagcctcgagagatct
B. 868 TCR 0:
cctaggcccgggatgggacccggcctgctgtgctgggccctgctgtgcctgctgggagccggactggtggacgccggagtgacccag
agccccacccacctgattaagaccaggggccagcaggtgaccctgagatgtagccctaagagcggccacgataccgtgtcctggtat
cagcaggccctgggccagggaccccagttcatcttccagtactacgaggaggaggagaggcagagaggcaacttccccgacagatt
cagcggccaccagttccccaattacagcagcgagctgaacgtgaatgccctgctgctgggcgacagcgccctgtacctgtgtgccag
cagcgacacagtgagctacgagcagtacttcggccctggcaccagactgaccgtgaccgaggacctgaagaacgtgttccctcctga
ggtggccgtgttcgagcccagcgaggccgagatcagccacacccagaaggccaccctggtgtgtctggccaccggcttctaccccga
ccacgtggagctgtcctggtgggtgaacggcaaggaggtgcacagcggcgtgtccaccgacccccagcccctgaaggagcagcccg
ccctgaacgatagcaggtactgcctgagcagcaggctgagagtgagcgccaccttctggcagaacccccggaaccacttcagatgcc
aggtgcagttctacggcctgagcgagaacgacgagtggacccaggatagagccaagcccgtgacccagatcgtgtccgccgaggcc
tggggcagagccgactgtggcttcaccagcgagagctaccagcagggcgtgctgtccgccaccatcctgtacgagatcctgctgggc
aaggccacactgtacgccgtgctggtgtccgccctggtgctgatggctatggtgaagcggaaggacagcaggggctgatagtcga
C. SGSG-2A sequence (T2A from the Thosea asigna virus):
agcggcagcgggcgcagcggcagcggcgaaggccgcggcagcctgctgacctgcggcgatgtggaagaaaaccctggcccg 
(Translates to: SGSGRSGSGEGRGSLLTCGDVEENPGP)
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Appendix 2: 868 TCR N-glycosylation sites
The 7 putative N-glycosylation sites found on the  868 TCR were located by subjecting the 868 
TCR am ino acid sequence to  an ExPASy (Prosite) search fo r the  N-X-[S/T]-Y N-linked 
glycosylation m o tif (where X and Y are any amino acid apart from  proline). Variable (v) 
dom ains are shown in green, and constant (c) domains in blue, and glycosylation motifs in 
red. The num bers underneath the sequences refer to  the  amino acid positions o f the 
corresponding glycosylation m otif in the variable o r constant region o f the alpha or beta TCR 
chain.
A. 868 TCR a:
RVLAATMMKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSG
KSPELIMFIYSNGDKEDGRFTAQLNKASQYISLLIRDSKLSDSATYLCAVRTNSGYALNFGKGTSLLVTPHIQ
NPDPAWQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFA
CANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSSLERS
v 22-24 NCT
c 31-33 NVS
c 66-68 NKS
C 77-79 NNS
C 112-114 NLS
B. 868 TCR 0:
PRPGMGPGLLCWALLCLLGAGLVDAGVTQSPTHLIKTRGQQVTLRCSPKSGHDTVSWYQQALGQGPQF
IFQYYEEEERQRGNFPDRFSGHQFPNYSSELNVNALLLGDSALYLCASSDTVSYEQYFGPGTRLTVTEDLKN
VFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYC
LSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVL
SATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG**S
v 70-72 NYS
C 65-67 NDS
346
Appendices
Appendix 3: List of primers for site directed mutagenesis of N-glycosylation sites located on 
the 868 TCR
The name o f each prim er is highlighted in red, while the glycosylation site being m utated and 
the  am ino acid position and substitu tion details are shown in blue. For example, the  G1 
fo rw ard  5 ' p rim er substitutes a glutam ine (Q) fo r an asparagine (N) a t position 94 in the beta 
chain o f the  868 TCR.
G1 => 5 'g lyclB_N 94Q  
ccagttcccccagtacagcagcgagc 
G2 => 3 'g lyclB_N 94Q  
gctcgctgctgtactgggggaactgg 
G3 =>5'glyc2B_N205Q 
gagcagcccgccctgcaagatagcaggtactgc 
6 4  => 3'glyc2B_N205Q 
gcagtacctgctatcgttcagggcgggctgctc 
G5 => 5 'g lyclA_N 50Q  
catcgccagcctgcagtgtacctacagc 
G6 => 3 'g lyclA_N 50Q  
gctgtaggtacactgcaggctggcgatg 
6 7  => 5'glyc2A_N172Q 
cgacagccagacccaggtgtcccagagc 
G8 => 3*glyc2A_N172Q 
gctctgggacacctgggtctggctgtcg 
G9 => 5'glyc3A_N206Q 
gtggcctggagccagaagagcgacttcg 
G10 => 3'glyc3A_N206Q. 
cgaagtcgctcttctggctccaggccac 
G i l  => 5 'glyc4A_N217/8Q 
tgtgccaacgccttccagcagagcatcatccccg 
G12 => 3 'glyc4A_N217/8Q 
cggggatgatgctctgctggaaggcgttggcaca 
G13 => 5'glyc5A_N253Q 
cctgaacttccagcagctgagcgtgatc 
G14 => 3'glyc5A_N253Q 
gatcacgctcagctgctggaagttcagg
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Appendix 4: DNA sequence alignment of the 868 TCR and 868 TCR glycosylation mutants
A. Sequence alignment results for 868 TCR a chain with the five a chain 
glycosylation mutants (A1-A5).
The point mutations are highlighted in green. (Al=Gal, A2= Ga2, A3= Ga3, A4= Ga4, A5= 
Ga5)
GLUSTAL 2.0.12 multiple sequence alignment
.p i vj a _ p r .a  a  .  —------------------------------------ A g g g  '■ j  - u t . A g G v  g C g .A C g  ~ A T  g A T g A A .g A G C C T  3 3
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3 g 3 g _ p  r . g 3 -----------— g C g A T  A. ~ T G u b  g g  C A  g  A  GCC T  2 3
'4bi -3 a .  c r . 3 A t . —  — g g g g g g A T G A T g g A g g g A g A g CC.T 24
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B. Sequence alignment results for 868 TCR 0 chain with the two 868 TCR 0 chain 
glycosylation mutants (B1 and B2).
The point mutations are highlighted in green. (beta= 0 wild type, Bl= G01, B2= G02)
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Appendices
Appendix 5: Summary of TCR Va and V0 antibodies.
Name Immunogen
Fluore
scence Brand
Anti-TCR Va24
Anti-TCR V$1 
Anti-TCR V$2
Anti-TCR V$5.1 
Anti-TCR V$5.2
Human T-cell clone
Rat cell line RBL-2H3 transfected with the human 
TCR-VP1 gene 
Human T-cell line
Murine T cell hybridoma transfected with human
V$5.1 gene segment
1C1 Vp5.2 positive cell line
FITC
FITC
FITC
FITC
FITC
Beckman Coulter
Beckman Coulter 
Beckman Coulter
Beckman Coulter 
Beckman Coulter
Anti-TCR V$7
Anti-TCR V07.2 
Anti-TCR V$8
Anti-TCR V$12
Anti-TCR V013.1
Murine T-cell hybridoma transfected with Vp7 
gene segment
Murine T-cell hybridoma 580$, transfected with 
the human TCR-V$7.2 gene 
MX3 positive cell line
Murine T-cell hybridoma transfected with human 
V$12 gene segment
Murine T-cell hybridoma transfected with human 
V013.1 gene segment
FITC
PE
FITC
FITC
FITC
Beckman Coulter
Immunotech (Coulter) 
Beckman Coulter
Beckman Coulter
Beckman Coulter
Anti-TCR V$13.2
Anti-TCR V013.2 
Anti-TCR V013.6
Anti-TCR V$14
Anti-TCR V$16
Murine T-cell hybridoma DS23-27.4 transfected
with human TCR-Vpl3.2 gene
Murine T-cell hybridoma DS23-27.4 transfected
with human TCR-Vpl3.2 gene
Human T-cell clone
Murine T-cell hybridoma transfected with human 
V$14 gene segment
Murine T-cell hybridoma transfected with human 
V$16 gene segment
PE
PE
FITC
FITC
FITC
Immunotech (Coulter)
Immunotech (Coulter) 
Beckman Coulter
Beckman Coulter
Beckman Coulter
Anti-TCR V$17 
Anti-TCR V018
Anti-TCR V$20
Anti-TCR V$20
Anti-TCR V$21.3
Murine T-cell hybridoma transfected with V$17 
gene segment 
Human T-cell clone
Murine T cell hybridoma transfected with human 
V$20 gene segment
Murine T cell hybridoma transfected with human 
V$20 gene segment
Murine T-cell hybridoma transfected with human 
V$21 gene segment
FITC
PE
FITC
PE
FITC
Beckman Coulter 
Beckman Coulter
Beckman Coulter
Beckman Coulter
Beckman Coulter
Anti-TCR V$22 
Anti-TCR V023 
Anti-TCR V$3 
Anti-TCR V05.3
Anti-TCR V$9
Murine T-cell hybridoma transfected with V$22
gene segment
Human T-cell line
Human T-cell clone A2
Human T cell clone
Murine T-cell hybridoma transfected with human 
V$9 gene segment
FITC
PE
FITC
PE
PE
Beckman Coulter 
Beckman Coulter 
Immunotech (Coulter) 
Immunotech (Coulter)
Immunotech (Coulter)
Anti-TCR V p ll  
Anti-TCR V$5(a) 
Anti-TCR Va2
Human T-cell clone 
Human T-cell clone 
Human T-cell clone
FITC
FITC
FITC
Immunotech (Coulter) 
Thermo Scientific 
Thermo Scientific
352
